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Metformin is the world’s most prescribed drug and is recommended first-line therapy for the 
treatment of Type 2 Diabetes Mellitus (T2DM). Numerous clinical studies have demonstrated that 
metformin is an effective oral agent in normalising blood glucose levels. Metformin is also one of the 
very few antidiabetic agents that causes modest weight loss in overweight and obese subjects. Despite 
its introduction into the clinic over 60 years ago, the mechanisms of metformin action are still elusive.  
Many of the previous studies into metformin action have focussed on its role in inhibiting endogenous 
glucose production in the liver, due the central role of the liver in insulin resistance and glycaemic 
control. However, metformin also accumulates at the highest concentrations in the small intestine, 
and clinical studies demonstrate that metformin formulations with low bioavailability achieve similarly 
effective glycaemic control compared to standard metformin formulations. These studies suggest that 
the gastrointestinal tract may also be an important site of metformin action. 
In this thesis, 2D monolayer cultures generated from intestinal organoids were used to investigate the 
mechanisms of metformin action in intestinal cells. Bulk RNA-sequencing and pathway analysis 
identified changes in glucose and amino acid metabolism pathways, as well as the upregulation of 
novel signalling pathways associated with the metformin response in intestinal cells. The results from 
RNA-seq experiments were used as the basis for functional studies into metformin action in intestinal 
cells.  
GDF-15 is a stress activated hormone that acts on its cognate receptor GFRAL expressed almost 
exclusively in the brainstem to elicit an inhibition of food intake. GDF-15 was one of the serum 
biomarkers identified in T2DM patients associated with metformin use. In a multidisciplinary 
collaboration, we demonstrated that Gdf15 upregulation in the distal small intestine and colon were 
associated with the weight loss effects of metformin. The results from transcriptomic analysis in this 
study identified Gdf15 as one of the most significantly upregulated genes in metformin treated 
intestinal cultures. Transcriptomic analysis of selected genes involved in mitochondrial function, and 
secretion studies reported that metformin stimulated GDF-15 secretion through mitochondrial stress 
and activating the integrated stress response.   
Previous observations from Position Emission Tomography-Computed Tomography (PET-CT) imaging 
in mice and T2DM patients demonstrated that oral metformin administration caused non-
metabolisable fluoro-deoxyglucose (F-2DG) tracer to accumulate predominantly in the gut. This 
suggests that metformin increased intestinal glucose utilisation as one mechanism associated with its 
glucose lowering effects. In intestinal cells, metformin increased the expression of Slc2a1 (encoding 
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GLUT1), whilst decreasing the expression of Slc2a2 (GLUT2) and Slc5a1 (SGLT1). This was replicated in 
the distal small intestine of HFD-fed mice treated with metformin. Metformin also increased GLUT-
transporter mediated glucose uptake in cultures. These mechanisms may potentially be mediated by 
AMPK and HIF1A signalling pathways. By inhibiting mitochondrial respiration, metformin also limited 
the metabolic plasticity of intestinal cells to utilise other metabolic fuels, which instead relied almost 
exclusively on glycolysis.  
In summary, this study suggests that increased glucose uptake mediated by GLUT transporters and 
increased glycolysis mediates intestinal glucose utilisation as a mechanism by which metformin causes 
its glucose lowering effects. Metformin may also stimulate GDF-15 secretion from the GI tract as an 
atypical “gut hormone”, which acts on the brainstem to reduce food intake and enhance weight loss.  
Together, the results from this study argue that the GI tract is an important site where metformin 
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Chapter 1: Introduction  
 
1.1. Type 2 Diabetes Mellitus and Obesity 
Type 2 diabetes (T2DM) and obesity are major global health concerns in the 21st century. As many as 
1.9 billion people worldwide were either overweight or obese in 2016, and 422 million people were 
living with diagnosed T2DM in 2014 according to the World Health Organisation (WHO) (1, 2). T2DM 
and obesity are strongly associated, with obesity being a prevalent risk factor for the development of 
T2DM (being overweight accounts for a 61% increased risk in developing T2DM) (3, 4). Patients with 
obesity and/or T2DM can develop cardiovascular complications (5–7). A total of £8.8 billion has been 
invested for the treatment of T2DM in 2012 and £7.4 billion has been invested for treating obesity by 
the NHS from 1998-2010, respectively (8, 9). Therefore, effective long-term management of T2DM 
and obesity is a strategic priority to delay disease complications and improve quality of life.  
The two core defects in T2DM are beta-cell dysfunction and insulin resistance (10). Insulin resistance 
(the inability of tissues such as the liver, skeletal muscle and adipose tissue to respond to insulin) 
frequently precedes the development of T2DM and causes stress on the beta-cells, contributing to 
beta-cell failure and impaired insulin secretion (10). This leads to incremental elevations in blood 
glucose levels, and T2DM is clinically diagnosed if fasting blood glucose levels are >7 mmol/L (10, 11). 
Obesity is the result of increased fat deposition as a result of imbalance between energy expenditure 
and food intake (12). Metabolic changes in adipose tissues and neuroendocrine changes in appetite 
also accompany obesity (12). Although obesity is associated with insulin resistance,  T2DM does not 
usually occur unless there is also beta-cell dysfunction (13). A complex association of genetic and 
environmental factors contributes to the development of obesity and T2DM (10, 12). Both obesity and 
T2DM have also been reported to be associated with systematic inflammation which contributes to 
insulin resistance (10, 12).  
1.3. Treatments for obesity and T2DM 
Although lifestyle interventions (diet and physical exercise) remain the basic component for mild 
T2DM or prediabetes and obesity, pharmacological and surgical approaches have been developed for 
patients who struggle to maintain glycaemic control and/or weight loss (12, 14). 
1.3.1. Glucose lowering agents  
1.3.1.1. Sulphonylureas 
Sulphonylureas (such as glibenclamide) and glinides (such as nateglinide) inhibit the KATP channels 
expressed in beta-cells to stimulate endogenous insulin secretion, which causes hyperinsulinaemia to 
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overcome insulin resistance (14). Although sulphonylureas are effective insulin secretagogues that 
causes an initial decline in fasting blood glucose levels, they do not provide long term protection of 
beta-cell function and may even accelerate beta-cell failure (15–17). Sulphonylurea use is commonly 
associated with weight gain and recurrent hypoglycaemia (when blood glucose levels reach 
dangerously low levels) (14).    
1.3.1.2. Thiazolidinediones 
Thiazolidinediones (TZDs such as rosiglitazone, pioglitazone and troglitazone) are insulin sensitising 
agents which enhance insulin sensitivity in the skeletal muscle, liver and adipose tissue, as well as 
augmenting and preserving beta-cell function (14). TZDs exert multiple insulin-sensitising effects, such 
as increasing peripheral glucose uptake, reducing systemic inflammation and stimulating lipogenesis 
in adipose tissues through the PPAR-γ and PGC-1α signalling pathways (14). TZDs are clinically effective 
in lowering stabilising glycated haemoglobin (HbA1c) levels in the long term (14). Amongst the side 
effects of TZDs are reduced bone density, weight gain and fluid retention (14). TZDs are either 
withdrawn or are currently not frequently used in the clinic due to potential adverse effects such as 
hepatotoxicity and risk of bladder cancer (14). 
1.3.1.3. Insulin 
Insulin is used for the treatment of T1DM, although under severe cases of T2DM insulin would be 
considered as the last-resort treatment option when all other pharmacological interventions fail in 
normalising blood glucose levels (18). Blood glucose levels needs to be closely monitored in patients 
given insulin injections to prevent hypoglycaemia (18). Like sulphonylureas, insulin therapy also causes 
weight gain (18). Recent developments in insulin analogues and the closed-loop insulin pump (artificial 
pancreas) aim to improve glucose monitoring and reduce hypoglycaemia risk (19, 20). 
1.3.1.4. GLP-1 Modulators 
Recently developed antidiabetic agents target the incretin hormone Glucagon-like peptide 1 (GLP-1) 
(14). The incretin effect, which is associated with higher insulin secretion in response to oral compared 
with intravenous administration of glucose due to the augmentation of insulin release by gut 
hormones such as GLP-1, is impaired during T2DM (14, 21, 22). Dipeptidyl peptidase 4 (DPP4) 
inhibitors (such as sitagliptin) inhibit circulating GLP-1 degradation and prolong the half-life of 
endogenous active GLP-1 (14). DPP4 inhibitors increase insulin secretion but have modest effects in 
lowering HbA1c (14). GLP-1 receptor agonists (such as liraglutide and exenatide) pharmacologically 
mimic the actions of GLP-1, stimulating insulin secretion and normalising glycaemic control (14). GLP-
1 receptor agonists also inhibit glucagon secretion, promote weight loss, delay gastric emptying and 
improve plasma lipid profiles (14). GLP-1 modulators are generally safe and well tolerated, although 
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there is mixed evidence on their association with pancreatitis and GLP-1 receptor agonists have been 
reported to cause nausea (14).  
1.3.1.4. SGLT2 Inhibitors 
Sodium/glucose co-transporter 2 (SGLT2) inhibitors (such as dapagliflozin and canagliflozin) block 
glucose reabsorption in the kidneys, leading to excretion of glucose in urine to reduce plasma glucose 
(14). SGLT2 inhibitors have been reported to be effective glucose-lowering agents that also improve 
insulin sensitivity (14). However, their efficacy is mitigated to some extent by the compensatory 
expression of SGLT1 to increase glucose reabsorption in the kidneys, as well as reported side effects 
associated with reduced blood pressure and urinary tract infections (14).       
 
1.3.2. Appetite regulating drugs for Obesity 
Pharmacological approaches for obesity are only reserved for cases of moderate to severe obesity, 
and there is not an ideal medication so far (12). The most widely used treatment is lifestyle 
intervention, and many appetite regulating drugs only augment better adherence to lifestyle 
interventions (12). 
1.3.2.1. Pancreatic lipase inhibitors 
Pancreatic lipase inhibitors (such as orlistat and cetilistat) reduce dietary lipid absorption in the 
intestines, which reduces circulating free-fatty acids, modulates adipokine release and causes modest 
weight loss (23). Orlistat is most effective when used in combination with a low-calorie diet and 
exercise to promote the weight loss benefits of T2DM (23). 
1.3.2.2. Lorcaserin 
Lorcaserin is a selective small-molecule agonist of the 5-HT or serotonin receptor (5HT2C), which 
suppresses appetite by targeting serotonergic neurotransmission in the hypothalamus (23). Lorcaserin 
preferentially inhibits 5HT2C over its isoform 5HT2B, which has led to the withdrawal of other 
serotonergic inhibitors from clinical use due to its association with cardiovascular disease (23). 
Lorcaserin has been demonstrated to cause effective weight loss by 4.5-10% in two clinical trials and 
was approved for the treatment of obesity by the FDA in 2012 (23–25). Side effects such as headache 
and nausea have been reported (23). 
1.3.2.3. Naltrexone and Bupropion combination treatment 
Naltrexone is an opioid receptor antagonist, whilst bupropion is a dopamine and noradrenaline 
reuptake inhibitor, both of which have been reported to suppress appetite by targeting pro-
opiomelanocortin (POMC) neurons in the hypothalamus (23). Combination treatments of Naltrexone 
9 
 
and Bupropion were shown to be more effective in achieving effective weight loss and appetite 
suppression compared to modest effects achieved by monotherapy regimens or placebo (23). Side 
effects include nausea, vomiting and constipation (23). 
 
1.3.3. Bariatric surgery  
Bariatric surgery is a clinically available option for the treatment of severe obesity (clinical criteria vary, 
but often it is only considered if BMI is >40kg/m2 or >35kg/m2 plus comorbidities) (26). There are three 
commonly used surgical procedures in bariatric surgery (26). Laparoscopic gastric banding involves 
placing an inflatable gastric band below the gastro-oesophageal junction, creating a small gastric 
pouch with a narrow stoma (26). Vertical sleeve gastrectomy (VSG) places a staple line across the 
greater curvature of the stomach, reducing the stomach to ~15% of its original size (26). Roux-en-Y 
gastric bypass (RYGB) is a more surgically complex approach that involves transection of the upper 
stomach and dividing the small intestine at the jejunum (26). The first anastomosis is then made 
between the stomach pouch and the distal jejunum (forming the Roux limb), bypassing the stomach 
and duodenum (26). A second anastomosis is made between the remaining stomach, duodenum and 
upper jejunum, and the roux limb (forming the Biliopancreatic limb) (26).  
The Swedish Obese Subjects study was the first prospective clinical study to investigate the long-term 
effects of bariatric surgery (RYGB and gastric banding) in over 2,000 individuals with obesity and T2DM 
(27–30). The study reported significant weight loss by 25% and 14% for RYGB and gastric banding after 
10 years, respectively (27). The study also reported drastically improved glycaemic control (and 
resolution of T2DM), decreased hyperlipidaemia and reduced overall mortality rates (27, 30). The 
Longitudinal Assessment for Bariatric Surgery (LABS) study conducted in the US demonstrated 
significant weight loss associated with RYGB (31.5%) and gastric banding (15.9%) after 3 years in 
addition to similar improvements in risk factors for comorbidities (31). 
The exact mechanisms underlying the effects of bariatric surgery in weight loss and glycaemic control 
are still debateable (32). Weight loss effects in bariatric surgery have been attributed in some studies 
to caloric malabsorption and altered levels of bile acids in the gut and circulation (32). Bariatric surgery 
also affects central control of food intake, since patients often report a loss of appetite following 
bariatric surgery (32, 33). More exaggerated release of the gut hormone Peptide YY (PYY) has been 
reported post-surgery, which acts as an anorexigenic hormone via signalling to the appetite regulating 
centres in the hypothalamus and brainstem (32). Studies in PYY receptor knockout mice  showed 
reduced effects of RYGB on weight loss, demonstrating the potential importance of this peptide in 
controlling food intake (34).  
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Although there is some evidence that the weight-dependent effects underlie improved glycaemic 
control after bariatric surgery, changes in glucose metabolism have been observed immediately after 
surgery in T2DM, suggesting weight-loss independent mechanisms (35). The foregut hypothesis 
suggests that exclusion of the proximal small intestine is associated with reduced circulating levels of 
an “anti-incretin” signal which counters incretin-stimulated insulin secretion (35–37). In support of 
this idea, studies involving duodenal-jejunal bypass surgery in rodents demonstrated normalisation of 
glycaemic control with limited effects on body weight and food intake (36, 37). The hindgut hypothesis 
suggests enhanced delivery of nutrients to the distal GI tract, which causes exaggerated GLP-1 release 
to stimulate insulin secretion, beta-cell function and mass (35, 38, 39). Experiments involving the GLP-
1 receptor antagonist Exendin 9-39 and antibodies against the receptor have demonstrated the roles 
of GLP-1 in glycaemic control after RYGB or VSG (40, 41). Other studies have reported adaptations in 
the alimentary (roux) limb such as tissue hypertrophy, increased glucose utilisation and transcriptomic 
changes (42, 43).   
 
1.4. Metformin in the clinic 
Currently, metformin is the world’s most prescribed drug and is recommended first-line monotherapy 
for T2DM by most clinical guidelines, including the American Diabetes Association (ADA) and European 
Association for the Study of Diabetes (EASD) (44, 45). 
1.4.1. Brief history of metformin  
The history of metformin could be linked to Galega officinialis, a medieval medical herb found in 
Europe which had been used to treat symptoms of diabetes from as early as 1772 (46, 47). Chemical 
analysis of the herb from the mid-1800s found that it was rich in Guanidine, a chemical which was 
later demonstrated to lower blood glucose levels in animals in 1918 (47, 48). The chemical 
development of biguanides was first reported in the 19th Century, which formed the basis of 
metformin (dimethylbiguanide) synthesis by Werner and Bell in 1922 (49). Metformin was first 
reported to lower blood glucose levels in animals in 1929, although it was temporarily ignored along 
with other guanide drugs for over a decade due to the widespread availability of insulin and the 
reported toxicity associated with guanides (47, 50, 51).  
Interest into the glucose lowering effects of metformin was revived in the 1950s when Jean Sterne, a 
clinician from Aron Laboratories in Suresnes, France, further investigated the physiological effects of 
metformin and other biguanides (such as phenformin) in animal studies (47). This led to the first 
breakthrough clinical study demonstrating that metformin reduced blood glucose levels and 
eliminated the need for insulin in patients with maturity onset diabetes in 1957 (47, 52). At the same 
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time, similar clinical studies were also reported for phenformin, which showed greater glucose 
lowering efficacy than other biguanides, resulting in its approval for clinical use (53–55). However, in 
the 1970s, the University Group Diabetes Programme trial in the USA and other clinics in the USA and 
Europe reported lactic acidosis associated with phenformin use, which led to its withdrawal in 1978 
(56–58). Interest into metformin resurfaced in the 1980s due to its better reported safety profile and 
its action as an insulin sensitizer during a time when the concept of insulin resistance was becoming 
central to the understanding of T2DM pathophysiology (47, 59–64). Metformin was reconsidered for 
clinical use by the US food and drug administration (FDA) in 1986, which led to its approval in the US 
in 1994 for the treatment of T2DM (although metformin has been introduced to treat diabetes in the 
UK and Europe from as early as 1958) (47).  
1.4.2. Metformin as a glucose-lowering agent to treat T2DM 
The therapeutic efficacy of metformin as a glucose-lowering agent for the treatment of T2DM was 
best demonstrated in a 1995 clinical trial from DeFronzo et al., involving 289 obese patients with 
uncontrolled T2DM (65). Daily administration of metformin for 29 weeks was reported to lower the 
mean fasting plasma glucose by 2.9mmol/l compared to the placebo group, whilst HbA1c also 
decreased by 1.4% (65). A subsequent clinical study involving 451 patients with T2DM demonstrated 
that the glucose-lowering efficacy of metformin was dose dependent, whereby 500mg metformin 
treatment for 14 weeks resulted in a reduction in HbA1c by 0.6%, whereas 2000mg treatment resulted 
in decrease in HbA1c by 2.0% (66). 
A landmark study investigating the long-term glucose-lowering efficacy of metformin is the UK 
Prospective Diabetes Study (UKPDS), a randomised trial which recruited 1,704 overweight patients 
with T2DM with two primary aims; (1) to investigate the effects of metformin on glucose control and 
(2) to compare the glycaemic efficacy of metformin with sulphonylureas chlorpropamide and 
glibenclamide, and insulin as separate monotherapies (44). The study was conducted over a period of 
10 years (44). The UKPDS trial reported decreased median HbA1c levels (metformin lowered HbA1c 
levels to 7.4% whilst conventional treatment groups achieved 8.0%) as well as reduced risk of diabetic 
complications (44). Compared to insulin and sulphonylureas, metformin was the most effective at 
decreasing other diabetes-related endpoints and incidences of death (44).   
Clinical observations from the A Diabetes Outcome Progression Trial (ADOPT) was reported in 2002, 
which compared the glycaemic efficacy of metformin with glibenclamide and the thiazolidinedione 
rosiglitazone as monotherapies in 4,360 recently diagnosed T2DM patients from 500 centres across 
Europe, Canada and North America (16). After 5 years, 21% of patients in the metformin group 
experienced glycaemic failure (classified as the inability to maintain blood glucose levels below 
12 
 
10mmol/l) compared to 15% and 34% of patients in the rosiglitazone and glibenclamide groups, 
respectively (16). Similarly, patients on metformin maintained intermediate optimal glycaemic control 
(as measured by HbA1c) with a mean duration of 45 months compared to 57 months for rosiglitazone 
and 33 months for glibenclamide, respectively (16). Patients from the metformin group experienced 
intermediate improvement in insulin sensitivity compared to the other treatment groups, but also 
experienced a gradual decline in β-cell function (16). The outcomes from the ADOPT trial 
demonstrated that despite achieving glucose-lowering efficacy compared to insulin secretagogues, 
metformin monotherapy was insufficient to prevent gradual β-cell failure and progression of T2DM 
(16). 
Clinical trials have also demonstrated improved efficacy of metformin in combination therapy with 
other antidiabetic agents for the management of T2DM (Reviewed in (45)). The original study by 
DeFronzo et al., showed that metformin treatment in combination with glibenclamide for 29 weeks 
gave superior glycaemic outcomes (as measured by HbA1c reduction) compared to glibenclamide 
monotherapy and switching back to metformin monotherapy later in the trial did not produce further 
clinical benefit (65). A 16-week trial involving 390 T2DM patients demonstrated that metformin and 
insulin combination therapy also improved glycaemic control and reduced dependence on insulin (67). 
Another randomised controlled trial in 96 patients with poorly controlled T2DM demonstrated that 
metformin and insulin treatment caused the greatest reductions in HbA1c levels after 1 year 
compared to other combination therapies involving insulin and glibenclamide or insulin treatment 
alone (68). A clinical study involving combination of insulin sensitizers metformin and troglitazone for 
T2DM treatment showed additive benefits in glycaemic control in a cohort of 29 T2DM patients, which 
was associated with differences in the drugs’ mechanisms of action (metformin reduced hepatic 
glucose production, whilst troglitazone increased peripheral glucose handling) (69). Recent studies 
have explored combination therapy involving metformin and novel antidiabetic agents such as DPP4 
inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors (70–75).        
1.4.3. Metformin and the prevention of T2DM  
The role of metformin in the prevention of T2DM was explored in two studies: Diabetes Prevention 
Programme (DPP) and Diabetes Prevention Programme Outcome Study (DPPOS) (76–80). The DPP was 
a double-blinded, randomised trial involving 3,234 participants at high risk of developing T2DM, who 
were given metformin or moderate-intensity lifestyle intervention from 1996 to 2001 (78, 79). During 
the 3.2 year follow-up of the trial, daily metformin administration was associated with a 31% reduced 
risk in diabetes incidence and significantly lowered mean HbA1c compared to placebo (79).  Following 
the DPP trial, 88% participants were enrolled in the follow-up DPPOS post-randomisation programme 
involving continued metformin therapy and lifestyle-intervention (76, 77, 80). From the DPPOS study, 
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metformin use was associated with an 18% reduced risk in developing T2DM although glycaemic, 
metabolic and cardiovascular complications were no different from placebo (77). The results from the 
DPP/DPPOS studies show the additional benefit of metformin in reducing the risk of T2DM 
development, in addition to its role in treating patients living with diagnosed T2DM (76, 77, 80).        
1.4.4. Effect of metformin on body weight 
About half of the clinical studies investigating metformin in T2DM reported weight loss after 
treatment whilst there are no studies to date reporting an indication of weight gain associated with 
metformin use (Reviewed in (81)). The ADOPT trial reported that patients from the metformin group 
lost weight over 4 years whereas the other antidiabetic agents (particularly participants on 
Rosaglitazone) were associated with weight gain (82). Other clinical studies demonstrated that 
metformin combination therapy with insulin or sulphonylureas either resulted in significant weight 
loss, or reduced the weight gain effects caused by insulin or sulphonylurea monotherapies (83–86). A 
trial involving magnetic resonance imaging in T2DM subjects showed that metformin use reduced 
visceral fat mass, as opposed to rosiglitazone (87).  
Multiple trials in obese but non-diabetic patients have also investigated the weight-loss effects of 
metformin (81). The Biguanides and Prevention of Risks in Obesity (BIGPRO) study was the first to 
show a trend towards weight loss and metformin treatment in 324 abdominally obese patients (88). 
A trial involving 150 obese women demonstrated that metformin treatment for 6 months displayed 
comparable efficacy in weight loss, BMI and waist circumference compared to other clinically 
approved weight loss drugs sibutramine and orlistat (89). The DPP study involving participants with 
impaired glucose tolerance (but not diagnosed with T2DM) also reported significantly greater weight 
loss and reduced waist circumference in the metformin treated group (particularly those who were 
highly adherent to their medications) compared to placebo (79). The follow up DPPOS study similarly 
reported slightly greater weight loss in the metformin group compared to placebo (~2% vs 0.2%) after 
10 years associated with metformin adherence (76).     
Multiple meta-analyses of numerous clinical trials demonstrated significant weight reduction 
associated with metformin therapy compared to patients on sulphonylurea treatment (which 
increased body weight in every trial), but not in the placebo group (63, 90, 91).  
From the reported clinical studies to date, the weight loss effects of metformin have been modest and 
were not entirely consistent across all of the studies (81). However, metformin is unlike most 
antidiabetic agents in that it does not cause weight gain and has been reported to limit the weight 
gain effects caused by insulin and sulphonylureas when given as combination therapy (83–86). 
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1.4.5. Other clinical effects and applications of metformin  
The effects of metformin in cardiovascular disease (CVD) were demonstrated in the UKPDS study, 
which reported that metformin use significantly reduced the incidence of cardiovascular events in 344 
obese patients (44). Similarly, the DPP study reported that metformin lowered CVD risk factors such 
as lipoprotein fractions, C-reactive protein and tissue plasminogen activator (79, 80). Although long 
term monitoring in the DPPOS study did not reveal differences in CVD risk factors compared to 
placebo, metformin use reduced the presence of coronary artery calcium levels, suggesting reduced 
atherosclerotic plaque formation (77). However, no substantial conclusions on the clinical benefits of 
metformin and cardiovascular disease were reached in a recent meta-analysis based on 4 clinical trials 
which collected data on CVD outcomes, due to the scarcity of data (92).  
Metformin is also clinically approved to treat women with polycystic ovarian syndrome (PCOS), based 
on studies in the 1990s reporting that metformin reduced testosterone levels in about 20-25% of 
women with PCOS and improved metabolic and reproductive abnormalities such as irregular 
menstruation and glucose intolerance (93, 94). The clinical benefit of metformin has been associated 
with improved insulin sensitivity and correction of hyperinsulinaemia, although the exact mechanisms 
are still unclear (93, 94). 
Several clinical studies and meta-analyses have highlighted the benefits of metformin for the 
treatment of gestational diabetes mellitus (GDM) (Reviewed in (95)). The Metformin in Gestational 
Diabetes (MiG) trial, which investigated 751 women with GDM randomised for metformin or insulin 
treatment, showed reduced incidence of severe hypoglycaemia and no safety problems (such as short-
term effects on fetal development) with metformin compared with insulin (96). However, since 
metformin is able to cross the placenta, many of the current concerns are associated with potential 
long-term effects on the child, and long term studies are currently ongoing (95).  
Beyond cardiometabolic and endocrine disorders, the effects of metformin on cancer have also been 
explored (97). Several meta-analyses of case-control and cohort studies have concluded that 
metformin use in diabetic patients was associated with as much as 10-40% reduction in incidence of, 
and mortality from, lung, breast, colon, liver, pancreas, prostate and endometrial cancers (98–108). 
To date, there are 17 reported clinical trials investigating the effects of metformin on cancer-related 
biomarkers (Reviewed in (97)). Several clinical trials involving patients with breast, prostate and 
endometrial cancers reported that oral metformin administration prior to surgery resulted in reduced 
expression of Ki-67 proliferation markers in tumour biopsies (109–114). Metformin treatment for 1 
month has also been reported to decrease the numbers of aberrant crypts in multiple colorectal 
cancer prevention studies (115). From this clinical and epidemiological evidence, several phase III 
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clinical trials are ongoing to provide more robust evidence in assessing the effects of metformin in 
cancer (97).  
1.4.6. Side effects of metformin use 
As previously discussed in section 1.4.1, metformin generally has a better safety profile compared to 
other biguanides (45). The most common side effects associated with oral metformin use are GI 
related, including abdominal discomfort, diarrhoea and nausea (45). A small number of patients have 
severe GI intolerance to metformin, associated with gene variants in metformin transporters (See 
section 1.4.7 below) (45, 116–118). By contrast to phenformin, the risk of metformin use and lactic 
acidosis is extremely rare, with 3-10 per 10,000 reported cases, which could have been attributed to 
reduced kidney clearance of lactate (45). Therefore, severe kidney dysfunction (with a glomerular 
filtration rate of <60 ml min-1) is a contraindication for metformin use, although metformin use is 
permitted in patients with mild or moderate impairment in kidney function (45, 119). Some clinical 
studies (including DPPOS) also report Vitamin B12 malabsorption as a side effect of metformin use in 
10% of patients and higher prevalence of peripheral neuropathy associated with chronic metformin 
use (120, 121).         
1.4.7. Genetic variants and patient responses to metformin 
Genome-wide complex trait analysis (GCTA) showed that as much as 34% of the glycaemic response 
to metformin is determined by heritability, demonstrating a genetic contribution to the individual 
responsiveness to metformin (122). Many studies have sought to identify the associated gene variants, 
which could identify potential mechanisms of metformin action as well as improving stratified 
medicine (Reviewed in (123)).    
Initial genetic investigations into the metformin response were performed by investigating 
associations in candidate genes (123). The DPP trial investigated 40 candidate genes (associated with 
monogenic obesity, diabetes, drug interactions and hormonal regulation) and their interaction with 
metformin response in overweight or obese subjects (see section 1.4.3) (124). The study reported 
interactions in the genes encoding AMPK subunits Prkaa1 and Prkaa2, AMPK regulatory kinase Stk11, 
and AMPK target genes Pgc1a and Hnf4a with the metformin response (124). Moreover, associations 
were also reported in Sulphonylurea responsive genes, including Abcc8 and Kcnj11 with the metformin 
response (124). 
The first genome-wide association study (GWAS) investigating metformin pharmacogenetics was the 
GoDARTs study, which investigated 3,200 metformin-treated diabetic patients using electronic health 
data from hospitals in Scotland (125). The study identified the variant rs11212617 located near the 
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locus encoding ataxia telangiectasia mutated gene (ATM) in chromosome 11, which was associated 
with 0.18% lower haemoglobin-A1c (HbA1c) levels in response to metformin treatment (125). ATM 
encodes a serine/threonine kinase involved in cell cycle control and DNA repair, although the 
investigators showed that ATM regulates AMPK activation in hepatocytes (yet the specificity of the 
ATM inhibitor involved has been disputed) (125, 126). Other studies replicated the association 
between ATM and the metformin response, although a separate cohort of 2,994 patients from the 
DPP study did not replicate any association, which could be due to differences in the ethnicity and 
genetic background of patients (127, 128).       
In a meta-analysis involving 10,557 participants of European descent, statistically significant 
associations were found in a variant rs8192675 identified within the Slc2a2 locus and 0.17% greater 
reductions in HbA1c associated with metformin treatment (129). Slc2a2 encodes the glucose 
transporter GLUT2, which is expressed in the liver and the gastrointestinal tract associated with 
hepatic glucose output and glucose absorption (129). Expression studies also demonstrated that the 
same variant was associated with levels of GLUT2 expression in liver samples, suggesting the potential 
importance of GLUT2 in glycaemic control associated with metformin (129). A recent study in a smaller 
cohort of 508 patients with recent onset T2DM in the German Diabetes Study (GDS) group also 
confirmed interactions with the GLUT2 variant and the metformin response (130). 
Perhaps the most studied genetic association of metformin treatment is Slc22a1, a highly polymorphic 
gene which encodes the metformin transporter OCT1 (131–133). Initial candidate pharmacogenetic 
studies by Shu et al., demonstrated that healthy volunteers with reduced-function variants in Slc22a1, 
namely R61C, G465R, G401S and M420del displayed significantly higher blood glucose levels following 
an oral glucose tolerance test compared to individuals without these variants during metformin 
treatment (131). These results were confirmed in a prospective South Danish Diabetes study showing 
that patients with more of these four variants achieved lower HbA1c reductions following metformin 
treatment, whereas radioisotope labelling in human liver samples showed that carriers of these 
variants had reduced tissue accumulation of metformin (134, 135). The Rotterdam study identified 
rs622342 A>C polymorphism in Slc22a1 associated with glycaemic response to metformin, although 
this finding was inconsistent with other studies in different cohorts (136). However, the GoDARTs 
study failed to identify any associations between two of the reduced-function Slc22a1 polymorphisms 
and glycaemic response to metformin in their cohort (137). The GoDARTs study did identify 
associations with at least two reduced function variants of Slc22a1 with gastrointestinal (GI) 
intolerance to metformin in 251 metformin-intolerant T2DM patients, suggesting the importance of 
OCT1 in metformin pharmacokinetics (see below section 1.6.2) (117).    
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Multiple studies have identified genetic associations between the variant rs2289669 in the intron of 
Slc47a1 (which encodes the metformin transporter MATE1) and improved efficacy of metformin in 
achieving HbA1c reduction (124, 138–140). A recent IMI DIRECT trial involving 286 severely 
metformin-intolerant patients reported that, in addition to a variant found in OCT1, another variant 
rs3889348 in the Slc29a4 was associated with reduced expression of the plasma membrane 
monoamine transporter (PMAT) in intestinal tissues and higher odds ratio of GI intolerance (118). 
Another GWAS study from 10,251 T2DM patients with a history of cardiovascular disease in the 
ACCORD trial identified common variants in the Cpa6 (encoding the carboxypeptidase A6) and Prpf31 
(encoding pre-mRNA processing factor 31) that were associated with better and worse glycaemic 
responses to metformin, respectively (141).  
The genetic studies highlight novel genes associated with metformin response and gastrointestinal 
intolerance and provide insights into the mechanisms of metformin action. However, the variants so 
far identified have a very minimal effect of the metformin response (most variants contribute to <1% 
of the difference of metformin treatment in the glycaemic response), suggesting that there are still 
yet to be identified variants that warrant investigation (123).  
 
1.5. Background of the digestive system and the gastrointestinal tract  
The digestive system includes the GI tract and its accessory organs, the liver, gallbladder and the 
pancreas. The GI tract is the centre of nutrient absorption and an important site of exocrine and 
endocrine secretions. A physical barrier guarding against ingested toxic chemicals and microbial and 
viral insults, the GI tract also hosts a biodiverse microbiota which regulates local gut interactions and 
is implicated in inter-organ physiology and disease (142). The GI tract is also richly innervated by the 
enteric nervous system and communicates with the central nervous system to regulate appetite (143). 
Within the GI tract, the stomach is important in mechanical and chemical digestion of foodstuffs, 
whilst regulation of stomach emptying controls the rates of nutrient absorption in the small intestine. 
The three parts of the small intestine (the duodenum, jejunum and ileum) are the primary sites of 
nutrient absorption. The different parts of the small intestine differ considerably in cell composition, 
protein expression and gastrointestinal functions (including nutrient transport and hormone 
secretion) (144). The colon is divided into the proximal colon, distal colon and the rectum. The colon 
is involved in the reabsorption of water and electrolytes and storing undigested material before 
excretion as faeces.  
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Within the accessory organs of the digestive system, the liver produces bile, which is then transported 
into the gallbladder for storage before release into the small intestinal lumen. The liver is also essential 
in regulating blood glucose levels by regulating glucose storage and endogenous glucose production. 
Bile acids are involved in the emulsification of fats and aids in absorption. The exocrine pancreas 
secretes digestive enzymes and bicarbonates to neutralise the acidity of the luminal contents, whilst 
the endocrine pancreas secretes insulin and glucagon necessary for systemic glycaemic control.      
1.5.1. The small intestinal epithelial architecture 
The intestinal epithelia are the second largest tissue in the body, consisting a complex monolayer of 
stem cells and different cell types involved in absorption of nutrients and secretion of mucus, 
hormones and immune mediators (142). The epithelial layer is highly dynamic and undergoes a cycle 
of renewal every 3-5 days in the small intestine (142). Small intestinal tissue homeostasis is highly 
organised into crypt-villus structures (see Figure 1.1) (142). At the base of the crypts, invaginates in 
the intestinal lumen, reside adult stem cells - pluripotent cells which self-renew and are responsible 
for providing the sources of new intestinal epithelial cells (142, 145–148). Also located in the stem cell 
niche are Paneth cells, which secrete antimicrobial chemicals such as defensins and lysozymes to 
protect the stem cell pool and provide nutrients and paracrine factors necessary for stem cell 
maintenance (142, 149, 150). 
Continuously dividing intestinal stem cells give rise to progenitors called transit amplifying cells, which 
rapidly proliferate but are committed to a particularly lineage (146, 151, 152). Once the cells leave the 
transit amplifying zone and begin to mature by migrating towards the villus, the cells differentiate into 
one of six intestinal epithelial cell types with specialised functions (142). The majority of cells are 
absorptive cells known as enterocytes, which maximise the surface area for transport and absorption 
of digested nutrients (142, 153, 154). M cells resides in Peyer’s patches which sense and transport 
antigens from the lumen to lymphoid cells (155, 156). Less than 5% of differentiated cells are secretory 
cells. These include goblet cells, which secrete mucus coating the epithelial layer (157), different 
subtypes of enteroendocrine cells (158–160), tuft cells, involved in host immunity and helminth 




Figure 1.1. The architectural organisation of the gastrointestinal tract. Above: the cellular 
components of the intestinal epithelium, including the crypt and villus domains. The different cell 
types in the intestinal epithelium are labelled (M cells are not included in the diagram). Picture of an 
intestinal organoid is shown on the right. Below: the expression of different transporters involved in 





Maintenance of the crypt-villus axis requires coordinated growth factor gradients, predominantly 
WNT and BMP (142). WNT factors are secreted by Paneth cells and mesenchymal cells at the base of 
the crypt (telocytes) that maintain the intestinal stem cell pool, with less WNT signalling further from 
the base of the crypts (149, 163–169). At the crypt-villus junction, BMP growth factors are abundant, 
which induce epithelial cell maturation, whilst BMP inhibitors are released by mesenchymal cells at 
the crypts, to establish a BMP gradient (170–173). EGF and TGF-α ligands are secreted by Paneth cells 
to maintain an intestinal stem cell pool at the base of the crypts (149). Notch signalling regulates the 
fate of neighbouring progenitor cells towards either absorptive or secretory lineages via lateral 
inhibition (151, 157, 160).  
1.5.2. Enterocytes and nutrient absorption 
Intestinal enterocytes are absorptive cells which encompass >90% of epithelial cells in the GI tract. On 
the apical side, enterocytes contain microvilli facing the lumen of the intestine whilst the basolateral 
side faces the blood supply and neurons innervating the GI tract (174). Enterocytes express different 
transporters according to their apical-basal polarity to enable sensing and transport directionality of 
digested nutrients from the lumen into the blood (see Figure 1.1) (174). Enterocytes predominantly 
transport digested carbohydrates as free glucose and fructose (174). The cells express the sodium-
dependent glucose co-transporter SGLT1 on the apical side which actively imports glucose using the 
inward sodium gradient, and the facilitative glucose transporter GLUT2 on the basolateral side for 
passive transport of glucose out into the bloodstream (174). Fructose transport is mediated by GLUT5 
mediated uptake on the apical side, and exit via GLUT2 (174). Proteins are either transported as di- or 
tri-peptides via the H+ dependent peptide transporter PEPT1 which are then hydrolysed into amino 
acids in the cytosol, or as free amino acids via apical amino acid transporters, and subsequently 
extruded from the cells via basolateral amino acid transporters (174). Free fatty acid uptake is 
mediated by passive diffusion as micelles or transported through cluster of differentiation 36 (CD36) 
or fatty acid transport protein 4 (FATP4) (174). Short chain fatty acids are transported in colonocytes 
via monocarboxylate transporters such as SCMT1 or MCT1-4 (174).    
1.5.3. Intestinal nutrient metabolism 
The small intestine is a highly metabolically active organ that sustains the energy demanding processes 
of nutrient digestion and absorption (175, 176). Initial studies using intestinal perfusion models have 
identified glucose and glutamine as the main sources of fuel utilised by intestinal cells (177–185). A 
recent study by Jang et al. measured arterial and venous differences in metabolite concentrations 
from 11 different organs in pigs to study organ-specific metabolite production and consumption, and 
reported that the intestines have the greatest absolute uptake flux of glucose and amino acids 
compared to other organs (186). Other studies have demonstrated the heterogeneity of nutrient 
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metabolism amongst different cell types, reflecting intestinal stem cell renewal and cell differentiation 
along the crypt-villus axis (150, 187–189).  
1.5.4. The GI tract as an endocrine organ 
The intestinal epithelium contains enteroendocrine cells (EECs), which are responsible for the release 
of gut hormones into the circulation such as GLP-1 and PYY (L-cells), GIP (K-cells), Cholecystokinin (I-
cells), Motilin (M-cells), Secretin (S-cells), Ghrelin (A-cells) or Serotonin (enterochromaffin cells) (see 
Figure 1.1) (190). The expression of the gut hormones overlaps between EECs and different EECs are 
localised with different frequencies along the GI tract (190). Two clinically relevant gut hormones are 
GLP-1 and GIP, which are responsible for the incretin effect and potentiate postrandial insulin 
secretion (190). Some gut hormones (such as PYY, Ghrelin and GLP-1) regulate food intake and 
appetite via receptor signalling in the hypothalamus and brainstem whilst others (such as CCK, 
Secretin and Motilin) play major roles in the regulation of GI secretion and motility (190).     
1.5.5. Intestinal organoids 
Breakthrough studies by Sato et al., Ootani et al., and Spence et al., demonstrated that intestinal stem 
cells are capable of growing into purely epithelial structures representing “mini-guts” in a three 
dimensional in vitro environment (see Figure 1.1) (148, 165, 191). These intestinal organoids are 
capable of self-renewal and form a morphological hierarchy of differentiated cells with crypt and villus 
domains resembling the intestinal epithelium in vivo  (148, 165, 191). The intestinal organoid cultures 
could be grown from isolated primary intestinal crypts from the stomach, small intestine and colon, 
or even from a single intestinal stem cell expressing the biomarker Lgr5 (148, 165, 191). Similar to a 
cell line, intestinal organoids could also be passaged and subjected to cryogenic freezing without any 
loss in viability (148). Furthermore, gene modifications of intestinal organoids have previously been 
reported to generate transgenic organoids expressing fluorescent proteins (192, 193) , or editing of a 
mutant gene (194).  Other studies have reported that the transcriptomic signatures of single cells 
isolated from intestinal organoids faithfully reproduce intestinal cells in vivo (144). Intestinal 
organoids have been used to study various physiological processes such as stem cell biology, 
enteroendocrine cell function and microbiome and immunity interactions, as well as disease 
modelling and drug screening approaches (148, 149, 195–200). Thus, the development of intestinal 




1.6. Mechanisms of metformin action in the liver and GI tract 
1.6.1 Cellular mechanisms of action 
Many of the cellular effects of metformin have focussed on mitochondria function, since metformin 
accumulates at high concentrations in the mitochondria compared to other cellular compartments 
(201). Previous studies reported that high concentrations of metformin inhibit complex I (NADH 
dehydrogenase) of the mitochondrial electron transport chain and thereby impair mitochondrial 
respiration (see Figure 1.2) (201–204). Consequent to inhibiting mitochondrial respiration, metformin 
has been reported to reduce flux of TCA cycle intermediates responsible for oxidative metabolism 
(205, 206), increasing lactate production from glycolysis (59, 64, 207, 208) and indirectly activating 
AMPK through increased intracellular AMP levels (see Figure 1.2) (209). Activation of AMPK has also 
been considered a central aspect of metformin action based on studies in primary hepatocytes (210–
214). AMPK regulates cellular processes through phosphorylation, but also regulates the 
transcriptome through the regulation of CREB co-transcriptional activators, CREB-binding protein 
(CBP), CRTC2 and SHP, which inhibit the ability of CREB to regulate gene expression (210, 215–217). 
AMPK activation occurs downstream of the serine/threonine kinase LKB-1, which phosphorylates the 
α-subunit of AMPK (218). However, metformin also mediates its effects through AMPK-independent 
mechanisms (219). Experiments by Foretz et al., reported that mice with liver-specific knockout of 
AMPK showed normal glycaemic control compared to wild-type controls (220). Other studies have 
highlighted the importance of inhibiting cAMP/PKA, mTORC1 and PPAR-α signalling pathways 
downstream of metformin action (221–224).  
1.6.2 Liver metabolism  
Considering the important effects of the liver as an insulin-sensitive, metabolically important organ, 
and that metformin has been reported to be an insulin sensitizer, many of the early studies into the 
metabolic effects of metformin action were focused on liver function (213). A key metabolic function 
of the liver is endogenous glucose production to regulate blood glucose levels (Figure 1.2). Numerous 
animal and human studies have since established that metformin inhibits endogenous glucose 
production to achieve its glucose lowering effects, although the exact mechanisms are unclear (220, 
225–227). However, some of the recent studies challenge this mechanism to show that metformin 
increases endogenous glucose production in HFD-fed mouse models and in patients with recent onset 
type-2 diabetes (207, 228).  
Metformin has also been associated with suppressing lipid biosynthesis and increasing fatty acid 









protective mechanisms of metformin against Non-alcoholic fatty liver disease (NAFLD) and improving 
insulin sensitivity during diet-induced obesity (231–233). These results were based on studies in liver-
specific constitutive AMPK active mice (231, 232) and in mouse models with loss-of-function 
mutations in fatty acid metabolism genes Acetyl-CoA carboxylase genes Acc1 and Acc2 (downstream 
targets of AMPK activation) (233). 
1.6.3 Intestinal glucose handling and lactate production 
There is also evidence that metformin directly regulates intestinal glucose handling (Figure 1.2). 
Several early studies demonstrated that administering biguanides or metformin in the intestinal 
lumen ex vivo or orally in vivo decreased intestinal absorption of glucose in isolated rat intestine 
models and the rate of glucose appearance in the blood, respectively (234, 235). A recent study using 
position emission tomography-computed tomography (PET/CT) scan imaging following orally 
administered fluoro-2-deoxy-2-D-glucose F-2DG demonstrated that oral metformin administration 
delayed intestinal glucose transit in HFD-fed mice (236). However, the underlying mechanisms and 
the glucose transporters involved, and whether metformin affects glucose absorption and intestinal 
glucose transit in humans have yet to be determined. 
Conversely, effects of metformin on intestinal uptake of glucose from the blood have also been 
reported in mouse models and patients with T2DM (237–239). Early experiments in rats demonstrated 
that intrajejunal administration of metformin increased accumulation of 2-deoxyglucose (2-DG) in 
intestinal tissues and increased the rate of plasma glucose disappearance when 2-DG introduced 
intravenously (239). Studies from PET/CT scans showed that the intravenously injected non-metabolic 
glucose tracer 18Fluoro-2DG selectively accumulates in the gastrointestinal tract in metformin users 
(237, 238). Increased uptake of the glucose tracer in the colon was associated with lower fasting 
plasma glucose levels in T2DM patients (237).  
Several studies performed in rodents and in human intestinal tissues demonstrated that metformin 
increased intestinal glucose metabolism into lactate, which was then released into the serosa fluid or 
splanchnic bed (64, 116, 207, 239–242). Since oral metformin use has been associated with increased 
lactate levels in the intestinal wall and the plasma, the gastrointestinal tract could be a major site of 
lactate production in the plasma during metformin therapy (64, 207, 240). Whether lactate production 
by the intestine is a cause for the side effects of lactic acidosis and gastrointestinal intolerance 




1.6.4 The microbiome  
The role of the microbiome is increasingly gaining attention, due to the important proposed roles of 
the microbiome in regulating intestinal function, metabolism and the gut-brain axis. Large-scale 
metagenome-wide studies have reported dysbiosis (dysregulation of the microbiome) in patients with 
obesity and T2DM (243–245). Metformin altered the biodiversity of the microbiome in mouse models 
and human studies, partially reversing the dysbiosis in patients with T2DM and obesity (Figure 1.2) 
(245–248). Analysis of 784 metagenomes from Swedish, Chinese and Danish cohorts demonstrated 
that metformin restored the abundance of Escherichia and butyrate producing bacterial strains and 
decreased the abundance of Intestinibacter strains in T2DM patients with dysbisosis (247). Faecal 
microbiota transplant experiments from metformin treated donors into obese mice resulted in 
improved glucose tolerance (246). Another metagenome-wide study in Columbian participants 
reported that metformin generally decreased the biodiversity of the microbiome and increased the 
composition of Akkermansia Muciniphila, a bacterial strain which increases mucus-secreting goblet 
cells (248). Increasing A.Muciniphila populations in HFD-fed mice and obese human subjects was 
associated with improved glucose tolerance, weight loss and reduced inflammatory markers (249, 
250). Metformin also increased the intestinal abundance of Lactobacillus in HFD-fed mice, associated 
with restoration of glucose sensing in intestinal cells (251).   
1.6.5. Bile acid homeostasis  
Bile acids are produced from cholesterol in the liver and released from the gallbladder into the 
intestinal lumen, to facilitate the absorption of lipids (252). Bile acids are then reabsorbed into the 
circulation through enterocytes in the jejunum and ileum (252). Metformin has been reported to 
stimulate bile acid pools in the small intestine through inhibiting active absorption of bile acids into 
the bloodstream (Figure 1.2) (253–256). Mechanistically, metformin, through the activation of AMPK 
signalling, suppresses the activation of the farnesoid receptor FXR, a bile acid receptor involved in 
regulating bile acid production and reabsorption in the ileum (257). Metformin treatment has also 
been associated with decreased serum FGF19 (human homologue of FGF15) levels in type 2 diabetes 
patients, a hormone expressed in the small intestine (particularly the ileum) which functions to inhibit 
bile acid production in the liver and promote gallbladder filling (258–260). A recent study from Sun et 
al., demonstrated that metformin use was associated with reduced abundance of the bacteria 
Bacteroides Fragilis in Chinese patients with early onset T2DM and poor glucose tolerance in mice 
(260). Reduced B. Fragilis composition increased the secretion of the bile acid salt 
glycoursodeoxycholic acid (GUDCA), which inhibited FXR signalling and FGF19 secretion to regulate 
bile acid homeostasis (260).  
26 
 
Increasing bile acids in the intestine could be a mechanism by which metformin reduces circulating 
cholesterol levels in the long term (as cholesterol is utilised for bile acid biosynthesis in the liver) (254, 
256). FXR activation by bile acids was associated with improved insulin sensitivity (260). Furthermore, 
bile acids retained in the intestines could regulate osmotic fluid flow and may contribute to diarrhoea 
in patients with metformin intolerance (256). 
1.6.6. GLP-1 and incretin hormones  
GLP-1, an incretin hormone produced from the preproglucagon gene by enteroendocrine L cells 
located predominantly in the ileum and colon, is associated with increased insulin secretion, 
decreased glucagon secretion and appetite suppression, resulting in lower plasma glucose levels (261). 
Numerous clinical studies showed that oral metformin administration increased circulating GLP-1 
levels in obese non-diabetic subjects (262) and in T2DM patients (73, 263–267). A recent clinical trial 
demonstrated that co-application of a GLP-1 receptor antagonist Exendin 9-39 reduced the beneficial 
effects of metformin on glucose tolerance in patients with T2DM, demonstrating a contribution of 
GLP-1 in the glucose lowering effects of metformin (263). Metformin modestly increased circulating 
PYY levels but did not increase circulating levels of GIP in one study (264).    
The mechanisms underlying metformin-elicited elevations in circulating GLP-1 levels are elusive. 
Numerous mouse and human studies have demonstrated that metformin reduces DPP4 activity, 
thereby increasing the half-life of active GLP-1 in the circulation by slowing its degradation (262, 265, 
266, 268–271). Other studies demonstrated that metformin directly stimulates GLP-1 secretion. 
Experiments in mice demonstrated that metformin increased the expression of proglucagon gene and 
GLP-1 protein levels in the intestines, as well as increasing GLP-1 secretion in intestinal cultures (263, 
272). However, there is no consensus regarding the precise secretion mechanisms targeted by 
metformin. Mechanisms such as insulin and WNT signalling (273), muscarinic receptors (274) and 
AMPK signalling (263) have been identified. Metformin has also been demonstrated to indirectly 
increase GLP-1 secretion through increasing bile acids, which activate the receptor TGR5 to stimulate 
GLP-1 secretion (267, 275).   
1.6.7. New metabolic hormones- GDF-15 and FGF21  
GDF-15 (Growth differentiation factor 15) has been identified as the top serum biomarker associated 
with metformin use in patients with Type 2 Diabetes (Figure 1.2) (276, 277). GDF-15 is a stress 
response cytokine and a distant member of the transforming growth factor β (TGF-β) superfamily of 
growth factors (278). Although almost every tissue type is capable of secreting GDF-15 in response to 
cellular stressors, under physiological conditions GDF-15 expression is only limited to the lung, liver, 
kidney, intestines, adipose tissues, and is produced in large amounts by placental trophoblasts (279–
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287). Circulating serum GDF-15 concentrations are relatively high in healthy individuals (288) but are 
especially elevated with age, pregnancy, recent surgery, mitochondrial disease and metabolic diseases 
such as cachexia, obesity and T2DM (reviewed in 12, 13). Various studies using transgenic knockout or 
overexpression studies in mice have demonstrated the importance of GDF-15 as an anorexigenic 
hormone (291–294). Recent studies have identified the receptor for GDF-15 called GFRAL, expressed 
in the area postrema and Nucleus Tractus Solitarii (NTS) located in the brainstem, whose functions 
include the control of taste aversion (295, 296).  
Metformin has also been reported to elevate circulating levels of FGF21 in rodents and human subjects 
and elicit FGF21 expression in hepatocytes (Figure 1.2) (297, 298). FGF21 is a hormone primarily 
released by the liver in response to low amino acid levels and high levels of carbohydrates (299–301). 
Initially identified from a phenotypic screening of glucose uptake in adipocytes in an insulin-
independent manner, FGF21 was later reported to greatly enhance insulin sensitivity in vivo via 
signalling in adipose tissues (302, 303). Exogenous FGF21 administration has also been reported to 
suppress sweet taste preference and sugar intake, and decrease activation of central reward pathways 
(301, 304, 305). Other studies reported that administration of FGF21 or its analogues reduced body 
weight and food intake in non-human primates and humans (304, 306–308). 
1.6.8. The gut-brain axis  
A recent study demonstrates that oral metformin increases the activity of AMPK in the duodenum, 
which activates the gut-brain axis to limit hepatic glucose production (212). In the proposed 
mechanism, metformin stimulates GLP-1 signalling in afferent nerve terminals, which relays the signal 
to NMDA receptors in the NTS (Figure 1.2). This in turn signals the liver to limit endogenous glucose 
production via hepatic vagus efferent nerves (212). Interference in any part of the pathway, either via 
GLP-1 receptor antagonists, NDMA receptor inhibitors, or hepatic vagotomy, limited the effects of 
metformin on endogenous glucose production (212). Metformin is reported to stimulate 5-HT 
secretion from enterochromaffin cells in human duodenal cultures (309). It remains to be determined 
whether metformin elevates circulating 5-HT levels in vivo, which could otherwise influence nausea 
and vomiting centres through 5-HT3 receptors (310).  
 
1.7. Metformin pharmacokinetics, bioavailability and biodistribution  
Metformin is administered orally as a hydrochloride salt, which exists as a hydrophilic cation in 
solution at physiological pH, limiting its diffusional passage through lipid membranes (311). Metformin 
is mostly absorbed in the small intestine (rarely in the stomach or the colon), with a bioavailability of 
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50-60%. In the circulation, metformin remains unbound to plasma proteins, and is not metabolised 
(311). Most of the plasma metformin is cleared in the kidney and excreted in urine (311). 
1.6.1 Metformin tissue biodistribution 
Studies by Wilcock and Bailey investigated the biodistribution of orally administered metformin in 
various tissues in wild-type and streptozotocin (STZ)-induced diabetic mice over a period of 24 hours 
(312). Following a single dose, 14C-metformin accumulated at the highest concentrations in the 
proximal jejunum (147-2297µmol/kg), jejunal ileal junction (419-1173µmol/kg) and the distal ileum 
(276-3355 µmol/kg) of wild-type mice within the first four hours following administration (312). After 
the small intestine, the kidneys also accumulated metformin at high concentrations (121-428 
µmol/kg), whilst similar concentrations were reported in the colon (160-350 µmol/kg) (312). The liver 
accumulated metformin at lower concentrations (37-182 µmol/kg) whilst metformin accumulation 
was modest in other tissues such as the white adipose tissue, skeletal muscle, heart and the brain 
(312). Plasma levels of metformin did not reach beyond 50 µmol/kg when sampled from the hepatic 
portal vein or inferior vena cava (312). Similar metformin biodistribution was also reported in STZ-
induced diabetic mice (312). Studies involving whole-body PET scan imaging of 11C-metformin 
biodistribution in human subjects reported similar findings, in which oral administered metformin 
accumulated predominantly in the small intestine, liver and kidneys (313). 
1.6.2 Intestinal metformin transporters 
Since metformin is unable to freely diffuse through the plasma membrane, metformin transporters 
are required for intestinal metformin absorption (116). Various metformin transporters have been 
identified, which include the organic cation transporter (OCT) family, plasma membrane monoamine 
transporter (PMAT), serotonin transporter (SERT), choline transporters (CHT) and multi-drug extrusion 
protein (MATE) (314). Pharmacological and knock-down experiments in Caco-2 cells demonstrated 
that multiple metformin transporters, OCT1, PMAT, SERT and CHT are localised in the apical 
membrane responsible for metformin uptake, although CHT expression was not found in human 
intestinal tissues in other studies (314). As discussed in section 1.4, pharmacogenetic studies have 
shown that gene variants in metformin transporters OCT1 and PMAT were associated with GI 
intolerance of metformin, supporting the important roles of these transporters in metformin 
transport in the gut (117, 118).  Studies of transport kinetics showed that whilst metformin was 
efficiently transported into cells from the apical side, this was more limited from the basolateral side 
of enterocytes, suggesting asymmetrical membrane localisation of metformin transporters (315). This 
mechanism might explain the observations from biodistribution studies that metformin accumulates 
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at high concentrations in the small intestine relative to the circulation, as it is readily absorbed from 
the lumen but not readily released into the bloodstream (312). 
 
1.8. The importance of the GI tract in metformin action  
In addition to the evidence for metformin accumulation in the intestines, other studies have altered 
the pharmacodynamics and pharmacokinetics of metformin to demonstrate that the GI tract is an 
important site of metformin action. 
1.7.1 Routes of metformin administration 
Pharmacokinetic studies attempted to investigate the primary site of metformin action in its glucose-
lowering response (311, 316). Stepensky et al., assessed the effects  of metformin administration in 
STZ-induced diabetic rats via different routes; intraduodenal bolus or infusions (administering 
metformin into the lumen of the GI tract), hepatic-portal infusion (administering metformin into the 
hepatic portal vein) and intravenous infusion (316). Although metformin reached similar plasma 
concentrations with each route of administration, metformin administration via the intraduodenal 
route resulted in the most potent glucose-lowering effects, seconded by hepatic-portal infusion, 
whereas intravenous administration exhibited minimal effects (316). Similarly, intravenous metformin 
injections in non-diabetic subjects did not significantly affect fasting plasma glucose, insulin, C-peptide 
or glucagon levels (317) and intravenous metformin injection in T2DM patients did not affect glucose 
disposal or endogenous glucose production (318). These studies suggest that metformin 
administration from the lumen of the intestine is more efficacious compared to administration directly 
into the circulation.  
1.7.1 Delayed release metformin formulations 
A recent phase I clinical study compared the effects of immediate release metformin (metformin-IR) 
and an extended release formulation of metformin (metformin-XR, a variant formulation coated with 
a polymer matrix which slows the release of metformin in the gut to improve GI tolerance but having 
similar bioavailability and efficacy) to a delayed release metformin (metformin-DR) formulation in 
healthy subjects (319). The metformin-DR formulation includes metformin encased in an enteric coat, 
which delays the dissolution of metformin until it reaches the ileum at a pH of 6.5, thus greatly 
delaying metformin absorption and decreasing plasma bioavailability by 50% compared to other 
metformin formulations (319). In these cohorts, daily oral administration of metformin-DR for a period 
of 12 weeks enhanced glycaemic control (measured fasting plasma glucose levels and baseline HbA1c) 
with 40% improved potency compared to extended release metformin formulations (319). The 
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metformin-DR formulation was also well tolerated, and plasma lactate measurements were similar 
compared to the placebo group (319). Similar conclusions were also reached in two separate clinical 
trials comparing metformin-DR and metformin-IR in patients with T2DM, particularly in a larger cohort 






1.9. Aims of the Thesis 
This thesis aims to establish the cellular effects of metformin action in intestinal cells. The results 
would provide further insight into the pharmacological effects of metformin on glycaemic control and 
weight loss.  
The effects of metformin on the signalling and metabolic pathways in the liver have been well 
established. The gastrointestinal tract is an important site of metformin pharmacokinetics and 
accumulates at the highest concentrations, although the cellular mechanisms of how intestinal cells 
respond to metformin treatment are not well established. The first aim of this thesis is to explore 
changes in signalling and metabolic pathways and gene expression profiles using RNA-sequencing in 
2D monolayer cultures from murine intestinal organoids in response to high dose metformin exposure 
(Chapter 3). The results from the RNA-sequencing data would inform on further investigations into 
responsive genes and pathways associated with metformin action. 
Metformin is one of the very few antidiabetic agents that causes modest weight loss as monotherapy 
or reduce the effects of weight-gain of other antidiabetic agents when given in combination. The 
newly discovered anorexigenic hormone GDF-15 has been identified as a key biomarker associated 
with metformin use in T2DM patients. Experiments performed by Tony Coll and Stephen O’Rahilly 
have found that GDF-15 expression is upregulated in the small intestine in HFD fed mice, which may 
be responsible for the observed increased serum levels of GDF-15 in mice and humans (321). Another 
aim of this study is to investigate the signalling pathways associated with metformin stimulated GDF-
15 secretion in intestinal cells (Chapter 4).   
The gastrointestinal tract is an important site of glucose absorption and consumption. Whilst evidence 
suggests that one of the glucose-lowering mechanisms of metformin is to reduce glucose absorption 
and increase glucose disposal in the gastrointestinal tract, the molecular mechanisms involved are not 
well understood. One of the aims of this thesis is to study the effect of metformin on the expression 
of glucose transporters in intestinal tissues from mice fed with HFD and short or long-term oral 
metformin gavage, and in 2D monolayer cultures from intestinal organoids, as well as the mechanisms 
regulating glucose flux in intestinal cells following metformin exposure (Chapter 5). Finally, the 
metabolic effects of metformin on nutrient metabolism are assessed via live-cell imaging of 





Chapter 2: Materials and Methods 
2.1 Materials and Reagents 
REAGENT/RESOURCE SOURCE IDENTIFIER 
Cell culture reagents 
Advanced DMEM-F12 (ADF) medium Life Technologies 12634010 
R-Spondin Trevigen #3710-001-01 
EGF Life Technologies PMG8041 
Noggin Peprotech EC Ltd 250-38-500 
N2 Supplement Life Technologies 17502048 
B27 Supplement Thermo Fisher A1895601 
Penecillin/Streptomycin Sigma P0781-100ml 
L-Glutamine Sigma G7513-100ml 
N-acetylcysteine Sigma A9165-5G 
ROCK inhibitor Y27632 Tocris 1254/10 
DMEM (no glucose, no pyruvate, no 
glutamine) 
Life Technologies A1443001 
Basement matrix extract R&D Technology 3533-010-02 
Matrigel Corning 354234 
TrypLE express reagent Life Technologies 12605010 
FBS Gibco 10270-106 500ml 
PBS Sigma D8537 
Lipofectamine 2000 Invitrogen 11668019 
Optimem Thermo Fisher 31985-062 
EDTA Sigma 03690-100ML 
70μm cell strainer Thermo Fischer 11597522 
Drugs/Reagents 
Glucose Sigma G7528-250G 
Fructose Sigma F0127 
Sodium Pyruvate Sigma S8636-100ml 
Metformin Sigma PHR1084-500MG 
Rotenone Sigma R8875-1G 
Antimycin A Sigma A8674-25mg 
Oligomycin A Sigma R8875-1G 
FCCP Tocris 0453/1 
UK-5099 Sigma PZ0160-5MG 
Az-991 Gift from AstraZeneca 
Β-Nicotinamide Mononucleotide Sigma N3501-25MG 
MitoTEMPO Sigma SML0737-5MG 
MitoPQ Gift from Mike Murphy 
MitoCDNB1 Gift from Mike Murphy 
Duroquinone Sigma D223204-1G 
Doxycycline Hyclate Sigma D9891-5G 
Actinonin Sigma A6671-10MG 
MitoBloCK6 Merck 505759 
ISRIB Gift from David Savage (originally from Sigma) 
GSK 2606414 Gift from David Savage (originally from Sigma) 
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A-92 Axon Medchem 2720 
KC7F2 Sigma SML-1043 
NSC-134754 Sigma 400086 
Phloretin Sigma P7912-25MG 
Phloridzin Sigma 274313-1G 
Forskolin Sigma F6886-10MG 
2-Deoxyglucose Sigma D8375-1G 
Oxamate Sigma O2751-5G 
AR-C155858 Tocris 4960/1 
Syrosingopine Sigma SML1908-5MG 
Aminooxyacetic Acid (AOA) Sigma C13408-1G 
β-chloro-L-alanine (βCLA) Sigma C9033-250MG 
Phenylsuccinic Acid (PhS) Sigma P35200-25G 
iGP1 Merck 530655 
GPi-688 Tocris 3967/10 
Etomoxir  Sigma E1905-5MG 
Plasmids and extraction reagents 
FLII12Pglu-700μδ6 plasmid Addgene #28002 
FLIPQ-TV3.0_2 m plasmid Addgene #63732 
GW1-PercevalHR plasmid Addgene #49082 
GW1-Peredox-mCitrine plasmid Addgene #32386 
PcDNA3.1-Pyronic plasmid Addgene #51308 
Midi Prep plasmid DNA purification kit Qiagen 12643 
Ampicillin Sigma A0166 
RNA extraction and RT-qPCR 
RNeasy Micro Plus kit Qiagen 74034 
RNeasy MinElute Cleanup kit Qiagen 74204 
Bioanalyser RNA Nano kit Agilent Technologies 5067 
Qiazol lysis reagent Qiagen 79306 
Rnase OUT (inhibitor) Thermo Fisher Scientific 10777019 
dNTP (25mM) Thermo Fisher Scientific R1121 
Random Primers Promega C1181 
Superscript II enzyme  Life Technologies 18080093 
TaqMan Universal master mix Thermo Fisher Scientific 4352042 
Taqman Assay Probes 
β-actin Thermo Fisher Scientific Mm02619580_g1 
Slc2a1 (GLUT1) Thermo Fisher Scientific Mm00441480_m1 
Slc2a2 (GLUT2) Thermo Fisher Scientific Mm00446229_m1 
Slc2a5 (GLUT5) Thermo Fisher Scientific Mm00600311_m1 
Slc5a1 (SGLT1) Thermo Fisher Scientific Mm00451203_m1 
Ddit3 (CHOP) Thermo Fisher Scientific Mm01135937_g1 
Seahorse and Secretion reagents 
Seahorse XF24 FluxPaks Agilent Technologies 100850-001 
Seahorse XF base medium without Phenol red Agilent Technologies 103335-100 
GDF-15 assay kit R&D Systems MGD-150 
Lactate assay kit Siemens Healthcare DF-16 
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LDH assay kit Siemens Healthcare DF-54 
Alanine transaminase assay kit Siemens Healthcare DF-143 




2.2 Media and Buffer components 
Saline buffer for imaging experiments: 138mM NaCl, 4.5mM KCl, 4.2mM NaHCO3, 1.2mM NaH2PO4, 
2.6mM CaCl2, 1.2mM MgCl2, 10mM HEPES. pH adjusted to 7.4 with 1M NaOH. 
 
Saline buffer for imaging experiments using Oxamate:  
(Buffer 1: no oxamate) 38mM NaCl, 100mM Mannitol, 4.5mM KCl, 4.2mM NaHCO3, 1.2mM NaH2PO4, 
2.6mM CaCl2, 1.2mM MgCl2, 10mM HEPES. pH adjusted to 7.4 with 1M NaOH. 
(Buffer 2: with oxamate) 38mM NaCl, 50mM Na-Oxamate, 4.5mM KCl, 4.2mM NaHCO3, 1.2mM 
NaH2PO4, 2.6mM CaCl2, 1.2mM MgCl2, 10mM HEPES. pH adjusted to 7.4 with 1M NaOH. 
Lysis buffer: 0.25g deoxycholic acid, 0.5ml of Igepal CA-630, 2.5ml of 1M Tris-HCL, 1.5ml 5M NaCl, 1 
tablet of complete EDTA-free protease inhibitor cocktail, made up to 50ml with water. 
EGF, Noggin, R-Spondin (ENR) media: 50ng/ml murine EGF, 100ng/ml murine noggin, 1µg/ml human 
RSpondin-1, 1% penicillin/streptomycin, 2mM L-glutamine, N2 supplement (1X), B27 supplement (2X), 
1µM N-acetyl-L-cysteine and 10µM Y-27632 ROCK inhibitor diluted in advanced DMEM/F-12 (ADF). 
Neutralisation media: 10% FBS and 10μM Y27632 in ADF. 
Cryopreservation media: 50% FBS, 10% DMSO and 10μM Y27632 in ADF. 
 
2.3 Intestinal organoid lines 
Most of experiments were performed using three organoid lines generated from: 
1. Wild-type mouse (ROSA26-GCaMP3+/+)  
2. GIP-cre/ROSA26-tdRFP+/+ mouse - transgenic mice expressing the reporter tdRFP in cre 
expressing cells, under the control of the GIP promoter, as described in (322).  
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3. SST-cre/ROSA26-tdRFP+/+ mouse -  transgenic mice expressing the reporter tdRFP in cre 
expressing cells, under the control of the SST promoter, as described previously (323). Organoids 
were initially established by Lawrence Billing. 
Note the presence of RFP fluorophore in GIP and SST positive cells does not affect imaging experiments 
as all of the sensors used were excited at <500nm and tdRFP would only be visualised upon excitation 
at ~535nm.  
CHOP knockout mouse used to generate organoids were a gift from Dr. Jane Goodall (University of 
Cambridge), with the line from Jackson Laboratory, Maine, USA (B6.129S(Cg)- Ddit3tm2.1Dron/J, 
Stock No: 005530). B0AT1 knockout (Slc6a19-/-) mouse to generate organoids were a gift from 
Professor Stefan Broer (Australian National University) . SNAT2 knockout (Slc38a2-/-) mouse to 
generate organoids were a gift from Dr. Miguel Constancia (University of Cambridge). 
 
2.4 High fat diet mouse experiments 
The experimental procedures used in HFD mouse experiments were described in (321). All mouse 
studies were performed in accordance with UK Home Office Legislation regulated under the Animals 
(Scientific Procedures) Act 1986 Amendment, Regulations 2012, following ethical review by the 
University of Cambridge Animal Welfare and Ethical Review Body (AWERB). The in vivo mouse studies 
involving metformin administration were performed by Anthony Coll, Irene Cimino and Debra 
Rimmington. 
2.4.1 Acute metformin gavage in HFD-fed wild type mice 
Male C57BL6/J mice were switched from standard chow to 45% HFD for 1 week and then fed with 60% 
HFD for 3 weeks. Metformin (Sigma Aldrich) was reconstituted in water and fed at a single dose of 
600mg/kg (or matched volume of sham) for oral gavage. The mice returned to 60% HFD diet ad 
libitum. After 6 hours, the mice were sacrificed. 
2.4.2 Long-term metformin dosing in HFD-fed wild type mice 
Male C57BL6/J mice were switched from standard chow to 60% HFD 3 days before the single dose of 
metformin treatment. Mice received daily oral gavage of metformin at 300mg/kg for 11 days and 
remained on 60% HFD ab libitum. On day 11, mice were sacrificed by terminal anaesthesia 4 hours 
post gavage.   
2.4.3 Tissue processing 
The small intestine (from the stomach to the ileal-cecal junction) was isolated into three equal length 
segments and intestinal tissues were taken from the middle of each segment (Figure 2.4). These 
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segments were termed proximal, middle and distal small intestine, respectively. The colon was 
isolated from the ileal-cecal junction to the anus, and the colonic tissue was taken from the middle of 
the segment. The tissues were collected in Lysing Matrix D homogenisation tube (MP Biomedicals) on 
dry ice and stored at -80oC before RNA extraction.  
 
  
Figure 2.1. Experimental protocol involving HFD-fed mice. (A) acute single-dose metformin oral 
gavage and (B) 11 day metformin oral gavage. (C) Schematic showing the different samples taken 
from different sections of the proximal, middle and distal small intestine and the colon. 
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2.5 Small intestinal organoid culture 
 
2.5.1 Crypt isolation from mouse intestine 
Intestinal organoid generation protocols were adapted from (148, 324). To establish duodenal 
intestinal organoids, the intestines were isolated from the proximal 3cm of the small intestine distal 
to the stomach. To establish ileal intestinal organoids, the intestines were isolated from the distal 
10cm of the small intestine proximal to the ileal-cecal junction. The intestines were sectioned into 
small segments. Crypt isolation from the small intestine was performed as previously described (324). 
Briefly, to facilitate crypt isolation, intestinal segments were treated with 30mM EDTA in ice cold PBS 
for 5 minutes followed by vigorous shaking in PBS. After 2-3 rounds of EDTA digestion, fractions 
containing the highest yield of dissociated crypts and lowest yield of villi were filtered through a 70μm 
cell strainer (Thermo Fisher) to remove villus contaminants. The purified fractions containing mostly 
crypts were centrifuged at 200 x g for 5 minutes at 23oC and the crypt pellet was resuspended with 
200μl of basement membrane extract (BME, R&D Technology) and pipetted dropwise to form a dome 
on the centre of each well in a 48 well plate. The plates were incubated at 37oC for 30-60 minutes to 
allow Matrigel polymerisation. Intestinal organoids were then supplemented with 250μl per well of 
EGF-Noggin-R-spondin-1 (ENR) media (modified from (148), see section 2.2 for materials) and placed 
in a 37pC humidifying incubator with 5% CO2.  
2.5.2 Maintenance 
After 5-8 days of culture, intestinal organoids were passaged by incubation with TryPLE express 
dissociation reagent (Life Technologies) at 37oC for 2-5 minutes, followed by neutralisation using ADF 
media containing 10% FBS and 10μM Y27632. The suspension was centrifuged at 300g for 5mins, and 
the supernatant removed. The organoid pellets were thoroughly triturated by pipetting using a P200 
pipette tip to facilitate mechanical breakup of organoids before resuspension in matrigel and plated 
dropwise in a 48 well plate in the same manner as seeding crypts (Nunc). Organoids were split 
between 1:2 to 1:8 ratio. Medium was changed twice a week. 
2.5.3 Cryopreservation and thawing  
After 4-7 days of culture, intestinal organoids were collected using ice cold TryPLE reagent 
immediately followed by addition of neutralisation media. The suspension was centrifuged at 300 g 
for 5 minutes at 23oC. After removal of supernatant, the organoids were resuspended in 
Cryopreservation media. The suspended organoids were aliquoted into 1ml cryogenic vials, which 
were placed into a Mr. Frosty cryopreservation container at -80oC overnight. The cryotubes were then 
transferred into liquid N2 filled tanks.   
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To recover frozen organoids, the cryogenic vials were warmed in a 37oC water bath and the contents 
were transferred into a falcon tube containing 5ml neutralisation media. The organoids were pelleted 
at 150 x g for 5 minutes at 23oC and resuspended using BME as described for the crypt isolation 
procedure. 
2.5.4 2D monolayer culture and drug treatments 
The experimental time from the generation of 2D monolayer cultures to the day of experiments 
requires multiple days, a schematic is shown in Figure 2.5. On day 1, intestinal organoids were 
dissociated to generate 2D monolayer cultures. Procedures for establishing intestinal organoids into 
2D monolayers were reproduced from (324). Briefly, wells of 24 well plate, 48 well plate, or 35mm2 
glass bottomed dishes were pre-coated with ADF media containing 2% matrigel (Corning) for 1 hour 
at 37oC. Intestinal organoids cultured in matrigel were collected in ice cold ADF media (for experiments 
requiring >16 organoid wells), and the suspension was centrifuged at 300 g for 5 mins, followed by 
removal of the supernatant. The above step was omitted for experiments requiring <16 wells and 
organoids were directly collected with warm TryPLE reagent. Organoids were treated with TryPLE 
reagent for 2-4 minutes at 37oC, followed by mechanical trituration using a P1000 tip and 
neutralisation. The organoid fragments were pelleted at 300-600xg for 5 minutes. The pellet was 
further mechanically dissociated by repeated trituration by ~50 times to form organoid fragments. 
The pellet was resuspended in ENR media with 10µM Y-27632 before pipetting the suspension onto 
each well/dish for incubation overnight. 
On day 2, after observing that the 2D monolayers were formed, the supernatant was removed from 
the wells/dishes and cultures were treated with ENR containing drug reagents. For metformin pre-
treatments, metformin was formulated at 10mM stock by dissolving into ADF. Metformin was used at 
a working concentration of 1mM (1:10 dilution in ENR). The plates/dishes were incubated for 37oC in 
the humidifying chamber for 24 hours.  
2.5.5 Plasmid amplification and Transfection 
Bacteria containing plasmids purchased from Addgene were plated onto agar plates containing 
Ampicillin and incubated at 37oC overnight. Bacterial colonies were picked using a P200 pipette tip 
and propagated as starter cultures for 4-6 hours at 37oC. 1ml of starter cultures were transferred into 
a conical flask containing 250ml of LB broth and Ampicillin (100µg/ml) and incubated for 16-20 hours 
at 37oC. The propagated cultures were collected into 50ml falcon tubes and spun at 4000 g for 10 
minutes at 4oC. Plasmids were extracted from the bacterial pellets using the Midi Prep plasmid DNA 
purification kit (Qiagen) according to manufacturer’s instructions. Plasmid sequence were verified by 
restriction digest.  
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For imaging studies, on day 2 of experiments (as described for section 2.5.4) and before drug pre-
treatment, the 2D monolayer cultures were transfected with the plasmid of interest. A transfection 
mix was prepared by mixing 2µg of plasmid DNA with 2µl of Lipofectamine 2000 reagent in 100µl of 
Lipofectamine per reaction and incubated for 10 minutes at 23oC. 100µl of transfection mix was added 
carefully onto the centre of the imaging dish and incubated at 37oC for 4-8 hours.   
 
Figure 2.2. Experimental protocol involving seeding of 2D monolayers and treatment of cultures 
with metformin. Images of organoids in 3D form and in 2D monolayers are shown below. 
 
 
2.6 Imaging experiments 
2.6.1 Live cell imaging preparations 
Before imaging, the 2D organoid cultures were washed thoroughly with 138 saline buffer (with no 
glucose, unless indicated). Cells were preincubated at 37oC for 5-15 minutes prior to measurements. 
All treatments were made up in 138 saline buffer. During imaging, treatments were perfused at a rate 
of ~2ml per minute.     
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2.6.2 Perceval imaging of intracellular ATP  
Perceval HR is a genetically encoded fluorescent intracellular ATP and ADP sensor as described in 
(325). The Perceval HR sensor contains an ATP/ADP binding bacterial histidine kinase (GlnK) tagged 
with a circularly permuted Venus fluorescent protein (Figure 2.6A) (325). The Perceval HR sensor is an 
improved variant of the original Perceval sensor identified from mutagenesis of amino acid residues 
around the ATP-binding pocket, with an increased fluorescence response to a wide range of 
intracellular ATP and ADP concentrations. The sensor has two excitation peaks, at ~420nm and 
~500nm to detect ATP and ADP binding to the sensor, as well as an isosbestic point at 455nm (Figure 
2.6B).  The sensor has an emission peak at ~520nm.  
Perceval imaging was performed on 2D monolayer cultures 2 days after seeding in 35mm2 glass 
bottomed dishes and a day following transfection of the plasmid encoding Perceval HR. Imaging was 
performed using an inverted fluorescence microscope (Olympus IX71, Olympus, Southend on Sea, UK) 
with a x40 oil-immersion objective lens. Perceval HR was excited at 490±2nm and 450nm sequentially 
using a 75W xenon arc lamp connected to a monochromator (Cairn Research, Faversham, UK), 
controlled by MetaFluor software (Molecular Devices, Wokingham, UK). Emissions were captured 
using an Orca ER camera (Hamamatsu, Welwyn Garden City, UK), and images were acquired every 10 
seconds. Images were background subtracted using MetaFluor software, and the fluorescence 
intensities were transcribed to an excel spreadsheet. The Perceval fluorescence ratio (FI/F0) was 
calculated by dividing the fluorescence at 490nm by 450nm (Figure 2.6C). Fluorescence at 490nm was 
dictated by changes in intracellular ATP concentrations, whilst the isosbestic point remained constant 
(Figure 2.6C). Data points were smoothened with a sliding average over 60 seconds. Changes in 
Perceval fluorescence were calculated by subtracting the differences from the minimum fluorescence 
response during treatment to the minimum fluorescence 120 seconds prior to treatment (basal). 
Figure 2.3. Measurement of intracellular ATP levels in live cells via Perceval-HR fluorescence. (A) 
Diagram of Perceval HR ATP sensing. (B) Excitation and emission spectra of Perceval HR. (C) Changes 
in Perceval HR fluorescence in response to Saline, 10mM glucose (10G) and glycolysis inhibitor 2-DG, 
as measured by monitoring 450nm and 490nm excitation wavelengths and calculation of the 
Perceval fluorescence ratio (F490nm/F450nm). 
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2.6.3 Peredox imaging of cytosolic NADH/NAD+ ratio 
Peredox is a genetically encoded fluorescent sensor exclusively localised in the cytosol and not in the 
mitochondria, enabling compartmentalised imaging of cytosolic NADH concentrations (as a 
measurement of the cytosolic NADH/NAD+ redox ratio), as described in (326). The Peredox sensor 
contains a bacterial NADH binding protein, T-Rex tagged with a circularly permuted GFP T-Sapphire 
with an excitation peak at ~400nm and emission at ~500nm and increases in fluorescence correlated 
with increased cytosolic NADH (Figure 2.7A-2.7B). The sensor also contains a sensor mCitrine attached 
in tandem to enable ratiometric measurements.      
Peredox imaging was performed on 2D monolayer cultures 2 days after seeding in 35mm2 glass 
bottomed dishes and a day following transfection of the plasmid encoding Peredox, using the same 
equipment and similar to the procedures described for Perceval imaging. The T-Sapphire and mCitrine 
fluorescence of Peredox was sequentially excited at 405±20nm and 480±10nm, respectively and 
images were acquired every 10 seconds. Background subtraction was performed on MetaFluor 
software and fluorescence measurements were transcribed in an excel spreadsheet. Peredox 
fluorescence ratio (FI/F0) was calculated by dividing the fluorescence at 405nm by 480nm (Figure 
2.7C). T-Sapphire fluorescence was increased correlating with cytosolic NADH concentrations, whilst 
the mCitrine fluorescence remained constant throughout the experiment (Figure 2.7C). Data points 
were smoothened with a sliding average over 60 seconds. Changes in Perceval fluorescence were 
calculated by subtracting the differences from the maximal fluorescence response during treatment 











Figure 2.4. Measurement of cytosolic NADH levels in live cells via Peredox 
fluorescence. (A) Diagram of Peredox-mCitrine NADH sensing. (B) Changes in Peredox 
and mCitrine fluorescence in response to LDH inhibitor Oxamate, as measured by 
monitoring fluorescence of the fluorophore when excited at 405nm and 480nm, and 
calculation of the Peredox fluorescence ratio (F405nm/F480nm). 
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2.6.4 Autofluorescence imaging of NAD(P)H and FAD  
The cellular redox states can be estimated by measuring NAD(P)H and FAD autofluorescence as 
described in (327). NAD(P)H has an autofluorescence characteristic of the nicotinamide ring at UV 
range of excitation, whilst FAD has a characteristic autofluorescence of the flavin ring excited at 
~450nm. Autofluorescence imaging was performed on untransfected 2D monolayer cultures 2 days 
after seeding in 35mm2 glass bottomed dishes. A phase contrast image of the cells was captured as a 
reference to identify cells/regions of interest. NAD(P)H and FAD autofluorescence were sequentially 
excited at 360±15nm and 465±10nm, respectively and images were acquired every 10 seconds. 
Background subtraction was performed using MetaFluor software and fluorescence measurements 
were transcribed in an excel spreadsheet. Data points were smoothened with a sliding average of 60 
seconds. Changes in NAD(P)H and FAD autofluorescence (measured as arbitrary units) were calculated 
by subtracting the differences from the maximal fluorescence response during treatment to the 
maximal fluorescence 120 seconds prior to treatment (basal).      
2.6.5 FRET imaging 
Imaging of fluorescent-resonance energy transfer (FRET) sensors were performed on 2D monolayer 
cultures 2 days after seeding in 35mm2 glass bottomed dishes and a day following transfection of the 
FRET sensor. Imaging was performed using an inverted fluorescence microscope (Olympus IX71, 
Olympus, Southend on Sea, UK) with a x40 oil-immersion objective lens. Cells were excited at 
435±10nm using a 75W xenon arc lamp connected to a monochromator (Cairn Research, Faversham, 
UK), controlled by the MetaFluor software (Molecular Devices, Wokingham, UK). CFP or mTFP 
emissions at ~470nm and YFP or Venus emissions at ~535nm were simultaneously monitored using 
an Optosplit II beam splitter (Cairn Research) and Orca ER camera (Hamamatsu, Welwyn Garden City, 
UK). The following FRET sensors were used for live cell imaging experiments. Background subtraction 
was performed using MetaFluor software and fluorescence measurements were transcribed into an 
excel spreadsheet. 
2.6.5.1 FLII12Pglu-700μδ6 Glucose sensor  
The FLII12Pglu-700μδ6 cytosolic glucose sensor was initially generated by Wolf Frommer lab with an 
affinity range of 0.05 – 10mM (328). The sensor contains a mutated bacterial glucose binding protein 
MglB combined with an mCitrine-eYFP and eCFP (Figure 2.8A) (328). The application of glucose caused 
a simultaneous increase in eCFP fluorescence and decrease in mCitrine-eYFP fluorescence, leading to 
a decrease in FRET upon glucose binding to the sensor (Figure 2.8A and 2.8B). CFP and YFP 






Figure 2.5. Measurement of intracellular metabolites by FRET imaging. (A) Diagram of intracellular 
glucose sensing using the FLII12Pglu-700μδ6 FRET sensor and (B) Changes in CFP and YFP fluorescence 
in response to 10mM glucose (10G), which are used to derive the YFP/CFP ratio as a measure of 
intracellular glucose levels. (C) Diagram of intracellular glutamine sensing using the FLIPQ-TV3.0_2 m 
FRET sensor and (B) Changes in mTFP and Venus fluorescence in response to 10mM glutamine (Gln). 
Fluorescent changes are used to derive the mTFP/Venus ratio as a measure of intracellular glutamine 
levels. (e) Diagram of intracellular pyruvate sensing using the Pyronic FRET sensor and (F) Changes in 
mTFP and Venus fluorescence in response to the mitochondrial pyruvate carrier inhibitor UK-5099 
(UK), which elevates cytosolic pyruvate levels by inhibiting mitochondrial pyruvate uptake. 




sensor were measured as the YFP/CFP ratio. Data points were smoothened with a sliding average over 
30 seconds. Relative changes in intracellular glucose levels were calculated by dividing the differences 
from the maximal fluorescence response during glucose application to the maximal fluorescence 60 
seconds prior to treatment (basal) and 60 seconds during washout (Figure 2.8B). 
2.6.5.2 FLIPQ-TV3.0_2 m Glutamine sensor 
The FLIPQ-TV3.0_2 m sensor has a cytosolic glutamine binding affinity of 1.6mM (329). The sensor 
contains a mutated E.Coli glutamine binding protein glnH combined with mTFP and Venus proteins 
(Figure 2.8C) (329). The application of glutamine caused a simultaneous increase in Venus 
fluorescence and decrease in mTFP fluorescence, leading to a decrease in FRET upon glutamine 
binding to the sensor (Figure 2.8C and 2.8D). mTFP and Venus fluorescence were acquired every 5 
seconds, and real time changes in fluorescence of the glutamine sensor were measured as the 
mTFP/Venus ratio. Data points were smoothened with a sliding average over 30 seconds. Changes in 
intracellular glutamine levels were calculated by dividing the differences from the maximal 
fluorescence response during glutamine application to the maximal fluorescence 60 seconds prior to 
treatment (basal) and 60 seconds during washout (Figure 2.8D). 
2.6.5.3 Pyronic sensor  
The Pyronic sensor was initially generated by Felipe Barros lab with an affinity range of 10µM – 1mM 
for intracellular pyruvate (330). The sensor contains an E.Coli pyruvate binding protein PdhR combined 
with mTFP and Venus proteins (Figure 2.8E) (329). Increases in intracellular pyruvate levels by 
inhibiting endogenous pyruvate uptake by the mitochondria caused a simultaneous increase in Venus 
fluorescence and decrease in mTFP fluorescence respectively, leading to a decrease in FRET upon 
pyruvate binding to the sensor (Figure 2.8E and 2.8F). mTFP and Venus fluorescence were acquired 
every 10 seconds, and real time changes in fluorescence of the pyruvate sensor were measured as the 
mTFP/Venus ratio. Data points were smoothened with a sliding average over 60 seconds. Changes in 
intracellular pyruvate levels were calculated by dividing the differences from the maximal 
fluorescence response during glutamine application to the maximal fluorescence 120 seconds prior to 
treatment (basal). 
2.7 Seahorse Measurements 
The Seahorse XF24 bioanalyser (Agilent) measures in real time the proton (H+) production/pH changes 
in the extracellular media to calculate the extracellular acidification rate (ECAR) and whilst detecting 
extracellular O2 concentrations via a fluorescence-based oxygen sensor to calculate oxygen 
consumption rate (OCR) to measure oxidative phosphorylation (331). The bioanalyser cartridge has 4 
injection ports to enable sequential application of drug compounds per experiment.  
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The protocols for Seahorse measurements were followed according to manufacturer’s instructions. 
Briefly, 20 of the 24 wells in the XF24 plates were used to establish 2D monolayer cultures at full 
confluency, with 4 wells used as blanks (no cell controls). The following day, the bioanalyser cartridge 
was hydrated with a calibrant and incubated overnight at 37oC in a non-CO2 incubator. The cultures 
were treated with/without metformin in random order for 24 hours at 37oC in the humidifying 
chamber in 5% CO2. On the day of the experiment, the cells were incubated with 525µl of Seahorse 
assay media (Phenol-red free media which does not contain glucose, glutamine, pyruvate, and low in 
bicarbonates) with the indicated compounds for 1 hour, 37oC in a non-CO2 incubator. The cartridge 
was loaded with 75µl of the indicated drugs. After calibration, the calibrant plate was replaced with 
the culture plate and the experiment was performed at 37oC. At each measurement, each well was 
mixed for 3 minutes followed by measurements for another 3 minutes.  
The mitochondrial stress test was performed to measure oxidative phosphorylation during incubation 
of 10mM glucose or 4mM glutamine. The basal OCR (before treatment) was monitored followed by 
addition of the ATP-synthase inhibitor oligomycin A (which decreases the OCR to measure ATP-linked 
mitochondrial respiration), the proton uncoupler FCCP (which maximises cellular respiration to 
measure the maximal capacity and respiratory reserve) and the respective complex I and III inhibitors 
rotenone and antimycin A to inhibit mitochondrial respiration (and calculate the uncoupled and non-
mitochondrial respiration) (table 2.2, Figure 2.9A).   
OCR parameter in 
mitochondrial stress test 
Biological meaning Measurement 
Basal respiration Mitochondrial respiration in the 
absence of any inhibitors, affected 
by substrate availability/oxidation. 
OCR before injection – OCR non-
mito respiration 
Maximal respiration Mitochondrial respiration in the 
presence of energy stress caused 
by FCCP. 
OCR during FCCP application – 
OCR non-mito respiration 
Spare reserve capacity A measure of the ability for the cell 
to meet an increased energy 
demand. 
OCR maximal respiration – OCR 
basal respiration 
ATP-linked respiration Mitochondrial respiration used for 
ATP synthesis 
OCR basal respiration – OCR 
during oligomycin application 
Uncoupled respiration Mitochondrial respiration caused 
by H+ leak independent of ATP 
synthesis 
OCR non-mito respiration – OCR 
during oligomycin application 
Non-mitochondrial 
respiration 
Respiration not associated with 
mitochondria (eg. NADPH oxidases) 
OCR during rotenone/antimycin A 
application 
Table 2.6. Bioenergetic parameters to calculate the oxygen consumption rate (OCR) of the 
mitochondrial stress test using the Seahorse XF24 bioanalyser. 
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The glycolysis stress test was performed to measure the glycolysis bioenergetics in cells incubated 
with 2mM glutamine. The basal ECAR (before treatment) was monitored followed by the sequential 
addition of glucose (which increases ECAR due to glycolysis), oligomycin A (to maximise ECAR and 
calculate the glycolytic capacity and reserve by shifting the burden of ATP production towards 
glycolysis) and the glycolysis inhibitor 2-deoxyglucose (2-DG, table 2.3, Figure 2.9B). 
 
ECAR parameter in 
mitochondrial stress test 
Biological meaning Measurement 
Glycolysis Medium acidification due to 
glycolytic turnover  
ECAR during glucose application – 
ECAR before injection 
Glycolytic Reserve A measure of the ability for the cell 
to further maximise glycolysis in 
response to increased energy 
demand 
ECAR during oligomycin A 
application – ECAR during glucose 
application 
Glycolytic Capacity Maximal glycolysis capacity of cells ECAR during oligomycin A 




Medium acidification not 
associated with glycolysis (e.g. TCA 
cycle activity). 
ECAR before glucose injection 
Table 2.7. Bioenergetic parameters to calculate the extracellular acidification rate (ECAR) of the 
glycolysis stress test using the Seahorse XF24 bioanalyser. 
 
 
The Seahorse data were acquired using the Wave 2.0 software. The results were normalised to total 
protein content measured using BCA assay (Thermo Fisher) performed according to manufacturer’s 














2.8. Secretion and Enzyme Activity Assays 
2.8.1 Lactate Secretion Assay 
Lactate secretion was performed 2 days after seeding mouse intestinal organoids into 2D monolayers 
in 48 well plates. On the day of experiment, media was removed and cultures were washed 3 times 
with warm PBS. Cultures were incubated for 4 hours at 37oC in the humidifying chamber treated with 
100µl of DMEM without phenol red, glucose, glutamine or pyruvate (Thermo Fisher) plus the indicated 
drugs. The medium was then collected and spun at 5,000 g for 5 minutes at 4oC to remove debris and 
dead cells. The supernatant was collected and lactate was measured at the Core Biochemical Assay 
Laboratory, University of Cambridge using the lactate assay kit (Siemens Healthcare, Germany). The 
lysates were treated with lysis buffer, and lysates were collected and spun at 10,000 g for 10 minutes 
at 4oC to remove debris. Secretion results were normalised to total protein content measured using 
BCA assay. 
2.8.2 GDF-15 Secretion Assay 
GDF-15 secretion was performed a day after seeding mouse intestinal organoids into 2D monolayers 
in 48 well plates. 2D organoid cultures were treated for 24 hrs at 37oC in the humidifying chamber 
Figure 2.8. Diagram of the different parameters used to investigate oxidative phosphorylation and 
glycolysis using the Seahorse XF24 bioanalyser. (A) Example graph of the mitochondrial stress test, 
which measures the oxygen consumption rate (OCR). Mitochondrial respiration parameters such as 
Basal, ATP-linked, uncoupled respiration, maximal capacity and non-mitochondrial respiration can be 
calculated from the addition of three mitochondrial respiration inhibitors: ATP synthase inhibitor 
Oligomycin A (OliA), proton uncoupler FCCP and respective Complex I and III inhibitor Rotenone and 
Antimycin A (Rot/AA). Note the concentrations of inhibitors are all used at 1μM. (B) Example graph of 
the glycolysis stress test, which measures the extracellular acidification rate (ECAR). Parameters used 
to measure glycolysis, glycolytic capacity, glycolytic reserve and non-glycolytic acidification using the 
reagents glucose (10G, 10mM), Oligomycin A (OliA, 1μM) and 2-deoxyglucose (2-DG, 50mM).   
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with 150µl of ENR and the indicated drugs. The medium was then collected and spun at 5,000 g for 5 
minutes at 4oC to remove debris and dead cells. The supernatant was collected and GDF-15 was 
measured at the Core Biochemical Assay Laboratory, University of Cambridge using the mouse GDF-
15 assay kit. Measurements were performed using a microtiter plate-based two-site 
electrochemiluminescence immunoassay using the MesoScale Discovery assay platform (MSD, 
Rockville, Maryland, USA). Unless stated, 2-3 wells were performed in parallel for each experiment. 
The secretion results were normalised to basal secretion (control) for each experiment to calculate 
the fold change.    
2.8.3 LDH (Lactate dehydrogenase), AST (Aspartate transaminase) and ALT (Alanine 
transaminase) Assay 
LDH, AST and ALT measurements in lysates were performed a day after seeding mouse intestinal 
organoids into 2D monolayers in 48 well plates. 2D organoid cultures were treated for 24 hrs at 37oC 
in the humidifying chamber with 150µl of ENR with and without 1mM metformin. The medium was 
then removed and the lysates were treated with Lysis buffer (see section 2.2) and spun at 10,000 g for 
10 minutes at 4oC to remove debris and dead cells. The supernatant was collected and LDH, AST and 
ALT activity were measured using their respective kits (Siemens Healthcare, Germany) by the Core 
Biochemical Assay Laboratory, University of Cambridge. The lysate results were normalised to total 
protein content measured using BCA assay. 
The basis for LDH, AST and ALT measurements are described in reference procedures (332–335). 
Briefly, LDH measurements involve supplying L-lactate substrate to the sample, whilst measuring the 
340nm absorbance formed due to increased NADH formation during the simultaneous reduction of 
lactate to pyruvate. ALT measurements involve supplying L-alanine substrate to the sample, which is 
metabolised to pyruvate. Pyruvate is then reduced to lactate via LDH, which simultaneously increases 
NADH oxidation to NAD+, the change of absorbance of which was then measured at 340nm. AST 
measurements involve supplying L-aspartate substrate to the sample, which is metabolised to α-
ketoglutarate as well as forming oxaloacetate. Oxaloacetate is then reduced to malate via malate 
dehydrogenase, which simultaneously increases NADH oxidation to NAD+, the change of absorbance 




2.9 Techniques to analyse Gene Expression 
2.9.1 Real-time quantitative PCR (RT-qPCR) 
Mouse intestinal 2D monolayer cultures plated in 48 well plates were lysed in RLT plus buffer and the 
RNA was extracted using the RNeasy Micro Plus kit (Qiagen) according to manufacturer’s instructions. 
RNA-extraction from frozen intestinal tissues of HFD-fed mice was performed as described in (321). 
Briefly, ~100mg of tissue was lysed in 1ml Qiazol lysis reagent (Qiagen 79306l) using a Lysing Matrix D 
homogenisation tube and Fastprep 24 Homogeniser (MP Biomedicals) according to manufacturer’s 
instructions. RNA-extraction of homogenates was performed using RNeasy Micro Plus Kit.   
300ng-1µg of RNA was used for cDNA synthesis using a reaction mixture detailed in table 2.1 according 
to manufacturer’s instructions. The reverse transcription reaction was performed at 25oC for 10 
minutes, 40oC for 50 minutes and 70oC for 15 minutes on the Thermo-Cycler. For RT-qPCR reactions, 
5-25ng of cDNA/well was used, with TaqMan Universal master mix (Applied Biosystems) and TaqMan 
primer/probes (all from Fisher Scientific) added to the mixture. The RT-qPCR reaction was performed 
using the 7900 HT Fast Real-Time PCR system (Applied Biosystems, Fisher Scientific, Waltham, MA, 
USA) at 95oC for 20 seconds, followed by alternating between 95oC for 1 second and 60oC for 20 
seconds for 50 cycles. The probes for the genes used for RT-qPCR experiments are detailed in Table 
2.3.  
The qPCR results were normalised by calculating the difference in cycle threshold values (ΔCT) 
between the housekeeper gene β-actin and the gene of interest (CTβactin – CTgene). Relative gene 




RNA (diluted in Rnase free 
water) 
14 
Random primers 1 
Anneal random primers to RNA at 65oC for 5 minutes in 
Thermal Cycler. 
 
Master Mix: Volume (μl) 
First Strand Buffer  5 
DTT (100mM)  2.5 
Rnase OUT (inhibitor) 0.625 
dNTP (25mM) 0.5 
Rnase free water 0.375 
Superscript II enzyme  1 
Total 10 




Two intestinal organoid lines (GIP-cre tdRFP and SST-cre tdRFP) were used for RNA-seq experiments. 
Mouse intestinal 2D monolayer cultures plated in 24 well plates were lysed in RLT plus buffer and the 
RNA was extracted using the RNeasy Micro Plus kit (Qiagen) according to manufacturer’s instructions. 
Removal of salt carryover was subsequently performed using RNeasy MinElute Cleanup kit (Qiagen). 
The quality of RNA was validated by Bioanalyser RNA Nano kit (Agilent) and Agilent Bioanalyser 2100 
system with RIN values were between 8.1-9.4.  
1µg of total RNA was used for library construction using Illumina's TruSeq Stranded mRNA Library Prep 
Kit according to the manufacturer’s protocol at the Institute of Metabolic Science Genomics and 
Transcriptomics Core Facility (Cambridge, UK).  Briefly, messenger RNA was enriched by poly-T oligo 
attached magnetic beads before reverse transcription.  Addition of a single ‘A’nucleotide 
(adenylation) after the synthesis of the double-stranded cDNA stopped the ligation of DNA fragments 
during the adapter ligation reaction.  Unique barcodes were added to individual samples allowing 
multiplexing in sequencing.  DNA fragments with successful adapters ligated were enriched with a 
limited amplification.  The second strand cDNA, with the incorporation of dUTP, was quenched during 
amplification to allow strand-specific sequencing.  Indexed libraries were purified, normalised, pooled 
and sequenced on the Illumina HiSeq 4000 platform at single read 50bp at the Genomics Core Facility, 
Cancer Research UK Cambridge Institute (Cambridge, UK).  
All RNA sequencing analyses were performed using Bioconductor software packages in RStudio. The 
Ensembl code for each read count of the gene was annotated to the corresponding gene name in the 
mouse genome using BiomaRt package. Differential expression of genes were calculated using the 
DESeq2 package. A first DESeq analysis was performed to obtain a list of non-differentially expressed 
(non-DE) genes (P adjusted value >0.05) between control and metformin treated samples pooled from 
both organoid lines combined by fitting a negative binomial generalised linear model. A second DESeq 
analysis was performed by estimating the size factors using only the non-DE genes from the first 
analysis. A local dispersion estimation fit were performed in the second DESeq analysis. A threshold 
with log2FoldChange of 0.3 was selected and any genes with <0.3 log2FoldChange were classified as 
non-DE genes. The raw counts were normalised by variance stabilising transformation (VST), which 
divides the raw count data by the Size Factors. PCA analysis was performed on the VST-normalised 
count data using the plotPCA function.  
Gene expression from the RNA-seq data were visualised using the following methods. Heatmaps were 
plotted using the Pheatmap package based on DE genes (filtered by P-adjusted value of <0.05, any 
gene with P adjusted value of >0.05 were excluded from the heatmap) which calculate the z-scores 
i.e. the relative expression of a VST-normalised gene in the sample compared to the calculated mean 
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expression of the gene in all 12 samples. Scatter plots were used to present the VST-normalised counts 
using the Geompoint function of the ggplot package. Volcano plots compare the Log2FoldChange (x-
axis) and –log10 P-adjusted value (y-axis) using the Geompoint function of the ggplot package, with 
DE genes highlighted in red compared to non-DE genes (grey).   
KEGG analysis was performed by mapping the KEGG pathway IDs to each gene associated with the 
pathway using the database extracted from the edgeR package. KEGG pathway enrichment analysis 
of DE genes were performed using the Clusterprofiler package, with a p-value cut-off of 0.05 and 
Benjamin-Hochberg corrections to account for false discovery rate. Gene Ontology (GO) analysis was 
performed in a subset of genes associated with the mitochondria, by mapping the GO terms for each 
gene using the Go.db package. GO enrichment analysis of DE genes were performed using the Goseq 
package, with a p-value cut-off of 0.05 and Benjamin-Hochberg corrections to account for false 
discovery rate. GO terms with over 300 DE genes in the category were automatically excluded from 
analysis.  
 
2.10 Statistical Analysis 
Results were analysed for normality distribution, and statistical differences between groups were 
analysed via GraphPad Prism 7.0 software. For RNA-seq data, statistical analysis of DE genes was 
performed via DE-Seq2 package using R Studio (Section 2.9). The specific statistical test used are stated 







Chapter 3: Transcriptomic characterisation of metformin responsive 




Although metformin is used in the clinic for the treatment of Type 2 Diabetes, the cellular mechanisms 
of metformin action are still being hotly debated. Whilst previous studies explaining cellular 
mechanisms of metformin action were based on the suppressing mitochondrial metabolism to inhibit 
ATP production and activation of the AMP-kinase signalling pathway downstream of increases in 
cellular AMP levels, other observations have suggested AMPK-independent mechanisms and the 
effects of metformin in other cellular processes (210, 220). Transcriptomic studies could provide 
insights into metformin responsive genes and identify novel pathways of metformin action in different 
cells and tissues. This chapter examines the effects of metformin in metabolic pathways, signalling 




3.2.1 AMPK-dependent mechanisms of Metformin 
Previous studies into metformin action have centred on the role of AMPK in the regulation of cellular 
processes, particularly glucose and lipid metabolism (210–214). Reported AMPK-dependent effects of 
metformin include the activation of fatty acid metabolism (210, 211, 233, 336), suppressing 
adipogenesis (337), skeletal muscle glucose uptake (210, 336, 338–341) and inhibiting hepatic 
gluconeogenesis (210, 212, 342) (see chapter 6 for detailed description of metabolic pathways); many 
of the enzymes involved are directly phosphorylated by AMPK. AMPK also regulate gene expression 
through the regulation of CREB co-transcription activators, CREB-binding protein (CBP), CRTC2 and 
SHP, which inhibits the ability of CREB to regulate the expression of gluconeogenic genes (215–217). 
The activation of AMPK by metformin have been demonstrated to involve the inhibition of 
mitochondrial metabolism through increasing intracellular AMP levels (209). Yet, metformin activates 
AMPK even at 50μM (210); the concentrations are below its affinity of inhibiting mitochondrial 
complex I activity (204). Metformin also increased serine/threonine kinase mediated phosphorylation 
of the α-subunit of AMPK (210, 343). Experiments using mouse models with liver-specific knockout of 
the kinase LKB-1 reported a total loss of AMPK activity, which completely attenuated the glucose-
lowering effects of metformin administration (218).  
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3.2.2 Metformin and other signalling pathways 
A seminal study by Foretz et al., argued that metformin also mediates its effects through AMPK-
independent mechanisms (220). They reported that liver-specific knockout of AMPK displayed 
comparable blood glucose levels, normal hepatic glucose production and expression of gluconeogenic 
genes compared to wild-type mice (220). Metformin also achieved glucose-lowering effects despite 
the deletion of hepatic AMPK, whilst the allosteric AMPK activator A-769662 failed to achieve any 
noticeable physiological effects (220). However, the AMP analogue AICAR (which is also a known 
activator of AMPK) was reported to mimic glucose-lowering effects of metformin in the liver-specific 
AMPK-/- mouse, leading to the speculation that AMP, as opposed to AMPK is important in regulating 
hepatic glucose production (220). A more recent study confirmed this hypothesis by demonstrating 
that metformin (and phenformin) inhibited cAMP accumulation and PKA activity by increasing AMP 
concentrations in mouse primary hepatocytes (224). This effect of metformin antagonised glucagon 
receptor signalling in vivo, which was dependent on cAMP signalling to stimulate hepatic 
gluconeogenesis (224).  
Other studies have argued for the role of mTOR signalling downstream of metformin effects (221, 222, 
344), although the role of AMPK in this pathway is uncertain. Mechanistic studies in mouse embryonic 
fibroblasts (MEFs) and prostate cancer cell lines demonstrated that metformin inhibits mTORC1 
signalling independent of AMPK through activation of a Rag GTPase or the mTOR signalling inhibitor 
kinase REDD1 (221, 344). By contrast, experiments in mouse primary hepatocytes have demonstrated 
that at 0.5mM metformin concentration, the mechanism is dependent on AMPK and the TSC1/2 
complex (222). The latter study also demonstrated that metformin consequently inhibited protein 
synthesis of primary hepatocytes via the mTOR signalling pathway (222). 
Metformin has also been reported to activate the tumour-suppressor gene ATM, which is involved in 
the DNA-damage response and cell cycle control (125). This has been supported by the observations 
that the glycaemic responses of T2DM patients to metformin are linked to common genetic variants 
near the ATM locus (125). Another study into the roles of metformin in pancreatic islets demonstrated 
that metformin induces the PPAR-α pathway, which is involved in the induction of GLP-1 receptor 
expression via a mechanism independent of AMPK (223). Experiments in cancer cell lines have also 
shown that metformin, by reducing oxygen consumption which leads to increased oxygen tension and 
increased cellular oxygenation capacity, reduced protein levels of HIF-1α (345, 346). Interactions 
between the PPAR-α and HIF-1α signalling pathways (whereby HIF-1α inhibits PPAR-α expression) 
during hypoxia have previously been reported (347). 
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3.2.3 Metformin and cellular processes 
Recent interest into the potential for metformin in cancer therapy owes to its ability to inhibit cancer 
cell proliferation (219). Whether this is due to its indirect effects as a metabolic inhibitor is not known, 
although there is some evidence that metformin regulates cell cycle arrest genes. The mechanisms 
involved depend entirely on the cellular context and include; the activation of REDD1 (downstream of 
mTOR signalling) and P53 signalling pathways in prostate cancer cells (344), activation of P27, P21 
kinases in esophageal cancers (348) or downregulation of Cyclin D1 and E2Fs in breast cancer cell lines 
(349). Other studies have also demonstrated that metformin decreases the expression of cell 
senescence markers  (350, 351) and inhibits apoptosis (351).  
Metformin also induces autophagy (352–354). Studies in primary hepatocytes have shown that 
metformin activates autophagy through the activation of the protein deacetylase Sirt1 and is 
associated with alleviating hepatosteatosis in Ob/Ob mice (355). Metformin has also been reported 
to activate autophagy via an AMPK-dependent mechanism to mediate its cardioprotective effects 
against diabetic cardiomyopathy (354). Similar studies in cancer cell lines have also shown that 
metformin induces AMPK and mTOR-dependent autophagy in lymphoma and melanoma cells (352, 
353). 
Other effects of metformin include its role in the inflammasome (356, 357), and the regulation of ER 
stress signalling pathways (see chapter 4) (358, 359). Overall, there is growing evidence that 
metformin regulates cellular processes beyond mitochondrial metabolism. 
3.2.4 Metformin and intestinal functions 
Since the intestinal tract is the first site of exposure to high concentrations of orally administrated 
metformin, accumulating evidence investigate the role of metformin on intestinal function (116, 312). 
Other than the effects of metformin on intestinal glucose transport and nutrient metabolism in 
intestinal cells (which are covered in subsequent chapters), metformin has been reported to directly 
influence various aspects of intestinal function. These include suppressing the expression of 
inflammatory markers (360), promoting tight junction barrier function (360–362), increasing GLP-1 
secretion (262, 263, 267) and bile-acid homeostasis (253, 257, 260). Activation of AMPK and regulation 
of mTOR signalling by metformin have also been confirmed in the intestine (212, 360, 363, 364). 
Metformin also increases the length of villus but not crypts in the mouse ileum as well as increasing 
the expression of Paneth and goblet cell markers, suggesting a role of metformin in influencing 
differentiation of cells in the intestinal mucosa (360). These studies provide some indication of the 
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vast effects of metformin action in the intestine, but systematic analysis into the cellular and metabolic 
pathways in the intestinal cells has yet to be reported to date. 
3.2.5 Transcriptomic and genomic studies into metformin action 
Recent studies using sequencing techniques and bioinformatics analysis have systematically 
investigated metformin action in various primary tissues and cancer cell lines to identify novel genes 
and mechanisms (365–368). An influential study using RNA-sequencing of metformin treated human 
primary hepatocytes have identified metformin-responsive gene clusters associated with AMPK 
dependent and independent pathways (365). The investigation was followed by ChIP-seq, which 
identified thousands of gene-regulatory elements associated with the metformin response, notably 
the cAMP-dependent transcription factor ATF3 and a potential regulatory element for the ATM gene 
(365). A more recent study used RNA-seq to characterise pathways in skeletal muscle and 
subcutaneous adipose tissue biopsies from elderly participants taking metformin (366). The study 
reported the effects of metformin in pathways that are unique to muscle and adipose tissue, whilst 
altering the expression of genes including Mtor, Myc, Tnf, Tgfb1 and miRNA-29b (366). Other studies 
have studied the transcriptomic responses to metformin in fibroblasts (368) and cancer cell lines (367).  
 
3.3 Aims 
The aims of this study are:  
1. To characterise transcriptomic changes to metformin in intestinal cells using bulk RNA-
sequencing and DE-Seq analysis.  
2. To investigate the metabolic pathways altered by metformin. 





3.4.1 DE-Seq analysis of differentially expressed genes altered by metformin treatment 
 
Note: RNA library preparation and Illumina sequencing of RNA samples were performed by Marcella 
Ma. Alignment analysis and raw count quantification of RNA-seq results were performed by Brian Lam, 




preparation of samples for RNA-sequencing, two transgenic organoid lines (called GIP-cre tdRFP and 
SST-cre tdRFP) were plated as 2D monolayer cultures in 3 separate 24-well plates on day 1 followed 
by treatment with or without 1mM metformin for 24 hours. RNA extraction was performed on day 3, 
followed by library preparation and RNA sequencing. Changes in the expression of genes altered by 
metformin were analysed using DE-Seq2. Cluster analysis of the bulk-seq output identified 4 distinct 
subgroups according to the organoid line and the treatment (Figure 3.1A). There is a 76% variance in 
gene expression (PC1) between control and metformin treatments, whilst only 13% variance in gene 
expression (PC2) is observed between the organoid lines. Of the 15,194 genes mapped to the 
database, 2,378 genes were significantly upregulated, and 1,660 genes were significantly 
downregulated by metformin treatment, respectively. 
A volcano plot compares the genes based on the effect of metformin treatment on differential 
expression (Log2 of the fold change, x-axis) and the statistical significance of expression (-log10 of the 
P-adjusted value, y-axis), with the top 50 genes labelled (ranked based on statistical significance) 
(Figure 3.1B). Amongst the top genes significantly upregulated by metformin include the microtubule 
associated protein Eml2, growth factors Gdf15 and Areg, membrane-bound protein Sema7a, protein 
kinase Plk3 and the cysteine/glutamate transporter Slc7a11. Metformin decreased the expression of 
genes encoding for alcohol dehydrogenases Adh1, Adh4 and Adh6a (see Figure 3.4), 
Figure 3.1. Gene expression profiling of duodenal organoid cells seeded into 2D monolayers following 
treatment of 1mM metformin or no treatment control.  
(A) Principle component analysis (PCA) of subgroups from the RNA-seq output. Four subgroups were 
identified based on the drug treatment (PC1) and organoid line (PC2). (B) Volcano plot displaying the fold 
change (X-axis) compared to the P-adjusted values (Y-axis) of individual genes altered by metformin 
treatment. Red dots represent gene expression changes that were statistically significant (P<0.05), whilst 
black dots represent gene expression changes that were not statistically significant (Not Sig). Labelled genes 




phosphomannomutase Pmm2 (see Figure 3.6), the glucose transporter Slc5a1 (See chapter 5 and 
figure 3.13), the mRNA decay regulation gene Smg5 and the FLAP endonuclease Fen1. 
The effect of metformin on the expression of different intestinal epithelial markers were investigated 
to provide some suggestion into whether metformin alters the populations of different intestinal cell 
types. There were no significant changes in any markers for enteroendocrine cells, with the exception 
for increased glucagon gene (Gcg) expression (Figure 3.2A). There were no changes in the expression 
of goblet cell markers Clca1 and Tff3 (Figure 3.2B), whilst the expression of the mucin goblet cell 
marker Muc2 was too low for detection (data not shown). Metformin increased the expression of the 
Paneth cell marker Lyz1, but not Defa22 or Defa24 (Figure 3.2C). Metformin also altered the 
expression of different stem cell markers (Figure 3.2D). Metformin increased the expression of the 
tuft cell marker Dclk1 (Figure 3.2E) and marginally altered the expression of enterocyte markers Alfi1 
and Gstm3 (Figure 3.2F). Whether metformin changes the different intestinal epithelial cell 
populations remain inconclusive based on the transcriptomic data. 
 
Figure 3.2. Expression of markers for the different intestinal cell types. 
The effect of metformin on the expression of biomarkers for (A) enteroendocrine cells, (B) goblet cells, 
(C) paneth cells, (D) stem cells, (E) tuft cells and (F) enterocytes. The raw count data for each gene is 
normalised by the size factors and the library size. *, P<0.05, **, P<0.01, ***, P<0.001 (P-adjusted 
values calculated via DE-Seq analysis). Biomarkers were identified based on single-cell RNA-seq data 




3.4.2 The effects of metformin on metabolic and signalling pathways in intestinal cells 
 
Next, Kyoto-Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was 
performed. The dataset was mapped to a particular biological pathway from the KEGG database, and 
the KEGG enrichment analysis identifies cellular/biochemical processes altered in metformin-treated 
cultures based on the numbers of differentially expressed (DE) genes within each pathway. The 
metabolic pathways and cellular processes found in the KEGG enrichment analysis is shown in Figure 
3.3A and 3.3B. The following sections cover gene expression profiles involved in many of these 
pathways highlighted from pathway analysis. Pathways known to be important to intestinal 
metabolism or are associated with metformin action, but have not been highlighted in the pathway 
analysis, were also studied in more detail. Other pathways identified from the analysis which play 
important roles in other tissues or with little previous evidence supporting their role in the intestine 
(such as adipocytokine signalling, insulin resistance, glycan degradation, drug metabolism and Fanconi 
anaemia pathway), were not investigated further.  
 
Figure 3.3. Scatterplot of KEGG enrichment statistical analysis of pathways altered by metformin 
treatment. Changes in (A) metabolic pathways and (B) signalling pathways and processes altered by 
metformin vs control. Gene ratio is the number of differentially expressed (DE) genes in a KEGG 
pathway divided by total number of genes in the pathway. Count represents the numbers of DE genes. 
P adjusted value is the P-value corrected for the false-discovery rate using the Benjamin-Hochberg 





3.4.2.1 Metabolism of glucose and hexose sugars       
Metformin has been reported to increase glycolytic production of lactate in the intestine (64, 116, 
207, 370). Glycolysis and gluconeogenesis were amongst the hexose sugar metabolism pathways 
highlighted in the KEGG enrichment analysis, with 21 out of 67 genes from the KEGG gene list being 
differentially expressed. Metformin increased the expression of all hexokinase isoforms (Hk1, Hk2 and 
Hkdc1), phosphofructokinases (Pfkm and Pfkp), aldolase A (Aldoa) and aldehyde dehydrogenases 
(Aldh1a3 and Aldh3b2) (Figure 3.4A, 3.4F). Metformin decreased the expression of enolase (Eno3), 
alcohol dehydrogenases (Adh1, Adh4, Adh7), and the gluconeogenesis glucose-6-phosphatase enzyme 
(G6pc). Starch and sucrose (glycogen) metabolism were also identified from the pathway analysis (14 
DE genes out of 33 genes total genes) and was investigated further. Metformin increased the 
expression of phosphoglucomutases (Pgm1 and Pgm2), genes promoting glycogen synthesis (Ugp2 
and Gyg) and the lysosomal glucosidase (Gaa), but decreased expression of phosphoglucomutase 
(Pgm1l1) (Figure 3.4B, 3.4F). Upregulated genes in the pentose phosphate pathway (enriched in the 
KEGG analysis, with 14 DE genes out of 32 genes total genes) include the rate-limiting enzyme glucose-
6-phosphate dehydrogenase (G6pdx), ribulose-phosphate 3 epimerase (Rpe) and transaldolase 
(Taldo1); the latter is involved in the reversible, non-oxidative reactions to generate more NADPH and 
re-join with the glycolysis pathway by generating fructose-6-phosphate. Ribokinase (Rbks), the 
enzyme involved in ribonucleotide biosynthesis in the pathway, was downregulated in metformin 
treated cultures (Figure 3.4C and 3.4F).  
Since glucose metabolism generates pyruvate and lactate, the expression of monocarboxylate 
transporters (MCTs) involved in their transport were investigated. Amongst the DE genes include Mct6 
and Mct13 (Figure 3.4D). Metformin decreased the expression of cytosolic glycerolphosphate shuttle 
gene Gpd1 but increased the expression of its mitochondrial counterpart Gpd2, both of which are 
involved in glycerol production and the transfer of reducing equivalents generated in glycolysis to the 
mitochondria (Figure 3.4E).  
Pyruvate metabolism and tricarboxylic acid (TCA) cycle were also investigated as the genes involved 
in glycolysis and pyruvate metabolism markedly overlap with each other.  Metformin increased the 
expression of pyruvate metabolism enzymes such as lactate dehydrogenase (Ldhd), malic enzymes 
(Me1, Me3) and dihydrolipoyl transacetylase involved in pyruvate dehydrogenase complex (Dlat) 
(Figure 3.5A, 3.5C). Metformin increased the expression of the mitochondrial phosphenolpyruvate 
carboxykinase (PEPCK) isoform Pck2 but decreased the expression of its cytosolic counterpart Pck1. 
Amongst the genes involved in TCA cycle flux, isocitrate dehydrogenase 1 (Idh1), citrate synthase (Cs) 
and oxoglutarate dehydrogenases (Ogdh, Ogdhl) were induced in metformin-treated cultures (Figure 
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3.5B). Metformin did not significantly alter the expression of most mitochondrial metabolite 
transporters, with the exception of Slc25a1 (the mitochondrial citrate transporter CIC) and Slc25a15 
(the mitochondrial ornithine translocase) (Figure 3.5C). 
 
Figure 3.4. The effect of metformin on the expression of genes involved in glucose metabolism. (A, 
B and C) Heatmaps showing DE genes (filtered by p-adjusted value of <0.05, genes with p-adjusted 
value of >0.05 were not included in the heatmap) involved in glycolysis and gluconeogenesis (pathway 
ID: mmu00010), glycogen metabolism (pathway ID: mmu00500) and pentose phosphate pathway 
(pathway ID: mmu00030), affected by metformin treatment. Since some genes are involved in 
multiple pathways, they are shown only in a single pathway to avoid duplication. The colour key is 
shown on the right and depicts the expression z-scores for each gene. Red indicates higher than 
average expression and blue indicates lower than average expression for a particular gene in a sample. 
(D and E) The effect of metformin on the expression of monocarboxylate transporters (MCT) and 
components of the glycerolphosphate shuttle. (F) Schematic showing the expression changes of genes 
involved in the glycolysis, glycogen metabolism and pentose phosphate pathways. For D and F, red 






Figure 3.5. The effect of metformin on the expression of genes involved in mitochondrial metabolic 
transporters and pathways. (A and B) Heatmaps showing DE genes (filtered by p-adjusted value of 
<0.05, genes with p-adjusted value of >0.05 were not included in the heatmap) involved in pyruvate 
metabolism (pathway ID: mmu00620) and tricarboxylic-acid (TCA) cycle (pathway ID: mmu00020) 
affected by metformin treatment. Since some genes are involved in multiple pathways, they are 
shown only in a single pathway to avoid duplication. The colour key is shown on the right and depicts 
the expression z-scores for each gene. Red indicates higher than average expression and blue indicates 
lower than average expression for a particular gene in a sample. (C) Schematic showing the expression 
changes of genes involved in pyruvate metabolism and the TCA cycle. (D) The effect of metformin on 
the expression of pyruvate transporters and carriers. For C and D, red and blue shows the upregulated 




Metformin decreased the expression of key genes involved in fructose metabolism, such as the rate-
limiting enzyme ketohexokinase (Khk), aldolase B (Aldob), and triokinase/FMN cyclase (Tkfc) (Figure 
3.6A, 3.6B). Genes involved in mannose metabolism include decreased expression of 
phosphomannomutase Pmm2 (involved in mannose metabolism to glycans) and increased expression 
of mannose-6-phosphate isomerase (Mpi), which connects mannose metabolism to glycolysis via 





Overall, the RNA-seq evidence suggests that metformin promotes the expression of genes involved in 
glycolysis and pyruvate metabolism. Metformin also seemed to increase the expression of several key 
pentose phosphate pathway genes despite decreasing ribokinase expression, but the effect on 
glycogen metabolism are inconclusive. Metformin decreased the expression of genes involved in 
fructose metabolism. 
3.4.2.2 Amino acid metabolism       
The expression profiles of genes involved in the glutamate/aspartate/alanine metabolism pathway 
were investigated in detail, since these amino acids play important roles in intestinal epithelial cells 
(178, 179, 183, 371). Metformin increased the expression of aspartate and alanine transaminases 
Figure 3.6. The effect of metformin on the expression of genes involved in fructose and mannose 
metabolism. (A) Heatmap showing DE genes (filtered by p-adjusted value of <0.05, genes with p-adjusted value 
of >0.05 were not included in the heatmap) involved fructose and mannose metabolism (pathway ID: 
mmu00051) affected by metformin treatment. The colour key is shown on the right and depicts the expression 
z-scores for each gene. Red indicates higher than average expression and blue indicates lower than average 
expression for a particular gene in a sample.  Some of the genes are involved in glucose metabolism pathways 
and are shown in the heatmaps in other figures. (B) Schematic showing the expression changes of genes 




(Got1 and Gpt) respectively (Figure 3.7A, 3.7E). Additionally, metformin increased the expression of 
aspartate metabolism genes Adss1, Adssl1, Ass1 and particularly Asns, which encodes asparagine  
  
Figure 3.7. The effect of metformin on the expression of genes involved in amino acid metabolism and 
transporters. (A-D) Heatmaps showing DE genes (filtered by p-adjusted value of <0.05, genes with p-adjusted 
value of >0.05 were not included in the heatmap) involved in (A) Glutamate, Aspartate, Alanine metabolism 
(pathway ID: mmu00250), (B) Arginine metabolism (pathway ID: mmu00220 and 00330), (C) Branched-chain 
amino acid metabolism (pathway ID: mmu00280 and 00290) and (D) Aromatic amino acid metabolism (pathway 
ID: mmu00350, 00360 and 00380). Since some genes are involved in multiple pathways, they are shown only in 
a single pathway to avoid duplication. The colour key depicts the expression z-score and is shown on the right. 
Red indicates higher than average expression and blue indicates lower than average expression for a particular 
gene in a sample. (E) An integrated schematic showing the expression changes of genes involved in amino acid 
metabolism. (F) The effect of metformin on the expression of amino acid metabolism. *: NHE3 is not an amino 
acid transporter but is involved in maintaining the ion gradients necessary for electrogenic transport of amino 
acids. The transporters were identified from the protein digestion and absorption KEGG pathway (pathway ID: 




synthetase, an indicator of amino acid deprivation (372). Metformin decreased the expression of 
adenylosuccinate lyase (Adsl) associated with purine biosynthesis from aspartate, and glutaminase 
(Gls), the rate-limiting enzyme of glutamine metabolism. Because 20-55% of ingested branched chain 
amino acids (BCAAs- leucine, isoleucine and valine) are metabolised by the intestinal mucosa (371), 
the effects of metformin in BCAA metabolism were investigated. Metformin decreased the expression 
of key genes Bckdha (the enzyme involved in the second step of BCAA catabolism) and Hmgcs2, but 
upregulated Hibadh, Mccc1 and Hmgcs1, which encode enzymes involved in Acetyl-CoA and ketone 
body metabolism (Figure 3.7BC, 3.7E). The KEGG enrichment analysis highlighted arginine biosynthesis 
as an enriched pathway in metformin treated cultures (16 DE genes out of 50 total genes). Metformin 
decreased the expression of key urea (arginine-citrulline) cycle genes such as Otc, Arg1, Arg2 and Nags 
(Figure 3.7C, 3.7E). Metformin also altered the expression of some aromatic amino acid metabolism 
genes including fumarylacetoacetase (Fah, Fahd1) and kyneurinase (Kynu) (Figure 3.7D, 3.7E).  
The effect of metformin on the expression of key amino acid transporters in intestinal epithelial cells 
were also investigated. From the transporters identified from the KEGG protein degradation and 
absorption pathway dataset, decreased expression of wide-spectrum amino acid transporters such as 
LAT1 (Slc7a8), B0AT1 (Slc16a9), SNAT1 (Slc38a1) and SNAT2 (Slc38a2) were observed (Figure 3.8A). 
The oligo-peptide transporter PEPT1 (Slc15a1) and the imino-based amino acid transporter PAT1 
(Slc36a1) were also downregulated, as well as the sodium/proton exchanger NHE3 (Slc9a3) involved 
in maintaining ion gradients for electrogenic activity to maintain amino acid transporter functions. To 
investigate whether decreased expression of the amino acid transporters would affect amino acid 
uptake, glutamine flux was monitored by live cell imaging of intestinal cells from Wild-type (Figure 
3.8B), SNAT2 null (Figure 3.8C) and B0AT1 null (Figure 3.8D) organoids transfected with a FRET-based 
glutamine sensor. No differences in glutamine flux were observed between the wild-type and 
knockout organoid lines, although SNAT2 null intestinal cells seemed to exhibit a reduced flux 
(P=0.123, Figure 3.8E). No differences were observed between control and metformin treated cells in 
any organoid line (Figure 3.8E). These results suggest that changes in amino acid transporter gene 
expression can be compensated by the functional activity of other glutamine transporters.   
Folate dependent metabolism was highlighted from the KEGG enrichment analysis. This pathway was 
investigated in more detail, along with glycine/serine/threonine metabolism (since serine is a key 1-
carbon substrate for the mitochondrial folate pool) and cysteine/methionine metabolism (the 
methionine cycle and folate metabolism pathways are interconnected). Metformin decreased the 




Figure 3.7. The effect of metformin on the expression of amino acid transporters and glutamine flux. (A) The 
effect of metformin on the expression of amino acid metabolism. *: NHE3 is not an amino acid transporter but 
is involved in maintaining the ion gradients necessary for electrogenic transport of amino acids. The transporters 
were identified from the protein digestion and absorption KEGG pathway (pathway ID: mmu04974). Red and 
blue shows the upregulated and downregulated genes, respectively. (B) Measurements of glutamine flux in 
intestinal cells from Wild-type organoids expressing a FRET-based glutamine sensor treated with control (Con) 
or metformin (Met). (C) Measurements of glutamine flux in intestinal cells from SNAT2 knockout organoids 
expressing a FRET-based glutamine sensor treated with control or metformin. (D) Measurements of glutamine 
flux in intestinal cells from B0AT1 knockout organoids expressing a glutamine sensor treated with control or 
metformin. (E) Changes in mTFP/Venus fluorescence of the glutamine sensor in control (red) or metformin (blue) 
treated intestinal cells from WT, SNAT2 KO and B0AT1 KO organoids. WT Control: N=62 cells from 18 dishes, WT 
Metformin: N=61 cells from 18 dishes, SNAT2 KO Control:  N=27 cells from 9 dishes, SNAT2 KO Metformin: N=25 
cells from 8 dishes, B0AT1 KO Control: N=32 cells from 7 dishes, B0AT1 KO Metformin: N=26 cells from 6 dishes. 




which encodes for a multifunctional, rate-limiting enzyme of the mitochondrial folate cycle and has 
been associated with one-carbon pool imbalance in mitochondrial myopathies (Figure 3.9A, 3.9D) 
(373, 374). Similarly, many of the genes involved in glycine, serine and threonine metabolism were 
downregulated by metformin treatment, except for aminolevulinic acid synthetase (Alas1) involved in 
glycine metabolism (Figure 3.9B). Metformin also decreased the expression of genes involved in 
cysteine and threonine metabolism (Figure 3.9C, 3.9D). This included DNA methyltransferases (Dnmt1 
and Dnmt3a) involved in DNA methylation. Other genes involved in cysteine/methionine metabolism 
such as glutamate-cysteine ligase (Gclc) (involved in cysteine metabolism to glutathione) and 
adenosylhomocysteinase-like 1 (Ahcyl1) (involved in methionine metabolism to homocysteine) were 
increased in metformin-treated cultures. 
 
  
Figure 3.9. The effect of metformin on the expression of genes involved in the folate and methionine cycle. 
(A-C) Heatmaps showing DE genes (filtered by p-adjusted value of <0.05, genes with p-adjusted value of >0.05 
were not included in the heatmap) involved in (A) Folate dependent Metabolism (pathway ID: mmu00790), (B) 
Glycine/Serine/Threonine metabolism (pathway ID: mmu00260) and (C) Glycine/Serine/Threonine metabolism 
(pathway ID: mmu00270). Colour key of the heatmap depicts the expression z-score. Red indicates higher than 
average expression and blue indicates lower than average expression for a particular gene in a sample. Since 
some genes are involved in multiple pathways, they are shown only in a single pathway to avoid duplication. (D) 
An integrated schematic showing the expression changes of genes involved in folate and methionine cycle. Red 
and blue shows the upregulated and downregulated genes, respectively. *M represents Mthfd2 (abbreviated), 




In summary, metformin increased the expression of genes involved in aspartate metabolism but 
decreased expression of genes involved in folate dependent metabolism, glycine/serine/threonine 
metabolism and cysteine/methionine metabolism. Many of the genes involved in the arginine-
citrulline cycle were decreased by metformin. The expression of some of the amino acid transporters 
were also downregulated, although functional studies did not report differences in glutamine uptake. 
3.4.2.3 Lipid metabolism, the PPAR signalling pathway, peroxisome and lysosome function       
Since metformin has been reported to associate with cellular lipid metabolism and KEGG enrichment 
analysis highlighted increased fatty acid biosynthesis and cholesterol metabolism, the effects of 
metformin on lipid metabolism were investigated. In the fatty acid 
biosynthesis/elongation/degradation pathways, metformin increased the expression of acyl-CoA 
synthetases (Acsl1, Acsl3 and Acsl4, but downregulated Acsl6), and fatty acid elongation enzyme 
Elovl4, but decreased the expression of fatty acid synthase (Fasn) and Acetyl-CoA thioesterase (Acot4 
and Acot5) (Figure 3.10A, 3.10B). Mitochondrial fatty acid oxidation genes such as Echs1, Eci2, Mcat2 
and Oxsm were increased in metformin treated cultures, whilst expression of the peroxisomal fatty 
acid oxidation gene Acaa1b was decreased.  
Transporters involved in fatty acid and cholesterol uptake, such as Cd36, Abcg5 and Abcg8 were 
decreased in metformin treated cultures (Figure 3.10C, 3.10D). Amongst the cholesterol uptake 
receptors, the LDL uptake receptor (Ldlr) was increased, but the LDL receptor related protein (Lrp2) 
was decreased by metformin treatment. In the mitochondria, cholesterol transporters and metabolic 
enzymes Tspo, Vdac2 and Cyp27a1 were upregulated. Other DE genes include the lysosomal 
cholesterol trafficking genes (Npc1 and Npc2- increased), the mitochondrial cholesterol uptake 
mediator (Stard3 decreased), sterol O-acetyltransferase (Soat2- decreased) and lipoproteins (Apoa1 
and Apoc3- decreased) (Figure 3.10C, 3.10D).  
The peroxisome proliferator-activated receptor (PPAR) pathway was also investigated, since 
activation of the pathway is closely associated with lipid metabolism and it is highlighted in the KEGG 
enrichment analysis (28 DE genes out of 85 total genes). Metformin increased the expression of Pparg 
but downregulated its transcriptional partner Rxrb (Figure 3.11A, 3.11B). Amongst the upstream PPAR 
pathway components, metformin increased the expression of long chain fatty acid transporter 
Slc27a1, but decreased the expression of very-LCFA and bile acid synthetases (Slc27a2 and Slc27a5 
respectively), and fatty acid binding protein (Fabp). In addition to fatty acid metabolism genes 
(discussed in Figure 3.9), metformin increased the expression of PPAR target genes involved in glycerol 





Figure 3.10. The effect of metformin on the expression of genes involved in fatty acid and cholesterol 
metabolism. (A and C) Heatmaps showing DE genes (filtered by p-adjusted value of <0.05, genes with p-
adjusted value of >0.05 were not included in the heatmap) involved fatty acid (pathway ID: mmu00061, 
00062 and 00071) and cholesterol metabolism (pathway ID: mmu04979). Since some genes are involved in 
multiple pathways, they are shown only in a single pathway to avoid duplication. The colour keys showing 
the expression z-scores are shown on the right. Red indicates higher than average expression and blue 
indicates lower than average expression for a particular gene in a sample. (B and D) Schematics showing 
the expression changes of genes involved in fatty acid and cholesterol metabolism. Red and blue shows the 















The peroxisome is closely associated with fatty acid and cholesterol metabolism and KEGG genesets 
associated with peroxisome function and was investigated further. Metformin decreased the 
expression of many peroxin subtypes (except Pex11b) involved in targeted peroxisomal transport, and 
purine/retinol metabolism genes (Figure 3.12A and 3.12B). Other peroxisome-targeted lipid 
metabolism genes such as Nudt9, Amacr and Far2 were downregulated, and Nudt7 was increased by 
metformin treatment. Amino acid metabolism genes spermine oxidase (Paox) was upregulated and 
sarcosine oxidase (Pipox) was downregulated, respectively. Metformin also increased the expression 
of the genes Mpv17l and Gstk1 involved in peroxisomal ROS and antioxidant metabolism.  
Within the genes involved in lysosome function (highlighted from KEGG enrichment analysis), 
Metformin increased the expression of most lysosomal peroxidases and membrane proteins (except 
lysosomal lipases Acp2, Acp5 and the lysosomal sulfatase Sgsh, which were decreased in expression) 
Figure 3.11. The effect of metformin on the expression of genes involved in the PPAR signalling 
pathway. (A) Heatmap showing DE genes (filtered by p-adjusted value of <0.05, genes with p-
adjusted value of >0.05 were not included in the heatmap) involved in the PPAR signalling pathway 
(pathway ID: mmu03320). Some of the genes shown are involved in glucose and lipid metabolism 
pathways and are duplicated from previous figures to show their involvement in this pathway. The 
colour keys showing the expression z-scores are shown on the right. Red indicates higher than 
average expression and blue indicates lower than average expression for a particular gene in a 
sample. (B) Schematic showing the expression changes of genes involved in the PPAR signalling 
pathway. Red and blue shows the upregulated and downregulated genes, respectively. Schematic 
is adapted from the Pathview version of the pathway. 
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(Figure 3.12C, 3.12D). The ATP-dependent H+ transporter subunits Atp6v0d1, Atp6v0b and Atp6ap1, 
which is essential for maintaining the acid environment of the organelle, was also upregulated by 
metformin. Genes involved in the transport of lysosomal proteins such as Nagba, Ap3d1 and Ap4s1 
were decreased by metformin treatment, but expression of M6pr and Cltc were increased. 
 
Figure 3.12. The effect of metformin on the expression of genes involved in peroxisome and lysosome processes. 
(A and C) Heatmaps showing DE genes (filtered by p-adjusted value of <0.05, genes with p-adjusted value of >0.05 
were not included in the heatmap) involved in peroxisome (pathway ID: mmu04142) and lysosome (pathway ID: 
mmu04146) processes. Some of the genes shown are involved in other metabolism pathways and are duplicated 
from previous figures to show their involvement in this pathway. The colour keys showing the expression z-scores 
are shown on the right. Red indicates higher than average expression and blue indicates lower than average 
expression for a particular gene in a sample. (B and D) Schematics showing the expression changes of genes 
involved in peroxisome and lysosome processes. Red and blue shows the upregulated and downregulated genes, 
respectively. Schematic is adapted from the Pathview versions of the pathways. 
71 
 
Although KEGG enrichment analysis identified fatty acid biosynthesis, cholesterol metabolism and 
PPAR signalling pathways, detailed investigations did not reveal a conclusive pattern of expression. 
Most of the genes involved in lysosome function were upregulated under metformin treatment.        
3.4.2.4 Signalling pathways involved in nutrient and energy sensing 
Since metformin activates AMPK signalling, the transcriptomic responses of the AMPK signalling 
pathway were investigated in detail, despite that the AMPK signalling pathway was not highlighted in 
the KEGG pathway analysis. Whilst expression of the α-subunit (Prkaa2) was increased by metformin, 
expression of other subunits (Prkab1, β-subunit and Prkag1, γ-subunit) were downregulated (Figure 
3.13A, 3.13B). The expression of inhibitory protein phosphatases of AMPK signalling (Ppp2r5a, 
Ppp2r5b and Ppp2r5c) were increased in metformin treated cultures. Although the effects of 
metformin in the expression profiles of other downstream AMPK signalling pathways were not 
particularly conclusive, the expression of vesicular transport genes (Tdc1d1, Rab10 and Rab14) were 
induced by metformin.  
Within the mTOR signalling complex, whilst Mtor and Rictor expression were both induced by 
metformin, the expression of Mlst8 and Telo2 were decreased (Figure 3.13C, 3.13D). Moreover, very 
few of the genes downstream of the mTOR signalling complex were differentially expressed (Figure 
3.13D). Therefore, the effect of metformin on the transcriptomic expression profiles of mTOR 
signalling genes are inconclusive.       
The HIF-1α pathway was also selected for investigation, as mitochondrial dysfunction caused by 
metformin treatment might be associated with HIF-1α signalling. Hif1a expression was increased by 
metformin, as well as its transcriptional co-activator HIF-1B (Arnt) and the ribosomal protein Rps6 that 
regulates HIF-1A translation (Figure 3.14A, 3.14B). Genes that regulate targeted degradation of HIF-
1a under normoxic conditions, such as the prolyl hydroxylase Egln1 and the ubiquitin ligase Vhl were 
downregulated in metformin-treated cultures (the exception is the scaffold protein Cul2 with 
upregulated expression). The effect of metformin on the expression of HIF-1a target genes was 
investigated using a catalogue of established HIF-1A target genes from (375). From the catalogue, 20 
out of 87 mapped genes were DE genes, with 16 upregulated and 4 downregulated genes, respectively 
(Figure 3.14C). Prominent genes involved in glycolysis as mentioned in Figure 3.4 and vascular 
associated genes (Serpine1, Edn1, Nos3 and Pdgfa) were upregulated in metformin treated cultures 







Figure 3.13. The effect of metformin on the expression of genes involved AMPK and mTOR signalling 
pathways. (A and C) Heatmaps showing DE genes (filtered by p-adjusted value of <0.05, genes with p-
adjusted value of >0.05 were not included in the heatmap) involved in the AMPK (pathway ID: 
mmu04152) and mTOR signalling (pathway ID: mmu04150) pathways, respectively. Some of the genes 
shown are involved in other pathways and are duplicated from previous figures to show their 
involvement in this pathway. The colour keys showing the z-scores are shown on the right. Red 
indicates higher than average expression and blue indicates lower than average expression for a 
particular gene in a sample. (B and D) Schematics showing the expression changes of genes involved in 
AMPK and mTOR signalling pathways. Red and blue shows the upregulated and downregulated genes, 





Figure 3.14. The effect of metformin on the expression of genes involved Hif1a signalling. (A) 
Heatmaps showing DE genes (filtered by p-adjusted value of <0.05) involved in the HIF1A signalling 
pathway identified from KEGG analysis (pathway ID: mmu04066). The colour keys showing the z-scores 
are shown on the right. (B) Schematics showing the expression changes of genes involved in HIF-1A 
signalling. Red and blue shows the upregulated and downregulated genes, respectively. Schematic is 
adapted from the Pathview version of the pathway. (C) Volcano plot showing the effects of metformin 
on the expression of HIF-1A signalling target genes, red shows significantly expressed genes (padj<0.05), 
black shows non-significant genes (Not Sig). The database is derived from (375). 
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3.4.2.5 Growth factor signalling pathways 
The KEGG enrichment analysis identified growth factor signalling pathways such as Hippo and MAPK 
signalling. There seems to be general upregulation of genes involved in the Hippo signalling pathway 
(Figure 3.15A). Metformin increased Wwtr1 expression, which encodes the TAZ transcription factor 
central to the Hippo signalling pathway, as well as its co-transcription partners Tc7 and Tead1 (Figure 
3.15A and 3.15B). Other upregulated genes include upstream regulatory proteins including Stk3, 
Ppp2r2a, Ppp1cb, Rassf6 and Actg1. Casein kinase (Csnk1e), which is involved in the targeted 
degradation of TAZ, was also induced by metformin. Upstream signalling pathways that interact with 
Hippo pathway involve TGFβ, WNT and cell adhesion signalling. TGFβ signalling pathway genes Tgfb2, 
Bmp2, Bmp8 and Bmpr2 were upregulated by metformin; the pathway is involved in the activation of 
Smad transcription factors that associate with YAP or TAZ to coactivate transcription of a specific 
subset of genes. Genes involved in cell function Cdh1 and Ctnna1 were also increased by metformin, 
although they are involved the cytosolic retention of YAP and TAZ. Increased expression of 
downstream YAP/TAZ pathway genes, such as Areg, Afp, Serpine1 and Birc5 was also observed.  
Since the MAPK signalling includes a broad spectrum of pathways activated by stress as well as growth 
factors, EGFR and TNFα signalling pathways were selected for further investigation as they activate 
MAPK signalling under different contexts. Various autocrine/paracrine growth factors involved in the 
EGFR signalling pathway, Areg, Ereg, Btc, Hbegf and Tgfa, and the EGF receptor (Egfr) were 
upregulated by metformin, although Erbb2 was downregulated and Egf expression remain unchanged 
(Figure 3.16A and 3.16B). The ERK arm of the EGFR signalling pathway seem to be increased by 
metformin, notably ERK gene Mapk3 and upstream signalling component Braf, Pak2 and Pak4, but 
the genes Pak6 and Hras were also downregulated. In the PI3K arm of the EGFR pathway, the PI3K 
genes Pik3r1 and Pik3r3 genes were downregulated in metformin treated cultures whilst Akt 
expression was not significantly different. Genes involved in the Ca2+ dependent signalling arm of the 
Prkca and Camk2d of the EGFR signalling pathway were also upregulated by metformin.  
In the TNFα signalling pathway, although the expression of MAPK signalling kinases (Mapk3, Mapk8 
and Mapk13), pro-apoptotic caspases (Casp3, Casp7 and Casp8) and TNFα activated transcription 
factor Creb3 were increased in metformin-treated cultures, TNF-receptor signalling adaptors Ripk1, 
Traf2 and Fadd expression were downregulated (except Tradd, which was increased) (Figure 3.16C 
and 3.16D). Amongst TNFα signalling target genes affected by metformin include leukocyte 
recruitment, activation and cell adhesion/extracellular matrix genes (Figure 3.16D).  
The transcriptomic evidence could potentially suggest that increased EGFR activation by growth 




Figure 3.15. The effect of metformin on the expression of genes involved in the Hippo signalling 
pathway. (A) Heatmap showing DE genes (filtered by p-adjusted value of <0.05) involved in the Hippo 
signalling pathway (pathway ID: mmu04390). Some of the genes shown are involved in other pathways 
and are duplicated from previous figures to show their involvement in this pathway. The colour keys 
showing the z-scores are shown on the right. (B) Schematic showing the expression changes of genes 
involved in Hippo signalling pathway. Red and blue shows the upregulated and downregulated genes, 





Figure 3.16. The effect of metformin on the expression of genes involved in TNFα and EGFR 
signalling. (A and C) Heatmaps showing DE genes (filtered by p-adjusted value of <0.05) involved in 
the EGFR (pathway ID: mmu04012) and TNFα (pathway ID: mmu044668) signalling pathways. Some 
of the genes shown are involved in other pathways and are duplicated from previous figures to show 
their involvement in this pathway. The colour keys showing the z-scores are shown on the right. (B 
and D) Schematics showing the expression changes of genes involved in EGFR and TNFα signalling 
pathways. Red and blue shows the upregulated and downregulated genes, respectively. Schematic is 
adapted from the Pathview versions of the pathways. 
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cultures, although this cannot be conclusive based on transcriptomic data alone. The effects of 
metformin in the TNFα signalling pathway is elusive.  
3.4.2.6 P53 and the cell cycle 
As well as TNFα, the P53 signalling pathway was also identified in the KEGG enrichment analysis. The 
gene Trp53 was unexpectedly downregulated by metformin treatment, as well as its upstream DNA-
damage kinase Atr (Figure 3.17A, 3.17B). However, prominent downstream P53 target genes involved 
in cell cycle arrest (Sfn, Gadd45a, Gadd45b and Gadd45g), apoptosis (Casp3, Casp8, Pmaip1, Shisha5, 
Perp and Zmat3), serpins (Serpine1 and Serpin5), exosome (Steap3) were upregulated in metformin 
treated cultures. Other P53 target genes include downregulated apoptotic genes (Siah1b and Pidd1), 
P53 negative feedback genes (Ccng, Ppm1d) and DNA repair (Sesn3, Rrm2).    
 
Figure 3.17. The effect of metformin on the expression of genes involved in the P53 signalling 
pathway. (A) Heatmap showing DE genes (filtered by p-adjusted value of <0.05) involved in the P53 
signalling pathway (pathway ID: mmu04115). The colour keys showing the z-scores are shown on the 
right. (B) Schematic showing the expression changes of genes involved in the P53 signalling pathway. 
Red and blue shows the upregulated and downregulated genes, respectively. Schematic is adapted 
from the Pathview version of the pathway.  
 
 
As well as P53 target genes involved in cell cycle arrest, other genes directly involved in cell cycle 
regulation was also differentially expressed in metformin treated cultures. In the G1 phase checkpoint, 
metformin decreased the expression of transcription factors E2f1 and Tfdp2 necessary to promote G1 
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progression, but increased the expression of G1 phase regulators E2f5 and Rb1, and CDK inhibitors 
Cdkn2b and Cdkn1c (Figure 3.18A, 3.18B). Metformin also seemed to inhibit S phase progression by 
decreasing the expression of all minichromosome maintenance MCM complex genes, Cdc6, Cdc7 and 
Cdc45, as well as origin recognition complex (ORC) genes Orc5 and Orc6 (although in the latter Orc3 
and Orc4 were upregulated). Cdc25a, which promote both G1 and S phase progression, was 
downregulated in metformin cultures. In the G2 phase checkpoint, metformin decreased the 
expression of Cdc25c, which activate cyclins involved in G2 phase progression. Metformin decreased 
the expression of mitotic spindle assembly checkpoint genes such as Mad1l1, Ttk, Cdc23, Cdc30, 
Separase (Espl1) (which hydrolyses cohesins and triggers anaphase) and Cohesin (Smc1a) but 
increased the expression of Mad2l2 and cohesion gene Stag2. The transcriptomic data suggests that 
metformin could stall cell cycle progression particularly during the G1 and S phases.       
 
  
Figure 3.18. The effect of metformin on the expression of genes involved in cell cycle regulation. (A) Heatmap 
showing DE genes (filtered by p-adjusted value of <0.05) involved in cell cycle regulation (pathway ID: mmu04110). 
Some of the genes shown are involved in other pathways and are duplicated from previous figures to show their 
involvement in this pathway. The colour keys showing the z-scores are shown on the right. (B) Schematic showing 
the expression changes of genes involved in the P53 signalling pathway. Red and blue shows the upregulated and 
downregulated genes, respectively. Schematic is adapted from the Pathview version of the pathway. 
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3.4.2.7 Pyrimidine metabolism and DNA/RNA processes        
Other pathways identified from KEGG enrichment analysis are nucleotide metabolism and DNA/RNA 
processes. 22 out of 58 genes were differentially expressed in the pyridine metabolism pathway, 
metformin downregulated genes favouring pyrimidine nucleotide biosynthesis include nucleotide 
kinases (Nme6, Dtymk, Tk2 and Uck1), ribonucleotide reductase (Rrm2), dCMP deaminase (Dctd) and 
thymidylate synthetase (Tyms) (Figure 3.19A and 3.19B). The nucleotidases (Nt5c2 and Nt5m) were 
also downregulated by metformin. Genes encoding enzymes involved in the catabolism of 
nucleotides, notably Ectonucleotide triphosphate diphosphohydrolase (Entpd3) and 5’-nucleotidase 
(Nt5c1a), were increased in metformin treated cultures (Figure 3.19A and 3.19B). These 
transcriptomic results suggest that metformin might favour nucleotide catabolism over biosynthesis.    
 
Figure 3.19. The effect of metformin on the expression of genes involved in pyrimidine metabolism. 
(A) Heatmap showing DE genes (filtered by p-adjusted value of <0.05) involved in pyrimidine 
metabolism (pathway ID: mmu00240). The colour keys showing the z-scores are shown on the right. 
(B) Schematic showing the expression changes of genes involved in pyrimidine metabolism. Red and 






With the exception of genes Snrnp27, Prpf40b and Sf3b1, metformin robustly decreased the 
expression of genes involved in the spliceosome, the machinery involved in regulating RNA splicing 
(42 out of 133 of genes in the pathway, Figure 3.20A). Metformin robustly downregulated the 
expression of RNA polymerases that regulate transcription (13 out of 30 genes), except Polr2g (Figure 
3.20B). Moreover, metformin decreased the expression of genes involved in DNA replication, except 
DNA polymerase subunit Pold4 (20 out of 35 genes, Figure 3.20C). Metformin also downregulated the 
expression of DNA repair genes except Endonuclease 8-like 1 Neil1 (Figure 3.20D). The RNA-seq data 
provides evidence that metformin might be involved in downregulating the gene-expression 
machinery involved in DNA and RNA processes.               
 
  
Figure 3.20. The effect of metformin on the expression of genes involved in DNA processes. (A-D) 
Heatmaps showing DE genes (filtered by p-adjusted value of <0.05) involved in (A) spliceosome 
assembly (pathway ID: mmu03040), (B) RNA polymerases (pathway ID: mmu03020), (C) DNA 
replication (pathway ID: mmu03030) and (D) DNA repair (pathway ID: mmu03410, 03420 and 
03430). Some of the genes shown overlap with other pathways and may be duplicated. The colour 
keys showing the z-scores are shown on the right of each heatmap. 
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3.5 Discussion  
 
3.5.1 Metformin and glucose/sugar metabolism 
In this study, KEGG enrichment analysis highlighted glycolysis/gluconeogenesis as a key pathway 
altered by metformin treatment, by increasing the expression of hexokinases, phosphofructokinases 
and aldolase A (Figure 3.3, 3.4). Overexpression studies suggested that hexokinases and 
phosphofructokinases were rate-limiting enzymes of glycolysis flux (376). Other studies have shown 
that metformin increased the activity of hexokinase and phosphofructokinase in diabetic 
cardiomyocytes (377). The RNA-seq data in this study also demonstrated that metformin increased 
the expression of malic enzyme isoforms, alanine transaminase and lactate dehydrogenase D; all of 
these are involved in converting pyruvate to metabolites alternative to mitochondrial pyruvate 
oxidation (Figure 3.5). The RNA-seq data suggests that metformin could increase glycolytic flux by 
increasing the expression of these glycolytic enzymes, to generate alternative products such as 
malate, lactate and alanine in response to impaired mitochondrial function.    
The mechanisms that explain how the expression of glycolytic enzymes are regulated by metformin is 
speculative, since this is the first study that shows the effects of metformin on the transcriptomic 
expression of glycolysis genes in intestinal cells. The mechanism might involve AMPK, although the 
transcriptomic data in this study did not identify a particular trend of DE genes within the AMPK 
pathway (Figure 3.13). This is despite substantial evidence demonstrating that metformin activates 
AMPK at the posttranslational level in intestinal tissues (212, 360, 364, 378). A recent transcriptomic 
study into the effects of human hepatocytes investigating the AMPK-dependent and independent 
effects of metformin on transcriptomic responses, reported an upregulation of AMPK-signalling 
pathway components (including the AMPK subunit Prkaa1 and CREB transcription factors); 6-
phosphofructo-2 kinases (which convert fructose-6-phosphate to fructose-2,6-bisphosphate, the 
latter regulates the activity of PFKs) and GLUT1 transporter (Slc2a1) amongst the AMPK-dependent 
pathways activated by metformin, but that study did not report increased expression of glycolysis 
enzymes (365). Moreover, AMPK has been reported to regulate glycolysis at the post-translational 
levels (such as phosphorylation of phosphofructokinases) (379). The role of AMPK in the 
transcriptomic regulation of glycolysis enzyme expression could be investigated in future studies using 
a selective AMPK activator.    
An alternative explanation for the upstream regulation of glycolysis enzyme expression is activation 
of the HIF-1A pathway, since many of the signalling components of the pathway (including Hif1a and 
Arnt) and many HIF-1A target genes were upregulated in metformin treated cultures (Figure 3.14). 
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Previous observations in cancer cell lines reported that metformin (and other electron transport chain 
inhibitors) suppressed HIF-1A signalling as a consequence of impairing oxygen consumption and 
increasing cellular oxygenation capacity in hypoxic conditions (203, 345, 346). However, some studies 
in colorectal cancer cell lines report that metformin increases ROS generation which is known to 
stabilise HIF-1A activity (380, 381). Alternatively, the TCA-cycle metabolite a-ketoglutarate is an 
essential substrate of prolyl hydroxylases that destabilise HIF-1a, thus reduced a-ketoglutarate levels 
associated with reduced TCA-cycle flux and impaired mitochondrial function by metformin could 
increase HIF-1a stability (382). Increased pyruvate and lactate levels due to increased glycolysis 
associated with metformin treatment may also increase HIF-1a levels and stability, as reported in 
cancer cell lines (383). Lactate has been reported as a signal in mediating changes in gene expression 
in response to metabolic changes (384). A recent study reported increased HIF-1A expression in the 
small intestine of mouse models of Roux-en-Y gastric bypass surgery to enhance systematic glucose 
utilisation (42). Therefore, HIF-1A could potentially be a general stress-activated signalling molecule 
activated by metformin in the intestinal cells to increase glucose utilisation by upregulating the 
expression of glycolytic enzymes.  
In the liver, the effect of metformin in the expression of gluconeogenesis genes are well known (215, 
220, 385). DNA microarray analysis of liver samples from obese diabetic db/db mice have highlighted 
G6pc as one of the top genes downregulated by metformin treatment (385). In this study, despite the 
reported downregulation of the gluconeogenesis genes Pck1 and G6pc (Figure 3.4), Pck2 was 
upregulated (Figure 3.4, 3.5) whilst none of the fructose-1,6-bisphosphatase (FBP) expression were 
differentially expressed (data not shown). Conclusions cannot be drawn on the effects of metformin 
on gluconeogenesis in intestinal cells based on the RNA-seq data alone. Indeed, the capabilities and 
contributions of the intestine as a gluconeogenic organ is not entirely clear, although the importance 
of the liver in gluconeogenesis is undisputed with a physiologically important impact on glucose 
homeostasis (179, 386).   
The RNA-seq data also identified transcriptomic changes in the pentose phosphate pathway (PPP) 
(Figure 3.3 and 3.4). The pentose phosphate pathway interacts with glycolysis and uses glucose-6-
phosphate to generate NADPH and ribose as end products (387). The RNA-seq data increased the 
expression of G6pd, the rate-limiting enzyme in the pentose phosphate pathway. Metformin also 
increased the expression of Rpe and Taldo1, enzymes involved in the non-oxidative phase of PPP and 
interacts with glycolysis through fructose-6-phosphate, but decreased the expression of ribokinase 
(Rbk), an enzyme important for ribonucleotide synthesis (Figure 3.4). Bias of the PPP in favouring 
NADPH production verses ribonucleotide generation has been demonstrated in metabolomic 
experiments of mouse livers deficient in Taldo1, which reported increased levels of ADP-ribose and 
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other nucleotides, but significantly lower levels of NADPH and marked oxidative stress (388). The RNA-
seq results suggest that metformin could potentially bias the PPP to favour NADPH production to 
protect against oxidative stress, over ribonucleotide biosynthesis. This needs to be clarified in the 
future by metabolic tracing studies into glucose-6-phosphate metabolism.  
Metformin also changed the expression of genes involved in glycogen metabolism, particularly 
phosphoglucomutases and glycogen synthesis genes (Ugp2 and Gyg) (Figure 3.3). However, the 
transcriptomic evidence is insufficient to suggest that metformin is increasing glycogen synthesis in 
the intestinal cells, since none of the key enzymes involved in glycogen metabolism- glycogen synthase 
(Gys family of genes) and glycogen phosphorylase (Pyg family of genes) are differentially expressed. 
Although glycogen stores have been reported in the intestine (389, 390), their functions are unclear.    
Decreased gene expression for key enzymes involved in fructose metabolism was also observed in 
metformin treated cells (Figure 3.6). There is increased evidence for the role of fructose metabolism 
in the intestine (391, 392). Isotope tracing studies demonstrated that the rat intestine is capable of 
clearing ~90% of fructose at low levels, of which 40% is used for gluconeogenesis (391). Since fructose 
metabolism for gluconeogenesis is an energy consuming process (ketohexokinase function is 
dependent on ATP hydrolysis in addition to other energy consuming steps in the gluconeogenesis 
pathway), decreased fructose metabolism may be a mechanism to conserve ATP expenditure.  
 
3.5.2 Transcriptomic changes of amino acid sensing, transport and metabolism pathways by 
metformin 
Metformin inhibits mitochondrial respiration; this is the main pathway of metabolism for amino acids 
such as glutamine and branched-chain amino acids (BCAAs) (393). Although the RNA-seq data reports 
downregulation of the rate-limiting enzyme for glutamine metabolism glutaminase (Gls), many genes 
associated with aspartate metabolism were increased by metformin treatment (Figure 3.7). Previous 
studies have reported that metformin decreases glutamine metabolism in various cancer cell lines and 
in ovarian tumour biopsies from patients (381, 394, 395). Emerging evidence also demonstrates that 
metformin, through inhibition of mitochondrial respiration and redox balance, reprograms aspartate 
metabolism towards nucleotide biosynthesis in cancer and other highly proliferative cells (396, 397). 
Intestinal cells have a high turnover and metformin could increase the expression of aspartate 
metabolism genes as an adaptive survival mechanism to sustain the biosynthesis of some nucleotides 
(through adenylosuccinate). This should be investigated in the future by tracing aspartate metabolism 
using 13-Carbon labelled glutamine substrates.      
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Despite previous studies demonstrating that metformin disrupts BCAA metabolism in cancer cells 
(394), the effect of metformin on BCAA metabolism is inconclusive based on the transcriptomic data 
alone. Since BCAA metabolism is oxidised in the mitochondria, metformin is likely to reduce BCAA 
oxidation as well through general impairment of mitochondrial function. 
KEGG enrichment analysis also highlighted that the arginine biosynthesis pathway was altered by 
metformin (Figure Figure 3.3, 3.7). Detailed RNA-seq analysis revealed that metformin decreased the 
expression several citrulline biosynthesis genes (Figure 3.7) and the citrulline transporter ORC1 (Figure 
3.5), which hints that metformin might also decrease citrulline biosynthesis. The intestine is a major 
source of citrulline from glutamine sources, which is used for renal arginine biosynthesis via the 
citrulline-arginine cycle (398–400). Elevated citrulline levels have been implicated as a biomarker for 
intestinal inflammation and damage (399, 401, 402). Decreased expression of citrulline biosynthesis 
enzymes by metformin could be a mechanism of ATP conservation.  
The RNA-seq data has also shown that metformin decreased the expression of many broad-spectrum 
amino acid transporters and peptide transporters (Figure 3.8). However, metformin did not influence 
glutamine uptake based on live cell imaging studies using the FRET-based glutamine-sensor using 
duodenal organoids generated from B0AT1 and SNAT2 null mice (Figure 3.8). This suggests that 
transcriptomic changes in glutamine transporters may not correlate with posttranslational/functional 
regulation, or the possibility that reduced transporter expression is compensated by increasing the 
membrane expression of other transporters. The functional studies into glutamine flux do not reflect 
upon the effect of metformin on the uptake of other amino acids, which are often dependent on 
transporters that differ from the ones used for glutamine uptake.         
Detailed inspection of amino acid metabolism pathways in the RNA-seq data showed decreased 
expression of metabolic genes unique to glycine/serine/threonine metabolism and 
cysteine/methionine metabolism (Figure 3.9). These amino acids are involved in folate dependent 
metabolism (enriched in the KEGG analysis), which are important in DNA methylation, purine 
nucleotide biosynthesis and cell proliferation (403–405). In the intestine, glycine and serine 
metabolism have been reported to play a role in DNA biosynthesis (371, 400, 406). Previous studies 
using human cells and mitochondrial myopathy mouse models with defects in mtDNA replication 
causes an imbalance of the methyl cycle and impairs one-carbon metabolism by driving de-novo serine 
and glutathione biosynthesis (373, 374, 407). Induced expression of the mitochondrial folate-
metabolism enzyme Mthfd2 was observed in these mouse models (the gene was also upregulated by 
metformin in this study), causing an imbalance of nucleotide pools. Impaired mitochondrial function 
by metformin could affect flux through this metabolic pathway, which should be investigated in the 
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future using metabolic tracing studies. Decreased metabolism of these amino acids might provide one 
possible explanation for the general transcriptomic downregulation of DNA and RNA processes.   
The mTOR signalling pathway is crucial to the regulation of amino acid metabolism and protein 
synthesis; disruption of mTOR affects intestinal differentiation and homeostasis (408). Metformin has 
been reported to inhibit mTOR signalling and reduce protein synthesis in hepatocytes (221, 222), 
whilst a recent study shows that constitutively activating mTOR in the small intestine of rats (by 
adenoviral delivery) decreased the glucose infusion rate (performed under euglycaemic clamp 
conditons) stimulated by metformin (363). The RNA-seq data in this study does not provide conclusive 
evidence that metformin regulates mTOR signalling pathways in the intestinal cultures (Figure 3.13). 
It is likely that regulation of mTOR signalling by metformin could occur at the post-translational level; 
the effect of metformin on the expression of the various mTOR complex proteins should be 
investigated in future studies.  
 
3.5.3 Metformin and intestinal lipid metabolism 
Fatty acid biosynthesis, cholesterol metabolism and PPAR signalling were pathways highlighted from 
the KEGG enrichment analysis, although detailed examination showed that each pathway includes 
both upregulated and downregulated genes, even in the same enzyme isoforms (Figure 3.10 and 3.11). 
Based on the transcriptomic data alone, no conclusions could be drawn into the effects of metformin 
on intestinal lipid metabolism and PPAR signalling. This is by contrast to studies in other tissues such 
as adipocytes and hepatocytes, where the impact of metformin on lipid metabolism is more robust 
(210, 211, 233, 366, 409). GO analysis of RNA-seq data of subcutaneous adipose tissue from elderly 
participants on metformin have similarly identified overrepresentation of pathways associated with 
lipid metabolism such as biosynthesis of unsaturated fatty acids, PPAR and SREBP signalling (366). 
Metformin alters adipose tissue metabolism by decreasing the release of FFA from adipose tissue, 
promoting VLDL triglyceride clearance or increasing fatty acid oxidation (233, 409). Metformin is 
known to reduce cholesterol synthesis and promote fatty acid oxidation via the AMPK pathway in liver 
hepatocytes (210, 211). Furthermore, the PPARγ signalling pathway is an essential signalling pathway 
regulating metabolism in liver and adipose tissues (410), but its role in intestinal metabolism is still 
elusive. This might suggest that most intestinal cells are probably less reliant on lipids as a source of 
fuel, whilst lipid storage and fatty acid oxidation are likely important metabolic functions in liver and 




3.5.4 Transcriptomic effects of metformin to signalling pathways and cellular processes 
Autophagy is associated with nutrient deprivation and energy stress, and numerous studies have 
demonstrated the role of metformin in inducing autophagy (352–355). The RNA-seq data shows that 
metformin induced the expression of genes encoding lysosomal hydrolases, lysosomal membrane 
proteins and the V-type H+ ATP-ase (Figure 3.12), which may suggest increased activation of autophagy 
pathways in intestinal cells. AMPK is an essential regulator for autophagy, since knockout of AMPK 
causes defective autophagy in mouse hepatocytes (411). AMPK has been reported to directly 
phosphorylate autophagy regulators such as the Beclin-1 complex and ULK-1 (411–414), or via an 
indirect mechanism involving mTOR inhibition (353). In the intestine, autophagy is an essential 
regulator of host defence and tissue homeostasis (415, 416). Genetic variants of autophagy genes 
have been associated with the risk of inflammatory diseases, and mutations causing autophagy 
defects disrupt intestinal tissue integrity and functions of paneth cells (417–420). Metformin induced 
autophagy in intestinal cells could be an adaptive response to preserve intestinal mucosal function in 
an energy-stress environment or to remove defective mitochondria (via mitophagy) caused by the 
inhibitory effects of metformin on mitochondrial metabolism (411, 421). Further studies should 
functionally verify the induction of autophagy markers (such as LC3 or Beclin-1) in intestinal cells to 
confirm transcriptomic observations.  
This study also reported the effects of metformin on new signalling pathways, which to our 
knowledge, have not previously been described in the literature. Metformin increased the expression 
of key Hippo signalling pathway genes, particularly Wwtr1, its upstream regulators and many Hippo 
signalling target genes (Figure 3.15). The Hippo signalling pathway is activated to control cell growth 
and organ size, and emerging evidence demonstrate its role in intestinal tissue regeneration and 
controlling stem cell fate by antagonising WNT signalling (422–424). Direct evidence between 
metformin and the Hippo signalling pathway is unknown, although AMPK and LKB-1 has been reported 
to regulate Hippo signalling (425–428).  
Metformin also increased the expression of many EGF family of growth factors, EGFR and MAPKs 
(Figure 3.16). This is unexpected since mitochondrial and energy stress caused by metformin seemed 
to inhibit growth signalling pathways to limit proliferation, and EGFR is important for growth of 
intestinal stem cells and crypt expansion (429–431). Whether metformin activates the EGFR signalling 
pathway at a posttranslational level is undetermined and should be investigated in the future. Since 
metformin causes the activation of stress pathways which can lead to growth arrest, senescence and 
apoptosis, concurrent activation of MAPK signalling may potentially be an adaptive counter-
mechanism to ensure survival in intestinal cells.      
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The KEGG enrichment analysis highlighted stress and inflammatory pathways, such as TNFα, IL-17 and 
RIG-1 like receptor signalling altered by metformin treatment. However, detailed examination of the 
expression profiles within the TNFα signalling pathway, which also mediate its effects via MAPK albeit 
differences in other signalling components and transcriptional targets, are inconclusive (Figure 3.16). 
A recent study reported that metformin treatment did not alter TNFα, IFN-γ nor IL-1β mRNA 
expression in the ileum of wild-type mice, but attenuated the elevated expression of these cytokines 
in a IL-10 knockout mouse model of inflammatory bowel disease (360). In that study, metformin 
treatment reduced the abundance of M1 macrophages in the ileum of the IL-10 knockout mice and 
improved barrier integrity in Caco-2 cells via activating an AMPK-dependent pathway (360).    
KEGG enrichment analysis highlighted the cell cycle and P53 signalling pathways. Although no 
conclusions could be drawn based on investigating the effects of metformin on the P53 signalling 
pathway, metformin alters the expression profiles of genes which promote cell cycle arrest (Figure 
5.17 and 5.18). A previous study demonstrated that metformin regulates genes to promote cell cycle 
arrest in cancer cells (348, 349, 432). In vivo morphological analysis of mouse ileum demonstrates that 
metformin administration increased villus length and staining for Paneth and goblet cells, without 
altering either the length of crypts or Ki67 proliferative marker expression (360). The authors from the 
study suggested that metformin promoted intestinal differentiation (360). Another study reported 
increased crypt proliferation, reduced expression of intestinal differentiation markers and decreased 
the height of mucosa in a villin-cre specific AMPKα knockout mouse model (433). Perhaps by 
promoting cell cycle arrest of intestinal progenitors, metformin could alternatively increase the 
differentiation of the intestinal progenitors via an AMPK-dependent mechanism.  
The RNA-seq analysis also decreased the expression of genes involved in RNA polymerases in gene 
transcription, DNA replication, repair and the spliceosome (Figure 5.20), which may suggest 
deactivation of these energetically expensive processes (434). Analysis of pyrimidine metabolism 
pathways show that metformin generally downregulates genes involved in nucleotide biosynthesis 
but increase the expression of some genes that catabolise nucleotides, potentially causing an 
imbalance or reduction of the nucleotide pool for DNA processes (Figure 5.19). Other contributions to 
an imbalanced nucleotide pool could come from alterations in the PPP, folate dependent metabolism 
and aspartate metabolism. Perhaps reduced nucleotide metabolism could explain decreased DNA 
replication in metformin treated cultures and increased expression of cell cycle arrest genes in 
metformin treated cultures. Particularly, all of the genes encoding MCM complexes that initiate 
chromosome replication were downregulated in metformin treated cells, suggesting that reduced 





In this study, bulk RNA-seq provided detailed examination of the metabolic and signalling pathways 
affected by metformin in intestinal cells. The RNA-seq analysis complemented existing studies that 
metformin altered pathways associated with glycolysis/gluconeogenesis, autophagy, the cell cycle and 
DNA/RNA processes, which are likely to play important roles in intestinal homeostasis and regulate 
the metabolism of intestinal cells. The data also provided insights into the potential roles of metformin 
in novel pathways, such as amino acid metabolism, EGFR/MAPK, Hippo and HIF-1A signalling, which 
may suggest additional mechanisms of action in intestinal cells.  
Transcriptomic analysis poses limitations in understanding the cellular processes that can also be 
influenced by translational and posttranslational control, or through compensatory mechanisms. For 
example, no difference in glutamine uptake was observed despite decreased mRNA expression of 
many amino acid transporters. A combination of transcriptomic, proteomic and metabolic analysis 
















Growth differentiation factor 15 (GDF-15) is a well-established marker of cellular stress and is a 
recently discovered metabolic stress hormone associated with appetite regulation. Serum GDF-15 
levels are highly elevated in patients receiving metformin treatment, which is speculated to contribute 
to weight loss effects of the drug (76, 276, 295). The cellular mechanisms by which metformin induces 
GDF-15 secretion is unknown. The RNA-seq data identified GDF-15 as one of the most significantly 
upregulated genes in metformin treated intestinal cultures (see chapter 3). This is supported by 
experiments in HFD-fed mice orally administered with metformin, which reported induction of GDF-
15 only in the proximal, distal small intestine and the colon, demonstrating the importance of the 
gastrointestinal tract in stimulating GDF-15 release (321). This chapter examines the cellular 




4.2.1 GDF-15 as a metabolic hormone  
The first insights into the metabolic effects of GDF-15 were from studies by Johnen et. al., who 
reported that mice bearing tumours overexpressing GDF-15 were cachexic and anorexic (291). When 
GDF-15 was injected into mice, or using transgenic mice overexpressing GDF-15, reduced food intake 
and secondary weight loss were observed without any effects on energy expenditure (291). GDF-15 
null mice were reportedly more obese when exposed to standard chow or high fat diet (HFD) than 
wild-type mice (292, 294). In human studies, GDF-15 levels were also elevated in obese patients, not 
just in patients with substantial weight loss, possibly due to increased adiposity during obesity and the 
ability of the adipose tissue to release GDF-15 (435, 436).  
Experiments in mice have demonstrated that GDF-15 administration directly results in conditioned 
taste aversion, whereby the animal associates the taste of a certain food with a toxic or aversive 
substance (287). The results indicate that the effects of GDF-15 on food intake involves a central 
mechanism. Interventricular administration of GDF-15 in mice led to reduced food intake and body 
weight, whereas intraperitoneal injection of GDF-15 increased cFos activation in the Area Postrema 
(AP) and the Nucleus Tractus Solitarii (NTS) of the brainstem, brain regions associated with nausea 
90 
 
and vomiting (293). Selective lesioning of these areas abolished the anorexigenic effects of GDF-15 
(293). Recent studies by Yang et. al., used cell-surface display screening of 2,762 potential 
transmembrane domains and identified GDNF family α-receptor like A (GFRAL) as a high affinity 
cognate receptor for GDF-15 (295). GFRAL associate with the receptor RET to form a heterodimer 
upon GDF-15 binding to facilitate signal transduction (295). The importance of GFRAL were 
demonstrated in knockout mice, which abolished the anorexigenic and weight-loss effects of GDF-15 
as well as sustained weight gain in response to HFD (295). Analysis of tissue expression of GFRAL found 
that they are only expressed in a selective number of neurons located exclusively in the NTS and AP 
of the brainstem (295). This reinforces the importance of GDF-15/GFRAL axis in the central regulation 
of food intake and body weight.   
Interestingly, transgenic mice with elevated GDF-15 levels also showed improvements in glucose 
tolerance and insulin sensitivity following high fat diet (HFD) (291). Some studies reported that GDF-
15 levels are transiently elevated in response to an oral glucose tolerance test, whilst euglycaemic 
hyperglycaemic clamp studies in obese women reported transient elevations in GDF-15 (437, 438). 
These studies suggest that acute changes in GDF-15 levels may correlate with insulin levels, although 
many of the patients in the study were also taking metformin, which could increase serum GDF-15 
levels (see Section 4.2.3 below) (437, 438). Furthermore, obese women with T2DM displayed elevated 
GDF-15 levels compared to obese women without diabetes (439). However, the physiological role of 
GDF-15 in diabetes is not completely understood to date (289).   
4.2.2 Mechanisms of GDF-15 induction 
GDF-15 was initially reported as a stress-responsive hormone elevated in various animal models of 
tissue injury, such as chemically induced liver and lung injury, surgical nephrectomy, ischaemic 
reperfusion injury and dilated cardiomyopathy (284, 285, 440, 441).  GDF-15 is also elevated in 
response to tissue inflammation, as in rheumatoid arthritis or liver cirrhosis (442, 443). GDF-15 has 
been reported to limit the extent of tissue damage, but its physiological role during injury and 
inflammation are incompletely understood (441, 443). Inflammatory markers such as C-reactive 
protein (CRP) have been reported to induce GDF-15 expression via the P53 pathway, which directly 
interacts with the Gdf15 promoter (444, 445). Activation of the NF-kB signalling pathway have also 
been reported to trigger GDF-15 induction by tumour cells to suppress the activity of inflammatory 
macrophages (446).  
GDF-15 is especially elevated in patients with mitochondrial diseases, a heterogeneous spectrum of 
genetically inherited disorders caused by mutations in proteins localised in the mitochondria which 
cause mitochondrial dysfunction (447, 448). Transcriptomic studies of skeletal muscle biopsies from 
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patients with mitochondrial encephalomyopathy caused by mutations of the thymidine kinase (Tk2) 
gene demonstrated substantial overexpression of GDF-15 amongst other genes associated with the 
P53 signalling pathway (449). Subsequent studies have identified elevated serum levels of GDF-15 and 
a similar stress-responsive hormone FGF-21 in patients with various mitochondrial disorders (447, 
448).    
Various in vivo and cellular models demonstrate that GDF-15 induction by cellular stressors are 
associated with the integrated stress response (ISR) (286, 374). Using a mouse model of mitochondrial 
myopathy caused by muscle specific mutations of the Twinkle mtDNA helicase (associated with 
mtDNA replication), Khan et. al., demonstrated induction of GDF-15 and FGF21 coinciding with ISR 
genes and mitochondrial unfolded protein response (mtUPR) genes downstream of mTORC1 
activation (374). Similarly, mouse models of mitochondrial myopathy due to mutations of the Crif1 
gene causing defective ribosomal translation, and global knockout of Polg (mitochondrial targeted 
DNA polymerase) caused GDF-15 overexpression and elevated serum levels associated with mtUPR 
and ISR genes (286). Inhibitors that disrupt mitochondrial dysfunction all associate with general ISR 
activation via induced ATF4 and CHOP expression (450). Recent studies by Patel et. al., demonstrated 
that other stressors that activate the ISR pathway, such as defective ER glycosylation, protein 
misfolding and hypoxia also caused an overexpression of GDF-15 in Mouse Embryonic Fibroblast (MEF) 
cells (287). CHOP has been demonstrated to bind directly to the promoter of GDF-15 to elicit gene 
expression, demonstrating that GDF-15 induction is directly regulated by ISR (451).  
4.2.3 Metformin and GDF-15  
A large scale clinical study (called the ORIGIN trial) involving 8,401 T2DM patients (and from this cohort 
2,317 patients on metformin) identified GDF-15 as a novel biomarker from a panel of 237 potential 
biomarkers that is strongly linked to the use and dosage of metformin (276). A recent study from the 
SUMMIT cohort of 1,438 patients with a history of T2DM and cardiovascular disease, revealed that 
metformin use was associated with a 40% elevation of serum GDF-15 levels that is independent of 
other factors (277). In a recent transcriptomic analysis of human hepatocytes pre-treated with 
metformin, Gdf15 was amongst the top upregulated genes associated with an AMPK-independent 
pathway of metformin action (365).  
As mentioned in chapter 3, Gdf15 is one of the most significantly upregulated genes in metformin 
treated intestinal 2D monolayer cultures (Figure 3.1). In a collaboration with Steve O’Rahilly and 
others, we have reported that metformin use in obese non-diabetic patients from the CAMERA clinical 
trial was associated with elevated GDF-15 levels (321). Metformin prevented weight gain in HFD mice 
but not in GDF15 and GFRAL knockout mice, demonstrating that the modest anorexigenic effects of 
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metformin are associated with GDF-15 (321). To investigate the site of metformin action, oral 
administration of metformin (single dose for 6 hours or long-term dosage for 11 days) elicited Gdf15 
mRNA expression in the small intestine, the colon and the kidneys, suggesting the potential 
involvement of these organs in the elevations of GDF-15 in response to metformin administration 
(321).   
 
4.3 Aims 
This chapter expands the investigation into the cellular mechanisms by which metformin causes GDF-
15 induction in the intestine.  The aims of this study are:  
1. To examine the mechanisms of mitochondrial stress caused by metformin in stimulating GDF-
15 secretion in intestinal organoids. 
2. To identify metformin responsive genes and pathways associated with mitochondria function 
to better understand the link between metformin and GDF-15 release. 




Note: Experiments involving metformin oral dosing in HFD-fed mice and RNA-extraction of organs 
were performed by Tony Coll, Irene Cimino and Debra Rimmington.  
4.4.1. Mitochondrial stress and GDF-15 induction in intestinal cells 
The effects of Gdf15 induction was compared with other GDF family growth factors, FGF family of 
growth factors and other known stress activated growth factors to investigate whether metformin 
treatment causes a general upregulation of stress hormones. Compared to other growth factors, the 
induction of Gdf15 expression by metformin was the most robust (Figure 4.1A). Metformin also, to a 
lesser extent, increased the expression of Fgf15, a hormone released in the GI tract involved in bile-
acid synthesis, and Tgfb1, the cytokine involved in inflammatory stress (Figure 4.1A). Metformin 
modestly increased the expression of Fgf21, another hormone that is induced by stress, although the 
expression of Fgf21 is very low compared to Gdf15 and other growth factor genes. Metformin 
treatment downregulated Gdf9 but was without effect on the expression of Gdf11 and other TGF-β 
growth factors. Confirming RNA expression studies, metformin also significantly increased the 
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secretion of GDF-15 in mouse duodenal organoids (between 2-6-fold) and ileal organoids (between 2-
3 fold) over a 24-hour period (Figure 4.1B and 4.1C). 
 
 
To provide some insight into how metformin elicited GDF-15 secretion, intestinal 2D monolayer 
cultures generated from mouse duodenal organoids were incubated with various inhibitors for 24 
hours. Rotenone, which like metformin inhibits Complex I of the electron transport chain, induced 
GDF-15 secretion response by 3.2 fold at a similar magnitude as metformin (4.1 fold) (Figure 4.2A and 
4.2B). Interestingly, the complex III inhibitor Antimycin A induced a more marked GDF-15 secretion 
response by 15.5 fold (Figure 4.2A and 4.2B). Other mitochondrial inhibitors such as the proton 
uncoupler FCCP (which dissipates the mitochondrial membrane potential) and the mitochondrial 
pyruvate carrier inhibitor UK-5099 (to investigate the effects of mitochondrial pyruvate oxidation from 
glucose metabolism) did not significantly increase GDF-15 secretion (Figure 4.2A and 4.2B). The AMPK 
activator Az-991 (to mimic the AMPK-dependent signalling arm of metformin) did not significantly 
increase GDF-15 secretion either (Figure 4.2B). Since other mitochondrial electron transport chain 
inhibitors in addition to metformin also stimulates GDF-15 secretion, the results suggest that 
metformin stimulates GDF-15 secretion through a mitochondrial dependent mechanism, but was 
independent to AMPK activation. 
Figure 4.1. Metformin stimulates Gdf15 expression and secretion in intestinal cultures. (A) The effect of 
metformin on the expression of Gdf15, other GDF family of growth factors, FGF family of hormones and TGF family 
of paracrine factors. The raw count data for each gene is normalised by the size factors and the library size. *, 
P<0.05, **, P<0.01, ***, P<0.001 (P-adjusted values calculated via DE-Seq analysis). N=6 plates from 2 different 
organoid lines. (B and C) Metformin (1mM) pre-treatment stimulates GDF-15 secretion in intestinal cultures 
generated from (B) mouse duodenal organoids (Control: N= 18 wells, Metformin: N=17 wells, 3-5 wells assessed 
in parallel from 5 independent experiments) and (C) mouse ileal organoids (N=9 wells from 3 independent 
experiments). Secretion normalised to the control. Results presented as mean ± SEM. Different colours represent 




Given that metformin inhibits Complex I activity (which oxidises NADH to NAD+ in the mitochondria), 












investigated by supplementing 2D organoid cultures with nicotinamide mononucleotide (NMN) to 
stimulate NAD+ biosynthesis via the nicotinamide mononucleotide adenylyltransferase NMNAT in the 
NAD+ salvage pathway (Figure 4.3A). Since NMN affects both mitochondrial and cytosolic NADH/NAD+ 
redox states, the effects of the compound duroquinone, which elicits NAD+ synthesis as a substrate 
for the cytosolic quinone reductase NQO1 was investigated in metformin treated cultures (Figure 
4.3A) (452, 453). NMNATs and NQO isoforms are all expressed in intestinal cells, and metformin 
induced Nqo1 expression (Figure 4.3B and 4.3C). NMN supplementation reduced metformin 
stimulated GDF-15 secretion in both of the experiments, whilst duroquinone was without effect 
(Figure 4.3D). The results implicate the role of mitochondrial NADH/NAD+ redox state in metformin 
stimulated GDF-15 secretion.  
Metformin has been shown to stimulate ROS generation in cancer cell lines (381). The role of ROS in 
metformin stimulated GDF-15 secretion in intestinal cells were investigated by treatment with 
Figure 4.2. Inhibitors of the electron transport chain stimulate GDF-15 secretion in intestinal cells. 
(A) Schematic showing the mechanisms of action of metformin and different mitochondrial respiration 
inhibitors. (B) GDF-15 secretion in mouse duodenal 2D monolayer cultures pre-treated with 
metformin (1mM, N=12 wells, 3 wells assessed in parallel from 4 independent experiments), antimycin 
A (10µM, N=9 wells, 3 wells from 3 independent experiments), rotenone (10µM, N=9 wells, 3 wells 
assessed in parallel from 3 independent experiments), UK-5099 (10µM, N=3 wells from 1 experiment), 
FCCP (10µM, N=9 wells, 3 wells from 3 independent experiments) and Az-991 (10µM, N=9 wells, 3 
wells assessed in parallel from 3 independent experiments) for 24 hours. Secretion is normalised to 
the control (N=9 wells, 3 wells assessed in parallel from 3 independent experiments). Results 
presented as mean ± SEM. *, P<0.05, ***, P<0.001. One-way ANOVA and Bonferroni post-hoc test.  
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mitochondrial targeted ROS inducers and antioxidants. Co-treatment with MitoTEMPO, a 













superoxides (454), modestly decreased metformin-stimulated GDF-15 secretion (in 3 out of 4 
experiments) but also modestly increased basal GDF-15 secretion in one experiment (Figure 4.4A and 
4.4B). Elevation of mitochondrial ROS using MitoParaquat (MitoPQ), a mitochondrial targeted redox 
cycler that elevates superoxide production (455), and MitoCDNB1, which disruption of thiol redox 
state by inhibiting glutathione-S-transferases (GSTs) and deplete mitochondrial glutathione (456), 
both modestly stimulated basal GDF-15 secretion (Figure 4.4B). The results suggest that mitochondrial 
ROS may make a small contribution to GDF-15 secretion and may be involved in metformin-stimulated 
GDF-15 secretion. It is unknown whether cytosolic ROS could play a more important role (since 
Figure 4.3. Restoring mitochondrial NADH/NAD+ redox balance reduces metformin-stimulated GDF-15 secretion. 
(A) Schematic showing the mechanisms of action of metformin, nicotinamide mononucleotide (NMN) and 
duroquinone. (B and C) The effect of metformin on the expression of (B) NMNATs and (C) NQOs. The raw count data 
for each gene is normalised by the size factors and the library size. ***, P<0.001 (P-adjusted values calculated via DE-
Seq analysis). (D) GDF-15 secretion in mouse duodenal 2D monolayer cultures co-treated with control or metformin 
(1mM) for 24 hours with NMN (5mM) and Duroquinone (50µM). Cultures were pre-treated with NMN or Duroquinone 
for an hour prior to co-treatment with or without metformin.  Secretion is normalised to the control. Results presented 
as mean ± SEM. N=6 wells, 3 wells assessed in parallel from 2 independent experiments. ***, P<0.001. Two-way 
ANOVA and Bonferroni post-hoc test.  
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MitoTEMPO may not eliminate all superoxide released from to the cytosolic side of Complex III), and 







The effects of the drugs that alter mitochondria protein homeostasis (proteostasis) were also 
investigated, since they have previously been shown to induce the mtUPR response which was linked 
to GDF-15 secretion (450). Co-treatment with doxycycline, an inhibitor of mitochondrial translation 
(457), stimulated GDF-15 secretion in control cultures, but did not further stimulate GDF-15 secretion 
in the presence of metformin in 3 out of 4 experiments, whereas there seems to be an additive effect 
in one experiment (Figure 4.5A and 4.5B). Actinonin, which affects the de novo turnover of 
mitochondrial proteins (458), further stimulated GDF-15 secretion in metformin co-treated cultures, 
and seemed to increased basal GDF-15 secretion, although not statistically significant (P=0.1644, 
Figure 4.5A and 4.5C).  Co-treatment with mitoBloCK6, an inhibitor of mitochondrial protein import 
through TIM22 and Mia40/Erv1 pathways (459), stimulated additional GDF-15 secretion in control and 
metformin treated cultures (Figure 4.5A and 4.5D). Ciprofloxacin, which inhibits mtDNA replication by 
inhibiting mitochondrial topoisomerases from relaxing its supercoil structure also further stimulated 
GDF-15 secretion in both control and metformin treated cultures (Figure 4.5A and 4.5E). These results 
Figure 4.4. The effect of ROS in metformin-stimulated GDF-15 secretion. (A) Schematic showing the mechanisms 
of action of metformin, and different mitochondrial ROS stimulators. (B) GDF-15 secretion in mouse duodenal 2D 
monolayer cultures pre-treated with MitoPQ (5µM, N=9 wells, 3 wells assessed in parallel from 3 independent 
experiments), MitoCDNB1 (5µM, N=6 wells, 3 wells assessed in parallel from 2 independent experiments) or 
metformin (1mM, N=12 wells, 3 wells assessed in parallel from 4 independent experiments) with MitoTEMPO 
(100µM N=9 wells, 3 wells assessed in parallel from 3 independent experiments). Secretion is normalised to the 
control (N=12 wells, 3 wells assessed in parallel from 4 independent experiments). Cultures were pre-treated with 
MitoTEMPO for an hour prior to co-treatment with or without metformin. Results presented as mean ± SEM. Basal 
control: N=12 wells, 3 wells assessed in parallel from 4 independent experiments. *, P<0.05, **, P<0.01, ***, 




suggest that mitochondrial translation, and not mitochondrial protein import or protein turnover, may 










Figure 4.5. The effect of mitochondrial proteostasis inhibitors in GDF-15 secretion. (A) Schematic 
showing the mechanisms of action of doxycycline, actininonin and MitoBloCK6 in the mitochondria. 
(B-D) GDF-15 secretion in mouse duodenal 2D monolayer cultures pre-treated with metformin (1mM) 
with (B) doxycycline (50µM, N=12 wells, 3 wells assessed in parallel from 4 independent experiments), 
(C) actinonin (100µM, N=9 wells, 3 wells assessed in parallel from 3 independent experiments), (D) 
MitoBloCK6 (50µM, N=6 wells, 3 wells assessed in parallel from 2 independent experiments) and (E) 
ciprofloxacin (100µg/ml, N=6 wells, 3 wells assessed in parallel from 2 independent experiments). 
Cultures were pre-treated with doxycycline, actinonin, MitoBloCK6 or ciprofloxacin for an hour prior 
to co-treatment with or without metformin. Secretion is normalised to the control. Results presented 
as mean ± SEM. *, P<0.05, ***, P<0.001 compared to control. ###, P<0.001 compared to metformin. 




4.4.2. The effect of metformin on the expression of mitochondria-associated genes 
Further insights into mechanisms of metformin stimulated GDF-15 secretion could be gained from 
investigating the expression profiles of genes assoaciated with the mitochondria function. Sub-
analysis of expression profiles from 1,158 nuclear-encoded genes associated with or localised to the 
mitochondria were performed using the MitoCarta 2.0 database (460). 1,056 out of 1,158 genes were 
mapped to the database, and 289 DE genes (27.3%) were identified. The most statistically significant 
DE genes from the MitoCarta 2.0 database are shown as a volcano plot (Figure 4.6A). Gene ontology 
(GO) enrichment analysis was conducted to identify the mitochondrial processes altered in the 
metformin treated cultures. The top 30 GO terms associated with upregulated genes mostly involve 
 
  
Figure 4.6. RNA-seq analysis of mitochondria associated genes based on the MitoCarta 2.0 database. (A) Volcano 
plot displaying the fold change (X-axis) compared to the P-adjusted values (Y-axis) of individual genes altered by 
metformin treatment. Red dots represent gene expression changes that were statistically significant (P<0.05), 
whilst black dots represent gene expression changes that were not statistically significant (Not Sig). Labelled genes 
represent the top 50 most differentially expressed genes (sorted by P-adjusted values). Con; Control, Met; 
Metformin. (B and C) Gene ontology (GO) analysis of (B) upregulated and (C) downregulated genes altered by 
metformin. Hits (%) is the number of differentially expressed (DE) genes in a particular GO term divided by total 
number of genes in the pathway. Count represents the numbers of DE genes in the GO term. P adjusted value is 
the P-value corrected for the false-discovery rate using the Benjamin-Hochberg method, with more statistically 
significant values representing greater shading intensity. 
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metabolic processes, although the terms were <15% hit, except for mitochondrial protein processing 
(Figure 4.6B). The top 30 GO terms associated with downregulated genes particularly include RNA 
processes and genome maintenance (Figure 4.6C). The hit % of downregulated GO processes were 
much more dispersed (between 5%-40% hit), which may suggest more notable influences of 
metformin on mitochondrial DNA and RNA processes (Figure 4.6C).  
The effect of metformin on the expression profiles of mitochondrial and cytosolic translation 
machinery were investigated since many of the downregulated GO terms were tRNA processes and 
translation. 8 out of 17 genes encoding mitochondrial aminoacyl tRNA synthetases were DE genes, 
with 7 downregulated and 1 upregulated by metformin (Figure 4.7A). In comparison, only 2 out of 25 
cytosolic aminoyacyl tRNA synthetases were DE genes (aminoacyl tRNA synthetase complex 
interacting protein Aimp2 and cysteinyl tRNA-synetase Cars) (Figure 4.7B). Similarly, 18 out of 78 
genes encoding mitochondrial ribosomes were DE genes, with 15 downregulated genes and 3 genes 
induced by metformin (Figure 4.7C). This was compared to only 7 out of 94 cytosolic ribosomes 
identified as DE genes (Figure 4.7D). Metformin also markedly decreased the expression of essential 
genes involved in mitochondrial DNA replication, particularly mitochondrial DNA polymerases (Polg 
and Polg2), mitochondrial RNA polymerase (Polrmt), mtDNA helicases (Twnk, Dna2), mtDNA 
ribonuclease (Rnaseh) and mitochondrial nucleotide metabolism enzymes (Mgme1, Ung, Apex2 and 
Tk2) (Figure 4.7E). These results indicate that metformin downregulates the expression of genes 
involved in mitochondrial translation and mtDNA replication.  
The effect of metformin on other aspects of mitochondrial function were also explored. The effects of 
metformin on the expression of mitochondrial import proteins were mixed- downregulation of inner 
membrane translocases (Timm8a1, Timm9 and Timm22), upregulation of mitochondrial peptidases 
(Pmpca and Pmpcb), as well as altered expression of outer membrane translocases (Tomm40l 
increased, Tomm5 decreased) and inner mitochondrial membrane proteases (Immp2l increased, 
Immp1l decreased) (Figure 4.8A). Amongst the genes associated with mitochondrial protein folding, 
metformin increased the expression of key genes encoding proteases involved in the mtUPR response 
(Lonp1, Yme1l1 and Oma1) and mitochondrial chaperones (Hspa9, Grpel2 and Dnajc2, although 
Dnajc11 was downregulated) (Figure 4.8B). The effects of metformin in the expression of oxidative 
phosphorylation genes were inconclusive, with up- and down-regulation of some complex enzyme 
subunits such as cytochrome c oxidases (Cox18 increased, Cox10 decreased) and NADH 
dehydrogenases (Ndufc2 and Ndufaf6 increased, Ndufaf4 decreased) (Figure 4.8C). Furthermore, no 
conclusions could be drawn on the effects of metformin on mitochondrial dynamics; whilst the 
mitochondrial fission protein Mtfp5, the mitophagy GTPase Rab35 and the mitophagy kinase Pink1 




Figure 4.7. Metformin decreased the expression of genes involved in mitochondrial translation 
and mtDNA replication. (A-D) Volcano plot displaying the fold change (X-axis) compared to the P-
adjusted values (Y-axis) of genes encoding (A) mitochondrial tRNA aminoacyl synthetases (B) 
cytosolic tRNA aminoacyl synthetases (C) mitochondrial ribosomal proteins and (D) cytosolic 
ribosomal proteins. Red dots represent gene expression changes that were statistically significant 
(P<0.05), whilst black dots represent gene expression changes that were not statistically significant 
(Not Sig). Labelled genes represent DE genes. (E) Heatmap showing DE genes (filtered by p-adjusted 
value of <0.05) involved in mtDNA replication, transcription and repair affected by metformin 







Figure 4.8. The effect of metformin on the expression of genes involved in mitochondrial processes. (A-E) 
Heatmaps showing DE genes (filtered by p-adjusted value of <0.05) involved in (A) mitochondrial protein import 
(B) Mitochondrial protein folding, , (C) oxidative phosphorylation (D) mitochondrial dynamics, (E) ROS defences and 
(F) mitochondrial Ca2+
 
signalling. The colour key depicts the z-score and is shown on the right of each heatmap. N=6 




Mff, Mtfr1l, Dnm1l and mitochondrial fusion protein Opa1 were also upregulated (Figure 4.8D). 
Metformin did not cause marked changes in the expression of genes involving ROS defences (Figure 
4.8E), Metformin increased the expression of genes associated with mitochondrial Ca2+ signalling, 
including the mitochondrial Ca2+ uptake transporter complex Mcu, Micu1 and Afg3l2 (although the 
regulatory protein Mcur1 was downregulated), the mitochondrial Ca2+ transport channel Vdac1 and 
the Ca2+ dependent mitochondrial phosphate carrier Slc25a33 (Figure 4.8E).  
4.4.3. Metformin activates ISR and the HIF-1A signalling pathway to stimulate GDF-15 induction 
Since GDF-15 induction is associated with activation of ISR in response to a number of stressors 
including mitochondrial dysfunction (287, 450), the possibility of ISR activation as part of metformin 
stimulated GDF-15 secretion were explored. From the intestinal tissues in HFD-fed mice, oral dosing 
of metformin for 6 hours elicited an increase in Ddit3 expression (which encodes the CHOP  
  
Figure 4.9. Metformin induces Ddit3 (CHOP) expression in the intestines of HFD-fed mice. (A-C) HFD-fed mice fed 
with a single dose of 600mg/kg metformin for 6 hours induced Ddit3 expression in (A) proximal small intestine (SI) and 
(C) colon, but not (B) distal SI. mRNA analysis of fresh frozen tissue normalised to expression levels of b-actin (Actb). 
N=6-7 mice per group. *, P<0.05. Two-tailed independent t-test. (D and E) HFD-fed mice fed with 300mg/kg metformin 
for 11 days induced Ddit3 expression in (D) distal SI and (E) colon. mRNA analysis of fresh frozen tissue normalised to 
expression levels of b-actin (Actb). N=6 mice per group. *, P<0.05. Two-tailed independent t-test.  
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transcription factor activated during ISR) in the proximal small intestine and colon, but not the distal 
small intestine (Figure 4.9A-4.9C). These segments of the intestine coincided with induction of Gdf15 
mRNA expression by metformin treatment (321). Similarly, long-term oral treatment of metformin for 
11 days also increased Ddit3 mRNA expression in the distal small intestine and colon (Figure 4.9D and 
4.9E), which correlates with the induction of Gdf15 expression (321). This suggests that metformin 
activates ISR to elicit Gdf15 expression in the intestine.  
To confirm the observations in the mouse intestine, the effects of ISR on GDF-15 secretion were 
confirmed using 2D monolayer cultures from intestinal organoids. ISR is activated by the 
phosphorylation of translation initiation factor eIF2α by serine/threonine kinases, which are in turn 
activated by various cellular stressors (Figure 4.10A) (461, 462). Phosphorylated eIF2α preferentially 
translates transcription factors with specific upstream open reading frames (uORFs) such as ATF4 and 
ATF5 over general protein synthesis, leading to induction of a transcriptional cascade such as 
upregulation of Ddit3 (CHOP) and Atf3, amongst others (463). The contribution of ISR to metformin 
stimulated GDF-15 secretion was investigated by co-treatment with ISRIB, an inhibitor which prevents 
the phosphorylation of the translation initiation factor eIF2α. ISRIB co-treatment significantly 
diminished metformin stimulated GDF-15 secretory response at 1µM but was without effect at 0.1µM 
concentrations and no differences were found on basal secretion (Figure 4.10B and 4.10C). Co-
treatment with the PERK inhibitor GSK-2606414 (associated with the ER stress arm of ISR) modestly 
reduced metformin-stimulated GDF-15 secretion and increased basal secretion in one experiment 
(Figure 4.10D), suggesting some contribution of PERK in metformin elicited ISR. Co-treatment with the 
GCN2 inibitor A-92 (activated by amino acid deprivation in the ISR pathway) did not alter metformin-
stimulated GDF-15 secretion but inhibited GDF-15 secretion stimulated by the histidyl-tRNA 
synthetase inhibitor Histidinol to mimic amino acid deprivation (Figure 4.10E).  
RNA-sequencing analysis demonstrate that metformin did not alter the expression of Eif2a, Eif2ak3 
(PERK) or Eif2ak4 (GCN2), but increased the expression of Eif2ak2 (PKR) and downregulated Eif2ak1 
(HRI) (Figure 4.10F). This likely reflects the importance of posttranslational regulation as opposed to 
transcriptomic changes in Eif2a and stress-activated kinases during ISR. The effects of metformin on 
the expression of confirmed ATF4 target genes were also investigated (Figure 4.10F). Only Asns and 
Pck2 expression were increased by metformin treatment (associated with asparagine and glucose 
metabolism, respectively), whilst Atf3 and Atf5 were downregulated by metformin treatment (Figure 
4.10F). Notably, metformin did not alter the expression of Atf4, Ddit3, Chac1 (involved in UPR and 
glutathione biosynthesis), Psph (serine metabolism) and Trib3 (involved in NF-kB and cytokine 
signalling responses) (Figure 4.10F). These results do not provide conclusive evidence that metformin 





Figure 4.10. Metformin activates ISR to stimulate GDF-15 secretion. (A) Schematic showing the ISR pathway and 
mechanisms of action of ISRIB, A-92 and GSK-2606414. (B-D) GDF-15 secretion in mouse duodenal 2D monolayer cultures 
pre-treated with metformin (1mM) with (B and C) ISRIB (0.1µM and 1µM respectively), (D) GSK-2606414 (0.2µM) and (E) 
A-92 (20µM). Cultures were pre-treated with ISRIB, GSK-2606414 or A-92 for an hour prior to co-treatment with or without 
metformin. ISRIB: N=6 wells, 3 wells assessed in parallel from 2 independent experiments. GSK-2606414: N=6 wells, 3 wells 
assessed in parallel from 3 independent experiments. A-92: N=6 wells, 3 wells assessed in parallel from 2 independent 
experiments except for Histindol, where N=3 wells from 1 experiment. For (B-E), *, P<0.05, **, P<0.01, ***, P<0.001 vs 
control, #, P<0.05, ###, P<0.001 vs metformin. Two-way ANOVA and Bonferroni’s post hoc test. (F and G) The effect of 
metformin on the expression of (F) Eif2a and stress-activated kinases and (G) ATF target genes from the RNA-seq data. The 
raw count data for each gene is normalised by the size factors and the library size. *, P<0.05, **, P<0.01, ***, P<0.001 (P-




Previous studies reported that overexpression of CHOP, but not ATF4, ATF5 or ATF6 was associated 
with increased Gdf15 promoter activity (286), the effects of CHOP in the downstream ISR pathway 
was examined. Duodenal organoids generated from CHOP null mice were still able to elicit GDF-15 
secretion in response to metformin comparable to wild-type organoids (when normalised to control 
of the organoid line) (Figure 4.11A). However, when the results were normalised to wild-type control, 
GDF-15 secretion in CHOP-KO organoids were lower, but metformin was able to still elicit GDF-15 
secretion (Figure 4.11B). The results suggests that metformin-stimulated GDF-15 secretion might be 








Since Hif1a gene expression and target genes in the HIF-1A signalling pathway were upregulated in 
the RNA-seq data (chapter 3, Figure 3.14), the effects of HIF-1A inhibitors on GDF-15 secretion were 
investigated using two inhibitors, KC7F2 (an inhibitor of HIF-1A translation) and NSC-134754 (an 
inhibitor of HIF-1A activity and protein levels) (464, 465). Metformin-stimulated GDF-15 secretion was 
completely abolished when co-treated with KC7F2, and NSC-134754 in all of the experiments (Figure 
4.12A and 4.12B). The inhibitors modestly reduced basal GDF-15 secretion (Figure 4.12A and 4.12B). 
The results suggest that activation of the HIF-1A signalling pathway is indispensable for metformin-
stimulated GDF-15 secretion. 
 
Figure 4.11. Metformin-stimulated GDF-15 secretion in CHOP knockout mouse duodenal organoids. (A) 
GDF-15 secretion in mouse duodenal 2D monolayer cultures generated from wild-type and CHOP-null (CHOP 
KO) mice pre-treated with metformin (1mM). Wild-type organoids control and metformin: N=6 wells, CHOP 
KO control: N=4 wells, CHOP KO metformin: N=6 wells, 1-3 wells assessed in parallel from 2 independent 
experiments. Metformin-stimulated GDF-15 secretion was normalised to the control of the organoid line. 
(B) The same set of data generated in A, but all of the data was normalised to basal control of the wild-type 
line only.  ***, P<0.001 vs wild-type control, ###, P<0.001 vs wild-type metformin. Two-way ANOVA and 

















4.5.1 Mechanisms of metformin-stimulated GDF-15 secretion in intestinal cells 
This study characterised the mechanisms of metformin stimulated GDF-15 secretion in cells seeded in 
2D monolayer cultures from intestinal organoids, using pharmacological compounds and analysis of 
mitochondrial genes by RNA-seq. The experiments were a follow up investigation based on the RNA-
seq data from intestinal organoids (chapter 3) and analysis of Gdf15 expression in intestinal tissues of 
HFD-mice treated with metformin (321), which revealed the importance of the intestine in GDF-15 
induction by metformin.  
This study provides two lines of evidence to show that metformin stimulated GDF-15 secretion is 
dependent on the inhibition of mitochondria Complex I activity, and not by AMPK activation (Figure 
4.2 and 4.3). First, metformin stimulated significant GDF-15 secretion in a comparable manner to 
rotenone, but the AMPK activator Az-991 failed to elicit significant GDF-15 secretion (Figure 4.2). 
Second, the NAD+ biosynthesis precursor NMN, which has been shown to reduce Complex I 
dependency of cancer cells treated with metformin (396), decreased GDF-15 secretion elicited by 
metformin (Figure 4.3). These observations complemented a similar RNA-seq study performed on 
Figure 4.12.  HIF-1A inhibitors inhibited GDF-15 secretion. (A) GDF-15 secretion in mouse duodenal 
2D monolayer cultures pre-treated with metformin (1mM) HIF-1A inhibitors KC7F2 (50uM, A) and NSC-
134754 (10uM, B). N=3 wells from 1 experiment. Cultures were pre-treated with KC7F2 or NSC-134754 
for an hour prior to co-treatment with or without metformin. (b) GDF-15 secretion in mouse duodenal 
2D monolayer cultures generated from wild-type and CHOP-null (CHOP KO) mice pre-treated with 
metformin (1mM). N=12 wells, 3 wells assessed in parallel from 4 independent experiments. For (B-
E), **, P<0.01, ***, P<0.001 vs control, ###, P<0.001 vs metformin. Two-way ANOVA and Bonferroni’s 
post hoc test.  
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metformin treated human hepatocytes, revealing that Gdf15 induction occurs via an AMPK 
independent pathway (365). Moreover, inhibitors that directly impair electron transport chain 
function (Antimycin A and oligomycin) induced Gdf15 expression in C2C12 myotubes, whilst various 
mouse models with other impaired mitochondrial processes also induced Gdf15 expression, as 
discussed later (286, 374). The strongest evidence comes from observations in patients with 
mitochondrial diseases, who were reported to have elevated serum GDF-15 levels (447, 448). This 
study supports the accumulating literature in confirming that metformin stimulated GDF-15 secretion 
via a direct mitochondrial mechanism in cells, mice and humans.  
Although metformin is known to inhibit mitochondrial metabolism, the mechanisms involving other 
mitochondria processes are less known. RNA-seq analysis was used to investigate the effect of 
metformin on mitochondrial genes to suggest which mitochondrial processes were disrupted in 
intestinal cells and further interpret the mechanisms of metformin stimulated GDF-15 secretion. The 
RNA-seq data showed downregulation of GO processes involving RNA processes and translation, and 
decreased expression of many genes encoding mitochondrial ribosomes and aminoacyl tRNA 
synthetases, but not a general shutdown of the cellular translation machinery (Figure 4.6 and 4.7). 
This is also supported by the observations that inhibition of mitochondrial translation by doxycycline 
did not elicit additive GDF-15 secretion upon co-treatment with metformin, in contrast to other 
mitochondrial proteostasis and mtDNA replication inhibitors (Figure 4.5). This is consistent with a 
recent study by Quiros et. al., who reported consistent downregulation of mitochondrial ribosomes at 
the proteomic level in response to different mitochondrial inhibitors, including FCCP (450). Whether 
this reflects decreased mitochondria numbers in the cells needs to be determined in the future. 
Doxycycline and muscle-specific Crif1 deleted mice also reported GDF-15 induction in muscle cells 
(286). These experiments suggest that metformin impairs OXPHOS and disrupting mitochondrial 
translation as a mechanism to stimulate GDF-15 secretion.  
Evidence from mitochondrial encephalomyopathy patients with a mutation of the gene encoding 
pyrimidine synthesis enzyme thymidine kinase (Tk2), and experiments in a mouse model with 
deletions of Twinkle mtDNA helicase, shows the importance of mtDNA replication in GDF-15 induction 
(374, 449). This study revealed that genes involved in mtDNA replication were downregulated by 
metformin treatment (Figure 4.7). However, unlike mitochondrial translation, metformin also 
downregulated genes involved in DNA transcription, replication and repair in the nucleus (see chapter 
3, Figure 3.20). Impaired mitochondrial respiration have been reported to decrease de novo 
nucleotide biosynthesis and nucleotide pools, which could affect mtDNA (as well as nuclear DNA) 
maintenance processes (466–470). However, co-treatment of ciprofloxacin, which inhibits mtDNA 
replication, increased GDF-15 secretion in both control and metformin-treated cultures (Figure 4.5), 
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suggesting that metformin stimulated GDF-15 secretion is unlikely to be dependent on decreased 
mtDNA replication.   
Metformin, as well as complex I inhibitor Rotenone and complex III inhibitor Antimycin A, has been 
reported to alter mitochondrial ROS production (381, 471–473). Mitochondrial targeted compounds 
that stimulate ROS production, MitoPQ and MitocDNB1, only elicited a modest GDF-15 secretory 
response, whilst high concentrations of MitoTEMPO also weakly decreased metformin stimulated 
GDF-15 secretion (Figure 4.4). Whether the partial inhibition observed in response to MitoTEMPO is 
due to the contribution of non-mitochondrial ROS should be considered in future studies. 
Furthermore, whether these compounds were influencing GDF-15 secretion at their optimal 
concentrations should be examined. RNA-seq analysis did not show any marked changes in the 
expression of ROS defence genes (Figure 4.8). Other studies using C2C12 myotubes have shown that 
the antioxidant Trolox did not affect Gdf15 mRNA expression induced by Antimycin A and Oligomycin, 
demonstrating that the mechanism might be ROS independent (448). This study shows that ROS 
signalling probably plays a minor role in metformin stimulated GDF-15 secretion.  
Perturbed mitochondria function activates the mtUPR, a mechanism associated with accumulation of 
misfolded and unfolded proteins which leads to the induction of mitochondrial proteases and 
chaperone expression to restore mitochondrial function (450, 474–476). The RNA-seq data revealed 
upregulation of mtUPR proteases such as Lonp1, Yme1l1, Oma1, Grpel and the chaperone Hspa9, 
suggesting that metformin might also activate mtUPR in intestinal cells (Figure 4.8). The mtUPR 
response, such as that elicited by doxycycline or inhibiting LONP1 proteases by CDDO, also activates 
ISR via the induction of the master regulator ATF4 (286, 450). This response may also be mediated by 
the eIF2α kinases GCN2 or PKR, although this is not completely understood (477, 478). However, the 
GCN2 inhibitor suppressed GDF-15 secretion elicited by histidinol but not metformin, suggesting that 
GCN2 function is redundant to metformin-stimulated GDF-15 secretion (Figure 4.10).  
As well as mitochondrial stress, metformin has also been reported to initiate ER stress via the 
activation of PERK-ATF4 signalling pathway in rat primary cardiomyocytes (479). Inhibition of PERK 
activity via GSK-2606414 modestly decreased metformin-stimulated GDF-15 secretion in intestinal 2D 
monolayer cultures (Figure 4.10). This contrasts with experiments in MEF cells, in which the same 
concentrations of GSK-2606414 had no effect on phenformin stimulated Gdf15 mRNA expression 
(321). The differences in effect could be time-dependent (6 hours in MEFs compared to 24 hours in 
organoids) or dependent on a cellular context (321). Perhaps depletion of cellular ATP levels by high 
dose metformin treatment could disrupt protein folding and trigger ER stress in intestinal cells, 
although the importance of this pathway remains to be elucidated.    
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Despite the modest effect (if at all) of the GCN2 and PERK inhibitors on metformin-stimulated GDF-15 
secretion, the eIF2a phosphorylation inhibitor ISRIB mostly inhibited metformin stimulated GDF-15 
secretion (Figure 4.10), demonstrating the importance of ISR and supporting other studies showing 
the importance of ISR in Gdf15 induction (286, 287, 374, 451). Other eIF2a kinases such as PKR or HRI 
could be involved in the upstream mechanisms of the ISR pathway, which should be investigated in 
future experiments with selective inhibitors. Similarly, metformin treatment induces the expression 
of ISR transcription factors ATF4 and CHOP in the colon (Figure 4.9 and (321)), although this is not 
reflected in the RNA-seq data in duodenal organoids (Figure 4.10). This could be due to a temporary 
induction of ISR genes at the transcriptomic level in the intestinal cells at an earlier time point, or 
increased abundance of the transcription factors at protein level, which should be confirmed in future 
studies.  
CHOP has been reported to bind directly to the promoter of Gdf15, and studies in MEF cells 
demonstrate that siRNA-mediated knockdown of CHOP reduced the induction of Gdf15 expression by 
Phenformin (286, 321, 451). Metformin pre-treatment still elicited significant GDF-15 secretion in 
CHOP knockout mouse intestinal cells despite that GDF-15 secretion were already lower in CHOP 
knockout compared to wild-type organoids (Figure 4.11). However, we acknowledge that no form of 
normalisation has been performed to account for differences in cellular content between different 
organoid lines. CHOP could be partially involved in metformin-stimulated GDF-15 secretion, whilst 
CHOP independent pathway such as activation of IRE1-XBP-1 signalling (as XBP-1 also binds to the 
promoter of GDF-15) could be involved (480, 481).      
Described in a recent study by Loubiere et. al., metformin stimulates mitochondrial Ca2+ uptake as an 
indirect result of triggering ER Ca2+ release in prostate cancer cells, which promotes mitochondrial 
swelling and disorganisation of cristae (482). In the study, metformin treatment for 24 hours increased 
the expression of MCU mRNA and VDAC protein levels (482). The RNA-seq data reported increased 
expression of many key mitochondrial Ca2+ signalling genes (including Mcu and Vdac1), which may 
suggest a role of mitochondrial Ca2+ signalling in mitochondrial stress or dysfunction in intestinal cells. 
This could have an impact on metformin stimulated GDF-15 secretion and should be tested in the 
future using MCU inhibitors.   
The RNA-seq data highlighted that metformin increased the expression of HIF-1A, its co-
transcriptional partners and many known HIF pathway target genes, whilst decreasing the expression 
of HIF regulatory factors (Chapter 3, Figure 3.14). The observations that HIF-1A inhibitors abolished 
metformin-stimulated GDF-15 secretion suggests that the mechanism is dependent on the HIF-1A 
signalling pathway (Figure 4.12). A previous study by Lakhsal et al., reported that chelation of iron with 
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2,2-Bipyridyl (BiP) induced Gdf15 gene expression in numerous human cell lines, but siRNA knockdown 
of Hif1a exhibited modest reduction on the induction response, by contrast to the effects of the HIF-
1A inhibitors (483). The mechanisms by which HIF-1A could be activated by metformin in this study is 
not known. This study contradicts with the results from previous studies which reported that 
metformin, via the inhibition of complex I of the electron transport chain, inhibited HIF-1A activity 
through decreasing oxygen consumption and increasing the cellular oxygenation ability in various 
cancer cells (203, 345, 346). Therefore, the alternative explanation for why Metformin could increase 
HIF-1A signalling is by an indirect mechanism, such as by increasing ROS production which could 
increase mRNA expression levels and stability of HIF-1A (484). Indeed as discussed above, MitoTEMPO 
modestly decreased metformin-stimulated GDF-15 secretion, although the effects were not as potent 
compared to the HIF-1A inhibitors. Future studies should measure the effects of metformin on ROS 
production in intestinal cells, such as measurements of superoxide production via MitoSOX indicator.  
4.5.2 The gastrointestinal tract in metformin-stimulated GDF-15 secretion 
This study, supporting collaborative in vivo observations in HFD-fed mice, suggests that the 
gastrointestinal tract is an important site for GDF-15 release in response to oral metformin treatment 
(321). The only other organ with elevated Gdf15 mRNA expression to metformin was the kidneys, the 
site by which metformin is excreted in urine (321). Other organs with putative metformin action, such 
as the liver and adipose tissues, did not report induction of Gdf15 expression despite previous 
evidence demonstrating that these tissues were capable of inducing Gdf15 expression under stress 
(279, 443).  
Studies involving oral gavage of C14-labelled metformin tracer by Wilcock and Bailey have 
demonstrated that the gastrointestinal tract accumulates metformin at the highest (millimole/kg) 
concentrations compared to other organs after a single oral gavage in wild type and STZ diabetic rats, 
which was followed by the kidney (~400µmol/kg) (312). Metformin concentrations in the liver and 
adipose tissues were always lower by comparison at these same time points in vivo (312). 
Furthermore, intestinal enterocytes have been reported to express various metformin transporters 
(PMAT, SERT, OCT1 and OCT3), particularly biased expression of transporters at the apical side rather 
than the basolateral side, which enables enterocytes to accumulate metformin at high concentrations 
and only permitting ≤60µmol/kg concentrations to be absorbed in the blood (263, 312, 315). Since 
metformin could only disrupt mitochondrial function at high concentrations inside cells (204), and 
GDF-15 induction occurs via a mitochondrial dependent mechanism, this study suggests that 
gastrointestinal tract is likely to be the main organ of GDF-15 release into the blood in response to 
oral metformin treatment.   
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Interestingly, in situ hybridisation studies demonstrate that Gdf15 expression is only localised in the 
crypts of a subset of enterocytes and colonocytes in mouse intestinal sections in response to 
metformin (321). Although the identity of these cell types were not clarified in the study, the 
abundance of these cells and their location in the intestinal mucosa likely represent transit amplifying 
cells, which are known to rely on mitochondrial function to determine cell fate (189, 485). Future 
studies should investigate the functional identity of these Gdf15 positive cells and whether selective 
ablation of Gdf15 in these intestinal cells can sufficiently reduce the effect of metformin on GDF-15 
levels in the serum. 
4.5.3 Comparing the effects of metformin on GDF-15 and other stress hormones/metabolic 
growth factors 
Similar to GDF-15, FGF21 is also elevated in children with mitochondrial disorders and in mouse 
models of defective mtDNA replication (374, 448). FGF21 levels are also elevated in the serum of 
patients on metformin therapy, and metformin induce FGF-21 mRNA expression and secretion in 
hepatocytes via an ISR-dependent mechanism (although an involvement of AMPK is debateable) (297, 
471). The induction of FGF21 seems to occur via a pathway which relies on oxidative stress, since 
MitoTEMPO suppressed metformin induced Fgf21 expression in hepatocytes and the antioxidant 
Trolox inhibited induction of Fgf21 by Antimycin A and Oligomycin in C2C12 myotubes (297, 448). 
Metformin increased Fgf21 expression in intestinal cells within the RNA-seq database, although the 
expression levels are low (Figure 4.1). This is not unexpected since FGF21 is known to be released 
primarily by the liver, where it mediates metabolic effects on adipose tissues to improve insulin 
sensitivity, as well as regulating food intake and energy expenditure (304, 306–308). 
In addition to FGF21, metformin also increased Fgf15 expression (the feedback hormone involved in 
bile acid homeostasis) in intestinal cells (Figure 4.1). This is in contrast to a recent study reporting that 
metformin treatment in T2DM patients decreased serum FGF19 (the human homologue of FGF15) 
levels (260). Perhaps these different observations could be due to species differences in metformin 
regulated Fgf15/19 expression, or comparisons between the 2D monolayer cultures to the human 
studies where human intestinal enterocytes are regularly exposed to an environment of high bile acid 
levels. 
The RNA-seq data also highlighted downregulation of Tgfb1 expression, a paracrine growth factor 
induced by cellular stress which is also involved in intestinal inflammation (486). This observation also 
supports a different study reporting that metformin inhibits TGF-B1 signalling and may explain 
putative inflammation protective effects of metformin (360, 487).  
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4.5.4 Conclusions  
The results from this chapter connects the findings presented from previous studies to suggest a 




4.13. In response to the inhibition of mitochondrial respiration by metformin, the mitochondria 
attenuate protein translation. This activates ISR via eIF2α phosphorylation to stimulate GDF-15 
secretion. Metformin also activates HIF-1A signalling pathway via an unknown mechanism (the most 
plausible candidate is oxidative stress) to stimulate GDF-15 secretion. ER stress could also contribute 
to metformin stimulated GDF-15 secretion to some extent.  This chapter implicates the role of the 




Figure 4.13. Working model describing the effects of metformin on GDF-15 induction.  
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Despite clinical application of metformin for the treatment of type 2 diabetes mellitus for over 50 
years, the mechanisms explaining the glucose lowering effects of metformin are not completely 
understood. Recent studies have identified glucose uptake and transport in the gut as targets of 
metformin action (116). Whilst some studies demonstrate that metformin could directly alter 
intestinal glucose absorption, metformin has also been reported to increase intestinal glucose 
utilisation from the blood (207, 236, 237, 488–490). However, the cellular mechanisms that explain 
the effects of metformin on glucose transport are unclear. This chapter examines the effects of 




5.2.1 Glucose transport in intestinal enterocytes  
In the gastrointestinal tract, glucose transporters play essential roles in the uptake and absorption of 
glucose in intestinal epithelial cells. Glucose absorption involves the uptake of glucose mediated by 
the sodium-dependent glucose transporter SGLT1 incorporated into the apical (brush border) 
membrane of epithelial cells (491, 492). This glucose transporter utilises the electrochemical gradient 
of sodium ions to transport glucose into cells (493). The predominant role of SGLT1 in glucose 
absorption was demonstrated from observations in patients with the potentially fatal condition of 
glucose and galactose malabsorption caused by loss-of-function mutations in the transporter (494–
496). Similarly, Sglt1 knockout mice displayed impaired glucose absorption and a decreased rate of 
glucose appearance in the blood following an oral glucose tolerance test (491).  
It has been generally accepted that the facilitative transporter GLUT2 is involved in the basolateral 
exit of intracellular glucose via facilitated diffusion from enterocytes. GLUT2 is a low affinity but high 
capacity glucose transporter also capable of transporting fructose and glucosamine (497, 498). The 
evidence supporting GLUT2 in glucose absorption was based on the observations of GLUT2 localisation 
in the basolateral membrane of enterocytes, and of GLUT2 mediated glucose and fructose transport 
in vesicles derived from basolateral membranes (492, 498, 499). Some evidence also suggests that 
GLUT2 vesicles could be recruited to the apical membrane under high glucose conditions, or in 
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response to taste receptor or GLP-2 receptor activation to further facilitate luminal glucose 
absorption, although evidence supporting this mechanism has been inconsistent (491, 492, 500–505). 
Unlike SGLT1 however, patients with Fanconi-Bickel syndrome (caused by inactivating mutations in 
the gene encoding GLUT2) and GLUT2 knockout mice showed normal intestinal glucose absorption 
and glucose appearance in the blood following glucose tolerance tests (506–508). This suggests a 
redundant role of GLUT2 in glucose absorption and possible compensation by other mechanisms, such 
as exocytosis mediated by glucose-6-phosphate translocase as was previously reported (506). 
The high affinity and low capacity glucose transporter GLUT1 is also expressed in the basolateral 
membrane of intestinal cells, although GLUT1 was detectable in the stomach and the colon but was 
barely expressed in the small intestine (509). The contributions of GLUT1 in intestinal glucose 
transport under physiological conditions is unknown. However, GLUT1 expression was induced in the 
basolateral membranes of the small intestine in mice with streptozocin-induced diabetes (510). 
Interestingly, GLUT1 was also overexpressed in the alimentary limbs of rats and patients after Roux-
en-Y gastric bypass, which was associated with intestinal hyperplasia and increased intestinal serosal 
to mucosal glucose transport in mice and patients with RYGB (RYGB) (42, 43). GLUT1 has also been 
shown to be upregulated in rats after sleeve-gastrectomy with duodenojejunal bypass, but not after 
sleeve-gastrectomy alone (43, 511).  
GLUT5 is also expressed in the apical membrane of the small intestine and transports solely fructose 
(512, 513). Experiments in GLUT5 knockout mice demonstrate reduced dietary fructose absorption in 
the jejunum by 75% and negligible appearance of fructose in the plasma following oral fructose 
administration (514). Moreover, the glucose transporter GLUT7 is expressed in the apical membrane 
of the jejunum, ileum and colon, although functional studies into its contribution to intestinal glucose 
transport are still lacking (515).      
 
5.2.2 Metformin and intestinal glucose absorption 
Several studies demonstrate that oral metformin administration alters intestinal glucose absorption, 
which may contribute to the glucose lowering effects of metformin (234–236, 488, 489, 516). Early 
studies using isolated hamster and rat intestine models demonstrated that following pre-treatment 
with various biguanides (234, 235) or 2 hours after oral metformin administration (489) intestinal 
glucose transport was inhibited. Similarly, intraduodenal, but not intravascular administration of 
metformin inhibited glucose transport in the perfused small intestines (488).  
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A recent study using PET/CT scan imaging demonstrated that oral metformin administration delayed 
intestinal transit of orally administered F-2DG in HFD-fed mice (236). The authors performed ex vivo 
examination of glucose transport using everted gut sacs from HFD-fed mice treated with oral 
metformin and observed that mucosal to serosal transport of F-2DG in the proximal jejunal and 
proximal ileal intestinal segments were decreased (236). Furthermore, the rate of glucose appearance 
in the blood following intraduodenal administration of glucose was lower in metformin treated mice 
compared to vehicle treated mice, providing direct evidence that metformin reduced glucose 
absorption (236).  
Metformin has also been reported to decrease intestinal glucose absorption in one clinical study 
involving 12 patients with T2DM (516). The study involved administering metformin to the patients 
for 30 minutes followed by introducing a non-metabolisable glucose analogue 3-O-methylglucose (3-
OMG) via an intraduodenal catheter over the course of 120 minutes (516). The results demonstrated 
that metformin administration was associated with reduced serum 3-OMG levels, which correlated 
with increased serum GLP-1 levels, possibly due to increased intestinal transit of glucose to the distal 
small intestine to stimulate GLP-1 secretion from L cells (516).  
 
5.2.3 The “glucose sink” model of metformin action in the intestines  
Metformin has also been reported to increase glucose utilisation in the mouse and human intestine 
(116). Multiple observations from position-emission tomography – computed tomography (PET-CT) 
imaging involving intravenous injection of a non-metabolisable glucose analogue tracer 18F-
fluorodeoxyglucose (18F-DG) demonstrated that long-term oral metformin administration was 
associated with accumulation of the tracer in the small intestine and the colon (237, 364, 490, 517–
519). Additionally, the tracer stops accumulating in the GI tract in patients who have ceased taking 
metformin (238, 490, 520, 521). The phenomenon of increased intestinal glucose uptake in patients 
on metformin has been reported to interfere with radiological assessments of gastrointestinal and 
genitourinary malignancies, leading to false-negative diagnoses (490, 522). Similar results have also 
been reported in metformin treated HFD-fed mice administered [3H]-2DG, which showed increased 
uptake only in the small intestines and the brain, but to a lesser extent in the liver (236).  
A recent phase 2 clinical trial in T2DM patients reported that under euglycaemic hyperinsulinaemic 
conditions (which maintain constant blood glucose levels), metformin increased F-DG uptake in the 
small intestine and colon, demonstrating that the mechanism is independent of insulin (237). The 
observed increase in F-DG uptake in the colon positively correlated with reduced fasting plasma 
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glucose levels in patients (237). The authors proposed that the gastrointestinal tract acts as a “sink” 
in depositing glucose from the circulation as a mechanism to explain the glucose-lowering effects of 
metformin (237). Studies in rodents and patients with type 2 diabetes demonstrate that glucose is 
most likely to be metabolised by intestinal enterocytes (64, 207). However, some studies 
demonstrated that AMPK activation (a pathway activated by metformin) increases the abundance of 
GLUT2 in the brush border membrane, which is associated with improved glucose homeostasis and 
could potentially facilitate glucose efflux into the lumen (523, 524). The molecular mechanisms 
underlying the effects of metformin in glucose utilisation are therefore still elusive.  
 
5.3 Aims 
This chapter investigates the cellular mechanisms of action of metformin on glucose uptake and 
expression of glucose transporters in the gastrointestinal tract.  The aims of this study are:  
1. To examine the effects of metformin on the expression of glucose transporters in intestinal 
enterocytes from organoids and intestinal tissues from HFD-fed mice administered with 
metformin. 
2. To investigate the effects of metformin on glucose uptake in enterocytes in vitro and identify 





5.4.1 The effect of metformin on the mRNA expression of glucose transporters in intestinal 
cultures 
To identify a lead into studying the molecular mechanisms of metformin on glucose transport in 
intestinal cells, the RNA-seq database obtained from murine intestinal 2D monolayer cultures treated 
for 24 hours with 1mM metformin was initially used to investigate the effects of metformin on the 
mRNA expression of the GLUT family of facilitative transporters (Slc2aX) and the sodium-dependent 
glucose transporter SGLT1 in mouse 2D monolayer cultures generated from duodenal organoids. 
Metformin treatment decreased the expression of GLUT transporters Slc2a2 (GLUT2), Slc2a4 (GLUT4), 
Slc2a5 (GLUT5), Slc2a7 (GLUT7) and the SGLT1 transporter Slc5a1 (Figure 5.1A). Slc2a1 (GLUT1) was 
the only glucose transporter transcript that was upregulated by metformin treatment from the list of 




Figure 5.1. The effect of metformin on the expression of GLUT and SGLT transporters in duodenal 
organoid cells seeded into 2D monolayer cultures. (A) RNA-sequencing analysis of the mRNA transcript 
expression of all GLUT (Slc2a) transporter isoforms and the SGLT1 (Slc5a1) transporter in duodenal 
organoid 2D monolayer cultures in response to 1mM metformin pre-treatment for 24 hours. ***, 
P<0.001 (p-adjusted value). DE-seq analysis and Benjamin-Hochberg corrections. Each point represents 
a plate (N=6 plates from 2 organoid lines). Red and blue labels surrounding each DE gene shows the 
up- and down-regulated genes, respectively. (B-E) qPCR analysis of expression of select glucose 
transporters in duodenal organoid 2D monolayer cultures; (B) Slc5a1 (SGLT1), (C) Slc2a1 (GLUT1), (D) 
Slc2a2 (GLUT2) and (E) the fructose transporter Slc2a5 (GLUT5) in response to metformin pre-
treatment from 10µM to 1mM for 24 hours. N=9 wells, with 3 wells assessed from 3 independent 
experiments except for SGLT1 where N=15 wells with 3 wells assessed in parallel from 5 independent 
experiments. *, P<0.05, **, P<0.01, ***, P<0.001. One way ANOVA and Bonferroni post-hoc test.  
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Slc2a5 were selected for further investigation since the expression levels for these genes were the 
highest in the RNA-seq data and previous literature confirmed their importance in intestinal cells (43, 
491, 492, 510, 514). RT-qPCR analysis demonstrated that treatment of metformin at 1mM, but not at 
any lower concentrations, significantly altered the expression of these transcripts in duodenal 2D 
monolayers that replicated the observations from the RNA-seq data (Figure 5.1B-E). These results 
demonstrate that the effects of metformin could only be observed at high concentrations. 
The effects of metformin on the mRNA expression of the glucose transporters were also examined in 
2D monolayer cultures generated from mouse ileal organoids. Metformin treatment at 1mM (but not 
at any lower concentrations) caused a trend towards lower expression of Slc5a1 (Figure 5.2A), Slc2a2 
(Figure 5.2C) and Slc2a5 (Figure 5.2D), although the results were not statistically significant. Similar to 
duodenal organoid 2D monolayers, metformin (only at 1mM concentration) significantly increased the 
expression of Slc2a1 (Figure 5.2B). These results suggest that the effects of metformin were not 
exclusive to duodenal organoids/cells. The effects of the different metformin treatments on the mRNA 





Figure 5.2. The effect of metformin on the expression of GLUT1, GLUT2, GLUT5 and SGLT transporters in 
ileal organoid cells seeded into 2D monolayers. (A-D) qPCR analysis of expression of select glucose 
transporters in ileal organoid 2D monolayer cultures; (B) Slc5a1 (SGLT1), (C) Slc2a1 (GLUT1), Slc2a2 (GLUT2) 
and the fructose transporter Slc2a5 (GLUT5) in response to metformin pre-treatment from 10uM to 1mM 
for 24 hours. N=9 wells, with 3 wells assessed in parallel from 3 independent experiments. *, P<0.05, **, 
P<0.01, ***, P<0.001. One way ANOVA and Bonferroni post-hoc test.  
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Unlike 2D monolayer cultures, metformin treatment did not alter the mRNA expression levels of 
Slc5a1 (Figure 5.3A) or Slc2a2 in 3D organoids (Figure 5.3B). This likely suggests that the “inside-out” 
conformation of 3D organoids (i.e. the apical face of intestinal cells facing the inside of the organoid 







5.4.2 Metformin increases glucose uptake in intestinal cells mediated by a GLUT transporter  
The effects of metformin on glucose uptake in intestinal 2D monolayer cultures were investigated via 
fluorescence imaging of cells transfected with the intracellular FRET glucose sensor, FLII12Pglu-
700µδ6. Duodenal 2D organoid cultures were treated overnight prior to analysis with either 1 mM 
metformin or vehicle control. Application of glucose at 10mM concentration increased the YFP/CFP 
ratio (a relative measure of increased glucose uptake) in control and metformin treated cells (Figure 
5.4A and 5.4B). Application of glucose at 1mM concentration increased the YFP/CFP ratio in all of the 
metformin-treated, but only 4/27 control cells (Figure 5.4A and 5.4B). Metformin treatment increased 
the uptake of glucose when applied at 1mM and 10mM concentrations (Figure 5.4C). Since different 
glucose concentrations were often applied sequentially in the same experiment, whether the function 
of the FRET sensor was saturated by repeated glucose exposure was investigated by monitoring the 
YFP/CFP ratio following two repeated applications of 10mM glucose. As expected, changes in the 
YFP/CFP ratio after applying 10mM glucose for a second time did not significantly differ from the first 
glucose application (Figure 5.4D and 5.4E).         
To explore the functional identity of the glucose transporter(s) involved in metformin stimulated 
glucose uptake, changes in the YFP/CFP ratio were monitored in response to 10mM glucose following 
pre-application of different glucose transport inhibitors. Application of the broad-spectrum SGLT  
Figure 5.3. The effect of metformin on the expression of SGLT1 and GLUT2 transporters in 3D 
duodenal organoids. (A and B) qPCR analysis of expression of glucose transporters (A) Slc5a1 (SGLT1) 
and (B) Slc2a2 (GLUT2) in 3D duodenal organoids in response to metformin pre-treatment from 

















inhibitor phloridzin at 5µM, which has been reported to inhibit SGLT1 and SGLT2-mediated glucose 
transport in previous studies (525), did not alter glucose uptake in either control or metformin treated 
cells (Figure 5.5A-5.5C). This suggests that the SGLT family of transporters (such as SGLT1) do not play 
a major role in glucose uptake in intestinal cells in the 2D monolayer cultures. Pre-treatment with the 
broad-spectrum GLUT transport inhibitor phloretin at both 10µM and 100µM reduced glucose uptake 
in control and metformin treated cells (Figure 5.6A-5.6F). This suggests that a GLUT transporter is 
responsible for the observed glucose uptake. In an attempt to examine which GLUT transporter 
isoform was involved in mediating glucose uptake, cytochalasin B was applied at 1µM, which had 
previously been reported to completely inhibit GLUT1, GLUT3 and GLUT4 dependent transport at that 
concentration but partially inhibits GLUT2 (as the Ki for GLUT2 was 2µM whereas the Ki for GLUT1, 
GLUT3 and GLUT4 were 0.1µM) (526). Application of cytochalasin B completely inhibited glucose 
Figure 5.4. Metformin increase glucose uptake in intestinal cells from duodenal organoid 2D 
monolayers. (A and B) Example traces of YFP/CFP fluorescence ratios from Control (A) and 
Metformin (B) treated cells. Glucose treatments at 1mM (1G) and 10mM (10G) concentrations were 
applied as indicated. (C) The effect of 1mM and 10mM glucose on the YFP/CFP fluorescence ratios 
in control (red) and metformin-treated (blue) cells normalised to the baseline (*; P<0.05, ***; 
P<0.001, Two-way ANOVA and Bonferroni post-hoc test). Results shown as a violin plot with the 
median and confidence intervals indicated as dotted lines. Numbers of cells studied for each 
condition are indicated in the graph. (D and E) The effect of repeated 10mM glucose application on 
the YFP/CFP fluorescence ratio (control: N= 17 cells from 7 dishes, metformin: N=16 cells from 5 
dishes, paired t-test).  Abbreviations: 10G; 10mM glucose, 1G; 1mM glucose. 
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transport in 11/13 of control cells and 14/15 of metformin treated cells (Figure 5.6G-5.6I). Forskolin, 
which had previously been reported to preferentially inhibit glucose uptake mediated by GLUT1 and 
GLUT4 over GLUT2 (527, 528), also reduced glucose uptake in control and metformin treated cells 




To examine the contribution of GLUT2 over other glucose transporters, the GLUT2 substrate 
glucosamine was co-applied with glucose in an attempt to inhibit glucose transport via competitive 
inhibition (since transport studies previously showed that glucosamine exhibited a Kd of ~1.5mM 
compared to a Kd of ~17mM for glucose) (497). Application of glucosamine (10mM) did not affect 
glucose transport in either control or metformin treated cells (Figure 5.7A-5.7C). Similarly, other 
studies have reported that fructose is transported via GLUT2 at a similar transport affinity compared 
to glucose, which could be used to inhibit GLUT2-dependent glucose transport through competitive 
inhibition (498). Co-application of fructose at 100mM (which should otherwise saturate GLUT2 
mediated transport) did not affect glucose uptake (Figure 5.7D-5.7F). The observations that 
glucosamine and fructose did not influence glucose uptake could suggest that glucose uptake in 
intestinal cells may not be dependent on GLUT2, although there are no positive controls to show that 




Figure 5.5. The SGLT inhibitor Phloridzin did not affect glucose transport in enterocytes. (A and B) 
Example traces of YFP/CFP fluorescence ratios from (A) Control and (B) Metformin treated cells. Glucose 
(10mM, 10G) and phloridzin (5µM) were applied as indicated. (C) The effect of glucose with and without 
5µM phloridzin on the YFP/CFP fluorescence ratios in control (red) and metformin-treated (blue) cells 
normalised to the baseline. Control: N= 9 cells from 4 dishes, metformin: N=7 cells from 3 dishes. Paired 





Figure 5.6. GLUT transporter inhibitors reduced glucose uptake in enterocytes. (A-B) Example traces of YFP/CFP 
fluorescence ratios from Control (A) and Metformin (B) treated cells. Glucose (10mM, 10G) and phloretin (10uM) 
were applied as indicated. (C) The effect of glucose with and without 10µM phloretin on the YFP/CFP fluorescence 
ratios in control (red) and metformin-treated (blue) cells normalised to the baseline (**; P<0.01, ***; P<0.001, 
paired T-test). Control: N= 23 cells from 9 dishes, metformin: N=24 cells from 8 dishes. (D-F) Same as A-C except 
where phloretin was applied at 100µM instead (***; P<0.001, paired-t-test). Control: N= 11 cells from 5 dishes, 
metformin: N=16 cells from 6 dishes. (G-I) Example traces of YFP/CFP fluorescence ratios from Control (A) and 
Metformin (B) treated cells. Glucose (10mM, 10G) and the GLUT transport inhibitor Cytochalasin B (1µM) were 
applied as indicated. (I) The effect of glucose with and without 1µM cytochalasin B on the YFP/CFP fluorescence 
ratios in control (red) and metformin-treated (blue) cells normalised to the baseline (***; P<0.001, paired T-test). 
Control: N= 13 cells from 4 dishes, metformin: N=15 cells from 5 dishes. (J-K) Example traces of YFP/CFP 
fluorescence ratios from Control (A) and Metformin (B) treated cells. Glucose (10mM, 10G) and the putative GLUT 
transport inhibitor Forskolin (10uM) were applied as indicated. (L) The effect of glucose with and without 10µM 
Forskolin on the YFP/CFP fluorescence ratios in control (red) and metformin-treated (blue) cells normalised to the 
baseline (***; P<0.001, paired T-test). Control: N= 23 cells from 8 dishes, metformin: N=24 cells from 9 dishes. For 
the example traces, different colours denote different cells as shown in the legends. Abbreviations: 10G; 10mM 






5.4.3 Signalling pathways involved in the regulation of glucose uptake and expression of 
glucose transporters by metformin 
The effects of different candidate signalling pathways on the expression of glucose transporters and 
glucose uptake were also examined. As discussed in chapter 3, AMPK and HIF-1A signalling were 
identified as the candidate pathways that were most likely to influence glucose metabolism based on 
the RNA-seq data. The role of the AMPK signalling pathway on glucose transporter expression and 
glucose transport was examined by investigating the effects of treating intestinal monolayer cultures 
with the AMPK activator Az-991 at 1µM or 10µM concentrations for 24 hours, concentrations which 
have previously been reported to activate AMPK (529, 530). Az-991 treatment at either concentration 
did not affect the expression of either Slc5a1, Slc2a1, Slc2a2 or Slc2a5 (Figure 5.8A-5.8D). However, 
the YFP/CFP ratio was modestly increased in Az-991 treated cells compared to control cells in response 
to 10mM glucose (Figure 5.8E-5.8G). These observations suggest that AMPK activation mediated by 
Figure 5.7. Co-application of GLUT2 substrates with glucose does not affect glucose transport. (A-B) Example 
traces of YFP/CFP fluorescence ratios from Control (A) and Metformin (B) treated cells. Glucose (10mM, 10G) 
and the high-affinity GLUT2 transporter glucosamine (10mM) were applied as indicated. (C) The effect of 
glucose with and without 10mM glucosamine on the YFP/CFP fluorescence ratios in control (red) and 
metformin-treated (blue) cells normalised to the baseline Control: N= 22 cells from 7 dishes, metformin: N=17 
cells from 9 dishes. Paired T-test. (D-F) Same as A-C except where fructose was applied at 100mM instead. 
Control: N= 16 cells from 6 dishes, metformin: N=15 cells from 6 dishes. For the example traces, different 




metformin may increase glucose uptake at a post-translational but not at a transcriptomic level, which 





The role of the HIF-1A signalling pathway on the expression of the glucose transporters was 
investigated using the two inhibitors, KC7F2 and NSC-134754 previously reported to inhibit 
metformin-stimulated GDF-15 secretion (Chapter 4, Figure 4.12). KC7F2 treatment alone decreased 
the expression of Slc5a1 (Figure 5.9A), Slc2a1 (Figure 5.9B) and Slc2a2 (Figure 5.9C). Treatment of 
KC7F2 abolished the effects of metformin in inducing Slc2a1 expression (Figure 5.9B). The expression 
of Slc5a1 and Slc2a2 were lower in metformin treated cells compared to control cells in the presence 
of the inhibitor (Figure 5.9A and 5.9C). Similar to KC7F2, application of NSC-134754 also decreased the 
expression of Slc5a1 (Figure 5.9D), Slc2a1 (Figure 5.9E) and Slc2a2 (Figure 5.9F) and abolished the  
Figure 5.8. The AMPK activator AZ-991 does not affect the expression of glucose transporters but 
modestly increased glucose uptake. (A-D) qPCR analysis of expression of select glucose transporters 
in 2D duodenal organoid monolayers; (a) Slc5a1 (SGLT1), (b) Slc2a1 (GLUT1), (C) Slc2a2 (GLUT2) and 
(D) fructose transporter Slc2a5 (GLUT5) in response to AZ-991 pre-treatment at 1µM and 10µM for 24 
hours. N=6 wells, with 3 wells assessed in parallel in 2 independent experiments. (E and F) Example 
traces of YFP/CFP fluorescence ratios from Control (A) and 10µM AZ-991 (B) pre-treated cells. Glucose 
(10mM, 10G) was applied as indicated. (G) The effect of AZ-991 on the YFP/CFP fluorescence ratios in 
control (red) and AZ-991-treated (orange) cells normalised to the baseline Control: N= 20 cells from 7 
dishes, AZ-991: N=20 cells from 7 dishes. *, P<0.05, Two-tailed independent t-test. 
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Figure 5.9. Inhibition of HIF1A decreased the expression of glucose transporters and inhibited glucose uptake.  
(A-F) The effect of metformin and HIF-1A translation inhibitors (A-C) 50µM KC7F2 or (D-F) NSC-134754 on Slc5a1 
(SGLT1), Slc2a1 (GLUT1) and Slc2a2 (GLUT2) mRNA expression in 2D duodenal organoid monolayers. KC7F2: N=3 
wells from 1 experiment. NSC-134754: N=8-9 wells, with 2-3 wells assessed in parallel from 3 independent 
experiments. Cells were pre-treated with vehicle, KC7F2 or NSC-134754 for 1 hour, followed by co-treatment 
with control or 1mM metformin for 24 hours. ***, P<0.001 vs vehicle control. ###, P<0.001 vs metformin and 
KC7F2 or NSC-134754 co-treatment. (G-J) Example traces of YFP/CFP fluorescence ratios from Control (G), 
Metformin (H), Control + 10µM NSC-134754 (I) and Metformin + 10µM NSC-134754 (J) pre-treated cells. The 
effect of NSC-134754 on the YFP/CFP fluorescence ratios in control (red) and metformin treated (blue) cells 
normalised to the baseline Control: N= 18 cells from 4 dishes, Control + NSC-134754: N=10 cells from 4 dishes, 
Metformin: N=25 cells from 5 dishes, Metformin + NSC-134754: N=13 cells from 5 dishes. ##, P<0.01 control vs 
metformin vehicle. ***, P<0.001 vs vehicle control, Two-way ANOVA and Bonferroni post hoc test. 
Abbreviations: 10G; 10mM glucose, NSC; NSC-134754.  
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effects of metformin in eliciting Slc2a1 expression (Figure 5.9E). Unlike KC7F2, NSC-134754 did not 
affect the expression of Slc5a1 or Slc2a2 in the presence of metformin (Figure 5.9D, 5.9F). This could 
suggest that KC7F2 might be less selective as KC7F2 is known also to affect the S6 kinase and EIF2B 
pathways (464). These results suggest that the HIF-1A pathway plays a role in inducing Slc2a1 
expression by metformin, but the changes in the expression of Slc5a1 or Slc2a2 mediated by 
metformin might be mediated by other, as yet to be identified pathways.  
To investigate the effects of the HIF-1A signalling on glucose uptake, intestinal cultures transfected 
with the FRET-based glucose sensor were pre-treated with and without metformin and/or NSC-
134754 for 24 hours. NSC-134754 markedly reduced glucose uptake in both control and metformin 
treated cells and abolished the differences in glucose uptake between control and metformin treated 
cells (Figure 5.9G-5.9K). These observations suggest that glucose uptake is controlled by the HIF-1A 
signalling pathway.   
 
5.4.4 The effects of metformin on the mRNA expression of glucose transporters in intestinal 
tissues of HFD-fed mice 
To confirm that the effects of metformin on the expression of glucose transporters were not exclusive 
to an intestinal monolayer culture system, the effects of metformin on the mRNA expression of 
glucose transporters in different tissue segments of the small intestine and colon were investigated 
using the HFD-fed mouse model. Oral dosing of metformin for 6 hours decreased the expression of 
Slc5a1 in the lower small intestine, but not the upper or middle small intestinal tissues (Figure 5.10A-
5.10C). Metformin also increased Slc2a1 expression in the lower small intestine (p=0.05) but no 
significant changes were observed in the upper or middle small intestine or the colon (Figure 5.10D-
5.10G). Similarly, metformin decreased Slc2a2 expression in the upper and lower small intestine, 
although there was a trend towards decreased expression in the middle small intestine, and the 
expression was very low in the colon (Figure 5.10H-5.10K).  
Similarly, long-term oral treatment with metformin for 11 days also reduced Slc5a1 mRNA expression 
in the lower, but not the upper or middle small intestine segments (Figure 11A-5.11C). Metformin also 
significantly increased the expression of Slc2a1 in the lower small intestine but not in the small 
intestinal tissues from other regions (Figure 5.11D-5.11G). Metformin decreased the expression of 
Slc2a2 in the middle small intestine, and there was a trend towards decreased expression in the lower 
small intestine, whereas transcript expression was not affected in the upper small intestine or the 




Figure 5.10. The effects of a single dose of metformin (600mg/kg) on the expression of glucose 
transporters in the small intestinal tissues of HFD-mice after 6 hours. (A-C) The effects of metformin 
on the mRNA expression of Slc5a1 (SGLT1) in the (A) upper small intestine (SI), (B) middle SI and (C) 
lower SI. (D-G) The effects of metformin on the mRNA expression of Slc2a1 (GLUT1) in the (D) upper 
SI, (E) middle SI, (F) lower SI and (G) colon. (H-K) The effects of metformin on the mRNA expression of 
Slc2a2 (GLUT2) in the (H) upper SI, (I) middle SI, (J) lower SI and (K) colon. mRNA analysis of fresh 
frozen tissue normalised to expression levels of b-actin (Actb). N=6 mice per group. *, P<0.05, **, 
P<0.01, ***, P<0.001. mRNA analysis of fresh frozen tissue normalised to expression levels of b-actin 






Figure 5.11. The effects of once daily oral metformin administration (300mg/kg) on the expression 
of glucose transporters in the small intestinal tissues of HFD-mice after 11 days. (A-C) The effects of 
metformin on the mRNA expression of Slc5a1 (SGLT1) in the (A) upper small intestine (SI), (B) middle 
SI and (C) lower SI. (D-G) The effects of metformin on the mRNA expression of Slc2a1 (GLUT1) in the 
(D) upper SI, (E) middle SI, (F) lower SI and (G) colon. (H-K) The effects of metformin on the mRNA 
expression of Slc2a2 (GLUT2) in the (H) upper SI, (I) middle SI, (J) lower SI and (K) colon. mRNA analysis 
of fresh frozen tissue normalised to expression levels of b-actin (Actb). N=6-7 mice per group (7 
control, 6 metformin). *, P<0.05, **, P<0.01. mRNA analysis of fresh frozen tissue normalised to 




The results demonstrated that metformin treatment for either 6 hours or 11 days altered the 
expression of glucose transporters in the distal intestine in a similar manner to that observed in 





5.5.1 Does metformin increase basal glucose uptake by upregulating GLUT1 transporters? 
To date, the number of studies reporting the cellular effects of metformin on glucose uptake have 
been limited, even though observations from multiple studies established that oral metformin 
administration dramatically increased intestinal glucose uptake and utilisation in rodents and humans 
(237, 364, 490, 517–519). This study examines the cellular mechanisms by which metformin increases 
glucose uptake and changes the expression of glucose transporters in the small intestine.   
The expression and functional studies presented in this study suggest that metformin increases GLUT1 
mediated glucose transport. These were supported by several lines of evidence. First, from the RNA-
seq and qPCR studies of the different expression of glucose transporters, the Slc2a1 gene encoding 
GLUT1 was amongst the highest in expression and was the only gene from the GLUT family of 
transporters upregulated by metformin treatment in both duodenal and ileal organoids, whereas the 
expression of other glucose transporters were either decreased or not affected by metformin 
treatment (Figure 5.1 and 5.2). Second, live-cell imaging studies using a FRET-based glucose sensor 
demonstrated that metformin increased the uptake of glucose that was inhibited by multiple GLUT 
transport inhibitors, particularly inhibitors with a preferential inhibition for GLUT1, GLUT3 and GLUT4 
over GLUT2, whereas inhibition of SGLT1 did not affect glucose uptake (Figure 5.4 and 5.6). Finally, 
glucosamine and fructose previously reported to be transported by GLUT2 did not alter glucose 
uptake, which could suggest that glucose uptake mediated by GLUT2 in intestinal cells is relatively 
unimportant (Figure 5.7). However, it should be acknowledged that there were no positive controls 
available to confirm that these GLUT2 co-substrates exhibit any competitive inhibition of glucose 
uptake, which could be confirmed in the future by using cell lines that overexpress GLUT2. Future 
experiments could involve transgenic knockout of GLUT1 in intestinal organoids to verify the role of 
GLUT1 in glucose uptake.        
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A recent study investigating the arterial-venous exchange of metabolites in pigs demonstrated that 
the gut consumes the largest quantities of glucose compared with other organs, establishing the 
importance of the gut as a “glucose sink” (186). However, the mechanisms involved in the basolateral 
uptake of glucose from the blood into intestinal epithelial cells are not known, despite well-established 
knowledge that SGLT1 and GLUT2 are involved in the transepithelial absorption of glucose. Two key 
glucose transporters are expressed in the basolateral membrane of intestinal epithelial cells; GLUT1 
and GLUT2, whereas SGLT1 is only expressed in the apical membrane of enterocytes that have apical-
basolateral polarity (492, 509, 510). This could explain why the SGLT transport inhibitor phloridzin did 
not affect glucose uptake in the intestinal 2D monolayers, which loses its apical-basal polarity when 
seeded onto a matrigel-coated surface. Alternatively, the transport capacity of SGLT1 could be much 
lower than GLUT1. Previous experiments demonstrated that expression of GLUT1 transporters in the 
GI tract is low in comparison with the expression of the transepithelial glucose transporters GLUT2 
and SGLT1 in the small intestine, although no functional studies were performed in that study 
regarding the contribution of GLUT1 on basolateral glucose uptake (509). However, it should be noted 
that GLUT1 is a high affinity (with a Km value of ~1.5mM) but low capacity transporter, whereas GLUT2 
is a low affinity (with a Km value of ~17mM) and high capacity transporter (497). This seems to suggest 
that GLUT1 could play a more important role in mediating glucose transport from the blood into 
intestinal epithelial cells compared to GLUT2, considering that the physiological concentrations of 
glucose in the blood are ~5-6mM.      
Furthermore, GLUT1 is overexpressed in the alimentary limb after RYGB surgery and has been 
reported to mediate increased intestinal glucose utilisation, along with adaptive changes such as 
hypertrophy and transcriptomic changes in glucose metabolism genes (42, 43). Similarly, GLUT1 gene 
expression was also increased in rats following sleeve-gastrectomy with duodenojejunal bypass (511). 
From the experiments performed on HFD-fed mice, oral metformin administration for 6 hours or 11 
days increased the expression of Slc2a1 in the distal small intestine, which could provide further 
evidence that metformin increases glucose uptake by upregulating GLUT1 transporters (Figure 5.10 
and 5.11). These experiments suggest that upregulating the GLUT1 transporter and increasing basal 
uptake of glucose in the intestine may be shared mechanisms of bariatric surgery and metformin in 
achieving the glucose lowering effects.        
 
5.5.2 The effect of metformin on the expression of other glucose transporters 
Although metformin has been reported to affect intestinal glucose absorption, the cellular 
mechanisms that explain this effect are unclear and often contradictory. An early study investigated 
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the effects of metformin on the expression of intestinal glucose transporters, revealing that oral 
metformin treatment in rats for 3 days increased the abundance of SGLT1 in the duodenum and 
jejunum, and GLUT5 in the jejunum, whilst the expression of GLUT2 was unaltered (531). A separate 
study demonstrated that acute administration of metformin (for 3 minutes) in intraluminal intestinal 
loops decreased the abundance of SGLT-1 protein associated with AMPK activation and decreased 
short circuit currents in acute metformin treated tissues as measured by Ussing chamber experiments 
(523). Observations reported by other groups studying the effects of the AMPK activator AICAR also 
argued that AMPK activation by metformin increases the abundance GLUT2 protein in the brush 
border membranes associated with AMPK activation (523, 524). Similarly, studies in insulin-resistant 
animal models argue for the case that GLUT2 is translocated to the brush border of enterocytes to 
allow glucose flux from the blood into the intestinal lumen (505, 523). However, the evidence 
regarding apical GLUT2 translocation is by itself conflicting as other studies could not replicate these 
observations (491, 492). A recent investigation by Bauer et al., reported that metformin increases 
SGLT-1 mediated glucose sensing in the small intestine by altering the composition of the microbiota, 
which was associated with improved glucose sensing and increased GLP-1 secretion, further 
complicating the molecular mechanisms of metformin action on glucose absorption (251).   
The data presented in this study demonstrated that metformin treatment decreased the expression 
of both Slc5a1 (SGLT1) and Slc2a2 (GLUT2) in intestinal cells from the 2D organoid monolayer model 
system (Figure 5.1 and 5.2) and the distal small intestinal tissues of HFD-fed mice treated with 
metformin for 6 hours or 11 days (although Slc2a2 expression was also decreased in the tissues from 
the middle small intestine as well) (Figure 5.10 and 5.11). The limitation of the intestinal 2D monolayer 
culture model should be acknowledged, as the lack of apical-basolateral polarity of intestinal cells in 
culture limits the ability to study transepithelial glucose transport. However, numerous other studies 
in mice have also reported that oral metformin use decreases the absorption of glucose and increases 
the transit of glucose down the small intestine (234–236, 488, 489). Furthermore, various 
pharmacogenetic studies demonstrate that a “reduced function” genetic variant for Slc2a2 
(rs8192675) was associated with a modestly greater effect of metformin on glycaemic control (129, 
130). Although Slc2a2 is the predominant glucose transporter in hepatocytes (involved in release of 
glucose produced from gluconeogenesis) and was therefore the main focus in one of the studies (129), 
reduced Slc2a2 function could also affect the ability of the gut to absorb glucose which may also 
contribute to the effects of metformin on glycaemic control. Future studies should examine the effect 
of metformin on transepithelial glucose transport in cells plated in transwell inserts, which have the 
advantage of retaining apical-basolateral polarity of intestinal cells.  
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It should be acknowledged from the experiments in HFD-fed mice that metformin only altered the 
expression of the glucose transporters (especially Slc5a1 and Slc2a1) in the distal small intestine, 
whereas the effects in other intestinal regions were highly variable (Figure 5.10 and 5.11). These 
regional differences are likely to be explained by variations of metformin biodistribution in the GI tract 
as opposed to differences in metformin action in different regions of the intestinal tract. Studies by 
Wilcock and Bailey demonstrated that metformin accumulates at the highest concentrations in the 
distal small intestine compared to other intestinal regions after metformin oral gavage in mice (312). 
The observations that metformin can also induce similar expression changes in duodenal organoids 
from 2D monolayers at millimolar concentrations also suggest that metformin concentrations in the 
intestinal tissues underlie the expression changes in glucose transporters. 
In the RNA-sequencing data and confirmation from RT-qPCR in intestinal cultures, metformin also 
decreased the expression of Slc2a5 (GLUT5), the predominant transporter for fructose (514). As 
discussed in chapter 3, metformin also decreased the expression of fructose metabolism genes, Khk, 
Aldob and Tkfc (Figure 3.6). This provides further evidence from the expression data that fructose 
uptake and metabolism could be decreased by metformin treatment, which requires functional 
validation in future studies. Furthermore, metformin also decreased the expression of Slc2a7 (GLUT7), 
a recently characterised glucose transporter expressed in the apical membranes of the small intestine 
which has a high affinity for glucose and fructose, although its role in intestinal glucose uptake is not 
known (515).  
 
5.5.3 The contributions of the AMPK and HIF-1A signalling pathways to glucose transport 
changes mediated by metformin  
Metformin is known to cause the activation of AMPK, which was postulated to be the initial candidate 
signalling pathway that regulates glucose uptake by metformin (210). Indeed, studies in skeletal 
muscle have reported that metformin increases glucose uptake via an AMPK-dependent mechanism 
involving the translocation of GLUT4 vesicles to the cell membrane (340). This study reports that 
treatment with the AMPK activator AZ-991 for 24 hours did not alter the mRNA expression of the 
glucose transporters that were altered in expression by metformin, but modestly increased glucose 
uptake (Figure 5.8). Although Slc2a1 has previously been identified as a target gene that was 
upregulated by the AMPK-dependent arm of metformin in hepatocytes (365), this study and others 
suggest that the effects of AMPK are translational or post-translational in intestinal cells. Furthermore, 
our RNA-seq data demonstrated that genes encoding vesicle trafficking proteins potentially 
responsible for the translocation of glucose transporters to the cell membrane, Rab10 and Rab14, 
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were upregulated in metformin treated cultures (Chapter 3, Figure 3.13). Of note, this study did not 
investigate whether metformin increases AMPK activation in the intestinal cultures, although previous 
studies have reported that metformin increases AMPK phosphorylation in intestinal cells/tissues in 
vitro and ex vivo (264, 378, 523).  
Since HIF-1A signalling activation is associated with transcriptional upregulation of genes encoding 
glucose transporters and glycolysis, this prompted further investigations into the effects of inhibiting 
HIF-1A on the expression of glucose transporter transcripts. Supporting the RNA-seq data, the results 
showed that pharmacological inhibition of HIF-1A abolished the effects of metformin on Slc2a1 
expression, but not Slc2a2 or Slc5a1 expression (Figure 5.9). Similarly, imaging studies of intracellular 
glucose concentrations demonstrate that the HIF-1A inhibitor NSC-134754 markedly attenuated 
glucose uptake in both control and metformin treated cells, suggesting that the HIF-1A signalling 
pathway is essential for maintenance of glucose uptake pathways (Figure 5.9). This also provides 
another indirect line of evidence that glucose uptake is mediated by GLUT1, since NSC-134754 
abolished any effects of metformin on glucose uptake, similar to its effects on Slc2a1 expression. Also, 
Slc2a1 is the bona fide target gene of the HIF-1A signalling pathway, upregulation of which drives 
glycolysis in cancer cells (532, 533).  
Interestingly, inhibition of HIF-1A also decreased the expression of Slc5a1 and Slc2a2 in control 
cultures (Figure 5.9). Although reduced Slc2a2 expression has previously been reported in isolated 
islets derived from HIF-1A knockout mouse (and therefore pharmacological inhibition of HIF-1A in this 
study achieved the same effect in intestinal cells) (534), the mechanisms that regulate Slc5a1 
transcript expression are unclear. The observations that metformin altered the mRNA expression of 
transporters at millimolar concentrations could potentially suggest a mitochondrial dependent 
mechanism, since metformin is known to only inhibit complex I activity at millimolar concentrations 
(204, 205).  
A role of HIF-1A was also demonstrated in experiments involving bariatric surgery (42, 43). Mouse 
models that had undergone RYGB surgery exhibited transcriptomic changes in HIF-1A and many of its 
target genes in the alimentary limb, which was responsible for the effects of increased glucose 
utilisation and intestinal hypertrophy post-surgery (43). The results from this study suggest that the 
HIF-1A signalling pathway is important in the effects of metformin and may share a similar mechanism 




5.5.4 Conclusions  
This study describes a potential cellular mechanism that supports the effects of metformin on glucose 
utilisation and absorption in the GI tract. High concentrations of metformin increased the expression 
of Slc2a1 (GLUT1) and increased glucose uptake in intestinal cells, which may explain the increased 
glucose utilisation by the small intestine in mice and humans. This mechanism could be mediated by 
the AMPK and especially HIF-1A signalling pathways. Future experiments should investigate the 
functional effects of AMPK and HIF-1A modulators in mouse models via glucose tolerance tests. In 
addition, metformin also decreased the expression of Slc2a2 (GLUT2) and Slc5a1 (SGLT1) by an 
unknown mechanism, which could potentially contribute to the effects of metformin in decreasing 











Intestinal nutrient metabolism has a major influence on whole-body energy expenditure (175). Since 
orally administered metformin is more effective at glycaemic control than intravenous administration 
(319), and metformin accumulates at high concentrations inside intestinal cells (312, 315), it is 
speculated that the actions of metformin on intestinal metabolism would greatly contribute to its 
effects as a glucose-lowering agent. However, knowledge into effects of metformin and nutrient 
metabolism in intestinal cells is still limited, since much of the existing literature were previously 
reported in liver and cancer cells (116, 240). This chapter examines the effects of metformin on 





6.2.1 Nutrient metabolism in intestinal cells 
The small intestine is highly metabolically active to sustain the energy demanding processes of 
nutrient digestion and absorption (175, 176). Earlier studies have identified glucose and glutamine as 
the main sources of fuel utilised by intestinal cells (177–185). Intestinal glucose metabolism is 
responsible for 15% and 30% of CO2 production from luminal and arterial sources, respectively (180). 
Carbon tracer studies demonstrated that intestinal cells are highly glycolytic, with most of the glucose 
metabolised to produce lactate or alanine (535), whilst only ~10% of glucose is oxidised in the 
mitochondria (177). Glutamine is reported to be a more important fuel; its oxidation is responsible for 
35% and 52-70% of total CO2 production during postabsorptive and fasting states, respectively (177, 
180). Glutamine is an important substrate for the generation of alanine through alanine 
aminotransferases, as well as other amino acids such as proline and citrulline (178, 179, 536), with 
some studies arguing that glutamine is an important substrate for intestinal gluconeogenesis (179, 
386, 535). The intestine has been demonstrated to also be capable of metabolising ketone bodies 
(177, 181, 182, 536) , fatty acids (177, 537–539) and fructose (391). 
Recent studies demonstrated that nutrient metabolism is heterogeneous amongst different cell types 
along the crypt-villus axis (150, 187–189). Intestinal organoids grown under high Wnt conditions (to 
model intestinal stem cells) were more reliant on glycolysis than organoids grown in standard medium 
136 
 
(150). Inhibitors of mitochondrial function (150) or using an intestine-selective HSP60 knockout mouse 
model that causes mitochondrial dysfunction (485) disrupted intestinal differentiation, demonstrating 
that mitochondrial respiration is a feature of more differentiated cells. Measurements of NADH 
lifetime distribution of cells along the crypt-villus axis similarly confirmed that intestinal stem cells are 
highly glycolytic, whilst terminally differentiated villus cells require mitochondrial oxidation (189). 
Intestinal organoids with impaired mitochondrial pyruvate metabolism (187), impaired fatty acid 
oxidation (188) or glutamine deprivation (540) displayed reduced intestinal crypt expansion and 
organoid formation. These observations were also supported by proteomic analyses of the crypt-villus 
axis in the intestines of neonatal piglets, which demonstrated increased expression of proteins 
involved in the tricarboxylic acid (TCA) cycle, fatty acid and amino acid oxidation in the villus factions 
compared to the crypts (541). These studies highlighted that, in contrast to earlier studies, fuel 
metabolism are heterogeneous and defines different intestinal cell types along the crypt-villus axis.  
6.2.2 Cellular mechanisms of metformin on nutrient metabolism 
At the cellular level, metformin accumulates at high concentrations in the mitochondria compared to 
other cellular compartments (201). Previous studies extensively focussed on the inhibition of complex 
I (NADH dehydrogenase) of the mitochondrial electron transport chain to attenuate oxidative 
phosphorylation, although much of these effects were studied at high concentrations of metformin 
(201–204). Other studies also reported that metformin inhibited other aspects of mitochondrial 
bioenergetics such as uncoupled respiration (205) or ATP-synthase activity (201). Metabolic tracing 
studies from cancer cells demonstrated that metformin reduced flux of TCA cycle intermediates 
responsible for oxidative metabolism (205, 206). As a result of inhibiting mitochondrial respiration, 
metformin indirectly increases lactate production from glycolysis in a variety of cell types (59, 64, 207, 
208). A recent study of whole-body metabolism in HFD-fed mice reported reduced whole-body 
glucose oxidation (calculated as the changes in respiratory quotient values as measured by indirect 
calorimetry in response to oral gavage) during an early response to a single oral metformin gavage, 
whilst increasing the amount of non-oxidised glucose (236). This translates the cellular effects of 
metformin in inhibiting mitochondrial respiration/glucose oxidation to an in vivo setting.     
The evidence associating metformin and hepatic gluconeogenesis is controversial. Earlier studies in 
rodent and humans support the hypothesis that metformin mediates its glucose-lowering effects by 
inhibiting hepatic gluconeogenesis (220, 225–227). The mechanisms involved is still disputed. 
Madiraju et al., demonstrated that low-dose metformin directly inhibited the mitochondrial 
glycerolphosphate dehydrogenase involved in the glycerolphosphate shuttle, which suppressed 
hepatic gluconeogenesis from lactate and glycerol (but not pyruvate or alanine) sources in a redox 
dependent manner (225, 226). Other studies demonstrate that metformin decreased hepatic 
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gluconeogenesis by inhibiting fructose 1,6-bisphosphatase (FBP-1) (542), or by decreasing glycogen 
cycling (389, 543, 544). However, some of the recent studies challenge this mechanism to show that 
metformin increases endogenous glucose production in Carbon-14 tracer experiments on liver 
samples from HFD-fed mouse models and in patients with recent onset type-2 diabetes (207, 228). 
Due to AMPK activation, metformin also suppresses lipogenesis and increase fatty acid oxidation 
(FAO) (210, 211, 229, 230). Several studies have demonstrated that metformin inhibits the activity of 
Acetyl-CoA carboxylase (ACC) to promote FAO, as well as inhibiting the expression of SREBP-1 and 
fatty acid synthase (Fasn) to suppress lipogenesis in hepatocytes (210, 211, 233, 545). The effects of 
metformin in promoting FAO despite inhibiting mitochondrial respiration seem paradoxical (since FAO 
is dependent on mitochondrial respiration). However,  Gonzalez-Barroso et al., demonstrated that 
metformin did not inhibit palmitate oxidation in 3T2-L1 adipocytes, despite inhibiting basal oxygen 
consumption, increasing extracellular acidification and activating AMPK (545). The mechanisms 
underlying the permissive effect of metformin on FAO remain elusive. 
6.2.3 Metformin and intestinal nutrient metabolism 
Metformin accumulates at milimole concentrations within intestinal cells despite micromolar 
concentrations present in plasma (312, 315, 394). Metformin decreases mitochondrial function in 
intestinal cells, as oral administration decreased the NADH/NAD+ ratio in the intestinal mucosa of HFD 
mice (207) and reduced oxygen consumption in intestinal organoids (546). Several ex vivo and in vivo 
studies performed in rodents demonstrated that metformin increased intestinal glucose utilisation 
and lactate release into the splanchnic bed as a result from inhibiting mitochondrial respiration (64, 
116, 207, 239–242, 312).  
 
6.3 Aims 
This chapter investigates the effects of metformin on nutrient metabolism to complement the 
observations that metformin increases glucose uptake in intestinal cells from the previous chapter. 
The aims of this study are:  
1. To examine the role of metformin in glycolysis and glucose oxidation in intestinal cells 
2. To investigate the mechanisms of metformin in maintaining glycolysis 
3. To examine the role of the mitochondria in pyruvate and glutamine oxidation in intestinal cells 






All metformin (1mM) treatments were overnight (18-28 hours) prior to imaging experiments or for 24 
hours prior to Seahorse and lactate measurements. 
6.4.1 Metformin decreases glucose oxidation but maximises glycolysis in intestinal cells 
 
To assess the effects of metformin on glucose oxidation and confirm that metformin inhibits 
mitochondrial respiration in intestinal cells, the mitochondrial stress test was performed using the 
Seahorse flux bioanalyser in the presence of glucose (10mM) in the Seahorse media. Oxygen 
consumption was consistently lower in metformin treated cells in comparison to control cells, even in 
the presence of mitochondrial respiration inhibitors; oligomycin (ATP-synthase inhibitor), FCCP 
(proton uncoupler) and Rotenone/Antimycin A (Complex I and III inhibitors, respectively) (Figure 
6.1A). Metformin treatment reduced basal, maximal, ATP-linked and uncoupled oxygen consumption 
rate, whilst the respiratory reserve was unaffected (Figure 6.1B). This confirms that metformin inhibits 
mitochondrial glucose metabolism (Figure 6.1B).  
 
  
Figure 6.1. Metformin decreases glucose oxidation in intestinal cells. (A) Changes in oxygen 
consumption rate (OCR) over time during the mitochondrial stress test in which intestinal cells were 
previously treated with control or without metformin for 24 hours. Cells were incubated with glucose 
(10mM) in XF basal media for 1 hour prior to measurements. Dotted lines indicate when a compound 
was added. Oligomycin-A (OliA, 1μM), FCCP (1μM), Rotenone/Antimycin A (Rot/AA, 1μM each). (B) 
The effect of metformin on the measured parameters. The methods on how the parameters were 
calculated are described in detail in chapter 2, section 2.7. N=4-5 wells from 4 independent 
experiments. ***; P<0.001. Two-way ANOVA and Bonferroni post-hoc test. 
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To support the observations from the mitochondrial stress test, the effects of metformin on the 
cellular redox state was studied by live-cell imaging of NAD(P)H and FAD autofluorescence. Previous 
studies have demonstrated that NAD(P)H autofluorescence is dominated by mitochondrial, as 
opposed to cytosolic NADH (547–550). Glucose increases NADH generation through TCA-cycle 
oxidation, whilst decreasing FAD autofluorescence mediated by succinate metabolism in the TCA cycle 
(551, 552). The proton uncoupler FCCP was used as a positive control, as depletion of the 
mitochondrial membrane potential by FCCP maximises fuel oxidation and electron transport chain 
activity, thereby forcing the mitochondria to oxidise NADH to NAD+ and oxidise FADH2 to FAD (327, 
553). Glucose simultaneously increased NAD(P)H and reduced FAD autofluorescence in control cells, 
respectively, which was reversed in the presence of FCCP (Figure 6.2A, 6.2C 6.2D). Metformin pre-
treatment significantly diminished the effects of glucose and FCCP on NAD(P)H and FAD 
autofluorescence (Figure 6.2B, 6.2C and 6.2D). This is consistent with metformin impairing 
mitochondrial function through redox metabolism.     
 
  
Figure 6.2. The effect of metformin on the redox state in intestinal cells. (A and B) Example 
traces of NAD(P)H (yellow) and FAD (green) autofluorescence measurements in control (A) and 
metformin (B) treated cells. (C and D) The effect of control (red dots) and metformin (blue dots) 
on NAD(P)H (C) and FAD (D) autofluorescence in the presence of glucose (Gluc, 10mM) with or 
without FCCP (1μM). Each dot denotes one cell. N= 92 cells (control) and 70 cells (metformin), 




A glycolytic stress test was performed to assess the glycolysis parameters of intestinal cells by 
measuring pH changes in the media to calculate the extracellular acidification rate (ECAR) (see chapter 
2, section 2.7 for methods). Metformin treated cultures increased glycolysis, and abolished the 
glycolytic reserve, suggested by the fact that they were unable to further increase glycolytic flux as 
measured by ECAR upon oligomycin addition (Figure 6.3A and 6.3B). Metformin also modestly 
increased the glycolytic capacity; the maximum cellular capacity to undergo glycolysis (Figure 6.3B) 
(554). Note that this appeared in part to be a consequence of a lower non-glycolytic acidification 
(changes in ECAR prior to glucose addition, thus not attributed to glycolysis and thought to be a 
consequence of CO2 production in the citric acid cycle) in the metformin-treated cells compared to 
control cells, although this did not reach statistical significance (Figure 6.3B). The results suggest that 








The effects of metformin on ATP generation from glucose metabolism was monitored via live-cell 
imaging of intestinal cells transfected with the fluorescent ATP sensor PercevalHR. Each glycolysis 
reaction produces a net 2 molecules of ATP for each molecule of glucose, whilst glucose oxidation 
produce ~36 molecules of ATP (Figure 6.4A). Changes in Perceval fluorescence was observed only in 
21/26 of control cells in response to washout of glucose with saline (Figure 6.4B-6.4D), whilst all of 
the cells treated with metformin responded, indicating that metformin pre-treatment robustly  
Figure 6.3 Metformin increases intestinal glycolysis to its maximal capacity. (A) Changes in extracellular 
acidification rate (ECAR) over time during the glycolytic stress test wherein intestinal cells were previously 
treated with control or with 1mM metformin for 24 hours. Dotted lines indicate when a compound was added: 
Gluc; glucose (10mM), OliA; oligomycin-A (1μM), 2-DG; 2-deoxyglucose (50mM). (B) The effect of metformin 
on the measured parameters of the glycolysis stress test. The methods on how the parameters were calculated 
are described in detail in Chapter 2, section 2.7. N=10 wells from 3 independent experiments. NS; not 




Figure 6.4. Metformin inhibits ATP generation from glucose oxidation but increases glycolytic ATP production. 
(A) Schematic showing the effects of rotenone and antimycin A (Rot and AA respectively) and 2-deoxyglucose (2-DG) 
on cellular ATP generation. (B and C) Example traces of Perceval fluorescence ratios from Control (B) and Metformin 
(C) treated cells. The treatments glucose (Gluc, 10mM), Rot/AA (1μM) and 2-DG (50mM) were applied as indicated. 
Different coloured lines denote responses from different cells. (D) Measured Perceval fluorescence ratios in control 
(red) and metformin-treated (blue) cells where glucose was switched to saline and re-applied. **; P<0.01, ***; 
P<0.001, control: Friedman test and Dunn’s post-hoc test, N=24 cells from 9 dishes, metformin: Repeated-measures 
ANOVA and Bonferroni post-hoc test, N=24 cells from 8 dishes). (E) The effect of 10mM glucose (Gluc), Rot/AA and 
2-DG on the Perceval fluorescence ratios in control (red) and metformin-treated (blue) cells (***; P<0.001, Repeated-
measures ANOVA and Bonferroni post-hoc test. Control: N=14 from 5 dishes, metformin: N=20 cells from 4 dishes). 
(F) Rot/AA decreased Perceval fluorescence in control cells, not metformin-treated cells. (***; P<0.001, Repeated 
measures Two-way ANOVA.). (G and H) Example traces of Perceval fluorescence ratios from Control (G) and 
Metformin (H) treated cells in response to 2-DG alone. Different coloured lines denote responses from different cells. 
(I) 2-DG significantly decreased Perceval fluorescence in metformin treated cells relative to control cells. ***; 
P<0.001, student’s t-test. Control; N=14 from 4 dishes and metformin; N=17 from 4 dishes).   
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increased ATP generation from glucose metabolism (Figure 6.4B-6.4D). The contribution of glucose 
oxidation in glycolytic ATP generation was assessed with rotenone and antimycin A (Rot/AA). Rot/AA 
decreased Perceval fluorescence ratio in control cells but was without a significant effect on 
metformin treated cells (Figure 6.4E and 6.4F). Subsequent exposure to 2-DG on top of Rot/AA 
markedly decreased Perceval fluorescence, to a larger extent in control than in metformin treated 
cells (Figure 6.4E-6.4F). Exposure to 2-DG alone in the presence of glucose decreased the Perceval 
fluorescence in metformin treated cells more than the control (Figure 6.4G-6.4I), confirming that 
metformin treated cells rely on glycolytic ATP production, whereas control cells show greater 
metabolic flexibility, presumably oxidising an alternative fuel to buffer ATP production through 
mitochondrial respiration.  
 
6.4.2 Metformin increases glycolytic metabolism of pyruvate towards lactate and alanine  
  
Lactate production could influence glycolysis in two ways: (1) The forward lactate dehydrogenase 
reaction regenerates NAD+ that is required to maintain glycolysis and (2) lactate production causes 
intracellular acidification which reduces the glycolysis rate by inhibiting phosphofructokinase, thus 
necessitating functional monocarboxylate transporters (MCTs) for lactate efflux (549, 555, 556). The 
competitive LDH inhibitor Oxamate, and high affinity MCT inhibitors AR-C155858 (MCT1/2 blocker) 
(557) and Syrosingopine (MCT1/4 blocker) (556) were used to study the pyruvate-lactate metabolism 
pathway (Figure 6.5A). Metformin pre-treatment increased lactate secretion in the intestinal cultures 
in the presence of 10mM glucose, whilst inhibition of LDH by Oxamate or inhibition of MCTs by AR-
C155858 and Syrosingopine partially reduced the lactate secretion response elicited by metformin 
(Figure 6.5B). Unexpectedly, metformin treatment significantly, but modestly decreased LDH activity, 
which likely reflects lower LDH levels (Figure 6.5C). The effects of these inhibitors on the cytosolic 
NAD+/NADH ratio was also investigated by live-cell imaging of cells transfected with the Peredox 
sensor. In control cells, Oxamate application did not elicit notable changes in the Peredox 
fluorescence, but significantly increased Peredox fluorescence in metformin pre-cultured cells (Figure 
6.5D). Similarly, application of MCT inhibitors AR-C155858 and Syrosingopine elicit increased Peredox 
fluorescence in metformin pre-cultured cells than control cells, although this did not reach statistical 
significance (Figure 6.5E).   
Similar observations were also observed in the Perceval imaging experiments to observe the effects 
of the inhibitors on intracellular ATP. Oxamate did not affect Perceval fluorescence in the presence of 
glucose in control cells, but significantly decreased Perceval fluorescence in metformin treated cells 




Figure 6.5. The effect of metformin on lactate production, LDH activity and Peredox fluorescence 
elicited by lactate metabolism/transport inhibitors (A) Schematic showing the effects of the LDH 
inhibitor Oxamate and MCT inhibitors AR-C155858 (MCT1 and MCT2) and Syrosingopine (MCT1 and 
MCT4) on glycolysis pathway. (B) Lactate secretion levels in control and metformin pre-treated cultures 
in glucose (10mM, 10G), with oxamate (50mM) or AR-C155858 (AR-C, 10μM) and Syrosingopine (Syro, 
50μM). Error bars are mean ± SEM. *; P<0.05, **; P<0.01, ***; P<0.001, vs control. †††; P<0.001 vs pre-
treated conditions in 10G.  Two-way ANOVA and Bonferroni post-hoc test. N=2-3 wells from 4 
independent experiments except AR-C/Syro, where 3 independent experiments were performed. (C) LDH 
activity in control and metformin treated cultures. Error bars are mean ± SEM. ***; P<0.001, vs control. 
Independent t test. N=3 wells from 4 independent experiments. (D) The effects of oxamate on Peredox 
fluorescence in Control (red) and Metformin (blue) treated cells. Glucose (Gluc, 10mM) and oxamate 
(50mM) were applied as indicated. Different coloured lines denote responses from different cells. Error 
bars are median ± confidence intervals.  *; P<0.05, Mann-Whitney test. Control: N= 15 cells from 4 dishes; 
Metformin: N=18 cells from 4 dishes. (E) The effects of AR-C155858 and Syrosingopine on Peredox 
fluorescence in Control (red) and Metformin (blue) treated cells. Glucose (Gluc, 10mM), AR-C155858 
(10μM) and Syrosingopine (50μM) were applied as indicated. Different coloured lines denote responses 
from different cells. Error bars are mean ± SEM.  Control: N= 14 cells from 4 dishes; Metformin: N=19 cells 





Figure 6.6. Inhibiting lactate production and transport decreases Perceval fluorescence but does 
not completely inhibit glycolysis in metformin treated cells. (A) The effects of oxamate on 
Perceval fluorescence in Control (red) and Metformin (blue) treated cells. Glucose (Gluc, 10mM), 
oxamate (50mM) and 2-DG (50mM) were applied as indicated. Different coloured lines denote 
responses from different cells. Control: N=23 cells from 6 dishes; metformin: N=25 cells from 6 
dishes. (B) The effects of MCT inhibitors AR-C155858 and Syrosingopine on Perceval fluorescence 
in Control (red) and Metformin (blue) treated cells. The treatments glucose (Gluc, 10mM), AR-
C155858 (AR-C, 10μM), Syrosingopine (Syro, 50μM) and 2-DG (50mM) were applied as indicated. 
Different coloured lines denote responses from different cells. Control: N=22 cells from 6 dishes; 
metformin: N=16 cells from 5 dishes. For A and B: repeated measures ANOVA and Bonferroni post 
hoc test or Friedman test with Dunn’s post-hoc test (if normality is not passed) for before-after 
comparisons. (C and D) Oxamate (C) and MCT inhibitors (D) decreased Perceval fluorescence more 
profoundly in metformin treated cells than control cells. For C and D, Error bars are mean ± SEM. 




fluorescence in control cells, but the effects were more profound in metformin treated cells (Figure 
6.6B). 2-DG further decreased Perceval fluorescence in both control and metformin treated cells 
independent of the inhibitors (Figure 6.6C, 6.6D). This could be due to incomplete inhibition of 
glycolysis by the LDH and MCT inhibitors, or that glycolysis could be sustained by the metabolism of 
pyruvate to alanine or other alternative pathways.  
Aspartate and alanine transaminases are also involved in glycolysis; aspartate transaminases are 
involved in the malate aspartate shuttle, another mechanism that regenerates cytosolic NAD+ (whilst 
mitochondrial NAD+ is simultaneously reduced), whereas alanine transaminases are involved in the 
metabolism of pyruvate to alanine. Particularly, alanine aminotransferases are expressed and 
functionally important in intestinal cells (535, 558) and both transaminases were upregulated by 
metformin treatment in monolayer cultures (See chapter 3). The activities of aspartate (AST) and 
alanine (ALT) transaminases were increased in metformin pre-treated cultures (Figure 6.7A and 6.7B). 
Aminooxyacetate (AOA), a broad-spectrum aminotransferase inhibitor, was used to examine changes 
in perceval fluorescence in metformin-treated cells (Figure 6.7C). Application of AOA decreased 
Perceval fluorescence in metformin-treated cells more so than control cells, although this was not 
statistically significant (Figure 6.7D, P=0.06). To distinguish the contribution of alanine transaminases 
from aspartate transaminases, Perceval fluorescence was monitored upon application of the selective 
alanine-aminotransferase inhibitor β-chloro-L-alanine (βCLA) and AOA sequentially (see Figure 6.7C 
for schematic). βCLA similarly decreased Perceval fluorescence in metformin, but not control cells 
(Figure 6.7E). Subsequent AOA application weakly reduced Perceval fluorescence, whilst 2-DG further 
decreased Perceval fluorescence independent of the inhibitors (Figure 6.7E). These observations 
suggest that despite increased activity of alanine and aspartate transaminases, alanine 
aminotransferases but not aspartate transaminases may contribute to glycolytic ATP production 
despite not being essential to maintain glycolysis.    
Further evidence against an important role of the malate-aspartate shuttle in glycolytic ATP 
production was demonstrated by Perceval fluorescence measurements involving the oxoglutarate-
glutamate transporter inhibitor phenylsuccinate. Application of phenylsuccinate did not differently 
affect the Perceval fluorescence between control and metformin pre-treated cells (Figure 6.8A and 
6.8C). The roles of the glycerolphosphate shuttle in Perceval fluorescence was also investigated, since 
the conversion of glycerol-3-phosphate (G3P) to dihydroxyacetone phosphate (DHAP) by cytosolic 
glycerolphosphate dehydrogenase (GPDH) also regenerates cytosolic NAD+ (but also requiring 
mitochondrial FAD metabolism). 100μM concentrations of the putative glycerolphosphate shuttle 





Figure 6.7. The effect of metformin on alanine and aspartate transaminases in intestinal cells. (A) Aspartate 
transaminase (AST, or GOT) and (B) Alanine transaminase (ALT or GPT) activity in control and metformin treated 
cultures. Error bars are mean ± SEM. **; P<0.01, *; P<0.05, vs control. Independent t test. N=3 wells from 4 
independent experiments. (C) Schematic showing the effects of transaminase inhibitors Aminooxyacetate (AOA) and 
β-chloro-L-alanine (βCLA) on metabolic pathways. (D) The effects of AOA on Perceval fluorescence in Control (red) 
and Metformin (blue) treated cells. Glucose (Gluc, 10mM), AOA (10mM) and 2-DG (50mM) were applied as indicated 
on the traces. Different coloured lines denote responses from different cells. Control: N=19 from 4 dishes, 
metformin: N=22 cells from 3 dishes. (E) Distinguishing alanine aminotransferase from aspartate aminotransferase 
activity on Perceval fluorescence in control (red) and metformin (blue) treated cells. Glucose (Gluc, 10mM), βCLA 
(1mM), AOA (10mM) and 2-DG (50mM) were applied as indicated. Control: N=16 from 3 dishes, Metformin: N=15 
cells from 3 dishes. *; P<0.05, **; P<0.01, ***; P<0.001. Error bars are means ± SEM. Repeated measures ANOVA 
and Bonferroni post hoc test or Friedman test with Dunn’s post-hoc test (if normality is not passed) for before-after 
comparisons between different treatments, two-way ANOVA and Bonferroni post-hoc test for ΔPerceval 





Figure 6.8. Inhibitors of the malate aspartate shuttle and glycerolphosphate shuttle does not affect 
Perceval fluorescence. (A) The effects of the oxoglutarate-glutamate transport inhibitor 
Phenylsuccinate (PhS) on Perceval fluorescence in Control (red) and Metformin (blue) treated cells. 
Glucose (Gluc, 10mM), Phenylsuccinate (10mM) and 2-DG (50mM) were applied as indicated. Control: 
N=18 from 4 dishes, metformin: N=33 cells from 5 dishes.  Repeated-measures ANOVA and Bonferroni 
post-hoc test.(B) The effects of the mitochondrial glycerolphosphate dehydrogenase inhibitor iGP1 on 
Perceval fluorescence in Control (red) and Metformin (blue) treated cells. Glucose (Gluc, 10mM), iGP1 
(100μM) and 2-DG (50mM) were applied as indicated on the traces. Different coloured lines denote 
responses from different cells. Control: N= 15 cells from 5 dishes, metformin: N=14 cells from 4 dishes. 
NS; not significant. ***; P<0.001, Repeated-measures ANOVA and Bonferroni post-hoc test. (C and D) 
Changes in Perceval fluorescence in control and metformin treated cells to PhS (C) or iGP-1 (D) and 2-
DG. NS; not significant, ***; P<0.001, Two-way ANOVA and Bonferroni post-hoc test. 
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metformin treated cells, despite reported effects on other cell types and animal models at the same 
concentrations (559–563) (Figure 6.8A-6.8D).  
 
6.4.3 The effect of metformin on pyruvate and glutamine metabolism 
 
Following glycolysis, pyruvate enters the mitochondria where it is converted into acetyl-CoA and joins 
the TCA cycle for oxidative metabolism. The contributions of endogenous mitochondrial pyruvate 
oxidation in control and metformin pre-treated cultures were investigated using the mitochondrial 
pyruvate carrier inhibitor UK-5099 (which inhibits mitochondrial uptake of pyruvate) in the presence 
of 10mM glucose. Application of UK-5099 (10µM) significantly decreased OCR in control cultures 
compared to DMSO, but the drug did not affect OCR in metformin treated cultures compared to DMSO 
(Figure 6.9A and 6.9B). This suggests that cells are not actively oxidising the pyruvate generated from 
glycolysis in metformin-treated cultures. UK-5099 also modestly decreased Perceval fluorescence in 
control but not metformin treated cells (Figure 6.9C-6.9E), but the changes in Perceval fluorescence 
were indistinguishable between treatments (Figure 6.9F). This might suggest that intestinal cells are 
not dependent on endogenous pyruvate oxidation for glycolytic ATP production. UK-5099 application 
also abolished the different effects of 2-DG on the Perceval fluorescence in control and metformin 
treated cells (Figure 6.9F). This probably indicates that at least in 5 out of 17 control cells, its metabolic 
flexibility is compromised in the presence of UK-5099 and is therefore more dependent on glycolysis 
for ATP production (Figure 6.9F). The other 12 of 17 cells are still resistant to the effects of 2-DG on 
Perceval fluorescence (compared to metformin treated cells), which could be that these control cells 
were able to utilise pyruvate from another source to sustain mitochondrial respiration and TCA-cycle 
metabolism (and therefore maintain their metabolic flexibility).  
Since intestinal cells express MCTs (see Chapter 3) which exports lactate generated from glycolysis 
(Figure 6.3), the effects of exogenous pyruvate (1mM) application, a substrate of MCTs, was also 
investigated using Perceval imaging. Perceval fluorescence in control intestinal cells did not change 
despite switching the perfusion from pyruvate to saline (Figure 6.10A-6.10B), although subsequent 
application of Rot/AA decreased Perceval fluorescence in control cells (Figure 6.10D). None of the 
treatments (not even Rot/AA) altered Perceval fluorescence in metformin treated cells (Figure 6.10C-
6.10D), except for 10mM glucose (Figure 6.10D). This observation also confirms the effects of UK-5099 
in demonstrating that intestinal cells are not dependent on pyruvate oxidation for ATP synthesis, 




Figure 6.9. Inhibiting mitochondrial pyruvate transport decreases oxygen consumption in control cells, 
but does not remarkably affect Perceval fluorescence in control and metformin treated cells.  
(A and B) The effects of the mitochondrial pyruvate carrier inhibitor UK-5099 compared to DMSO on oxygen 
consumption of control and metformin cultured cells as measured by the seahorse bioanalyser.  For B, 
normalised OCR was calculated as differences after drug application and third time point measured before 
application ***, P<0.001 compared to DMSO in control cultures. N=4-5 wells from 4 independent 
experiments. (C and D) The effects of the mitochondrial pyruvate carrier inhibitor UK-5099 on Perceval 
fluorescence in Control (red, C) and Metformin (blue, D) treated cells. Glucose (Gluc, 10mM), UK-5099 
(10μM) and 2-deoxyglucose (2-DG, 50mM) were applied as indicated on the traces. Different coloured lines 
denote responses from different cells. (E) Measured Perceval fluorescence ratios in control (red) and 
metformin-treated (blue) cells in the presence of UK-5099. Control: N= 17 cells from 3 dishes, metformin: 
N=24 cells from 3 dishes. NS; not significant. ***; P<0.001, Repeated-measures ANOVA and Bonferroni post-
hoc test. (F) Changes in Perceval fluorescence in control and metformin treated cells to iGP-1 and 2-DG. NS; 




















Live cell imaging of intracellular pyruvate generated from glycolysis were also performed by using the 
genetically encoded FRET-based fluorescent pyruvate sensor Pyronic. Inhibition of mitochondrial 
pyruvate uptake using UK-5099 in the presence of glucose (10mM) modestly increased pyruvate levels 
in control cells, but not metformin treated cells (Figure 6.11A). However, inhibiting the mitochondrial 
electron transport chain using rotenone and antimycin A in the presence of glucose did not increase  
Figure 6.10. Exogenous pyruvate exposure does not affect Perceval fluorescence.  
(A and B) The effects of pyruvate exposure on Perceval fluorescence in Control (red, A) and 
Metformin (blue, B) treated cells. For metformin treated cells, glucose (Gluc, 10mM) was 
applied as a positive control, but not included for analysis. Pyruvate (Pyr, 1mM) and 
Rotenone/Antimycin A (Rot/AA, 1μM each) were applied as indicated on the traces. 
Different coloured lines denote responses from different cells. (C) Measured Perceval 
fluorescence ratios in control (red) and metformin-treated (blue) cells to pyruvate, saline 
and Rot/AA. Control: N= 17 cells from 6 dishes, metformin: N=16 cells from 5 dishes. NS; not 
significant. ***; P<0.001, Friedman test and Dunn’s post-hoc test. (D) Changes in Perceval 
fluorescence in response to Rot/AA in control and metformin treated cells. Bars are median 
± 95% confidence interval. ***, P<0.001. Mann-Whitney test.   
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pyruvate levels in either control or metformin treated cells (Figure 6.11B). This suggests that under 
conditions where mitochondrial electron transport is blocked, pyruvate is not accumulating in the 
cytosol but instead metabolised through alternative pathways.  
The effects of glutamine metabolism on oxygen consumption and ATP generation was also studied, 
since glutamine is highly metabolised in intestinal cells, and like pyruvate can only generate ATP via 
oxidative phosphorylation. In the presence of glutamine (4mM), metformin treated cells displayed 
lower basal, ATP-linked, maximal and uncoupled oxygen consumption (Figure 6.12A, 6.12B). The 
respiration in the presence of FCCP was lower than basal respiration in control cells  
  
Figure 6.11. The effects of UK-5099 and electron transport chain inhibitors on Pyronic fluorescence.  
(A) The effects of the mitochondrial pyruvate carrier inhibitor UK-5099 (10µM) on Pyronic fluorescence 
in Control (red) and Metformin (blue) treated cells. Different coloured lines denote responses from 
different cells. Changes in Pyronic fluorescence expressed as fold change. Data expressed as Bars are 
median ± 95% confidence interval. Control: N= 27 cells from 4 dishes, metformin: N=17 cells from 3 
dishes. **, P<0.01. Mann-Whitney U test.  (B) The effects of rotenone and antimycin A (Rot/AA, 1µM 
each) on Pyronic fluorescence in Control (red) and Metformin (blue) treated cells. Different coloured 
lines denote responses from different cells. Changes in Pyronic fluorescence expressed as fold change. 
Data expressed as Bars are mean ± SEM. Control: N= 15 cells from 2 dishes, metformin: N=12 cells from 





Figure 6.12. Metformin decreases glutamine oxidation in intestinal cells, but glutamine is not a dependent 
fuel for ATP production. (A) Changes in oxygen consumption rate (OCR) over time during the mitochondrial 
stress test in intestinal cells previously treated with control or without metformin for 24 hours. Cells were 
incubated with glutamine (4mM) for 1 hour prior to measurements. Dotted lines indicate when a compound 
was added. Oligomycin-A (OliA, 1μM), FCCP (1μM), Rotenone/Antimycin A (Rot/AA, 1μM each). (B) The 
effect of metformin on the parameters measured during the mitochondrial stress test. N=4-5 wells from 4 
independent experiments. ***; P<0.001. Two-way ANOVA and Bonferroni post-hoc test. (C and D) The 
effects of glutamine on Perceval fluorescence in Control (red, C) and Metformin (blue, D) treated cells. For 
metformin treated cells, glucose (Gluc, 10mM) was applied as a positive control, but was not included for 
analysis. Glutamine (Gln, 4mM) and Rotenone/Antimycin A (Rot/AA, 1μM each) were applied as indicated 
on the traces. Different coloured lines denote responses from different cells.(E) Measured Perceval 
fluorescence ratios in control (red) and metformin-treated (blue) cells to glutamine, saline and Rot/AA. 
Control: N= 20 cells from 4 dishes, metformin: N=18 cells from 4 dishes. NS; not significant. ***; P<0.001, 
Friedman test and Dunn’s post-hoc test. (F) Changes in Perceval fluorescence in response to Rot/AA in 
control and metformin treated cells. Bars are mean ± SEM. ***, P<0.001. Student’s t-test. 
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(Figure 6.12B). This observation was also previously reported for palmitate metabolism in neonatal 
cardiomyocytes (564). This could suggest that basal glutamine oxidation is already at maximal levels 
and intestinal cells might be running out of glutamine before the addition of FCCP. Abolition of the 
mitochondrial membrane potential via FCCP could also disrupt the transport of glutamate into the 
mitochondria via the aspartate-glutamate carrier (AGC), which is dependent on H+ co-transport (565). 
Alternatively, prior inhibition of mitochondrial ATP synthesis by oligomycin could also perturb the 
functions of Na+/K+ ATP-ase, which maintains Na+ electrochemical gradient and suppress electrogenic 
transport of glutamine across the plasma membrane. Perceval fluorescence imaging demonstrated 
that glutamine exposure was without effect on Perceval fluorescence in control and metformin 
treated cells (Figure 6.12C-6.12F). Rot/AA application consistently attenuated Perceval fluorescence 
in control but not metformin treated cells (Figure 6.12E and 6.12F).  
 
6.4.4 The effect of metformin on ATP generation from glycogen and lipid sources in intestinal 
cells 
 
Although the mitochondrial fuels pyruvate and glutamine did not affect Perceval fluorescence, 
decreased Perceval fluorescence was observed in control treated intestinal cells in the presence of 
Rotenone and Antimycin A, suggesting that intestinal cells are able to metabolise an endogenous 
energy store to sustain intracellular ATP levels in the absence of these fuels. The role of glycogen 
metabolism was explored by measuring the Perceval fluorescence of cells exposed to saline buffer and 
the sequential exposure of: (1) glycogen phosphorylase inhibitor GPi-688, (2) glycolysis inhibitor 2-DG 
(inhibits glucose phosphorylation via hexokinase) to inhibit other pathways of glycogen mobilisation 
such as debranching enzyme activity or lysosomal α-glucosidases which produce glucose from 
glycogen and (3) Rotenone and antimycin A as a positive control (Figure 6.13A). GPi-688 treatment 
alone decreased Perceval fluorescence in 26/31 control cells and 11/27 metformin-treated cells 
incubated in saline, although the changes in metformin treated cells were small and not statistically 
significant. 2-DG and Rot/AA treatments further reduced Perceval fluorescence in control cells (Figure 
6.13B, 6.13C). 2-DG modestly but significantly alter the Perceval fluorescence in metformin treated 
cells (Figure 6.13D, 6.13E). The changes in Perceval fluorescence to all the treatments was consistently 
lower in metformin treated cells compared to control cells (Figure 6.13F). This suggests that there 
were less glycogen stores in metformin treated cells at the start of the imaging experiment.  It should 
also be noted that Perceval fluorescence was markedly lower in metformin treated cells from the 
beginning of the experiment, which is likely to be due to low intracellular ATP levels and metabolism 




Figure 6.13. Metformin decreases glycogen mobilisation in intestinal cells. (A) Diagram showing the 
actions of glycogenolysis inhibitors used in the experiments. (B and C) The effects of glycogenolysis 
inhibitors on Perceval fluorescence in Control (red, B) and Metformin (blue, C) treated cells. GPi-688 
(20μM), 2-deoxyglucose (2-DG, 50mM) and Rotenone/Antimycin A (Rot/AA, 1μM each) were applied 
as indicated on the traces. The cells were incubated with 4mM glutamine prior to experiments, before 
switching to saline during the first 3 minutes of imaging. Different coloured lines denote responses 
from different cells. (D) Measured Perceval fluorescence ratios in control (red) and metformin-treated 
(blue) cells to GPi-688, 2-DG and Rot.AA. Control: N=30 cells from 8 dishes, metformin: N=27 cells 
from 7 dishes. NS; not significant. *; P<0.05, **; P<0.01, ***; P<0.001, Friedman test and Dunn’s post-
hoc test. (E) Changes in Perceval fluorescence in control and metformin treated cells to GPi-688, 2-DG 
and Rot/AA. **; P<0.01, ***; P<0.001. Two-way ANOVA and Bonferroni post-hoc test. 
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Endogenous lipid mobilisation was also considered as a candidate internal fuel source since fatty acid 
oxidation has previously been reported in intestinal cells (177, 537–539). Contributions of fatty acid 
oxidation were investigated by measuring the effect of the mitochondrial carnitine 
palmitoyltransferase 1 (CPT1) shuttle inhibitor etomoxir (which prevents fatty acid transport into the 
mitochondria) on Perceval fluorescence in cells exposed to saline. Rotenone/antimycin A was used as 
positive control. When used at 20μM concentrations, etomoxir was without effect in control cells, but 
modestly reduced Perceval fluorescence in metformin treated cells (Figure 6.14A-6.14E). Considering 
that the Perceval fluorescence in metformin treated cells were already low at the beginning of the 
experiments, whether the changes in perceval fluorescence was due to the genuine effects of 
etomoxir, or a false positive effect due to the gradual decline in intracellular ATP levels in the absence 
of glucose, is unknown. 100μM etomoxir decreased Perceval fluorescence in both control and 
metformin treated cells, but the differences between treatments were not observed (Figure 4.14F). 
This is likely due to the reported off-target effects of etomoxir on mitochondrial respiration when used 
at ≥100μM concentrations, such as complex I inhibition and disruption of CoA homeostasis, in addition 
to inhibiting FAO (566–568). The observations do not suggest that stored lipids are an important fuel 







Figure 6.14. Metformin slightly increased fatty acid oxidation in intestinal cells. (A and B) The effects of 20μM 
etomoxir on Perceval fluorescence in Control (red, A) and Metformin (blue, B) treated cells. Etomoxir (Eto, 20μM) 
and Rotenone/Antimycin A (Rot/AA, 1μM each) were applied as indicated on the traces. Different coloured lines 
denote responses from different cells. (C) Measured Perceval fluorescence ratios in control (red) and metformin-
treated (blue) cells to 20μM etomoxir and Rot/AA. Control: N=30 cells from 8 dishes, metformin: N=27 cells from 
7 dishes. NS; not significant. ***; P<0.001, Friedman test and Dunn’s post-hoc test. (D) Changes in Perceval 
fluorescence in response to 20μM etomoxir and Rot/AA in control and metformin treated cells. Data are mean ± 
SEM. ***, P<0.001. Two-way ANOVA and Bonferroni post-hoc test. (E) Changes in Perceval fluorescence in 
response to 100μM etomoxir and Rot/AA in control and metformin treated cells. Data are mean ± SEM. ***, NS; 





6.5.1 Metformin and mitochondrial oxidation in intestinal cells 
Confirming a vast body of literature that metformin is a complex I inhibitor of mitochondrial 
respiration (203, 204, 207, 569, 570), the metabolic flux experiments demonstrated that metformin 
decreased oxygen consumption rate during glucose and glutamine metabolism in intestinal 
monolayers (Figure 6.1 and Figure 6.12), whilst metformin abolished the effect of rotenone and 
antimycin A in Perceval fluorescence from glucose oxidation (Figure 6.4). Furthermore, application of 
the mitochondrial pyruvate carrier UK-5099 to inhibit the uptake of pyruvate (produced from 
glycolysis) had little to no effect on Pyronic fluorescence or oxygen consumption in metformin treated 
cells, demonstrating little to no oxidation of pyruvate produced from glycolysis (Figure 6.9 and Figure 
6.11). Autofluorescence imaging experiments demonstrated that metformin diminished the 
magnitude of NAD(P)H autofluorescence increased by glycolysis and lowered by FCCP (Figure 6.2). 
Metformin treatment also blunted the effect of glucose and FCCP on FAD autofluorescence. These 
results support existing literature reporting that metformin reduces TCA cycle flux (205, 206), either 
caused by elevated mitochondrial NADH (which would indirectly inhibit oxidative TCA cycle reactions 
and thus FAD oxidation) (396, 569, 571), or extraneous effects on mitochondrial bioenergetics such as 
uncoupled respiration (205).  
The mitochondria of intestinal cells seem to exhibit some degree of fuel flexibility. This is supported 
by multiple observations. First, application of UK-5099 to inhibit mitochondrial pyruvate transporter 
changes the Pyronic fluorescence and oxygen consumption but has no effect on the Perceval 
fluorescence in control cells (Figure 6.9 and Figure 6.11). Second, exogenous pyruvate and glutamine 
treatments (Figure 6.10 and Figure 6.12) showed negligible effects on Perceval fluorescence in 
intestinal cells, despite evidence for glutamine oxidation and endogenous pyruvate oxidation in 
control cells in the Seahorse data. Since Rotenone and Antimycin A drastically decreased 
mitochondrial respiration in control cells in the presence of glucose, glutamine or pyruvate (with 
limited effect in metformin treated cells), this clearly indicates an important role of the mitochondria 
in ATP production. Metformin, by inhibiting mitochondrial respiration, could potentially handicap the 
capability of the mitochondria to metabolise fuels resulting in a lower cellular ATP/AMP ratio (204), 
which would activate AMPK signalling (210) and glycolysis (207).  
Although metformin has been demonstrated to deplete TCA cycle intermediates in cancer cells from 
some studies (205, 206, 572), others argue that inhibition of mitochondrial complex I rewires the TCA 
cycle towards alternative pathways involving biosynthesis (394, 396, 397, 571, 573, 574). Amongst 
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these pathways include altering the malate aspartate shuttle towards aspartate synthesis (396, 397, 
573), and increased reductive glutamine carboxylation towards lipid and amino acid generation (394, 
571, 574, 575). Although it remains to be proven whether these pathways are altered by metformin 
in intestinal cells, the observations that intestinal cells do not depend on glutamine and pyruvate as 
fuels for ATP generation may alternatively suggest the roles of these fuels in metabolic biosynthesis. 
The observations that pyruvate (187), glutamine (540) and fatty acid (188) metabolism are important 
in regulating proliferation and/or fate determination of intestinal cells along the crypt/villus axis 
seems to suggest the importance of mitochondrial metabolism beyond ATP generation. 
6.5.2 Metformin and intestinal glucose metabolism 
The evidence presented in this study demonstrates that metformin maximises glycolysis, increased 
glycolytic capacity and glycolytic ATP production in intestinal cells (Figure 6.3 and Figure 6.4). This is 
supported by the transcriptomic data which highlighted increased expression of key glycolytic 
enzymes by metformin (see chapter 3). Increased glucose utilisation and lactate production were 
previously observed as the intestinal mucosa accumulates high levels of metformin (64, 116, 207, 239–
242, 312). A recent study by Schommers et al., further elaborated this by demonstrating that 
metformin increased lactate release from the intestinal wall into the splanchnic bed, and that 
metformin increased the ratio of Ldha/Ldhb expression in the intestine (favouring pyruvate 
metabolism to lactate) and decreased Ldha/Ldhb expression (favouring lactate metabolism to 
pyruvate) in the liver (207). The authors suggested that metformin causes a futile glucose-lactate cycle 
involving glycolysis in the intestine and gluconeogenesis in the liver predominantly through altered 
LDH expression, despite several studies demonstrating that metformin suppresses hepatic 
gluconeogenesis (207, 220, 225–227). In the RNA-seq data, metformin did not change mRNA 
expression of either of those LDH isoforms (data not shown), despite increasing the expression of Ldhd 
expression (see chapter 3). However, LDH activity was decreased in metformin treated cells (Figure 
6.5C), which challenges the observations in that study in describing the precise molecular mechanisms 
involved in glucose metabolism to lactate.  
Inhibition of LDH by oxamate or inhibiting lactate-transport by MCT inhibitors AR-C155858 and 
Syrosingopine partially suppressed lactate secretion, elicited increases in Peredox fluorescence (Figure 
6.5) and modestly decreased Perceval fluorescence in metformin treated cells (Figure 6.6). This could 
suggest that pyruvate metabolism to lactate plays only a minor contribution in maintaining glycolysis 
under metformin treatment, with some flexibility to discard of surplus pyruvate/lactate through other 
pathways, for example transamination to alanine (see below). The alternative explanation is 
incomplete pathway inhibition by the drugs. Inhibiting NAD+ regeneration through the LDH pathway 
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could also lead to compensation by other pathways such as the glycerolphosphate shuttle in sustaining 
glycolysis. In the case of MCT transport inhibition, changes in intracellular pH mediated by lactate 
accumulation may decrease Perceval fluorescence due to interference of the fluorescent protein, 
although lactate accumulation would also inhibit NAD+ regeneration and this could reduce glycolysis 
flux (556).  
 
Metformin treatment also increased aspartate and alanine transaminase activity in metformin treated 
cells (confirming increased Gpt1 expression in transcriptomic data), and perceval imaging studies 
demonstrate some role for alanine aminotransferases in contributing to intestinal glycolysis (Figure 
6.7). In the liver, pyruvate-alanine cycling is important in regulating gluconeogenesis from alanine as 
substrates, particularly under conditions where mitochondrial uptake of pyruvate is blocked (535, 
576–580). Gpt1 transcript and protein expression in the mouse and rat intestine is comparable to the 
liver (558, 581). Several studies have confirmed that pyruvate generated from glycolysis are used for 
glutamine transamination in intestinal cells, and that alanine is a major fate of glutamine metabolism 
(177–179, 535). A recent study investigating L-alanine administration in hepatic cell lines reported 
decreased ATP levels, but increased the NAD+/NADH ratio and intracellular lactate levels (582). If 
transamination to alanine is an important fate of pyruvate in intestinal cells in the presence of 
metformin, inhibiting alanine aminotransferases could lead to pyruvate accumulation and redirecting 
pyruvate towards lactate production, which may decrease Perceval fluorescence via lactate 
accumulation and alter the intracellular pH or the cytosolic NAD+/NADH ratio.  
 
However, neither LDH nor alanine aminotransferase inhibition alone influenced the effects of 2-DG on 
the Perceval fluorescence in control and metformin treated cells, suggesting that neither of these 
pathways are rate-limiting to glycolysis. Future studies should investigate whether combining LDH or 
alanine aminotransferase inhibitors are sufficient to inhibit glycolysis by measuring Perceval 
fluorescence in control and metformin treated cells. The limitations of pharmacological compounds 
used in this study should also be acknowledged, particularly the putative glycerolphosphate shuttle 
inhibitor iGP1 and the MAS inhibitor phenylsuccinate (Figure 6.8), in which no appropriate controls 
were available. Even so, the steps that control glycolytic flux are still debateable. Whilst previous 
literature suggested that NADH regeneration via mitochondrial shuttles and LDH activity involved in 
maintaining glycolysis flux (583, 584), other studies identified the importance of enzymes such as 
aldolase A (585), GAPDH (586), pyruvate kinase (587) and LDHA (207, 588). A recent study 
demonstrated that glucose uptake, lactate export, hexokinase and phosphofructokinase activity were 
essential in determining glycolytic flux when glycolysis enzymes or transporters were individually 
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overexpressed in two mammalian cell lines(376). The transcriptomic and functional data in this study 
suggests that glycolysis and glycolytic capacity is determined by the functions of glycolysis enzymes 
such as hexokinases, as opposed to downstream pyruvate metabolism enzymes such as LDH or alanine 
transaminases. 
 
What are the signalling mechanisms that explain the effect of metformin on glycolysis? The evidence 
in this study suggests that attenuating mitochondrial respiration seem sufficient to increase glycolysis 
as a compensatory mechanism. The observations that (1) oligomycin A further increased glycolytic 
ECAR (Figure 6.3) and (2) inhibition of pyruvate uptake into the mitochondria abolished the differences 
of 2-DG in glycolytic ATP production between control and metformin treated cells (Figure 6.9), seem 
to support this hypothesis. Moreover, hexokinase and phosphofructokinase directly interacts with, 
and are regulated by ATP/AMP (219). Alternative explanations could be the regulation of 
phosphofructokinases by AMPK (379), or transcriptomic changes in glycolysis genes (Chapter 3). This 
would explain metformin causing a Warburg effect in intestinal cells to maximise glycolytic ATP 
production as a quick ATP source to sustain cellular processes. 
6.5.3 Metformin and intestinal energy stores 
The existence of intestinal glycogen stores has previously been reported and is particularly elevated 
in diabetic or suckling rats, which were associated with increased intestinal gluconeogenesis (386, 390, 
589). The observations from the Perceval fluorescence imaging seem to suggest a role of glycogen 
breakdown in sustaining ATP levels in intestinal cells in the absence of glucose. Existing literature 
reporting the functional significance of intestinal glycogen are limited, with some speculating that it 
may contribute to intestinal gluconeogenesis (590, 591). Metformin seemed to decrease 
glycogenolysis in intestinal cells, and it seems that intestinal cells metabolise glycogen for ATP 
production in the absence of glucose (Figure 6.13). The effects of metformin on intestinal glycogen 
stores remains to be determined. The role of metformin in hepatic glycogenolysis is controversial, with 
some studies demonstrating reduced glycogenolysis or a glycogen-sparing effect of metformin in the 
liver (389, 543, 544), whilst a study in type-2 diabetic patients indicated that metformin does not affect 
hepatic glycogenolysis (227). 
In contrast to the effects of metformin in glucose and glutamine oxidation, metformin paradoxically 
increases fatty acid oxidation (210, 211, 229, 230). Etomoxir (at 20µM) seemed to mediate a slight 
reduction in Perceval fluorescence in metformin (but not control) treated cells, which may suggest 
increased endogenous fatty acid oxidation in metformin treated cells(Figure 6.14). The RNA-seq data 
does not show substantialchanges in fatty acid metabolism genes either (chapter 3). Although 
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evidence for intestinal fatty acid metabolism has been reported (177, 537–539), stored lipids does not 
seem to be the main choice of fuel in intestinal cells. 
 
 6.6 Conclusions 
In summary, the following working model is proposed (see Figure 6.15). Intestinal cells normally 
produce ATP from glycolysis and mitochondrial oxidation, whilst maintaining some intestinal glycogen 
to maintain ATP levels in the absence of glucose. The mitochondria may also have the flexibility to 
metabolise glutamine or pyruvate. Metformin inhibits mitochondrial respiration, which causes the 
cells to compensate by increasing glucose uptake and glycolysis to produce lactate and alanine. 
Metformin could potentially increase the limited metabolism of stored lipids although it is not certain 
whether the modest effects of etomoxir on ATP levels are genuine, or a false positive effect associated 
with declining ATP levels in the absence of glucose. Therefore, intestinal cells could metabolise glucose 
(via glycolysis), pyruvate, glutamine and glycogen, but seem to mostly rely on glycolysis in the 
presence of metformin. 
 
  
Figure 6.15. Working model describing the effects of metformin on intestinal metabolism. Red indicates 
hallmarks of cellular metabolism in control cells, whilst blue indicates changes in metabolic pathways by 
metformin. GLUTs; facilitative glucose transporters, MCTs; monocarboxylate transporters, MPC; 
mitochondrial pyruvate carrier.  
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Altogether, this model provides a cellular mechanism supporting the existing literature to 
demonstrate the importance of metformin in increasing glucose utilisation in the intestine (116). This 
supports the developing hypothesis that the intestine acts as a “glucose sink” to metabolise glucose 
from the blood as a potential mechanism to support the effects of metformin in improving glycaemic 
control in patients with Type 2 Diabetes. Future studies should follow up the data with metabolomic 
or metabolic flux experiments to confirm the effects of metformin on the metabolic pathways in 




Chapter 7: General Discussion 
 
7.1. Summary of findings 
7.1.1. Metformin alters the transcriptome of intestinal cells 
Previous transcriptomic profiling to investigate mechanisms of metformin action have been 
performed on hepatocytes, skeletal muscle and adipose tissue biopsies, but not in intestinal cells (365, 
366). In chapter 3, RNA-Sequencing was performed in duodenal 2D monolayer cultures, which 
identified metformin-responsive genes and pathways. Amongst the prominent findings in the RNA-
seq data were the alterations in glucose metabolism pathways. This included upregulation of key 
genes involved in glycolysis, downregulation of fructose metabolism genes and altered expression of 
genes involved in the pentose phosphate pathway. Metformin also altered the expression of genes 
involved in amino acid metabolism, such as serine/threonine and folate metabolism. In mouse 
hepatocytes, metformin has been reported to alter the expression of genes and result in suppression 
of gluconeogenesis and lipogenesis, and it was speculated that these changes are part of the 
mechanism by which metformin lowers blood glucose levels and reduces fatty liver disease 
development, respectively (210, 365). In human skeletal muscle, metformin increased the expression 
of genes involved in glycolysis and pyruvate metabolism; supporting other functional studies that 
metformin may be involved in peripheral glucose uptake (366). The transcriptomic studies suggest 
that differences in metabolism in different organs could contribute to the beneficial metabolic effects 
of metformin.  
In contrast to hepatocytes, metformin did not cause a consistent alteration of genes involved in the 
AMPK signalling pathway in intestinal cells (365). However, the potential post-translational effects of 
metformin on AMPK activity in intestinal cells cannot be ruled out. Changes in other signalling 
pathways such as the upregulation of HIF1A signalling, Hippo signalling and lysosome pathways were 
also identified. As discussed in chapter 4 and 5, HIF1A appears to be involved in GDF-15 secretion and 
glucose uptake in intestinal cells. Furthermore, activation of autophagy is an established downstream 
mechanism of AMPK activation by metformin and autophagy is essential to preserve intestinal 
epithelia function (352–355). No previous study has identified transcriptomic changes in the Hippo 
signalling pathway associated with the metformin response, which warrants further confirmation via 
functional studies.        
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 7.1.1.1 Future directions 
Although transcriptomic changes could suggest potential changes in function in intestinal cells, it is 
possible that the gene expression findings may not be entirely replicated at the protein level (450). 
Therefore, assessment of protein changes should also be incorporated in future studies to provide a 
more substantial picture of metformin action in intestinal cells. The transcriptomic changes in 
metabolism genes should also be studied further, such as via metabolic tracing of metabolites. This 
would support the functional effects of the transcriptomic changes in metabolic pathways in the 
presence of metformin and possibly identify novel metabolic pathways. Metabolic tracing has 
provided detailed insights into the different metabolic adaptations by metformin in cancer cells (206, 
394, 396).  
Some of the metabolism/signalling genes (such as key glycolysis and HIF1A signalling genes) identified 
in the organoid studies should be confirmed in the intestinal tissues of metformin-treated HFD-fed 
mice. An even more ambitious future direction would be to compare global expression changes in 
different sections of the mouse intestines, as well as other metabolically important organs such as the 
liver, adipose tissue and skeletal muscle in HFD-fed mice that had been orally administered metformin. 
A “temporal” transcriptomic analysis could be performed to compare acute (e.g. 6 hours) or chronic 
(11 days) effects of metformin in different organs. A similar inter-organ systems transcriptomic 
approach has been performed to investigate organ-specific changes in metabolism and signalling 
genes after Roux-en-Y gastric bariatric surgery in mice and humans (42). Investigating the 
transcriptomic changes in different organs following metformin treatment could validate many of the 
previous observations regarding metformin in mice and provide a more integrative picture into the 
metabolic responses of the different organs to metformin. 
 
7.1.2. Metformin stimulates GDF-15 secretion through mitochondrial stress 
As mentioned in chapter 4, our collaborators observed that plasma GDF-15 concentrations are 
associated with the weight-loss effects of metformin and that GDF-15 expression is upregulated in 
small intestinal and colonic tissues (but not in the other metabolically important organs such as the 
liver and adipose tissue) after oral metformin gavage. From the RNA-seq data in 2D monolayer 
intestinal cultures, Gdf15 was one of the top significantly upregulated genes by metformin, and 
metformin robustly stimulated GDF-15 secretion from these cultures. The RNA-seq and secretion data 
also demonstrated that metformin stimulated GDF-15 secretion via mitochondrial stress whilst 
metformin downregulated the expression of genes involved in mitochondrial translation and mtDNA 
genome maintenance. Studies involving human primary hepatocytes also identified Gdf15 as an 
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upregulated gene not associated with the activation of the AMPK signalling pathway by high 
concentrations of metformin (365). Similarly, serum levels of GDF-15 are elevated in patients with 
mitochondrial disease and mouse models of mitochondrial myopathy (286, 374, 447, 448). This study, 
consistent with studies in other models, suggested that metformin increases GDF-15 expression and 
secretion via a mitochondria-dependent mechanism.   Metformin stimulated GDF-15 secretion via the 
ISR, since the EIF2A phosphorylation inhibitor ISRIB attenuated metformin-stimulated GDF-15 
secretion whilst Ddit3 mRNA expression was upregulated in intestinal tissues of HFD-fed mice treated 
with metformin. These studies are consistent with the findings from other collaborators involving 
metformin in primary hepatocytes and the effects of phenformin on ISR in MEF cells (321). The ISR 
has previously been reported to be important for the induction of Gdf15 expression in response to a 
variety of cellular stressors such as ER stress and hypoxia (287). It is unknown how mitochondrial stress 
elicited by metformin stimulates GDF-15 secretion; inhibition of GCN2 (reportedly activated by 
oxidative stress) did not affect GDF-15 secretion and the PERK inhibitor GSK-2606414 modestly 
reduced metformin-stimulated GDF-15 secretion. Other EIF2A kinases (such as PKR or HRI) might be 
associated with metformin-stimulated GDF-15 secretion, which could be investigated in future 
studies.       
Interestingly, HIF-1A inhibitors also inhibited metformin stimulated GDF-15 secretion, which to our 
knowledge have not previously been reported in the literature. The results suggest that the HIF 
signalling pathway is important in determining metformin stimulated GDF-15 secretion. Currently, 
studies are underway to investigate metformin and HIF-1A protein levels in intestinal cells. Future 
studies would investigate the effects prolyl hydroxylase or VHL inhibitors, or using Hif1a or Vhl 
knockout mouse intestines on GDF-15 secretion.      
The results in chapter 4 confirm that intestinal cells are capable of secreting GDF-15 into the media in 
response to metformin and other mitochondrial stressors. From the in situ hybridisation data, Gdf15 
induction by metformin seems to be localised to the numerous transit-amplifying cells of the epithelia 
in the distal small intestine and colonocytes in the colonic epithelia, whereas almost all other gut 
hormones identified to date are released by enteroendocrine cells that encompass 1% of the intestinal 
epithelial population (159). Therefore, based on this study and supporting in vivo data (321), GDF-15 
could be a novel and atypical “gut hormone” released by intestinal epithelial cells that may provide a 
cellular mechanism that explains the effects of metformin on body weight.        
7.1.2.1 Future directions 
Although this study suggests that metformin stimulates GDF-15 secretion via mitochondrial stress, 
there is no direct evidence that metformin causes other aspects of mitochondrial dysfunction other 
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than inhibiting oxidative phosphorylation (OXPHOS) in intestinal cells. Furthermore, transcriptomic 
analysis did not reveal changes in mitochondrial OXPHOS or oxidative stress genes. A more 
comprehensive study into other aspects of mitochondrial stress is warranted, such as superoxide 
production (such as using the MitoSOX dye) as an indicator of oxidative stress, mitochondrial 
membrane potential (using Mitotracker Orange), mitochondrial morphology (such as Mitotracker 
Green or electron microscopy), or mitochondrial calcium signalling (via measurements using the Rhod-
2 dye). Downregulation of mitochondrial translation genes and altered expression of mitochondrial 
folding genes could also be studied via other in vitro studies (e.g. proteomics of mitochondrial 
translation proteins).  
The results in chapter 4 and findings from our collaborators collectively suggest that the weight loss 
effects of metformin might be mediated by a mechanism involving the gut-brain axis involving GDF-
15 released from the gut, which targets the brainstem to cause weight loss (see Figure 7) (321). To 
provide direct evidence and fully establish the role of GDF-15 as a potential hormone involved in a 
gut-brain axis that addresses the weight loss effects of metformin, one of the future directions could 
involve physiological investigations into an intestine specific (e.g. Villin-cre) Gdf15 knockout mouse 
model. The effects of metformin on metabolic parameters such as body weight, food intake and 
energy expenditure could be measured in these mice to investigate the role of this gut-brain cross-
talk in metformin suppression of appetite. Alternatively, comparisons in serum levels of GDF-15 and 
food intake could be made in mice that had been intravenously or orally administered metformin, as 
differences in glycaemic control have previously been reported to be dependent on different routes 
of metformin administration (316).   
 
7.1.3. Metformin increases GLUT transporter mediated glucose uptake 
In chapter 5, expression data in 2D monolayer cultures and intestinal tissues from HFD-fed mice 
showed that metformin decreased the expression of numerous hexose transporters, such as Slc2a2 
(GLUT2) and Slc5a1 (SGLT1), but increased the expression of Slc2a1 (GLUT1). Metformin also increased 
glucose uptake in intestinal cells mediated by GLUT (presumably GLUT1) transporters (See Figure 7). 
To our knowledge, no previous study has investigated the effects of metformin on GLUT1 expression 
in intestinal cells. The upregulation of GLUT transporters in the small intestine may explain the 
observed increase in intestinal glucose accumulation as reported in PET-CT imaging studies in mice 
and humans (Figure 7) (237, 364, 490, 517–519). After RYGB surgery, GLUT1 expression was increased 
in the alimentary limb, which was directly associated with increased glucose utilisation and glucose-
lowering effects (42, 43). Similarly, downregulation of Slc2a2 (GLUT2) and Slc5a1 (SGLT1) genes could 
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potentially suggest a molecular basis by which metformin decreases intestinal absorption of ingested 
glucose (234–236, 488, 489, 516, 523). Yet, these findings do not support other investigations that 
report increased GLUT2 abundance in the intestinal epithelium (523, 592). 
 
 
The roles of the AMPK and HIF1A signalling pathways in metformin altered glucose transporter 
expression and glucose uptake in intestinal cells were investigated to identify the plausible signalling 
pathways involved. The results suggest that upregulation of the HIF1A pathway, and to a lesser extent 
increased post-translational AMPK activation, are involved in metformin stimulated glucose uptake. 
The role of AMPK activation in glucose uptake in muscle cells has been well established (210, 336, 
338–341), so it is not surprising that the AMPK activator stimulates glucose uptake in intestinal cells. 
HIF1A is important in regulating intestinal function (593), but the apparent role of the HIF-1A signalling 
pathway in the mechanism of metformin-stimulated glucose transporter expression and glucose 
uptake was unexpected. The observations that HIF-1A inhibitors decreased Slc2a1 (GLUT1) expression 
and glucose uptake in both control and metformin treated cells suggests that GLUT mediated glucose 
uptake seems to be dependent on the HIF-1A signalling pathway (chapter 4). The results also 
Figure 7. A proposed physiological mechanism of metformin action in increasing GDF-15 secretion 




complement the RNA-seq data which identified upregulation of HIF1A signalling/target genes in 
metformin treated intestinal cultures.  
7.1.3.1 Future directions 
This results in chapter 5 suggest that metformin increases glucose uptake mediated by GLUT1 
transporters, based on the RNA-seq data and examination of pharmacological inhibitors on glucose 
uptake. Generation of a GLUT1 knockout mouse intestinal organoid line is currently in progress. 
Studies investigating glucose transporter expression and glucose uptake involving GLUT1 knockout 
organoids would provide direct evidence of GLUT1 on glucose uptake.  
Furthermore, the role of HIF1A on glucose utilisation in intestinal cells could be investigated using 
HIF1A inhibitors, HIF1A knockout mice, or mouse models of increased HIF1A stability (such as VHL 
knockout mice). This could strengthen the evidence in support of a role for HIF1A downstream of 
metformin action in intestinal cells. 
Since the distal small intestine is predominantly associated with changes in glucose transporter 
expression in metformin treated HFD fed mice, it would also be important to replicate the experiments 
of glucose uptake in mouse ileal organoids.  
 
7.1.4. Metformin limits the metabolic plasticity of intestinal cells 
Although the evidence for metformin action on intestinal glucose uptake is well established based on 
PET-CT scan observations, the effects on glucose handling in the small intestine are not fully 
understood since there is evidence supporting both altered intestinal glucose metabolism as well as 
basal-to-apical export of glucose into the lumen via GLUT2 expression on the brush-border membrane 
(207, 488, 523). The results from chapter 6 in this study support the RNA-seq data, showing that 
metformin increases glucose metabolism through glycolysis and lactate production/secretion as an 
indirect consequence of inhibiting OXPHOS. Indeed, the results from Perceval imaging measurements 
suggest that intestinal cells exhibit metabolic flexibility of glutamine, pyruvate (generated from 
glycolysis) and glycogen metabolism, which is lost in metformin treated cells as they rely almost solely 
on glycolysis (and very limited oxidation of fatty acids) for ATP synthesis.  
Recent studies involving metabolomics measurements of arterial-venous differences in pigs revealed 
that visceral organs (including the GI tract) are the biggest consumers of glucose (60%) and amino 
acids (186). Furthermore, orally administered metformin also accumulates at the highest 
concentrations in the GI tract; these concentrations are high enough to inhibit mitochondrial 
respiration (204, 312). Furthermore, Schommers et al., used metabolic tracing in HFD-fed mice to 
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demonstrate that metformin increases glucose metabolism to lactate in the intestine as a result of 
mitochondrial dysfunction (207). These studies provide in vivo evidence in support of our observations 
in intestinal 2D cultures in suggesting the importance of intestinal glucose metabolism in metformin 
action.     
The effects of metformin in increasing fasting plasma lactate levels are well established, and lactic 
acidosis is a side effect in a small number of patients associated with metformin use (45, 594). 
However, the underlying physiological mechanisms are not clear. The kidney was thought to be 
involved due to the clinical observations that the risk of lactic acidosis was more closely associated 
with metformin use in patients with acute kidney injury (312, 595). The liver was another candidate 
since inhibition of the glycerolphosphate shuttle by metformin has been associated with reduced 
metabolism of lactate to glucose via gluconeogenesis, which would instead lead to the release of 
lactate by the liver (226). The exact mechanisms that explain the effects of metformin on lactic acidosis 
are therefore not completely understood. In pigs, the spleen and the colon made the largest 
contributions to net lactate release into the circulation whereas the liver and kidneys were associated 
with net lactate uptake under physiological conditions (186). Oral metformin administration has been 
associated with increased lactate generation in the walls of the small intestine in mice and human 
intestinal tissues (64, 207, 370). It remains to be demonstrated how much the GI tract contributes to 
lactate generation during metformin administration, and studies into the contributions of different 
organs in lactate generation in metformin treatment are warranted.        
7.1.4.1 Future directions 
This study provides evidence to support the observations from the KEGG pathway analysis through 
live cell imaging of metabolites and Seahorse bioanalyser assays in 2D monolayer cultures. As 
mentioned in section 7.1.1.1, a metabolomics approach to study the effects of metformin in intestinal 
cells would provide the most direct evidence to support the observations that metformin alters 
nutrient metabolism. Another warranted investigation is to examine the contributions of glucose 
metabolism and lactate production by the small intestine in contributing to the glucose lowering 
effects of metformin. Currently, collaborations are underway with Professor Jens Holst (University of 
Coppenhagen, Denmark) to examine mechanisms of metformin treatment on glucose metabolism and 
lactate release in the perfused intestine model. Validation of this technique to study glucose 
metabolism could enable more detailed investigations into the signalling mechanisms and metabolic 
alterations affected by metformin in intestinal tissues in a more physiological setting.   
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As an extension from chapter 3 and 5, the contributions of the various cellular pathways such as AMPK 
and HIF1A signalling to the changes of glucose metabolism in metformin treated cells should also be 
investigated using the Seahorse bioanalyser or Perceval/Peredox imaging of intracellular metabolites.      
 
7.2 Limitations of this study 
One of the limitations of this study is the use of the 2D monolayer culture system involving intestinal 
cells seeded in Matrigel-coated dishes/plates to investigate the transcriptomic and functional changes 
triggered by metformin in intestinal cells. Although these intestinal cultures do not alter the 
specifications of cell-types in the intestine (the presence of goblet cells and enteroendocrine cells is 
maintained, and GLP-1 secretion has been reported using this model), the intestinal cells in this culture 
system lose apical-basolateral polarity (324, 596). This limits the ability to study the roles of SGLT1 and 
GLUT2 in transepithelial transport, which could not be investigated using this model. Future studies 
could incorporate transport studies using monolayers seeded into transwell systems, which maintain 
this apical-basolateral polarity (597, 598). However, using the transwell system also limits the ability 
to study other aspects of intestinal function, such as nutrient metabolism via live-cell imaging and 
Seahorse bioanalyser assays. The effects of metformin on the mRNA expression of glucose 
transporters and Gdf15 in the intestinal 2D monolayer culture model were also validated in intestinal 
tissues of HFD-fed mice, which suggests that some of these observations in vitro might not be too 
different from the intestinal epithelia in vivo.        
Another limitation in this study is that the RNA-seq data was generated using murine intestinal cells 
from organoids. Transcriptomic observations performed in human intestinal cells are likely to be 
different. This was the case in investigating the effects of metformin in hepatocytes since genes 
encoding the glucose-6-phosphatase (G6pc) isoforms were amongst the top downregulated genes 
identified in hepatocytes from db/db mice treated with metformin but were not differentially 
expressed in human hepatocyte cultures (365, 599). Furthermore, the transcriptomic changes 
observed in mouse organs and tissues after RYGB surgery in mice were only partially replicated in 
humans (42). Future experiments should replicate and validate the experiments in human organoids 




7.3. Other considerations into metformin action in the GI tract 
7.3.1. The physiological effects of metformin: the liver or the gut? 
This study suggests that the GI tract is an important site of metformin action in the regulation of 
glycaemic control and body weight. The results from this study support other findings in suggesting 
that accumulation of metformin at high concentrations in intestinal cells increased intestinal glucose 
utilisation and GDF-15 secretion, both of which probably involve the mitochondria. Metformin also 
inhibits hepatic glucose production in the liver to regulate blood glucose levels (210, 220, 225–227, 
544). However, several recent studies reported an opposite effect of increasing hepatic glucose 
production by metformin (207, 228). Particularly, Schommers et al., demonstrated that lactate 
generated from intestinal glycolysis is taken up by the liver for gluconeogenesis (207). Clinical trials 
involving the “delayed-release” formulation of metformin also seem to suggest a more important role 
of the gut compared to the liver in mediating the glycaemic control effects of metformin (86, 319, 
320). Moreover, although the liver is capable of inducing Gdf15 expression in primary hepatocytes in 
response to supraphysiological metformin concentrations in culture, Gdf15 expression was induced in 
the distal intestine, but not in the liver of HFD-fed mice given metformin for 6 hours or 11 days (321). 
This observation suggests that the small intestine, rather than the liver, is the primary organ that 
releases GDF-15 in response to metformin to mediate its weight-loss effects (321).   
7.3.2. Metformin stimulated GDF-15 secretion and glucose utilisation- all of the cells? 
Two of the key findings presented in this study are the roles of metformin in stimulating GDF-15 
secretion and increasing glucose uptake and glycolysis which may explain the roles of metformin in 
weight loss and glycaemic control, respectively. The imaging experiments and other in vitro assays did 
not specify whether all, or some of the intestinal cells are involved. It would be interesting to 
investigate whether the same effects of metformin occur in every cell type in the small intestinal 
epithelium or in a specialised group of cells. As discussed in chapter 4 and in section 7.1.2, in-situ 
hybridisation experiments in mouse colonic tissues suggest that cells situated predominantly in the 
crypts are involved in metformin induced Gdf15 expression (321). This suggests that some, but not all 
of the intestinal cells in the small intestine and colon respond with induction of Gdf15 expression. 
Although GLUT1 expression is generally low in the small intestine, it is unknown how GLUT1 expression 
changes in the small intestine in response to metformin and this should be investigated via in-situ 
hybridisation.     
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7.3.3 Are the mechanisms of metformin action in the gut the same as those following bariatric 
surgery? 
Bariatric surgery greatly improves glycaemic control and causes profound weight loss. Like metformin, 
the alimentary limb of the small intestine also exhibits upregulated HIF1A and GLUT1 expression, and 
increased glucose uptake and glycolysis after RYGB surgery (42, 43). Increased intestinal glucose 
utilisation after RYGB has also been reported to contribute to its glucose-lowering effects (43, 600). 
Other gastrointestinal changes during metformin treatment and after gastric bypass exhibit a number 
of similarities. First, metformin and RYGB cause altered bile acid metabolism, although this is due to 
reconstruction of the GI tract in bariatric surgery as opposed to reduced intestinal reabsorption of bile 
acids by metformin (601). Second, like metformin, RYGB surgery decreases glucose absorption and 
postrandial glucose response in humans, which has been reported to associate with diversion of bile 
and decreasing the amount of sodium usually brought about with bile transit in the intestines, which 
decreases sodium dependent glucose cotransport (602). Third, metformin and bariatric surgery 
increased circulating GLP-1 and PYY levels, likely due to a relative shift of glucose absorption to the 
distal gut (41). Fourth, both metformin and RYGB cause changes in the gut microbiome (603). 
Furthermore, serum levels of GDF-15 were significantly elevated after 2 weeks in a cohort of 47 obese 
patients that had undergone RYGB surgery (604). However, by contrast to the crucial role of the GDF-
15/GFRAL axis in mediating the weight loss effects of metformin from food intake studies in knockout 
mice, GDF-15 does not seem to be necessary for mediating the weight loss effects after bariatric 
surgery in mice (321, 605). Unlike bariatric surgery, the clinical trials investigating the effects of 
metformin on body weight did not report consistent weight loss across all of the studies (32, 81). There 
are no clinical trials to date that compared the effects of metformin and bariatric surgery interventions 
on glycaemic control. It would be tempting to speculate that some of the effects of metformin in the 
gut are similar to, but more modest than, those observed after bariatric surgery.      
7.4. Concluding remarks 
This PhD thesis has provided a comprehensive transcriptomic characterisation of metformin action in 
small intestinal cells, which was used as a basis to study functional mechanisms of metformin action. 
Metformin caused transcriptomic changes in metabolism and signalling pathways in intestinal cells. 
Metformin also robustly stimulated GDF-15 secretion in intestinal cells via a mechanism dependent 
on mitochondrial stress, the integrated stress response and the HIF-1A signalling pathway. Increased 
basal intestinal glucose uptake mediated by metformin could be associated with upregulation of GLUT 
transporters by a mechanism that could involve AMPK and HIF-1A signalling. By inhibiting 
mitochondrial respiration, metformin limits the metabolic plasticity of intestinal cells, which instead 
rely predominantly on glycolysis for energy. Together, the results of this thesis argue for the role of 
173 
 








1.  World Health Organisation (2014). 
2.  World Health Organisation (2016). 
3. J. E. Manson, W. C. Willett, S. Liu, C. G. Solomon, G. Colditz, F. B. Hu, M. J. Stampfer, Diet, Lifestyle, 
and the Risk of Type 2 Diabetes Mellitus in Women, Obstet. Gynecol. Surv. (2003), 
doi:10.1097/00006254-200203000-00018. 
4. S. N. Bhupathiraju, F. B. Hu, Epidemiology of obesity and diabetes and their cardiovascular 
complications, Circ. Res. (2016), doi:10.1161/CIRCRESAHA.115.306825. 
5. J. M. Chan, E. B. Rimm, G. A. Colditz, M. J. Stampfer, W. C. Willett, Obesity, fat distribution, and 
weight gain as risk factors for clinical diabetes in men., Diabetes Care 17, 961–9 (1994). 
6. G. A. Colditz, W. C. Willett, A. Rotnitzky, J. E. Manson, Weight gain as a risk factor for clinical 
diabetes mellitus in women, Ann. Intern. Med. (1995), doi:10.7326/0003-4819-122-7-199504010-
00001. 
7. K. G. M. M. Alberti, R. H. Eckel, S. M. Grundy, P. Z. Zimmet, J. I. Cleeman, K. A. Donato, J. C. 
Fruchart, W. P. T. James, C. M. Loria, S. C. Smith, Harmonizing the metabolic syndrome: A joint 
interim statement of the international diabetes federation task force on epidemiology and 
prevention; National heart, lung, and blood institute; American heart association; World heart 
federation; International atherosclerosis society; And international association for the study of 
obesityCirculation (2009), doi:10.1161/CIRCULATIONAHA.109.192644. 
8. P. A. Dyson, The therapeutics of lifestyle management on obesityDiabetes, Obes. Metab. (2010), 
doi:10.1111/j.1463-1326.2010.01256.x. 
9. A. Liebl, K. Khunti, D. Orozco-Beltran, J. F. Yale, Health economic evaluation of type 2 diabetes 
mellitus: A clinical practice focused reviewClin. Med. Insights Endocrinol. Diabetes (2015), 
doi:10.4137/CMED.S20906. 
10. R. A. Defronzo, in Diabetes, (2009), vol. 58, pp. 773–795. 
11.  2. Classification and diagnosis of diabetes, Diabetes Care (2015), doi:10.2337/dc15-S005. 
12. P. González-Muniesa, M.-A. Mártinez-González, F. B. Hu, J.-P. Després, Y. Matsuzawa, R. J. F Loos, 




13. G. I. Shulman, Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease., N. 
Engl. J. Med. 371, 2237–8 (2014). 
14. A. A. Tahrani, A. H. Barnett, C. J. Bailey, Pharmacology and therapeutic implications of current 
drugs for type 2 diabetes mellitus., Nat. Rev. Endocrinol. 12, 566–92 (2016). 
15. K. Maedler, R. D. Carr, D. Bosco, R. A. Zuellig, T. Berney, M. Y. Donath, Sulfonylurea induced beta-
cell apoptosis in cultured human islets., J. Clin. Endocrinol. Metab. 90, 501–6 (2005). 
16. S. E. Kahn, S. M. Haffner, M. A. Heise, W. H. Herman, R. R. Holman, N. P. Jones, B. G. Kravitz, J. M. 
Lachin, M. C. O’Neill, B. Zinman, G. Viberti, Glycemic Durability of Rosiglitazone, Metformin, or 
Glyburide Monotherapy, N. Engl. J. Med. 355, 2427–2443 (2006). 
17. R. C. Turner, C. A. Cull, V. Frighi, R. R. Holman, Glycemic control with diet, sulfonylurea, 
metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple 
therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group., JAMA 281, 2005–12 (1999). 
18. D. E. DeWitt, I. B. Hirsch, Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: 
Scientific ReviewJ. Am. Med. Assoc. (2003), doi:10.1001/jama.289.17.2254. 
19. C. K. Boughton, R. Hovorka, Advances in artificial pancreas systems, Sci. Transl. Med. (2019), 
doi:10.1126/scitranslmed.aaw4949. 
20. C. Mathieu, P. Gillard, K. Benhalima, Insulin analogues in type 1 diabetes mellitus: Getting better 
all the timeNat. Rev. Endocrinol. (2017), doi:10.1038/nrendo.2017.39. 
21. M. A. Nauck, E. Homberger, E. G. Siegel, R. C. Allen, R. P. Eaton, R. Ebert, W. Creutzfeldt, Incretin 
effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses., J. 
Clin. Endocrinol. Metab. 63, 492–8 (1986). 
22. H. Elrick, L. Stimmler, C. J. Hlad, Y. Arai, PLASMA INSULIN RESPONSE TO ORAL AND 
INTRAVENOUS GLUCOSE, J Clin Endocrinol Metab (1964), doi:http://dx.doi.org/10.1210/jcem-24-10-
1076. 
23. L. Van Gaal, E. Dirinck, Pharmacological Approaches in the Treatment and Maintenance of 
Weight Loss., Diabetes Care 39 Suppl 2, S260-7 (2016). 
24. P. M. O’Neil, S. R. Smith, N. J. Weissman, M. C. Fidler, M. Sanchez, J. Zhang, B. Raether, C. M. 
Anderson, W. R. Shanahan, Randomized placebo-controlled clinical trial of lorcaserin for weight loss 
in type 2 diabetes mellitus: the BLOOM-DM study., Obesity (Silver Spring). 20, 1426–36 (2012). 
25. S. R. Smith, M. Sanchez, E. Chuang, W. R. Shanahan, C. M. Anderson, H. Bays, N. J. Weissman, S. 
176 
 
Stubbe, Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management, N. Engl. J. Med. 
(2010), doi:10.1056/nejmoa0909809. 
26. N. T. Nguyen, J. E. Varela, Bariatric surgery for obesity and metabolic disorders: State of the 
artNat. Rev. Gastroenterol. Hepatol. (2017), doi:10.1038/nrgastro.2016.170. 
27. L. Sjöström, A.-K. Lindroos, M. Peltonen, J. Torgerson, C. Bouchard, B. Carlsson, S. Dahlgren, B. 
Larsson, K. Narbro, C. D. Sjöström, M. Sullivan, H. Wedel, Swedish Obese Subjects Study Scientific 
Group, Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery., N. Engl. J. 
Med. 351, 2683–93 (2004). 
28. C. L.M.S., P. M., A. S., A. Å., B. C., C. B., J. P., L. H., M. C., N. I., P. C., R. S., S. K., S. E., W. H., S. P.-A., 
S. L., L. M. S. Carlsson, M. Peltonen, S. Ahlin, A. Anveden, C. Bouchard, B. Carlsson, P. Jacobson, H. 
Lonroth, C. Maglio, I. Naslund, C. Pirazzi, S. Romeo, K. Sjoholm, E. Sjostrom, H. Wedel, P.-A. 
Svensson, L. Sjostrom, Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects, 
N. Engl. J. Med. (2012), doi:10.1056/NEJMoa1112082. 
29. L. Sjostrom, Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective 
controlled intervention study of bariatric surgery, J. Intern. Med. (2013), doi:10.1111/joim.12012. 
30. L. Sjöström, K. Narbro, C. D. Sjöström, K. Karason, B. Larsson, H. Wedel, T. Lystig, M. Sullivan, C. 
Bouchard, B. Carlsson, C. Bengtsson, S. Dahlgren, A. Gummesson, P. Jacobson, J. Karlsson, A.-K. 
Lindroos, H. Lönroth, I. Näslund, T. Olbers, K. Stenlöf, J. Torgerson, G. Ågren, L. M. S. Carlsson, Effects 
of Bariatric Surgery on Mortality in Swedish Obese Subjects, N. Engl. J. Med. (2007), 
doi:10.1056/nejmoa066254. 
31. A. P. Courcoulas, N. J. Christian, S. H. Belle, P. D. Berk, D. R. Flum, L. Garcia, M. Horlick, M. A. 
Kalarchian, W. C. King, J. E. Mitchell, E. J. Patterson, J. R. Pender, A. Pomp, W. J. Pories, R. C. Thirlby, 
S. Z. Yanovski, B. M. Wolfe, Weight change and health outcomes at 3 years after bariatric surgery 
among individuals with severe obesity, JAMA - J. Am. Med. Assoc. (2013), 
doi:10.1001/jama.2013.280928. 
32. A. D. Miras, C. W. Le Roux, Mechanisms underlying weight loss after bariatric surgeryNat. Rev. 
Gastroenterol. Hepatol. (2013), doi:10.1038/nrgastro.2013.119. 
33. S. N. Karamanakos, K. Vagenas, F. Kalfarentzos, T. K. Alexandrides, Weight loss, appetite 
suppression, and changes in fasting and postprandial ghrelin and peptide-yy levels after roux-en-y 




34. K. Chandarana, C. Gelegen, E. Karra, A. I. Choudhury, M. E. Drew, V. Fauveau, B. Viollet, F. 
Andreelli, D. J. Withers, R. L. Batterham, Diet and gastrointestinal bypass-induced weight loss: the 
roles of ghrelin and peptide YY., Diabetes 60, 810–8 (2011). 
35. R. L. Batterham, D. E. Cummings, Mechanisms of diabetes improvement following 
bariatric/metabolic surgery, Diabetes Care (2016), doi:10.2337/dc16-0145. 
36. F. Rubino, A. Forgione, D. E. Cummings, M. Vix, D. Gnuli, G. Mingrone, M. Castagneto, J. 
Marescaux, The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of 
the proximal small intestine in the pathophysiology of type 2 diabetes., Ann. Surg. 244, 741–9 
(2006). 
37. F. Rubino, P. Zizzari, C. Tomasetto, M.-T. Bluet-Pajot, A. Forgione, M. Vix, D. Grouselle, J. 
Marescaux, The role of the small bowel in the regulation of circulating ghrelin levels and food intake 
in the obese Zucker rat., Endocrinology 146, 1745–51 (2005). 
38. M. Salehi, R. L. Prigeon, D. A. D’Alessio, Gastric bypass surgery enhances glucagon-like peptide 1-
stimulated postprandial insulin secretion in humans, Diabetes (2011), doi:10.2337/db11-0203. 
39. C. Dirksen, D. L. Hansen, S. Madsbad, L. E. Hvolris, L. S. Naver, J. J. Holst, D. Worm, Postprandial 
diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and 
is associated with exaggerated GLP-1 secretion: A case report, Diabetes Care (2010), 
doi:10.2337/dc09-1374. 
40. A. P. Chambers, L. Jessen, K. K. Ryan, S. Sisley, H. E. Wilson-Pérez, M. A. Stefater, S. G. Gaitonde, 
J. E. Sorrell, M. Toure, J. Berger, D. A. D’Alessio, S. C. Woods, R. J. Seeley, D. A. Sandoval, Weight-
independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve 
gastrectomy in rats., Gastroenterology 141, 950–8 (2011). 
41. P. Larraufie, G. P. Roberts, A. K. McGavigan, R. G. Kay, J. Li, A. Leiter, A. Melvin, E. K. Biggs, P. 
Ravn, K. Davy, D. C. Hornigold, G. S. H. Yeo, R. H. Hardwick, F. Reimann, F. M. Gribble, Important Role 
of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery, Cell Rep. (2019), 
doi:10.1016/j.celrep.2019.01.047. 
42. D. Ben-Zvi, L. Meoli, W. M. Abidi, R. C. Anafi, A. P. Courcoulas, N. Stylopoulos Correspondence, E. 
Nestoridi, C. Panciotti, E. Castillo, P. Pizarro, E. Shirley, W. F. Gourash, C. C. Thompson, R. Munoz, C. 
B. Clish, N. Stylopoulos, Time-Dependent Molecular Responses Differ between Gastric Bypass and 
Dieting but Are Conserved Across Species Cell Metabolism Resource Time-Dependent Molecular 
Responses Differ between Gastric Bypass and Dieting but Are Conserved Across Species, Cell Metab. 
178 
 
28, 310-323.e6 (2018). 
43. J.-B. Cavin, A. Couvelard, R. Lebtahi, R. Ducroc, K. Arapis, E. Voitellier, F. Cluzeaud, L. Gillard, M. 
Hourseau, N. Mikail, L. Ribeiro-Parenti, N. Kapel, J.-P. Marmuse, A. Bado, M. Le Gall, Differences in 
Alimentary Glucose Absorption and Intestinal Disposal of Blood Glucose After Roux-en-Y Gastric 
Bypass vs Sleeve Gastrectomy, Gastroenterology 150, 454-464.e9 (2016). 
44. UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood-glucose control with 
metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet (2002), 
doi:10.1016/s0140-6736(98)07037-8. 
45. E. Sanchez-Rangel, S. E. Inzucchi, Metformin: clinical use in type 2 diabetesDiabetologia (2017), 
doi:10.1007/s00125-017-4336-x. 
46. C. J. Bailey, C. Day, Metformin: Its botanical background, Pract. Diabetes Int. (2004), 
doi:10.1002/pdi.606. 
47. C. J. Bailey, Metformin: historical overviewDiabetologia (2017), doi:10.1007/s00125-017-4318-z. 
48. C. K. WATANABE, STUDIES IN THE METABOLIC CHANGES INDUCED BY THE ADMINISTRATION OF 
GUANIDINE BASES, J. Biol. Chem. , 253–265 (1917). 
49. E. A. Werner, J. Bell, CCXIV. - The preparation of methylguanidine, and of ββ- dimethylguanidine 
by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides 
respectively, J. Chem. Soc. Trans. (1922), doi:10.1039/CT9222101790. 
50. K. H. Slotta, R. Tschesche, Über Biguanide, II.: Die blutzucker-senkende Wirkung der Biguanide, 
Berichte der Dtsch. Chem. Gesellschaft (A B Ser. (1929), doi:10.1002/cber.19290620605. 
51. E. Hesse, G. Taubmann, Die Wirkung des Biguanids und seiner Derivate auf den 
Zuckerstoffwechsel, Arch. für Exp. Pathol. und Pharmakologie (1929), doi:10.1007/BF02000097. 
52. J. STERNE, [Blood sugar-lowering effect of 1,1-dimethylbiguanide]., Therapie 13, 650–9 (1958). 
53. G. UNGAR, L. FREEDMAN, S. L. SHAPIRO, Pharmacological studies of a new oral hypoglycemic 
drug., Proc. Soc. Exp. Biol. Med. 95, 190–2 (1957). 
54. A. BERINGER, [Treatment of diabetes mellitus with biguanides]., Wien. Med. Wochenschr. 108, 
880–2 (1958). 
55. J. B. McKendry, K. Kuwayti, P. P. Rado, Clinical experience with DBI (phenformin) in the 
management of diabetes., Can. Med. Assoc. J. (1959). 
179 
 
56. D. Luft, R. M. Schmülling, M. Eggstein, Lactic acidosis in biguanide-treated diabetics - A review of 
330 cases, Diabetologia (1978), doi:10.1007/BF01263444. 
57. R. S. WALKER, A. L. LINTON, Phenethyldiguanide: a dangerous side-effect., Br. Med. J. 2, 1005–6 
(1959). 
58.  The University Group Diabetes Program. A study of the effects of hypoglycemic agents on 
vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy., 
Diabetes 24 Suppl 1, 65–184 (1975). 
59. O. Jalling, C. Olsen, The effects of metformin compared to the effects of phenformin on the 
lactate production and the metabolism of isolated parenchymal rat liver cell., Acta Pharmacol. 
Toxicol. (Copenh). 54, 327–32 (1984). 
60. N. Wollen, C. J. Bailey, Inhibition of hepatic gluconeogenesis by metformin. Synergism with 
insulin., Biochem. Pharmacol. 37, 4353–8 (1988). 
61. C. J. Bailey, J. A. Puah, Effect of metformin on glucose metabolism in mouse soleus muscle., 
Diabete Metab. (1986). 
62. L. S. Hermann, Metformin: a review of its pharmacological properties and therapeutic use., 
Diabete Metab. 5, 233–45 (1979). 
63. I. W. Campbell, H. C. S. Howlett, Worldwide Experience of Metformin as an Effective Glucose‐
lowering Agent: A Meta‐analysis, Diabetes. Metab. Rev. (1995), doi:10.1002/dmr.5610110509. 
64. C. J. Bailey, C. Wilcock, C. Day, Effect of metformin on glucose metabolism in the splanchnic bed., 
Br. J. Pharmacol. 105, 1009–13 (1992). 
65. R. A. DeFronzo, A. M. Goodman, Efficacy of metformin in patients with non-insulin-dependent 
diabetes mellitus. The Multicenter Metformin Study Group., N. Engl. J. Med. (1995), 
doi:10.1056/NEJM199508313330902. 
66. A. J. Garber, T. G. Duncan, A. M. Goodman, D. J. Mills, J. L. Rohlf, Efficacy of metformin in type II 
diabetes: Results of a double-blind, placebo-controlled, dose-response trial, Am. J. Med. 103, 491–
497 (1997). 
67. M. G. Wulffelé, A. Kooy, P. Lehert, D. Bets, J. C. Ogterop, B. Borger van der Burg, A. J. M. Donker, 
C. D. A. Stehouwer, Combination of insulin and metformin in the treatment of type 2 diabetes., 
Diabetes Care 25, 2133–40 (2002). 
68. H. Yki-Järvinen, L. Ryysy, K. Nikkilä, T. Tulokas, R. Vanamo, M. Heikkilä, Comparison of bedtime 
180 
 
insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial., Ann. 
Intern. Med. 130, 389–96 (1999). 
69. S. E. Inzucchi, D. G. Maggs, G. R. Spollett, S. L. Page, F. S. Rife, V. Walton, G. I. Shulman, Efficacy 
and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus, N. Engl. J. Med. 
338, 867–873 (1998). 
70. J. Rosenstock, L. Chuck, M. González-Ortiz, K. Merton, J. Craig, G. Capuano, R. Qiu, Initial 
Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy 
for Drug-Naïve Type 2 Diabetes., Diabetes Care 39, 353–62 (2016). 
71. C. J. Bailey, J. L. Gross, A. Pieters, A. Bastien, J. F. List, Effect of dapagliflozin in patients with type 
2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, 
placebo-controlled trial., Lancet (London, England) 375, 2223–33 (2010). 
72. E. Søfteland, J. J. Meier, B. Vangen, R. Toorawa, M. Maldonado-Lutomirsky, U. C. Broedl, 
Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With 
Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial., Diabetes 
Care 40, 201–209 (2017). 
73. I. Vardarli, E. Arndt, C. F. Deacon, J. J. Holst, M. A. Nauck, Effects of Sitagliptin and Metformin 
Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and “Isoglycemic” 
Intravenous Glucose, Diabetes 63, 663–674 (2014). 
74. R. Scott, T. Loeys, M. J. Davies, S. S. Engel, Sitagliptin Study 801 Group, Efficacy and safety of 
sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes., Diabetes. 
Obes. Metab. 10, 959–69 (2008). 
75. C. F. Deacon, E. Mannucci, B. Ahrén, Glycaemic efficacy of glucagon-like peptide-1 receptor 
agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 
2 diabetes-a review and meta analysis., Diabetes. Obes. Metab. 14, 762–7 (2012). 
76. Diabetes Prevention Program Research Group, T. D. P. P. R. Diabetes Prevention Program 
Research Group, Long-term safety, tolerability, and weight loss associated with metformin in the 
Diabetes Prevention Program Outcomes Study., Diabetes Care 35, 731–7 (2012). 
77. Diabetes Prevention Program Research Group, 10-year follow-up of diabetes incidence and 
weight loss in the Diabetes Prevention Program Outcomes Study, Lancet (2009), doi:10.1016/S0140-
6736(09)61457-4. 
78. G. A. Bray, K. S. Polonsky, P. G. Watson, R. B. Goldberg, S. M. Haffner, R. F. Hamman, E. S. Horton, 
181 
 
S. F. Kahn, A. E. Kitabchi, B. E. Metzger, D. M. Nathan, J. M. Olefsky, F. X. Pi-Sunyer, M. J. Prince, R. E. 
Ratner, M. F. Saad, S. Dagogo Jack, C. D. Saudek, D. S. Schade, H. Shamoon, R. R. Wing, R. F. Arakaki, 
W. C. Krowler, R. Bain, S. M. Marcovina, P. M. Rautaharju, E. J. Mayer-Davis, D. H. O’Leary, E. R. 
Stamm, The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention 
of type 2 diabetesDiabetes Care (1999), doi:10.2337/diacare.22.4.623. 
79. N. D. D. P. P. R. G. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, 
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin., N. Engl. J. 
Med. 346(6), 393–403 (2002). 
80. V. R. Aroda, W. C. Knowler, J. P. Crandall, L. Perreault, S. L. Edelstein, S. L. Jeffries, M. E. Molitch, 
X. Pi-Sunyer, C. Darwin, B. M. Heckman-Stoddard, M. Temprosa, S. E. Kahn, D. M. Nathan, Metformin 
for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention 
Program Outcomes StudyDiabetologia (2017), doi:10.1007/s00125-017-4361-9. 
81. A. Golay, Metformin and body weightInt. J. Obes. (2008), doi:10.1038/sj.ijo.0803695. 
82. G. Viberti, S. E. Kahn, D. A. Greene, W. H. Herman, B. Zinman, R. R. Holman, S. M. Haffner, D. 
Levy, J. M. Lachin, R. A. Berry, M. A. Heise, N. P. Jones, M. I. Freed, A Diabetes Outcome Progression 
Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, 
glyburide, and metformin in recently diagnosed type 2 diabetes, Diabetes Care (2002), 
doi:10.2337/diacare.25.10.1737. 
83. E. J. Bastyr, C. A. Stuart, R. G. Brodows, S. Schwartz, C. J. Graf, A. Zagar, K. E. Robertson, Therapy 
focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. 
IOEZ Study Group., Diabetes Care 23(9), 1236–41 (2000). 
84. M. Hanefeld, P. Brunetti, G. H. Schernthaner, D. R. Matthews, B. H. Charbonnel, QUARTET Study 
Group, One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus 
metformin in patients with type 2 diabetes., Diabetes Care 27, 141–7 (2004). 
85. J. Gerich, P. Raskin, L. Jean-Louis, D. Purkayastha, M. A. Baron, PRESERVE-beta: two-year efficacy 
and safety of initial combination therapy with nateglinide or glyburide plus metformin., Diabetes 
Care 28, 2093–9 (2005). 
86. R. A. DeFronzo, J. B. Buse, T. Kim, C. Burns, S. Skare, A. Baron, M. Fineman, Once-daily delayed-
release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: 
results from two randomised trials, Diabetologia 59, 1645–1654 (2016). 
87. K. A. Virtanen, K. Hällsten, R. Parkkola, T. Janatuinen, F. Lönnqvist, T. Viljanen, T. Rönnemaa, J. 
182 
 
Knuuti, R. Huupponen, P. Lönnroth, P. Nuutila, Differential effects of rosiglitazone and metformin on 
adipose tissue distribution and glucose uptake in type 2 diabetic subjects., Diabetes 52, 283–90 
(2003). 
88. A. Fontbonne, M. A. Charles, I. Juhan-Vague, J. M. Bard, P. André, F. Isnard, J. M. Cohen, P. 
Grandmottet, P. Vague, M. E. Safar, E. Eschwège, The effect of metformin on the metabolic 
abnormalities associated with upper-body fat distribution. BIGPRO Study Group., Diabetes Care 19, 
920–6 (1996). 
89. A. Gokcel, Y. Gumurdulu, H. Karakose, E. Melek Ertorer, N. Tanaci, N. BascilTutuncu, N. Guvener, 
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of 
obesity., Diabetes. Obes. Metab. 4, 49–55 (2002). 
90. A. Saenz, A. Mataix, A. S. M, R. F. M, D. Moher, Metformin monotherapy for type 2 diabetes 
mellitus (Review), Cochrane Database Syst Rev (2013), doi:10.1002/14651858.CD002966.pub3. 
91. K. Johansen, Efficacy of metformin in the treatment of NIDDM: Meta-analysis, Diabetes Care 
(1999), doi:10.2337/diacare.22.1.33. 
92. S. J. Griffin, J. K. Leaver, G. J. Irving, Impact of metformin on cardiovascular disease: a meta-
analysis of randomised trials among people with type 2 diabetes, Diabetologia 60, 1620–1629 
(2017). 
93. J. E. Nestler, D. J. Jakubowicz, Decreases in ovarian cytochrome P450c17 alpha activity and serum 
free testosterone after reduction of insulin secretion in polycystic ovary syndrome., N. Engl. J. Med. 
335, 617–23 (1996). 
94. J. E. Nestler, D. J. Jakubowicz, Lean women with polycystic ovary syndrome respond to insulin 
reduction with decreases in ovarian P450c17 alpha activity and serum androgens., J. Clin. Endocrinol. 
Metab. 82, 4075–9 (1997). 
95. R. S. Lindsay, M. R. Loeken, Metformin use in pregnancy: promises and uncertaintiesDiabetologia 
(2017), doi:10.1007/s00125-017-4351-y. 
96. J. A. Rowan, W. M. Hague, W. Gao, M. R. Battin, M. P. Moore, Metformin versus Insulin for the 
Treatment of Gestational Diabetes, N. Engl. J. Med. 358, 2003–2015 (2008). 
97. B. M. Heckman-Stoddard, A. DeCensi, V. V. Sahasrabuddhe, L. G. Ford, Repurposing metformin 




98. I. C. Lega, P. S. Shah, D. Margel, J. Beyene, P. A. Rochon, L. L. Lipscombe, The effect of metformin 
on mortality following canceramong patients with diabetesCancer Epidemiol. Biomarkers Prev. 
(2014), doi:10.1158/1055-9965.EPI-14-0327. 
99. A. DeCensi, M. Puntoni, P. Goodwin, M. Cazzaniga, A. Gennari, B. Bonanni, S. Gandini, Metformin 
and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis, Cancer Prev. Res. 3, 
1451–1461 (2010). 
100. M. Franciosi, G. Lucisano, E. Lapice, G. F. M. Strippoli, F. Pellegrini, A. Nicolucci, Metformin 
therapy and risk of cancer in patients with type 2 diabetes: systematic review., PLoS One 8, e71583 
(2013). 
101. R. J. Stevens, R. Ali, C. R. Bankhead, M. A. Bethel, B. J. Cairns, R. P. Camisasca, F. L. Crowe, A. J. 
Farmer, S. Harrison, J. A. Hirst, P. Home, S. E. Kahn, J. H. McLellan, R. Perera, A. Plüddemann, A. 
Ramachandran, N. W. Roberts, P. W. Rose, A. Schweizer, G. Viberti, R. R. Holman, Cancer outcomes 
and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-
analysis of randomised clinical trials., Diabetologia 55, 2593–2603 (2012). 
102. Z. J. Zhang, S. Li, The prognostic value of metformin for cancer patients with concurrent 
diabetes: A systematic review and meta-analysis, Diabetes, Obes. Metab. (2014), 
doi:10.1111/dom.12267. 
103. P. Zhang, H. Li, X. Tan, L. Chen, S. Wang, Association of metformin use with cancer incidence 
and mortality: a meta-analysis., Cancer Epidemiol. 37, 207–18 (2013). 
104. B. M. Heckman-Stoddard, S. Gandini, B. K. Dunn, E. Szabo, A. DeCensi, M. Puntoni, L. Ford, 
Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into 
Account Biases and Confounders, Cancer Prev. Res. (2014), doi:10.1158/1940-6207.capr-13-0424. 
105. L. Wu, J. Zhu, L. J. Prokop, M. Hassan Murad, Pharmacologic Therapy of Diabetes and Overall 
Cancer Risk and Mortality: A Meta-Analysis of 265 Studies, Sci. Rep. (2015), doi:10.1038/srep10147. 
106. B. Thakkar, K. N. Aronis, M. T. Vamvini, K. Shields, C. S. Mantzoros, Metformin and sulfonylureas 
in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published 
studies., Metabolism. 62, 922–34 (2013). 
107. D. Soranna, L. Scotti, A. Zambon, C. Bosetti, G. Grassi, A. Catapano, C. La Vecchia, G. Mancia, G. 
Corrao, Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-
analysis., Oncologist 17, 813–22 (2012). 
108. H. Noto, A. Goto, T. Tsujimoto, M. Noda, Cancer risk in diabetic patients treated with 
184 
 
metformin: A systematic review and meta-analysis, PLoS One (2012), 
doi:10.1371/journal.pone.0033411. 
109. A. M. Joshua, V. E. Zannella, M. R. Downes, B. Bowes, K. Hersey, M. Koritzinsky, M. Schwab, U. 
Hofmann, A. Evans, T. van der Kwast, J. Trachtenberg, A. Finelli, N. Fleshner, J. Sweet, M. Pollak, A 
pilot “window of opportunity” neoadjuvant study of metformin in localised prostate cancer., 
Prostate Cancer Prostatic Dis. 17, 252–8 (2014). 
110. S. Hadad, T. Iwamoto, L. Jordan, C. Purdie, S. Bray, L. Baker, G. Jellema, S. Deharo, D. G. Hardie, 
L. Pusztai, S. Moulder-Thompson, J. A. Dewar, A. M. Thompson, Evidence for biological effects of 
metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial., 
Breast Cancer Res. Treat. 128, 783–94 (2011). 
111. A. Mitsuhashi, T. Kiyokawa, Y. Sato, M. Shozu, Effects of metformin on endometrial cancer cell 
growth in vivo: a preoperative prospective trial., Cancer 120, 2986–95 (2014). 
112. V. N. Sivalingam, S. Kitson, R. McVey, C. Roberts, P. Pemberton, K. Gilmour, S. Ali, A. G. 
Renehan, H. C. Kitchener, E. J. Crosbie, Measuring the biological effect of presurgical metformin 
treatment in endometrial cancer., Br. J. Cancer 114, 281–9 (2016). 
113. K. M. Schuler, B. S. Rambally, M. J. DiFurio, B. P. Sampey, P. A. Gehrig, L. Makowski, V. L. Bae-
Jump, Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for 
endometrial cancer., Cancer Med. 4, 161–73 (2015). 
114. B. Bonanni, M. Puntoni, M. Cazzaniga, G. Pruneri, D. Serrano, A. Guerrieri-Gonzaga, A. Gennari, 
M. S. Trabacca, V. Galimberti, P. Veronesi, H. Johansson, V. Aristarco, F. Bassi, A. Luini, M. Lazzeroni, 
C. Varricchio, G. Viale, P. Bruzzi, A. Decensi, Dual effect of metformin on breast cancer proliferation 
in a randomized presurgical trial., J. Clin. Oncol. 30, 2593–600 (2012). 
115. K. Hosono, H. Endo, H. Takahashi, M. Sugiyama, E. Sakai, T. Uchiyama, K. Suzuki, H. Iida, Y. 
Sakamoto, K. Yoneda, T. Koide, C. Tokoro, Y. Abe, M. Inamori, H. Nakagama, A. Nakajima, Metformin 
suppresses colorectal aberrant crypt foci in a short-term clinical trial, Cancer Prev. Res. (2010), 
doi:10.1158/1940-6207.CAPR-10-0186. 
116. L. J. McCreight, C. J. Bailey, E. R. Pearson, Metformin and the gastrointestinal tract, Diabetologia 
59, 426–435 (2016). 
117. T. Dujic, K. Zhou, L. A. Donnelly, R. Tavendale, C. N. A. Palmer, E. R. Pearson, Association of 
Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study, 
Diabetes 64, 1786–1793 (2015). 
185 
 
118. A. Y. Dawed, K. Zhou, N. van Leeuwen, A. Mahajan, N. Robertson, R. Koivula, P. J. M. Elders, S. P. 
Rauh, A. G. Jones, R. W. Holl, J. C. Stingl, P. W. Franks, M. I. McCarthy, L. M. ’t Hart, E. R. Pearson, IMI 
DIRECT Consortium, Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded 
by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and Gastrointestinal 
Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study., Diabetes Care 42, 1027–1033 
(2019). 
119. F. F. Richy, M. Sabidó-Espin, S. Guedes, F. A. Corvino, U. Gottwald-Hostalek, Incidence of lactic 
acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: 
a retrospective cohort study., Diabetes Care 37, 2291–5 (2014). 
120. J. de Jager, A. Kooy, P. Lehert, M. G. Wulffelé, J. van der Kolk, D. Bets, J. Verburg, A. J. M. 
Donker, C. D. A. Stehouwer, Long term treatment with metformin in patients with type 2 diabetes 
and risk of vitamin B-12 deficiency: randomised placebo controlled trial., BMJ 340, c2181 (2010). 
121. V. R. Aroda, S. L. Edelstein, R. B. Goldberg, W. C. Knowler, S. M. Marcovina, T. J. Orchard, G. A. 
Bray, D. S. Schade, M. G. Temprosa, N. H. White, J. P. Crandall, Diabetes Prevention Program 
Research Group, Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention 
Program Outcomes Study., J. Clin. Endocrinol. Metab. 101, 1754–61 (2016). 
122. K. Zhou, L. Donnelly, J. Yang, M. Li, H. Deshmukh, N. Van Zuydam, E. Ahlqvist, C. C. Spencer, L. 
Groop, A. D. Morris, H. M. Colhoun, P. C. Sham, M. I. McCarthy, C. N. A. Palmer, E. R. Pearson, 
Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis, 
Lancet Diabetes Endocrinol. 2, 481–487 (2014). 
123. J. C. Florez, The pharmacogenetics of metforminDiabetologia (2017), doi:10.1007/s00125-017-
4335-y. 
124. K. A. Jablonski, J. B. McAteer, P. I. W. de Bakker, P. W. Franks, T. I. Pollin, R. L. Hanson, R. 
Saxena, S. Fowler, A. R. Shuldiner, W. C. Knowler, D. Altshuler, J. C. Florez,  for the D. P. P. R. 
Diabetes Prevention Program Research Group, Common variants in 40 genes assessed for diabetes 
incidence and response to metformin and lifestyle intervention in the diabetes prevention program., 
Diabetes 59, 2672–81 (2010). 
125. K. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, C. Wellcome Trust Case 
Control Consortium 2, K. Zhou, C. Bellenguez, C. C. A. Spencer, A. J. Bennett, R. L. Coleman, R. 
Tavendale, S. A. Hawley, L. A. Donnelly, C. Schofield, C. J. Groves, L. Burch, F. Carr, A. Strange, C. 
Freeman, J. M. Blackwell, E. Bramon, M. A. Brown, J. P. Casas, A. Corvin, N. Craddock, P. Deloukas, S. 
Dronov, A. Duncanson, S. Edkins, E. Gray, S. Hunt, J. Jankowski, C. Langford, H. S. Markus, C. G. 
186 
 
Mathew, R. Plomin, A. Rautanen, S. J. Sawcer, N. J. Samani, R. Trembath, A. C. Viswanathan, N. W. 
Wood, A. T. MAGIC investigators, L. W. Harries, A. T. Hattersley, A. S. F. Doney, H. Colhoun, A. D. 
Morris, C. Sutherland, D. G. Hardie, L. Peltonen, M. I. McCarthy, R. R. Holman, C. N. A. Palmer, P. 
Donnelly, E. R. Pearson, Common variants near ATM are associated with glycemic response to 
metformin in type 2 diabetes., Nat. Genet. 43, 117–20 (2011). 
126. S. W. Yee, L. Chen, K. M. Giacomini, The role of ATM in response to metformin treatment and 
activation of AMPKNat. Genet. (2012), doi:10.1038/ng.2236. 
127. J. C. Florez, K. A. Jablonski, A. Taylor, K. Mather, E. Horton, N. H. White, E. Barrett-Connor, W. C. 
Knowler, A. R. Shuldiner, T. I. Pollin,  for the D. P. P. R. Diabetes Prevention Program Research Group, 
The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes 
Prevention Program., Diabetes Care 35, 1864–7 (2012). 
128. N. van Leeuwen, G. Nijpels, M. L. Becker, H. Deshmukh, K. Zhou, B. H. C. Stricker, A. G. 
Uitterlinden, A. Hofman, E. van ’t Riet, C. N. A. Palmer, B. Guigas, P. E. Slagboom, P. Durrington, R. A. 
Calle, A. Neil, G. Hitman, S. J. Livingstone, H. Colhoun, R. R. Holman, M. I. McCarthy, J. M. Dekker, L. 
M. ’t Hart, E. R. Pearson, A gene variant near ATM is significantly associated with metformin 
treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts., Diabetologia 
55, 1971–7 (2012). 
129. K. Zhou, S. W. Yee, E. L. Seiser, N. van Leeuwen, R. Tavendale, A. J. Bennett, C. J. Groves, R. L. 
Coleman, A. A. van der Heijden, J. W. Beulens, C. E. de Keyser, L. Zaharenko, D. M. Rotroff, M. Out, K. 
A. Jablonski, L. Chen, M. Javorský, J. Židzik, A. M. Levin, L. K. Williams, T. Dujic, S. Semiz, M. Kubo, H.-
C. Chien, S. Maeda, J. S. Witte, L. Wu, I. Tkáč, A. Kooy, R. H. N. van Schaik, C. D. A. Stehouwer, L. 
Logie, C. Sutherland, J. Klovins, V. Pirags, A. Hofman, B. H. Stricker, A. A. Motsinger-Reif, M. J. 
Wagner, F. Innocenti, L. M. ’t Hart, R. R. Holman, M. I. McCarthy, M. M. Hedderson, C. N. A. Palmer, 
J. C. Florez, K. M. Giacomini, E. R. Pearson, J. C. Florez, K. M. Giacomini, E. R. Pearson, Variation in 
the glucose transporter gene SLC2A2 is associated with glycemic response to metformin, Nat. Genet. 
48, 1055–1059 (2016). 
130. W. Rathmann, K. Strassburger, B. Bongaerts, O. Kuss, K. Müssig, V. Burkart, J. Szendroedi, J. 
Kotzka, B. Knebel, H. Al-Hasani, M. Roden,  for the G. Group, A variant of the glucose transporter 
gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 
diabetes, Diabetologia 62, 286–291 (2019). 
131. Y. Shu, S. A. Sheardown, C. Brown, R. P. Owen, S. Zhang, R. A. Castro, A. G. Ianculescu, L. Yue, J. 
C. Lo, E. G. Burchard, C. M. Brett, K. M. Giacomini, Effect of genetic variation in the organic cation 
187 
 
transporter 1 (OCT1) on metformin action, J. Clin. Invest. 117, 1422–1431 (2007). 
132. Y. Shu, M. K. Leabman, B. Feng, L. M. Mangravite, C. C. Huang, D. Stryke, M. Kawamoto, S. J. 
Johns, J. DeYoung, E. Carlson, T. E. Ferrin, I. Herskowitz, K. M. Giacomini, Pharmacogenetics Of 
Membrane Transporters Investigators, Evolutionary conservation predicts function of variants of the 
human organic cation transporter, OCT1., Proc. Natl. Acad. Sci. U. S. A. 100, 5902–7 (2003). 
133. R. Kerb, U. Brinkmann, N. Chatskaia, D. Gorbunov, V. Gorboulev, E. Mornhinweg, A. Keil, M. 
Eichelbaum, H. Koepsell, Identification of genetic variations of the human organic cation transporter 
hOCT1 and their functional consequences., Pharmacogenetics 12, 591–5 (2002). 
134. J. Gram, J. E. Henriksen, E. Grodum, H. Juhl, T. B. Hansen, C. Christiansen, K. Yderstræde, H. 
Gjessing, H. M. Hansen, V. Vestergaard, J. Hangaard, H. Beck-Nielsen, Pharmacological treatment of 
the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes 
Study., Diabetes Care 34, 27–33 (2011). 
135. E. I. O. Sundelin, L. C. Gormsen, J. B. Jensen, M. H. Vendelbo, S. Jakobsen, O. L. Munk, M. M. H. 
Christensen, K. Brøsen, J. Frøkiær, N. Jessen, Genetic Polymorphisms in Organic Cation Transporter 1 
Attenuates Hepatic Metformin Exposure in Humans, Clin. Pharmacol. Ther. (2017), 
doi:10.1002/cpt.701. 
136. M. L. Becker, L. E. Visser, R. H. N. N. van Schaik, A. Hofman, A. G. Uitterlinden, B. H. C. C. 
Stricker, Genetic variation in the organic cation transporter 1 is associated with metformin response 
in patients with diabetes mellitus, 9, 242–247 (2009). 
137. K. Zhou, L. A. Donnelly, C. H. Kimber, P. T. Donnan, A. S. F. Doney, G. Leese, A. T. Hattersley, M. 
I. Mccarthy, A. D. Morris, C. N. a Palmer, E. R. Pearson, Organic Cation Transporter 1 and Glycemic 
Response to Metformin : A GoDARTS Study, Diabetes (2009), doi:10.2337/db08-0896. 
138. M. L. Becker, L. E. Visser, R. H. N. Van Schaik, A. Hofman, A. G. Uitterlinden, B. H. C. Stricker, 
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-
lowering effect of metformin in patients with diabetes: A preliminary study, Diabetes (2009), 
doi:10.2337/db08-1028. 
139. M. L. Becker, L. E. Visser, R. H. N. van Schaik, A. Hofman, A. G. Uitterlinden, B. H. C. Stricker, 
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response., 
Pharmacogenet. Genomics 20, 38–44 (2010). 
140. I. Tkáč, L. Klimčáková, M. Javorský, M. Fabianová, Z. Schroner, H. Hermanová, E. Babjaková, R. 
Tkáčová, Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic 
188 
 
response to metformin in type 2 diabetes., Diabetes. Obes. Metab. 15, 189–91 (2013). 
141. D. M. Rotroff, S. W. Yee, K. Zhou, S. W. Marvel, H. S. Shah, J. R. Jack, T. M. Havener, M. M. 
Hedderson, M. Kubo, M. A. Herman, H. Gao, J. C. Mychaleckyi, H. L. McLeod, A. Doria, K. M. 
Giacomini, E. R. Pearson, M. J. Wagner, J. B. Buse, A. A. Motsinger-Reif, M. MetGen Investigators, A. 
ACCORD/ACCORDion Investigators, Genetic Variants in CPA6 and PRPF31 Are Associated With 
Variation in Response to Metformin in Individuals With Type 2 Diabetes., Diabetes 67, 1428–1440 
(2018). 
142. H. Gehart, H. Clevers, Tales from the crypt: new insights into intestinal stem cellsNat. Rev. 
Gastroenterol. Hepatol. (2019), doi:10.1038/s41575-018-0081-y. 
143. J. B. Furness, The enteric nervous system and neurogastroenterologyNat. Rev. Gastroenterol. 
Hepatol. (2012), doi:10.1038/nrgastro.2012.32. 
144. A. L. Haber, M. Biton, N. Rogel, R. H. Herbst, K. Shekhar, C. Smillie, G. Burgin, T. M. Delorey, M. 
R. Howitt, Y. Katz, I. Tirosh, S. Beyaz, D. Dionne, M. Zhang, R. Raychowdhury, W. S. Garrett, O. 
Rozenblatt-Rosen, H. N. Shi, O. Yilmaz, R. J. Xavier, A. Regev, A single-cell survey of the small 
intestinal epithelium, Nature 551, 333–339 (2017). 
145. H. Cheng, C. P. Leblond, Origin, differentiation and renewal of the four main epithelial cell types 
in the mouse small intestine. V. Unitarian Theory of the origin of the four epithelial cell types., Am. J. 
Anat. 141, 537–61 (1974). 
146. S. J. A. Buczacki, H. I. Zecchini, A. M. Nicholson, R. Russell, L. Vermeulen, R. Kemp, D. J. Winton, 
Intestinal label-retaining cells are secretory precursors expressing lgr5, Nature (2013), 
doi:10.1038/nature11965. 
147. N. Barker, J. H. Van Es, J. Kuipers, P. Kujala, M. Van Den Born, M. Cozijnsen, A. Haegebarth, J. 
Korving, H. Begthel, P. J. Peters, H. Clevers, Identification of stem cells in small intestine and colon by 
marker gene Lgr5, Nature (2007), doi:10.1038/nature06196. 
148. T. Sato, R. G. Vries, H. J. Snippert, M. van de Wetering, N. Barker, D. E. Stange, J. H. van Es, A. 
Abo, P. Kujala, P. J. Peters, H. Clevers, Single Lgr5 stem cells build crypt-villus structures in vitro 
without a mesenchymal niche., Nature 459, 262–5 (2009). 
149. T. Sato, J. H. van Es, H. J. Snippert, D. E. Stange, R. G. Vries, M. van den Born, N. Barker, N. F. 
Shroyer, M. van de Wetering, H. Clevers, Paneth cells constitute the niche for Lgr5 stem cells in 
intestinal crypts. Supplementary information, Nature (2011), doi:10.1038/nature09637. 
150. M. J. Rodríguez-Colman, M. Schewe, M. Meerlo, E. Stigter, J. Gerrits, M. Pras-Raves, A. 
189 
 
Sacchetti, M. Hornsveld, K. C. Oost, H. J. Snippert, N. Verhoeven-Duif, R. Fodde, B. M. T. Burgering, 
Interplay between metabolic identities in the intestinal crypt supports stem cell function, Nature 
543, 424–427 (2017). 
151. J. H. van Es, T. Sato, M. van de Wetering, A. Lyubimova, A. N. Yee Nee, A. Gregorieff, N. Sasaki, 
L. Zeinstra, M. van den Born, J. Korving, A. C. M. Martens, N. Barker, A. van Oudenaarden, H. Clevers, 
Dll1+ secretory progenitor cells revert to stem cells upon crypt damage., Nat. Cell Biol. 14, 1099–
1104 (2012). 
152. P. W. Tetteh, O. Basak, H. F. Farin, K. Wiebrands, K. Kretzschmar, H. Begthel, M. van den Born, J. 
Korving, F. de Sauvage, J. H. van Es, A. van Oudenaarden, H. Clevers, Replacement of Lost Lgr5-
Positive Stem Cells through Plasticity of Their Enterocyte-Lineage Daughters., Cell Stem Cell 18, 203–
13 (2016). 
153. M. Bjerknes, C. Khandanpour, T. Möröy, T. Fujiyama, M. Hoshino, T. J. Klisch, Q. Ding, L. Gan, J. 
Wang, M. G. Martín, H. Cheng, Origin of the brush cell lineage in the mouse intestinal epithelium., 
Dev. Biol. 362, 194–218 (2012). 
154. N. F. Shroyer, M. A. Helmrath, V. Y.-C. Wang, B. Antalffy, S. J. Henning, H. Y. Zoghbi, Intestine-
specific ablation of mouse atonal homolog 1 (Math1) reveals a role in cellular homeostasis., 
Gastroenterology 132, 2478–88 (2007). 
155. K. A. Knoop, N. Kumar, B. R. Butler, S. K. Sakthivel, R. T. Taylor, T. Nochi, H. Akiba, H. Yagita, H. 
Kiyono, I. R. Williams, RANKL is necessary and sufficient to initiate development of antigen-sampling 
M cells in the intestinal epithelium., J. Immunol. 183, 5738–47 (2009). 
156. N. A. Mabbott, D. S. Donaldson, H. Ohno, I. R. Williams, A. Mahajan, Microfold (M) cells: 
Important immunosurveillance posts in the intestinal epitheliumMucosal Immunol. (2013), 
doi:10.1038/mi.2013.30. 
157. J. H. Van Es, M. E. Van Gijn, O. Riccio, M. Van Den Born, M. Vooijs, H. Begthel, M. Cozijnsen, S. 
Robine, D. J. Winton, F. Radtke, H. Clevers, Notch/γ-secretase inhibition turns proliferative cells in 
intestinal crypts and adenomas into goblet cells, Nature (2005), doi:10.1038/nature03659. 
158. F. Reimann, A. M. Habib, G. Tolhurst, H. E. Parker, G. J. Rogers, F. M. Gribble, Glucose sensing in 
L cells: a primary cell study., Cell Metab. 8, 532–9 (2008). 
159. F. M. Gribble, F. Reimann, Enteroendocrine Cells: Chemosensors in the Intestinal Epithelium, 
Annu. Rev. Physiol. 78, annurev-physiol-021115-105439 (2015). 
160. N. Petersen, F. Reimann, J. H. van Es, B. M. van den Berg, C. Kroone, R. Pais, E. Jansen, H. 
190 
 
Clevers, F. M. Gribble, E. J. P. de Koning, Targeting development of incretin-producing cells increases 
insulin secretion., J. Clin. Invest. 125, 379–85 (2015). 
161. F. Gerbe, E. Sidot, D. J. Smyth, M. Ohmoto, I. Matsumoto, V. Dardalhon, P. Cesses, L. Garnier, M. 
Pouzolles, B. Brulin, M. Bruschi, Y. Harcus, V. S. Zimmermann, N. Taylor, R. M. Maizels, P. Jay, 
Intestinal epithelial tuft cells initiate type 2 mucosal immunity to helminth parasites., Nature 529, 
226–30 (2016). 
162. J. Von Moltke, M. Ji, H. E. Liang, R. M. Locksley, Tuft-cell-derived IL-25 regulates an intestinal 
ILC2-epithelial response circuit, Nature (2016), doi:10.1038/nature16161. 
163. N. Barker, R. A. Ridgway, J. H. van Es, M. van de Wetering, H. Begthel, M. van den Born, E. 
Danenberg, A. R. Clarke, O. J. Sansom, H. Clevers, Crypt stem cells as the cells-of-origin of intestinal 
cancer., Nature 457, 608–11 (2009). 
164. M. van den Born, B.-K. Koo, S. F. Boj, H. Clevers, J. Korving, P. Kujala, A. Haegebarth, A. van 
Oudenaarden, S. Itzkovitz, J. H. van Es, S. Robine, A Critical Role for the Wnt Effector Tcf4 in Adult 
Intestinal Homeostatic Self-Renewal, Mol. Cell. Biol. (2012), doi:10.1128/mcb.06288-11. 
165. A. Ootani, X. Li, E. Sangiorgi, Q. T. Ho, H. Ueno, S. Toda, H. Sugihara, K. Fujimoto, I. L. Weissman, 
M. R. Capecchi, C. J. Kuo, Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem 
cell niche., Nat. Med. 15, 701–6 (2009). 
166. C. J. Kuo, F. Kuhnert, J. Yuan, C. R. Davis, P. Chu, H.-T. Wang, M. Lee, R. Nusse, Essential 
requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by 
adenoviral expression of Dickkopf-1, Proc. Natl. Acad. Sci. (2004), doi:10.1073/pnas.2536800100. 
167. V. Korinek, N. Barker, P. Moerer, E. van Donselaar, G. Huls, P. J. Peters, H. Clevers, Depletion of 
epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4., Nat. Genet. 19, 379–
83 (1998). 
168. M. Shoshkes-Carmel, Y. J. Wang, K. J. Wangensteen, B. Tóth, A. Kondo, E. E. Massassa, S. 
Itzkovitz, K. H. Kaestner, Subepithelial telocytes are an important source of Wnts that supports 
intestinal crypts, Nature (2018), doi:10.1038/s41586-018-0084-4. 
169. W. De Lau, N. Barker, T. Y. Low, B. K. Koo, V. S. W. Li, H. Teunissen, P. Kujala, A. Haegebarth, P. J. 
Peters, M. Van De Wetering, D. E. Stange, J. Van Es, D. Guardavaccaro, R. B. M. Schasfoort, Y. Mohri, 
K. Nishimori, S. Mohammed, A. J. R. Heck, H. Clevers, Lgr5 homologues associate with Wnt receptors 
and mediate R-spondin signalling, Nature (2011), doi:10.1038/nature10337. 
170. J. C. H. Hardwick, G. R. Van Den Brink, S. A. Bleuming, I. Ballester, J. M. H. Van Den Brande, J. J. 
191 
 
Keller, G. J. A. Offerhaus, S. J. H. Van Deventer, M. P. Peppelenbosch, Bone Morphogenetic Protein 2 
Is Expressed by, and Acts Upon, Mature Epithelial Cells in the Colon, Gastroenterology (2004), 
doi:10.1053/j.gastro.2003.10.067. 
171. C. Kosinski, V. S. W. Li, A. S. Y. Chan, J. Zhang, C. Ho, W. Y. Tsui, T. L. Chan, R. C. Mifflin, D. W. 
Powell, S. T. Yuen, S. Y. Leung, X. Chen, Gene expression patterns of human colon tops and basal 
crypts and BMP antagonists as intestinal stem cell niche factors, Proc. Natl. Acad. Sci. (2007), 
doi:10.1073/pnas.0707210104. 
172. X. C. He, J. Zhang, W.-G. Tong, O. Tawfik, J. Ross, D. H. Scoville, Q. Tian, X. Zeng, X. He, L. M. 
Wiedemann, Y. Mishina, L. Li, BMP signaling inhibits intestinal stem cell self-renewal through 
suppression of Wnt-beta-catenin signaling., Nat. Genet. 36, 1117–21 (2004). 
173. A.-P. G. Haramis, H. Begthel, M. van den Born, J. van Es, S. Jonkheer, G. J. A. Offerhaus, H. 
Clevers, De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine., 
Science 303, 1684–6 (2004). 
174. S. Steensels, I. Depoortere, Chemoreceptors in the Gut., Annu. Rev. Physiol. 80, 117–141 (2018). 
175. S. R. D. van der Schoor, P. J. Reeds, B. Stoll, J. F. Henry, J. R. Rosenberger, D. G. Burrin, J. B. van 
Goudoever, The high metabolic cost of a functional gut, Gastroenterology 123, 1931–1940 (2002). 
176. M. A. Mcnurlan, P. J. Garlick, Contribution of Rat Liver and Gastrointestinal Tract to Whole-Body 
Protein Synthesis in the Rat (1980; http://www.biochemj.org/content/186/1/381.full-text.pdf). 
177. E. A. Newsholme, A. L. Carrié, Quantitative aspects of glucose and glutamine metabolism by 
intestinal cells., Gut 35, S13-7 (1994). 
178. M. Watford, P. Lund, H. A. Krebs, Isolation and metabolic characteristics of rat and chicken 
enterocytes., Biochem. J. 178, 589–96 (1979). 
179. G. Mithieux, New data and concepts on glutamine and glucose metabolism in the gutCurr. Opin. 
Clin. Nutr. Metab. Care (2001), doi:10.1097/00075197-200107000-00004. 
180. B. Stoll, D. G. Burrin, J. Henry, H. Yu, F. Jahoor, P. J. Reeds, Substrate oxidation by the portal 
drained viscera of fed piglets, Am. J. Physiol. Metab. 277, E168–E175 (1999). 
181. M. S. Ardawi, Glutamine and ketone-body metabolism in the gut of streptozotocin-diabetic 
rats., Biochem. J. 249, 565–72 (1988). 
182. H. G. Windmueller, A. E. Spaeth, Identification of ketone bodies and glutamine as the major 
respiratory fuels in vivo for postabsorptive rat small intestine., J. Biol. Chem. 253, 69–76 (1978). 
192 
 
183. H. G. Windmueller, A. E. Spaeth, Respiratory Fuels and Nitrogen Metabolism in Vivo in Small 
Intestine of Fed Rats QUANTITATIVE IMPORTANCE OF GLUTAMINE, GLUTAMATE, AND ASPARTATE* 
(1980; http://www.jbc.org/). 
184. C. Rich-Denson, R. E. Kimura, Evidence in vivo that most of the intraluminally absorbed glucose 
is absorbed intact into the portal vein and not metabolized to lactate., Biochem. J. 254, 931–4 
(1988). 
185. L. M. Srivastava, G. Hübscher, Glucose metabolism in the mucosa of the small intestine. 
Glycolysis in subcellular preparations from the cat and rat., Biochem. J. 100, 458–66 (1966). 
186. C. Jang, S. Hui, X. Zeng, A. J. Cowan, L. Wang, L. Chen, R. J. Morscher, J. Reyes, C. Frezza, H. Y. 
Hwang, A. Imai, Y. Saito, K. Okamoto, C. Vaspoli, L. Kasprenski, G. A. Zsido, J. H. Gorman, R. C. 
Gorman, J. D. Rabinowitz, Metabolite Exchange between Mammalian Organs Quantified in Pigs, Cell 
Metab. (2019), doi:10.1016/j.cmet.2019.06.002. 
187. J. C. Schell, D. R. Wisidagama, C. Bensard, H. Zhao, P. Wei, J. Tanner, A. Flores, J. Mohlman, L. K. 
Sorensen, C. S. Earl, K. A. Olson, R. Miao, T. C. Waller, D. Delker, P. Kanth, L. Jiang, R. J. DeBerardinis, 
M. P. Bronner, D. Y. Li, J. E. Cox, H. R. Christofk, W. E. Lowry, C. S. Thummel, J. Rutter, Control of 
intestinal stem cell function and proliferation by mitochondrial pyruvate metabolism, Nat. Cell Biol. 
(2017), doi:10.1038/ncb3593. 
188. M. M. Mihaylova, C. W. Cheng, A. Q. Cao, S. Tripathi, M. D. Mana, K. E. Bauer-Rowe, M. Abu-
Remaileh, L. Clavain, A. Erdemir, C. A. Lewis, E. Freinkman, A. S. Dickey, A. R. La Spada, Y. Huang, G. 
W. Bell, V. Deshpande, P. Carmeliet, P. Katajisto, D. M. Sabatini, Ö. H. Yilmaz, Fasting Activates Fatty 
Acid Oxidation to Enhance Intestinal Stem Cell Function during Homeostasis and Aging, Cell Stem Cell 
(2018), doi:10.1016/j.stem.2018.04.001. 
189. C. Stringari, R. A. Edwards, K. T. Pate, M. L. Waterman, P. J. Donovan, E. Gratton, Metabolic 
trajectory of cellular differentiation in small intestine by Phasor Fluorescence Lifetime Microscopy of 
NADH, Sci. Rep. 2, 568 (2012). 
190. F. M. Gribble, F. Reimann, Function and mechanisms of enteroendocrine cells and gut 
hormones in metabolismNat. Rev. Endocrinol. (2019), doi:10.1038/s41574-019-0168-8. 
191. J. R. Spence, C. N. Mayhew, S. A. Rankin, M. F. Kuhar, J. E. Vallance, K. Tolle, E. E. Hoskins, V. V. 
Kalinichenko, S. I. Wells, A. M. Zorn, N. F. Shroyer, J. M. Wells, Directed differentiation of human 
pluripotent stem cells into intestinal tissue in vitro, Nature 470, 105–109 (2010). 
192. B.-K. Koo, D. E. Stange, T. Sato, W. Karthaus, H. F. Farin, M. Huch, J. H. van Es, H. Clevers, 
193 
 
Controlled gene expression in primary Lgr5 organoid cultures, Nat. Methods 9, 81–83 (2011). 
193. G. Schwank, A. Andersson-Rolf, B.-K. Koo, N. Sasaki, H. Clevers, D. Unutmaz, Ed. Generation of 
BAC Transgenic Epithelial Organoids, PLoS One 8, e76871 (2013). 
194. G. Schwank, B.-K. Koo, V. Sasselli, J. F. Dekkers, I. Heo, T. Demircan, N. Sasaki, S. Boymans, E. 
Cuppen, C. K. van der Ent, E. E. S. Nieuwenhuis, J. M. Beekman, H. Clevers, Functional Repair of CFTR 
by CRISPR/Cas9 in Intestinal Stem Cell Organoids of Cystic Fibrosis Patients, Cell Stem Cell 13, 653–
658 (2013). 
195. N. Petersen, F. Reimann, S. Bartfeld, H. F. Farin, F. C. Ringnalda, R. G. J. Vries, S. van den Brink, 
H. Clevers, F. M. Gribble, E. J. P. de Koning, Generation of L cells in mouse and human small intestine 
organoids., Diabetes 63, 410–20 (2014). 
196. J. F. Dekkers, G. Berkers, E. Kruisselbrink, A. Vonk, H. R. De Jonge, H. M. Janssens, I. Bronsveld, 
E. A. Van De Graaf, E. E. S. Nieuwenhuis, R. H. J. Houwen, F. P. Vleggaar, J. C. Escher, Y. B. De Rijke, C. 
J. Majoor, H. G. M. Heijerman, K. M. De Winter-De Groot, H. Clevers, C. K. Van Der Ent, J. M. 
Beekman, Characterizing responses to CFTR-modulating drugs using rectal organoids derived from 
subjects with cystic fibrosis, Sci. Transl. Med. (2016), doi:10.1126/scitranslmed.aad8278. 
197. M. Van De Wetering, H. E. Francies, J. M. Francis, G. Bounova, F. Iorio, A. Pronk, W. Van Houdt, 
J. Van Gorp, A. Taylor-Weiner, L. Kester, A. McLaren-Douglas, J. Blokker, S. Jaksani, S. Bartfeld, R. 
Volckman, P. Van Sluis, V. S. W. Li, S. Seepo, C. Sekhar Pedamallu, K. Cibulskis, S. L. Carter, A. 
McKenna, M. S. Lawrence, L. Lichtenstein, C. Stewart, J. Koster, R. Versteeg, A. Van Oudenaarden, J. 
Saez-Rodriguez, R. G. J. Vries, G. Getz, L. Wessels, M. R. Stratton, U. McDermott, M. Meyerson, M. J. 
Garnett, H. Clevers, Prospective derivation of a living organoid biobank of colorectal cancer patients, 
Cell (2015), doi:10.1016/j.cell.2015.03.053. 
198. P. H. Dedhia, N. Bertaux-Skeirik, Y. Zavros, J. R. Spence, Organoid Models of Human 
Gastrointestinal Development and DiseaseGastroenterology (2016), 
doi:10.1053/j.gastro.2015.12.042. 
199. P. Schlaermann, B. Toelle, H. Berger, S. C. Schmidt, M. Glanemann, J. Ordemann, S. Bartfeld, H. 
J. Mollenkopf, T. F. Meyer, A novel human gastric primary cell culture system for modelling 
Helicobacter pylori infection in vitro., Gut 65, 202–13 (2016). 
200. J. G. In, J. Foulke-Abel, M. K. Estes, N. C. Zachos, O. Kovbasnjuk, M. Donowitz, Human mini-guts: 
New insights into intestinal physiology and host-pathogen interactionsNat. Rev. Gastroenterol. 
Hepatol. (2016), doi:10.1038/nrgastro.2016.142. 
194 
 
201. H. R. Bridges, A. J. Y. Jones, M. N. Pollak, J. Hirst, Effects of metformin and other biguanides on 
oxidative phosphorylation in mitochondria., Biochem. J. 462, 475–87 (2014). 
202. M. R. OWEN, E. DORAN, A. P. HALESTRAP, Evidence that metformin exerts its anti-diabetic 
effects through inhibition of complex 1 of the mitochondrial respiratory chain, Biochem. J. 348, 607 
(2000). 
203. W. W. Wheaton, S. E. Weinberg, R. B. Hamanaka, S. Soberanes, L. B. Sullivan, E. Anso, A. 
Glasauer, E. Dufour, G. M. Mutlu, G. S. Budigner, N. S. Chandel, Metformin inhibits mitochondrial 
complex I of cancer cells to reduce tumorigenesis., Elife 3, e02242 (2014). 
204. M. R. Owen, E. Doran, A. P. Halestrap, Evidence that metformin exerts its anti-diabetic effects 
through inhibition of complex 1 of the mitochondrial respiratory chain., Biochem. J. 348 Pt 3, 607–14 
(2000). 
205. S. Andrzejewski, S.-P. Gravel, M. Pollak, J. St-Pierre, Metformin directly acts on mitochondria to 
alter cellular bioenergetics., Cancer Metab. 2, 12 (2014). 
206. T. Griss, E. E. Vincent, R. Egnatchik, J. Chen, E. H. Ma, B. Faubert, B. Viollet, R. J. DeBerardinis, R. 
G. Jones, D. R. Green, Ed. Metformin Antagonizes Cancer Cell Proliferation by Suppressing 
Mitochondrial-Dependent Biosynthesis, PLOS Biol. 13, e1002309 (2015). 
207. P. Schommers, A. Thurau, I. Bultmann-Mellin, M. Guschlbauer, A. R. Klatt, J. Rozman, M. 
Klingenspor, M. H. de Angelis, J. Alber, D. Gründemann, A. Sterner-Kock, R. J. Wiesner, Metformin 
causes a futile intestinal-hepatic cycle which increases energy expenditure and slows down 
development of a type 2 diabetes-like state., Mol. Metab. 6, 737–747 (2017). 
208. E.-M. Blumrich, R. Dringen, Metformin Accelerates Glycolytic Lactate Production in Cultured 
Primary Cerebellar Granule Neurons, Neurochem. Res. 44, 188–199 (2019). 
209. S. A. Hawley, F. A. Ross, C. Chevtzoff, K. A. Green, A. M. Evans, S. Fogarty, M. C. Towler, L. J. 
Brown, O. A. Ogunbayo, A. M. Evans, D. G. Hardie, Use of Cells Expressing γ Subunit Variants to 
Identify Diverse Mechanisms of AMPK Activation, Cell Metab. 11, 554–565 (2010). 
210. G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. 
Fujii, N. Musi, M. F. Hirshman, L. J. Goodyear, D. E. Moller, Role of AMP-activated protein kinase in 
mechanism of metformin action., J. Clin. Invest. 108, 1167–74 (2001). 
211. M. Zang, A. Zuccollo, X. Hou, D. Nagata, K. Walsh, H. Herscovitz, P. Brecher, N. B. Ruderman, R. 
A. Cohen, AMP-activated Protein Kinase Is Required for the Lipid-lowering Effect of Metformin in 
Insulin-resistant Human HepG2 Cells, J. Biol. Chem. 279, 47898–47905 (2004). 
195 
 
212. F. A. Duca, C. D. Côté, B. A. Rasmussen, M. Zadeh-Tahmasebi, G. A. Rutter, B. M. Filippi, T. K. T. 
Lam, Metformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose 
production in rats, Nat. Med. 21, 506–511 (2015). 
213. G. Rena, E. R. Pearson, K. Sakamoto, Molecular mechanism of action of metformin: old or new 
insights?, Diabetologia 56, 1898–1906 (2013). 
214. M. Foretz, B. Guigas, L. Bertrand, M. Pollak, B. Viollet, Metformin: From Mechanisms of Action 
to Therapies, Cell Metab. 20, 953–966 (2014). 
215. Y. D. Kim, K.-G. Park, Y.-S. Lee, Y.-Y. Park, D.-K. Kim, B. Nedumaran, W. G. Jang, W.-J. Cho, J. Ha, 
I.-K. Lee, C.-H. Lee, H.-S. Choi, Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated 
Protein Kinase–Dependent Regulation of the Orphan Nuclear Receptor SHP, Diabetes 57, 306–314 
(2008). 
216. L. He, A. Sabet, S. Djedjos, R. Miller, X. Sun, M. A. Hussain, S. Radovick, F. E. Wondisford, 
Metformin and Insulin Suppress Hepatic Gluconeogenesis through Phosphorylation of CREB Binding 
Protein, Cell 137, 635–646 (2009). 
217. J.-M. Lee, W.-Y. Seo, K.-H. Song, D. Chanda, Y. D. Kim, D.-K. Kim, M.-W. Lee, D. Ryu, Y.-H. Kim, J.-
R. Noh, C.-H. Lee, J. Y. L. Chiang, S.-H. Koo, H.-S. Choi, AMPK-dependent repression of hepatic 
gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small 
heterodimer partner., J. Biol. Chem. 285, 32182–91 (2010). 
218. R. J. Shaw, K. A. Lamia, D. Vasquez, S.-H. Koo, N. Bardeesy, R. A. Depinho, M. Montminy, L. C. 
Cantley, The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of 
Metformin, Science (80-. ). 310, 1642–1646 (2005). 
219. I. Pernicova, M. Korbonits, Metformin—mode of action and clinical implications for diabetes 
and cancer, Nat. Rev. Endocrinol. 10, 143–156 (2014). 
220. M. Foretz, S. Hébrard, J. Leclerc, E. Zarrinpashneh, M. Soty, G. Mithieux, K. Sakamoto, F. 
Andreelli, B. Viollet, Metformin inhibits hepatic gluconeogenesis in mice independently of the 
LKB1/AMPK pathway via a decrease in hepatic energy state, J. Clin. Invest. 120, 2355–2369 (2010). 
221. A. Kalender, A. Selvaraj, S. Y. Kim, P. Gulati, S. Brûlé, B. Viollet, B. E. Kemp, N. Bardeesy, P. 
Dennis, J. J. Schlager, A. Marette, S. C. Kozma, G. Thomas, Metformin, Independent of AMPK, Inhibits 
mTORC1 in a Rag GTPase-Dependent Manner, Cell Metab. 11, 390–401 (2010). 
222. J. J. Howell, K. Hellberg, M. Turner, A. Saghatelian, R. J. Shaw, B. D. Manning, Metformin Inhibits 
Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex In 
196 
 
Brief, Cell Metab. 25, 463–471 (2017). 
223. A. Maida, B. J. Lamont, X. Cao, D. J. Drucker, Metformin regulates the incretin receptor axis via a 
pathway dependent on peroxisome proliferator-activated receptor-α in mice, Diabetologia 54, 339–
349 (2011). 
224. R. A. Miller, Q. Chu, J. Xie, M. Foretz, B. Viollet, M. J. Birnbaum, Biguanides suppress hepatic 
glucagon signalling by decreasing production of cyclic AMP, Nature 494, 256–260 (2013). 
225. A. K. Madiraju, Y. Qiu, R. J. Perry, Y. Rahimi, X.-M. Zhang, D. Zhang, J.-P. G. Camporez, G. W. 
Cline, G. M. Butrico, B. E. Kemp, G. Casals, G. R. Steinberg, D. F. Vatner, K. F. Petersen, G. I. Shulman, 
Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo, Nat. Med. 24, 1384–
1394 (2018). 
226. A. K. Madiraju, D. M. Erion, Y. Rahimi, X.-M. Zhang, D. T. Braddock, R. A. Albright, B. J. Prigaro, J. 
L. Wood, S. Bhanot, M. J. MacDonald, M. J. Jurczak, J.-P. Camporez, H.-Y. Lee, G. W. Cline, V. T. 
Samuel, R. G. Kibbey, G. I. Shulman, Metformin suppresses gluconeogenesis by inhibiting 
mitochondrial glycerophosphate dehydrogenase., Nature 510, 542–6 (2014). 
227. R. S. Hundal, M. Krssak, S. Dufour, D. Laurent, V. Lebon, V. Chandramouli, S. E. Inzucchi, W. C. 
Schumann, K. F. Petersen, B. R. Landau, G. I. Shulman, Mechanism by which metformin reduces 
glucose production in type 2 diabetes., Diabetes 49, 2063–9 (2000). 
228. L. C. Gormsen, E. Søndergaard, N. L. Christensen, K. Brøsen, N. Jessen, S. Nielsen, Metformin 
increases endogenous glucose production in non-diabetic individuals and individuals with recent-
onset type 2 diabetes., Diabetologia 62, 1251–1256 (2019). 
229. B. Cool, B. Zinker, W. Chiou, L. Kifle, N. Cao, M. Perham, R. Dickinson, A. Adler, G. Gagne, R. 
Iyengar, G. Zhao, K. Marsh, P. Kym, P. Jung, H. S. Camp, E. Frevert, Identification and characterization 
of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic 
syndrome, Cell Metab. 3, 403–416 (2006). 
230. A. Herms, M. Bosch, B. J. N. Reddy, N. L. Schieber, A. Fajardo, C. Rupérez, A. Fernández-Vidal, C. 
Ferguson, C. Rentero, F. Tebar, C. Enrich, R. G. Parton, S. P. Gross, A. Pol, AMPK activation promotes 
lipid droplet dispersion on detyrosinated microtubules to increase mitochondrial fatty acid 
oxidation, Nat. Commun. 6, 7176 (2015). 
231. N. Boudaba, A. Marion, C. Huet, R. Pierre, B. Viollet, M. Foretz, AMPK Re-Activation Suppresses 
Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development, EBioMedicine 
28, 194–209 (2018). 
197 
 
232. D. Garcia, K. Hellberg, A. Chaix, M. Wallace, S. Herzig, M. G. Badur, T. Lin, M. N. Shokhirev, A. F. 
M. Pinto, D. S. Ross, A. Saghatelian, S. Panda, L. E. Dow, C. M. Metallo, R. J. Shaw, Genetic Liver-
Specific AMPK Activation Protects against Diet-Induced Obesity and NAFLD, Cell Rep. 26, 192-208.e6 
(2019). 
233. M. D. Fullerton, S. Galic, K. Marcinko, S. Sikkema, T. Pulinilkunnil, Z.-P. Chen, H. M. O’Neill, R. J. 
Ford, R. Palanivel, M. O’Brien, D. G. Hardie, S. L. Macaulay, J. D. Schertzer, J. R. B. Dyck, B. J. van 
Denderen, B. E. Kemp, G. R. Steinberg, Single phosphorylation sites in Acc1 and Acc2 regulate lipid 
homeostasis and the insulin-sensitizing effects of metformin, Nat. Med. 19, 1649–1654 (2013). 
234. W. F. Caspary, W. Creutzfeldt, Analysis of the inhibitory effect of biguanides on glucose 
absorption: Inhibition of active sugar transport, Diabetologia 7, 379–385 (1971). 
235. E. Lorch, Inhibition of Intestinal Absorption and Improvement of 0ral Glucose Tolerance by 
Biguanldes in the Normal and in the Streptozotocin-Diabetic Rat (Springer-Verlag, 1971; 
https://link.springer.com/content/pdf/10.1007/BF01212553.pdf). 
236. O. Horakova, P. Kroupova, K. Bardova, J. Buresova, P. Janovska, J. Kopecky, M. Rossmeisl, 
Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport, Sci. Rep. 
9, 6156 (2019). 
237. J. P. Koffert, K. Mikkola, K. A. Virtanen, A.-M. D. Andersson, L. Faxius, K. Hällsten, M. Heglind, L. 
Guiducci, T. Pham, J. M. U. Silvola, J. Virta, O. Eriksson, S. P. Kauhanen, A. Saraste, S. Enerbäck, P. 
Iozzo, R. Parkkola, M. F. Gomez, P. Nuutila, Metformin treatment significantly enhances intestinal 
glucose uptake in patients with type 2 diabetes: Results from a randomized clinical trial, Diabetes 
Res. Clin. Pract. 131, 208–216 (2017). 
238. J.-R. Oh, H.-C. Song, A. Chong, J.-M. Ha, S.-Y. Jeong, J.-J. Min, H.-S. Bom, Impact of Medication 
Discontinuation on Increased Intestinal FDG Accumulation in Diabetic Patients Treated With 
Metformin, Am. J. Roentgenol. 195, 1404–1410 (2010). 
239. C. J. Bailey, K. J. Mynett, T. Page, Importance of the intestine as a site of metformin-stimulated 
glucose utilization., Br. J. Pharmacol. 112, 671–5 (1994). 
240. C. J. Bailey, C. Wilcock, J. H. B. Scarpello, Metformin and the intestine, Diabetologia 51, 1552–
1553 (2008). 
241. J. D. Lalau, C. Lacroix, P. Compagnon, B. de Cagny, J. P. Rigaud, G. Bleichner, P. Chauveau, P. 
Dulbecco, C. Guérin, J. M. Haegy, Role of metformin accumulation in metformin-associated lactic 
acidosis., Diabetes Care 18, 779–84 (1995). 
198 
 
242. T. M. Davis, D. Jackson, W. A. Davis, D. G. Bruce, P. Chubb, The relationship between metformin 
therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study., Br. J. Clin. 
Pharmacol. 52, 137–44 (2001). 
243. Y. Li, Z. Cai, S. S. Li, J. Zhu, F. Zhang, S. Liang, W. Zhang, Y. Guan, D. Shen, Y. Peng, D. Zhang, Z. 
Jie, W. Wu, Y. Qin, W. Xue, J. Li, L. Han, D. Lu, P. Wu, Y. Dai, X. Sun, Z. Li, A. Tang, S. Zhong, X. Li, W. 
Chen, R. Xu, M. Wang, Q. Feng, M. Gong, J. Yu, Y. Zhang, M. Zhang, T. Hansen, G. Sanchez, J. Raes, G. 
Falony, S. Okuda, M. Almeida, E. LeChatelier, P. Renault, N. Pons, J.-M. Batto, Z. Zhang, H. Chen, R. 
Yang, W. Zheng, S. S. Li, H. Yang, J. J. Wang, S. D. Ehrlich, R. Nielsen, O. Pedersen, K. Kristiansen, J. J. 
Wang, J. Qin, Y. Li, Z. Cai, S. S. Li, J. Zhu, F. Zhang, S. Liang, W. Zhang, Y. Guan, D. Shen, Y. Peng, D. 
Zhang, Z. Jie, W. Wu, Y. Qin, W. Xue, J. Li, L. Han, D. Lu, P. Wu, Y. Dai, X. Sun, Z. Li, A. Tang, S. Zhong, 
X. Li, W. Chen, R. Xu, M. Wang, Q. Feng, M. Gong, J. Yu, Y. Zhang, M. Zhang, T. Hansen, G. Sanchez, J. 
Raes, G. Falony, S. Okuda, M. Almeida, E. LeChatelier, P. Renault, N. Pons, J.-M. Batto, Z. Zhang, H. 
Chen, R. Yang, W. Zheng, S. S. Li, H. Yang, J. J. Wang, S. D. Ehrlich, R. Nielsen, O. Pedersen, K. 
Kristiansen, J. J. Wang, A metagenome-wide association study of gut microbiota in type 2 diabetes, 
Nature (2012), doi:http://dx.doi.org/10.1038/nature11450. 
244. P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, J. I. Gordon, An obesity-
associated gut microbiome with increased capacity for energy harvest, Nature (2006), 
doi:10.1038/nature05414. 
245. F. H. Karlsson, V. Tremaroli, I. Nookaew, G. Bergström, C. J. Behre, B. Fagerberg, J. Nielsen, F. 
Bäckhed, Gut metagenome in European women with normal, impaired and diabetic glucose control, 
Nature (2013), doi:10.1038/nature12198. 
246. H. Wu, E. Esteve, V. Tremaroli, M. T. Khan, R. Caesar, L. Mannerås-Holm, M. Ståhlman, L. M. 
Olsson, M. Serino, M. Planas-Fèlix, G. Xifra, J. M. Mercader, D. Torrents, R. Burcelin, W. Ricart, R. 
Perkins, J. M. Fernàndez-Real, F. Bäckhed, Metformin alters the gut microbiome of individuals with 
treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug, Nat. Med. 
(2017), doi:10.1038/nm.4345. 
247. K. Forslund, F. Hildebrand, T. Nielsen, G. Falony, E. Le Chatelier, S. Sunagawa, E. Prifti, S. Vieira-
Silva, V. Gudmundsdottir, H. Krogh Pedersen, M. Arumugam, K. Kristiansen, A. Yvonne Voigt, H. 
Vestergaard, R. Hercog, P. Igor Costea, J. Roat Kultima, J. Li, T. Jørgensen, F. Levenez, J. Dore, H. 
Bjørn Nielsen, S. Brunak, J. Raes, T. Hansen, J. Wang, S. Dusko Ehrlich, P. Bork, O. Pedersen, O. 
Pedersen, Disentangling type 2 diabetes and metformin treatment signatures in the human gut 
microbiota, Nature 528, 262–266 (2015). 
199 
 
248. E. P. Velásquez-Mejía, J. M. Abad, V. Corrales-Agudelo, N. T. Mueller, J. S. Escobar, J. de la 
Cuesta-Zuluaga, J. A. Carmona,  Metformin Is Associated With Higher Relative Abundance of Mucin-
Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid–Producing Microbiota in the 
Gut , Diabetes Care (2016), doi:10.2337/dc16-1324. 
249. A. Everard, C. Belzer, L. Geurts, J. P. Ouwerkerk, C. Druart, L. B. Bindels, Y. Guiot, M. Derrien, G. 
G. Muccioli, N. M. Delzenne, W. M. de Vos, P. D. Cani, Cross-talk between Akkermansia muciniphila 
and intestinal epithelium controls diet-induced obesity, Proc. Natl. Acad. Sci. (2013), 
doi:10.1073/pnas.1219451110. 
250. C. Depommier, A. Everard, C. Druart, H. Plovier, M. Van Hul, S. Vieira-Silva, G. Falony, J. Raes, D. 
Maiter, N. M. Delzenne, M. de Barsy, A. Loumaye, M. P. Hermans, J.-P. Thissen, W. M. de Vos, P. D. 
Cani, Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a 
proof-of-concept exploratory study, Nat. Med. (2019), doi:10.1038/s41591-019-0495-2. 
251. P. V. Bauer, F. A. Duca, T. M. Z. Waise, B. A. Rasmussen, M. A. Abraham, H. J. Dranse, A. Puri, C. 
A. O’Brien, T. K. T. Lam, Metformin Alters Upper Small Intestinal Microbiota that Impact a Glucose-
SGLT1-Sensing Glucoregulatory Pathway, Cell Metab. (2018), doi:10.1016/j.cmet.2017.09.019. 
252. F. G. Schaap, M. Trauner, P. L. M. Jansen, Bile acid receptors as targets for drug 
developmentNat. Rev. Gastroenterol. Hepatol. (2014), doi:10.1038/nrgastro.2013.151. 
253. D. Carter, H. C. S. Howlett, N. F. Wiernsperger, C. Bailey, Effects of metformin on bile salt 
transport by monolayers of human intestinal Caco-2 cells, Diabetes, Obes. Metab. 4, 424–427 (2002). 
254. D. Carter, H. C. S. Howlett, N. F. Wiernsperger, C. J. Bailey, Differential effects of metformin on 
bile salt absorption from the jejunum and ileum., Diabetes. Obes. Metab. 5, 120–5 (2003). 
255. W. F. Caspary, I. Zavada, W. Reimold, U. Deuticke, D. Emrich, B. Willms, Alteration of bile acid 
metabolism and vitamin-B12-absorption in diabetics on biguanides., Diabetologia 13, 187–93 (1977). 
256. J. H. B. Scarpello, E. Hodgson, H. C. S. Howlett, Effect of metformin on bile salt circulation and 
intestinal motility in Type 2 diabetes mellitus, Diabet. Med. 15, 651–656 (1998). 
257. F. Lien, A. Berthier, E. Bouchaert, C. Gheeraert, J. Alexandre, G. Porez, J. Prawitt, H. Dehondt, M. 
Ploton, S. Colin, A. Lucas, A. Patrice, F. Pattou, H. Diemer, A. Van Dorsselaer, C. Rachez, J. Kamilic, A. 
K. Groen, B. Staels, P. Lefebvre, Metformin interferes with bile acid homeostasis through AMPK-FXR 
crosstalk, J. Clin. Invest. 124, 1037–1051 (2014). 
258. T. Inagaki, M. Choi, A. Moschetta, L. Peng, C. L. Cummins, J. G. McDonald, G. Luo, S. A. Jones, B. 
Goodwin, J. A. Richardson, R. D. Gerard, J. J. Repa, D. J. Mangelsdorf, S. A. Kliewer, Fibroblast growth 
200 
 
factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis, Cell Metab. 2, 217–
225 (2005). 
259. M. Choi, A. Moschetta, A. L. Bookout, L. Peng, M. Umetani, S. R. Holmstrom, K. Suino-Powell, H. 
E. Xu, J. A. Richardson, R. D. Gerard, D. J. Mangelsdorf, S. A. Kliewer, Identification of a hormonal 
basis for gallbladder filling, Nat. Med. 12, 1253–1255 (2006). 
260. L. Sun, C. Xie, G. Wang, Y. Wu, Q. Wu, X. Wang, J. Liu, Y. Deng, J. Xia, B. Chen, S. Zhang, C. Yun, 
G. Lian, X. Zhang, H. Zhang, W. H. Bisson, J. Shi, X. Gao, P. Ge, C. Liu, K. W. Krausz, R. G. Nichols, J. Cai, 
B. Rimal, A. D. Patterson, X. Wang, F. J. Gonzalez, C. Jiang, Gut microbiota and intestinal FXR mediate 
the clinical benefits of metformin, Nat. Med. 24, 1919–1929 (2018). 
261. L. L. Baggio, D. J. Drucker, Biology of incretins: GLP-1 and GIP., Gastroenterology 132, 2131–57 
(2007). 
262. E. Mannucci, A. Ognibene, F. Cremasco, G. Bardini, A. Mencucci, E. Pierazzuoli, S. Ciani, G. 
Messeri, C. M. Rotella, Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in 
obese nondiabetic subjects., Diabetes Care 24, 489–94 (2001). 
263. E. Bahne, E. W. L. Sun, R. L. Young, M. Hansen, D. P. Sonne, J. S. Hansen, U. Rohde, A. P. Liou, M. 
L. Jackson, D. de Fontgalland, P. Rabbitt, P. Hollington, L. Sposato, S. Due, D. A. Wattchow, J. F. 
Rehfeld, J. J. Holst, D. J. Keating, T. Vilsbøll, F. K. Knop, D. de Fontgalland, P. Rabbitt, P. Hollington, L. 
Sposato, S. Due, D. A. Wattchow, J. F. Rehfeld, J. J. Holst, D. J. Keating, T. Vilsbøll, F. K. Knop, 
Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in 
type 2 diabetes, JCI Insight 3 (2018) (available at https://insight.jci.org/articles/view/93936). 
264. A. Napolitano, S. Miller, A. W. Nicholls, D. Baker, S. Van Horn, E. Thomas, D. Rajpal, A. Spivak, J. 
R. Brown, D. J. Nunez, Novel gut-based pharmacology of metformin in patients with type 2 diabetes 
mellitus., PLoS One 9, e100778 (2014). 
265. T. Wu, S. S. Thazhath, M. J. Bound, K. L. Jones, M. Horowitz, C. K. Rayner, Mechanism of 
increase in plasma intact GLP-1 by metformin in type 2 diabetes: Stimulation of GLP-1 secretion or 
reduction in plasma DPP-4 activity?, Diabetes Res. Clin. Pract. 106, e3–e6 (2014). 
266. J. R. Lindsay, N. A. Duffy, A. M. McKillop, J. Ardill, F. P. M. O’Harte, P. R. Flatt, P. M. Bell, 
Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes, Diabet. Med. 22, 
654–657 (2005). 
267. A. Brønden, A. Albér, U. Rohde, J. F. Rehfeld, J. J. Holst, T. Vilsbøll, F. K. Knop, Single-Dose 
Metformin Enhances Bile Acid–Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 
201 
 
Diabetes, J. Clin. Endocrinol. Metab. 102, 4153–4162 (2017). 
268. S. A. Hinke, K. Kühn-Wache, T. Hoffmann, R. A. Pederson, C. H. S. McIntosh, H.-U. Demuth, 
Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1, Biochem. 
Biophys. Res. Commun. 291, 1302–1308 (2002). 
269. B. D. Green, N. Irwin, N. A. Duffy, V. A. Gault, F. P. M. O’Harte, P. R. Flatt, Inhibition of dipeptidyl 
peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1, Eur. 
J. Pharmacol. 547, 192–199 (2006). 
270. J. Cuthbertson, S. Patterson, F. P. M. O’Harte, P. M. Bell, Investigation of the effect of oral 
metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes, Diabet. Med. 26, 649–654 
(2009). 
271. S. K. Thondam, A. Cross, D. J. Cuthbertson, J. P. Wilding, C. Daousi, Effects of chronic treatment 
with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese 
patients with Type 2 diabetes mellitus, Diabet. Med. 29, e205–e210 (2012). 
272. E. M. Migoya, R. Bergeron, J. L. Miller, R. N. K. Snyder, M. Tanen, D. Hilliard, B. Weiss, P. Larson, 
M. Gutierrez, G. Jiang, F. Liu, K. A. Pryor, J. Yao, L. Zhu, J. J. Holst, C. Deacon, G. Herman, N. 
Thornberry, J. Amatruda, D. Williams-Herman, J. A. Wagner, R. SinhaRoy, Dipeptidyl Peptidase-4 
Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma 
Concentration of Active GLP-1, Clin. Pharmacol. Ther. 88, 801–808 (2010). 
273. M.-H. Kim, J.-H. Jee, S. Park, M.-S. Lee, K.-W. Kim, M.-K. Lee, Metformin enhances glucagon-like 
peptide 1 via cooperation between insulin and Wnt signaling, J. Endocrinol. 220, 117–128 (2014). 
274. A. J. Mulherin, A. H. Oh, H. Kim, A. Grieco, L. M. Lauffer, P. L. Brubaker, Mechanisms Underlying 
Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell, Endocrinology 
152, 4610–4619 (2011). 
275. C. Thomas, A. Gioiello, L. Noriega, A. Strehle, J. Oury, G. Rizzo, A. Macchiarulo, H. Yamamoto, C. 
Mataki, M. Pruzanski, R. Pellicciari, J. Auwerx, K. Schoonjans, TGR5-mediated bile acid sensing 
controls glucose homeostasis., Cell Metab. 10, 167–77 (2009). 
276. H. C. Gerstein, G. Pare, S. Hess, R. J. Ford, J. Sjaarda, K. Raman, M. McQueen, S. Lee, H. Haenel, 
G. R. Steinberg, ORIGIN Investigators, Growth Differentiation Factor 15 as a Novel Biomarker for 
Metformin., Diabetes Care 40, 280–283 (2017). 
277. A. Natali, L. Nesti, E. Venturi, A. C. Shore, F. Khan, K. Gooding, P. E. Gates, H. C. Looker, F. Dove, 
I. Goncalves, M. Persson, J. Nilsson, Metformin is the key factor in elevated plasma growth 
202 
 
differentiation factor-15 levels in type 2 diabetes: A nested, case-control study, Diabetes, Obes. 
Metab. 21, 412–416 (2019). 
278. M. R. Bootcov, A. R. Bauskin, S. M. Valenzuela, A. G. Moore, M. Bansal, X. Y. He, H. P. Zhang, M. 
Donnellan, S. Mahler, K. Pryor, B. J. Walsh, R. C. Nicholson, W. D. Fairlie, S. B. Por, J. M. Robbins, S. N. 
Breit, MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the 
TGF-  superfamily, Proc. Natl. Acad. Sci. 94, 11514–11519 (1997). 
279. Q. Ding, T. Mracek, P. Gonzalez-Muniesa, K. Kos, J. Wilding, P. Trayhurn, C. Bing, Identification 
of Macrophage Inhibitory Cytokine-1 in Adipose Tissue and Its Secretion as an Adipokine by Human 
Adipocytes, Endocrinology 150, 1688–1696 (2009). 
280. W. D. Fairlie, A. G. Moore, A. R. Bauskin, P. K. Russell, H.-P. Zhang, S. N. Breit, MIC-1 is a novel 
TGF-β superfamily cytokine associated with macrophage activation, J. Leukoc. Biol. 65, 2–5 (1999). 
281. M. Böttner, C. Suter-Crazzolara, A. Schober, K. Unsicker, Expression of a novel member of the 
TGF-beta superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1 (GDF-
15/MIC-1) in adult rat tissues., Cell Tissue Res. 297, 103–10 (1999). 
282. M. Yokoyama-Kobayashi, M. Saeki, S. Sekine, S. Kato, Human cDNA encoding a novel TGF-beta 
superfamily protein highly expressed in placenta., J. Biochem. 122, 622–6 (1997). 
283. L. N. Lawton, M. F. Bonaldo, P. C. Jelenc, L. Qiu, S. A. Baumes, R. A. Marcelino, G. M. de Jesus, S. 
Wellington, J. A. Knowles, D. Warburton, S. Brown, M. B. Soares, Identification of a novel member of 
the TGF-beta superfamily highly expressed in human placenta., Gene 203, 17–26 (1997). 
284. T. A. Zimmers, X. Jin, E. C. Hsiao, S. A. McGrath, A. F. Esquela, L. G. Koniaris, Growth 
differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury., 
Shock 23, 543–8 (2005). 
285. E. C. Hsiao, L. G. Koniaris, T. Zimmers-Koniaris, S. M. Sebald, T. V Huynh, S. J. Lee, 
Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily 
member induced following liver injury., Mol. Cell. Biol. 20, 3742–51 (2000). 
286. H. K. Chung, D. Ryu, K. S. Kim, J. Y. Chang, Y. K. Kim, H.-S. Yi, S. G. Kang, M. J. Choi, S. E. Lee, S.-B. 
Jung, M. J. Ryu, S. J. Kim, G. R. Kweon, H. Kim, J. H. Hwang, C.-H. Lee, S.-J. Lee, C. E. Wall, M. Downes, 
R. M. Evans, J. Auwerx, M. Shong, Growth differentiation factor 15 is a myomitokine governing 
systemic energy homeostasis., J. Cell Biol. 216, 149–165 (2017). 
287. S. Patel, A. Alvarez-Guaita, A. Melvin, D. Rimmington, A. Dattilo, E. L. Miedzybrodzka, I. Cimino, 
A.-C. Maurin, G. P. Roberts, C. L. Meek, S. Virtue, L. M. Sparks, S. A. Parsons, L. M. Redman, G. A. 
203 
 
Bray, A. P. Liou, R. M. Woods, S. A. Parry, P. B. Jeppesen, A. J. Kolnes, H. P. Harding, D. Ron, A. Vidal-
Puig, F. Reimann, F. M. Gribble, C. J. Hulston, I. S. Farooqi, P. Fafournoux, S. R. Smith, J. Jensen, D. 
Breen, Z. Wu, B. B. Zhang, A. P. Coll, D. B. Savage, S. O’Rahilly, GDF15 Provides an Endocrine Signal of 
Nutritional Stress in Mice and Humans, Cell Metab. 29, 707-718.e8 (2019). 
288. D. A. Brown, A. R. Bauskin, W. D. Fairlie, M. D. Smith, T. Liu, N. Xu, S. N. Breit, Antibody-based 
approach to high-volume genotyping for MIC-1 polymorphism., Biotechniques 33, 118–20, 122, 124 
passim (2002). 
289. V. W. W. Tsai, Y. Husaini, A. Sainsbury, D. A. Brown, S. N. Breit, Cell Metabolism The MIC-
1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other 
Associated Diseases, (2018), doi:10.1016/j.cmet.2018.07.018. 
290. S. E. Mullican, S. M. Rangwala, Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity 
and Beyond., Trends Endocrinol. Metab. 29, 560–570 (2018). 
291. H. Johnen, S. Lin, T. Kuffner, D. A. Brown, V. W.-W. Tsai, A. R. Bauskin, L. Wu, G. Pankhurst, L. 
Jiang, S. Junankar, M. Hunter, W. D. Fairlie, N. J. Lee, R. F. Enriquez, P. A. Baldock, E. Corey, F. S. 
Apple, M. M. Murakami, E.-J. Lin, C. Wang, M. J. During, A. Sainsbury, H. Herzog, S. N. Breit, Tumor-
induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1, Nat. Med. 
13, 1333–1340 (2007). 
292. V. W.-W. Tsai, L. Macia, H. Johnen, T. Kuffner, R. Manadhar, S. B. Jørgensen, K. K. M. Lee-Ng, H. 
P. Zhang, L. Wu, C. P. Marquis, L. Jiang, Y. Husaini, S. Lin, H. Herzog, D. A. Brown, A. Sainsbury, S. N. 
Breit, C. Morrison, Ed. TGF-b Superfamily Cytokine MIC-1/GDF15 Is a Physiological Appetite and 
Body Weight Regulator, PLoS One 8, e55174 (2013). 
293. V. W.-W. Tsai, R. Manandhar, S. B. Jørgensen, K. K. M. Lee-Ng, H. P. Zhang, C. P. Marquis, L. 
Jiang, Y. Husaini, S. Lin, A. Sainsbury, P. E. Sawchenko, D. A. Brown, S. N. Breit, M. Covasa, Ed. The 
Anorectic Actions of the TGFβ Cytokine MIC-1/GDF15 Require an Intact Brainstem Area Postrema 
and Nucleus of the Solitary Tract, PLoS One 9, e100370 (2014). 
294. T. Tran, J. Yang, J. Gardner, Y. Xiong, J. M. Peterson, Ed. GDF15 deficiency promotes high fat 
diet-induced obesity in mice, PLoS One 13, e0201584 (2018). 
295. L. Yang, C.-C. Chang, Z. Sun, D. Madsen, H. Zhu, S. B. Padkjær, X. Wu, T. Huang, K. Hultman, S. J. 
Paulsen, J. Wang, A. Bugge, J. B. Frantzen, P. Nørgaard, J. F. Jeppesen, Z. Yang, A. Secher, H. Chen, X. 
Li, L. M. John, B. Shan, Z. He, X. Gao, J. Su, K. T. Hansen, W. Yang, S. B. Jørgensen, GFRAL is the 




296. J.-Y. Hsu, S. Crawley, M. Chen, D. A. Ayupova, D. A. Lindhout, J. Higbee, A. Kutach, W. Joo, Z. 
Gao, D. Fu, C. To, K. Mondal, B. Li, A. Kekatpure, M. Wang, T. Laird, G. Horner, J. Chan, M. McEntee, 
M. Lopez, D. Lakshminarasimhan, A. White, S.-P. Wang, J. Yao, J. Yie, H. Matern, M. Solloway, R. 
Haldankar, T. Parsons, J. Tang, W. D. Shen, Y. Alice Chen, H. Tian, B. B. Allan, Non-homeostatic body 
weight regulation through a brainstem-restricted receptor for GDF15, Nature 550, 255–259 (2017). 
297. K. H. Kim, Y. T. Jeong, S. H. Kim, H. S. Jung, K. S. Park, H.-Y. Lee, M.-S. Lee, Metformin-induced 
inhibition of the mitochondrial respiratory chain increases FGF21 expression via ATF4 activation, 
Biochem. Biophys. Res. Commun. 440, 76–81 (2013). 
298. Y. Wang, N. Dang, P. Sun, J. Xia, C. Zhang, S. Pang, The effects of metformin on fibroblast 
growth factor 19, 21 and fibroblast growth factor receptor 1 in high-fat diet and streptozotocin 
induced diabetic rats, Endocr. J. 64, 543–552 (2017). 
299. S. M. Solon-Biet, V. C. Cogger, T. Pulpitel, M. Heblinski, D. Wahl, A. C. McMahon, A. Warren, J. 
Durrant-Whyte, K. A. Walters, J. R. Krycer, F. Ponton, R. Gokarn, J. A. Wali, K. Ruohonen, A. D. 
Conigrave, D. E. James, D. Raubenheimer, C. D. Morrison, D. G. Le Couteur, S. J. Simpson, Defining 
the Nutritional and Metabolic Context of FGF21 Using the Geometric Framework, Cell Metab. (2016), 
doi:10.1016/j.cmet.2016.09.001. 
300. T. Laeger, T. M. Henagan, D. C. Albarado, L. M. Redman, G. A. Bray, R. C. Noland, H. Münzberg, 
S. M. Hutson, T. W. Gettys, M. W. Schwartz, C. D. Morrison, FGF21 is an endocrine signal of protein 
restriction, J. Clin. Invest. (2014), doi:10.1172/JCI74915. 
301. S. Talukdar, B. M. Owen, P. Song, G. Hernandez, Y. Zhang, Y. Zhou, W. T. Scott, B. Paratala, T. 
Turner, A. Smith, B. Bernardo, C. P. Müller, H. Tang, D. J. Mangelsdorf, B. Goodwin, S. A. Kliewer, 
FGF21 regulates sweet and alcohol preference, Cell Metab. (2016), doi:10.1016/j.cmet.2015.12.008. 
302. L. D. BonDurant, M. Ameka, M. C. Naber, K. R. Markan, S. O. Idiga, M. R. Acevedo, S. A. Walsh, 
D. M. Ornitz, M. J. Potthoff, FGF21 Regulates Metabolism Through Adipose-Dependent and -
Independent Mechanisms, Cell Metab. (2017), doi:10.1016/j.cmet.2017.03.005. 
303. A. Kharitonenkov, T. L. Shiyanova, A. Koester, A. M. Ford, R. Micanovic, E. J. Galbreath, G. E. 
Sandusky, L. J. Hammond, J. S. Moyers, R. A. Owens, J. Gromada, J. T. Brozinick, E. D. Hawkins, V. J. 
Wroblewski, D. S. Li, F. Mehrbod, S. R. Jaskunas, A. B. Shanafelt, FGF-21 as a novel metabolic 
regulator, J. Clin. Invest. (2005), doi:10.1172/JCI23606. 
304. S. von Holstein-Rathlou, L. D. BonDurant, L. Peltekian, M. C. Naber, T. C. Yin, K. E. Claflin, A. I. 
205 
 
Urizar, A. N. Madsen, C. Ratner, B. Holst, K. Karstoft, A. Vandenbeuch, C. B. Anderson, M. D. Cassell, 
A. P. Thompson, T. P. Solomon, K. Rahmouni, S. C. Kinnamon, A. A. Pieper, M. P. Gillum, M. J. 
Potthoff, FGF21 Mediates Endocrine Control of Simple Sugar Intake and Sweet Taste Preference by 
the Liver, Cell Metab. 23, 335–343 (2016). 
305. S. Søberg, C. H. Sandholt, N. Z. Jespersen, U. Toft, A. L. Madsen, S. von Holstein-Rathlou, T. J. 
Grevengoed, K. B. Christensen, W. L. P. Bredie, M. J. Potthoff, T. P. J. Solomon, C. Scheele, A. 
Linneberg, T. Jørgensen, O. Pedersen, T. Hansen, M. P. Gillum, N. Grarup, FGF21 Is a Sugar-Induced 
Hormone Associated with Sweet Intake and Preference in Humans, Cell Metab. (2017), 
doi:10.1016/j.cmet.2017.04.009. 
306. B. M. Owen, X. Ding, D. A. Morgan, K. C. Coate, A. L. Bookout, K. Rahmouni, S. A. Kliewer, D. J. 
Mangelsdorf, FGF21 Acts Centrally to Induce Sympathetic Nerve Activity, Energy Expenditure, and 
Weight Loss, Cell Metab. 20, 670–677 (2014). 
307. K. R. Markan, M. C. Naber, M. K. Ameka, M. D. Anderegg, D. J. Mangelsdorf, S. A. Kliewer, M. 
Mohammadi, M. J. Potthoff, Circulating FGF21 is liver derived and enhances glucose uptake during 
refeeding and overfeeding., Diabetes 63, 4057–63 (2014). 
308. B. Emanuelli, S. G. Vienberg, G. Smyth, C. Cheng, K. I. Stanford, M. Arumugam, M. D. Michael, A. 
C. Adams, A. Kharitonenkov, C. R. Kahn, Interplay between FGF21 and insulin action in the liver 
regulates metabolism, J. Clin. Invest. 124, 515–527 (2014). 
309. L. X. Cubeddu, H. Bönisch, M. Göthert, G. Molderings, K. Racké, G. Ramadori, K. J. Miller, H. 
Schwörer, Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 
receptors., Naunyn. Schmiedebergs. Arch. Pharmacol. 361, 85–91 (2000). 
310. G. M. Mawe, J. M. Hoffman, Serotonin signalling in the gut-functions, dysfunctions and 
therapeutic targetsNat. Rev. Gastroenterol. Hepatol. (2013), doi:10.1038/nrgastro.2013.105. 
311. G. G. Graham, J. Punt, M. Arora, R. O. Day, M. P. Doogue, J. K. Duong, T. J. Furlong, J. R. 
Greenfield, L. C. Greenup, C. M. Kirkpatrick, J. E. Ray, P. Timmins, K. M. Williams, Clinical 
Pharmacokinetics of Metformin, Clin. Pharmacokinet. 50, 81–98 (2011). 
312. C. Wilcock, C. J. Bailey, Accumulation of metformin by tissues of the normal and diabetic 
mouse, Xenobiotica 24, 49–57 (1994). 
313. L. C. Gormsen, E. I. Sundelin, J. B. Jensen, M. H. Vendelbo, S. Jakobsen, O. L. Munk, M. M. 
Hougaard Christensen, K. Brøsen, J. Frøkiær, N. Jessen, In Vivo Imaging of Human 11C-Metformin in 




314. T. Han, W. R. Proctor, C. L. Costales, H. Cai, R. S. Everett, D. R. Thakker, Four Cation-Selective 
Transporters Contribute to Apical Uptake and Accumulation of Metformin in Caco-2 Cell 
Monolayers, J. Pharmacol. Exp. Ther. (2015), doi:10.1124/jpet.114.220350. 
315. W. R. Proctor, D. L. Bourdet, D. R. Thakker, Mechanisms Underlying Saturable Intestinal 
Absorption of Metformin, Drug Metab. Dispos. 36, 1650–1658 (2008). 
316. D. Stepensky, M. Friedman, I. Raz, A. Hoffman, Pharmacokinetic-pharmacodynamic analysis of 
the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect., 
Drug Metab. Dispos. 30, 861–8 (2002). 
317. E. Bonora, M. Cigolini, O. Bosello, C. Zancanaro, L. Capretti, I. Zavaroni, C. Coscelli, U. Butturini, 
Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, 
glucagon and growth hormone in non-diabetic subjects, Curr. Med. Res. Opin. 9, 47–51 (1984). 
318. C.-F. Sum, J. M. Webster, A. B. Johnson, C. Catalano, B. G. Cooper, R. Taylor, The Effect of 
Intravenous Metformin on Glucose Metabolism During Hyperglycaemia in Type 2 Diabetes, Diabet. 
Med. 9, 61–65 (1992). 
319. J. B. Buse, R. A. DeFronzo, J. Rosenstock, T. Kim, C. Burns, S. Skare, A. Baron, M. Fineman, The 
Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation. Results From 
Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies, Diabetes Care 39, dc150488 
(2015). 
320. R. R. Henry, J. P. Frias, B. Walsh, S. Skare, J. Hemming, C. Burns, T. A. Bicsak, A. Baron, M. 
Fineman, D. Samocha-Bonet, Ed. Improved glycemic control with minimal systemic metformin 
exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 
weeks in a randomized trial in subjects with type 2 diabetes, PLoS One 13, e0203946 (2018). 
321. A. P. Coll, M. Chen, P. Taskar, D. Rimmington, S. Patel, J. Tadross, I. Cimino, M. Yang, P. Welsh, 
S. Virtue, D. A. Goldspink, E. Miedzybrodzka, Y. C. L. Tung, S. Rodriguez-Cuenca, R. A. Tomaz, H. P. 
Harding, A. Melvin, G. S. H. Yeo, D. Preiss, A. Vidal-Puig, L. Vallier, D. Ron, F. M. Gribble, F. Reimann, 
N. Sattar, D. B. Savage, B. B. Allan, S. O’Rahilly, GDF15 and the beneficial actions of metformin in pre-
diabetes, bioRxiv , 677831 (2019). 
322. B. Svendsen, R. Pais, M. S. Engelstoft, N. B. Milev, P. Richards, C. B. Christiansen, A. Habib, K. L. 
Egerod, S. M. Jensen, F. Gribble, T. W. Schwartz, F. Reimann, J. J. Holst, GLP1 and GIP cells rarely 




323. A. Adriaenssens, B. Y. H. Lam, L. Billing, K. Skeffington, S. Sewing, F. Reimann, F. Gribble, A 
Transcriptome-Led Exploration of Molecular Mechanisms Regulating Somatostatin-Producing D-Cells 
in the Gastric Epithelium., Endocrinology 156, 3924–36 (2015). 
324. D. A. Goldspink, V. B. Lu, L. J. Billing, P. Larraufie, G. Tolhurst, F. M. Gribble, F. Reimann, 
Mechanistic insights into the detection of free fatty and bile acids by ileal glucagon-like peptide-1 
secreting cells, Mol. Metab. 7, 90–101 (2018). 
325. M. Tantama, J. R. Martínez-François, R. Mongeon, G. Yellen, Imaging energy status in live cells 
with a fluorescent biosensor of the intracellular ATP-to-ADP ratio., Nat. Commun. 4, 2550 (2013). 
326. Y. P. Hung, J. G. Albeck, M. Tantama, G. Yellen, Imaging Cytosolic NADH-NAD+ Redox State with 
a Genetically Encoded Fluorescent Biosensor, Cell Metab. 14, 545–554 (2011). 
327. F. Bartolomé, A. Y. Abramov, in Methods in molecular biology (Clifton, N.J.), (2015), vol. 1264, 
pp. 263–270. 
328. H. Takanaga, B. Chaudhuri, W. B. Frommer, GLUT1 and GLUT9 as major contributors to glucose 
influx in HepG2 cells identified by a high sensitivity intramolecular FRET glucose sensor, Biochim. 
Biophys. Acta - Biomembr. 1778, 1091–1099 (2008). 
329. K. Gruenwald, J. T. Holland, V. Stromberg, A. Ahmad, D. Watcharakichkorn, S. Okumoto, S. 
Strack, Ed. Visualization of Glutamine Transporter Activities in Living Cells Using Genetically Encoded 
Glutamine Sensors, PLoS One 7, e38591 (2012). 
330. A. San Martín, S. Ceballo, F. Baeza-Lehnert, R. Lerchundi, R. Valdebenito, Y. Contreras-Baeza, K. 
Alegría, L. F. Barros, K.-W. Koch, Ed. Imaging Mitochondrial Flux in Single Cells with a FRET Sensor for 
Pyruvate, PLoS One 9, e85780 (2014). 
331. A. S. Divakaruni, A. Paradyse, D. A. Ferrick, A. N. Murphy, M. Jastroch, in Methods in 
enzymology, (2014), vol. 547, pp. 309–354. 
332. G. Schumann, R. Bonora, F. Ceriotti, G. Férard, C. A. Ferrero, P. F. H. Franck, F.-J. Gella, W. 
Hoelzel, P. J. Jørgensen, T. Kanno, A. Kessner, R. Klauke, N. Kristiansen, J.-M. Lessinger, T. P. J. 
Linsinger, H. Misaki, M. Panteghini, J. Pauwels, F. Schiele, H. G. Schimmel, IFCC Primary Reference 
Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37°C. Part 4. 
Reference Procedure for the Measurement of Catalytic Concentration of Alanine Aminotransferase, 
Clin. Chem. Lab. Med. 40 (2002), doi:10.1515/CCLM.2002.124. 
208 
 
333. G. Schumann, R. Aoki, C. a Ferrero, G. Ehlers, G. Férard, F.-J. Gella, P. J. Jørgensen, T. Kanno, A. 
Kessner, R. Klauke, H.-J. Kytzia, J.-M. Lessinger, W. G. Miller, R. Nagel, J. Pauwels, H. Schimmel, L. 
Siekmann, G. Weidemann, K. Yoshida, F. Ceriotti, IFCC primary reference procedures for the 
measurement of catalytic activity concentrations of enzymes at 37 degrees C., Clin. Chem. Lab. Med. 
(2006), doi:10.1515/CCLM.2006.212. 
334. L. Siekmann, R. Bonora, C. A. Burtis, F. Ceriotti, P. Clerc-Renaud, G. Férard, C. A. Ferrero, J.-C. 
Forest, P. F. H. Franck, F.-J. Gella, W. Hoelzel, P. J. Jørgensen, T. Kanno, A. Kessner, R. Klauke, N. 
Kristiansen, J.-M. Lessinger, T. P. J. Linsinger, H. Misaki, M. M. Mueller, M. Panteghini, J. Pauwels, F. 
Schiele, H. G. Schimmel, A. Vialle, G. Weidemann, G. Schumann, IFCC primary reference procedures 
for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International 
Federation of Clinical Chemistry and Laboratory Medicine. Part 7. Certification of four reference 
materials for the determination of enzymatic activity of gamma-glutamyltransferase, lactate 
dehydrogenase, alanine aminotransferase and creatine kinase accord., Clin. Chem. Lab. Med. (2002), 
doi:10.1515/CCLM.2002.127. 
335. G. Schumann, R. Bonora, F. Ceriotti, G. Férard, C. A. Ferrero, P. F. H. Franck, F.-J. Gella, W. 
Hoelzel, P. J. Jørgensen, T. Kanno, A. Kessner, R. Klauke, N. Kristiansen, J.-M. Lessinger, T. P. J. 
Linsinger, H. Misaki, M. Panteghini, J. Pauwels, F. Schiele, H. G. Schimmel, G. Weidemann, L. 
Siekmann, International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Primary 
Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37°C. 
Part 5. Reference Procedure for the Measurement of Catalytic Concentration of Aspartate 
Aminotransferase, Clin. Chem. Lab. Med. (2002), doi:10.1515/CCLM.2002.125. 
336. G. F. Merrill, E. J. Kurth, D. G. Hardie, W. W. Winder, AICA riboside increases AMP-activated 
protein kinase, fatty acid oxidation, and glucose uptake in rat muscle, Am. J. Physiol. Metab. 273, 
E1107–E1112 (1997). 
337. S. C. Chen, R. Brooks, J. Houskeeper, S. K. Bremner, J. Dunlop, B. Viollet, P. J. Logan, I. P. Salt, S. 
F. Ahmed, S. J. Yarwood, Metformin suppresses adipogenesis through both AMP-activated protein 
kinase (AMPK)-dependent and AMPK-independent mechanisms., Mol. Cell. Endocrinol. 440, 57–68 
(2017). 
338. N. Musi, M. F. Hirshman, J. Nygren, M. Svanfeldt, P. Bavenholm, O. Rooyackers, G. Zhou, J. M. 
Williamson, O. Ljunqvist, S. Efendic, D. E. Moller, A. Thorell, L. J. Goodyear, Metformin Increases 
AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes, Diabetes 
51, 2074–2081 (2002). 
209 
 
339. E. C. Cokorinos, J. Delmore, A. R. Reyes, B. Albuquerque, R. Kjøbsted, N. O. Jørgensen, J.-L. Tran, 
A. Jatkar, K. Cialdea, R. M. Esquejo, J. Meissen, M. F. Calabrese, J. Cordes, R. Moccia, D. Tess, C. T. 
Salatto, T. M. Coskran, A. C. Opsahl, D. Flynn, M. Blatnik, W. Li, E. Kindt, M. Foretz, B. Viollet, J. Ward, 
R. G. Kurumbail, A. S. Kalgutkar, J. F. P. Wojtaszewski, K. O. Cameron, R. A. Miller, Activation of 
Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human Primates 
and Mice, Cell Metab. 25, 1147-1159.e10 (2017). 
340. J. O. Lee, S. K. Lee, J. H. Jung, J. H. Kim, G. Y. You, S. J. Kim, S. H. Park, K.-O. Uhm, H. S. Kim, 
Metformin induces Rab4 through AMPK and modulates GLUT4 translocation in skeletal muscle cells, 
J. Cell. Physiol. 226, 974–981 (2011). 
341. H. C. Chen, G. Bandyopadhyay, M. P. Sajan, Y. Kanoh, M. Standaert, R. V Farese, R. V Farese, 
Activation of the ERK pathway and atypical protein kinase C isoforms in exercise- and 
aminoimidazole-4-carboxamide-1-beta-D-riboside (AICAR)-stimulated glucose transport., J. Biol. 
Chem. 277, 23554–62 (2002). 
342. P. A. Lochhead, I. P. Salt, K. S. Walker, D. G. Hardie, C. Sutherland, 5-aminoimidazole-4-
carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic 
genes PEPCK and glucose-6-phosphatase, Diabetes 49, 896–903 (2000). 
343. S. Meng, J. Cao, Q. He, L. Xiong, E. Chang, S. Radovick, F. E. Wondisford, L. He, Metformin 
activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complex., 
J. Biol. Chem. 290, 3793–802 (2015). 
344. I. Ben Sahra, C. Regazzetti, G. Robert, K. Laurent, Y. Le Marchand-Brustel, P. Auberger, J.-F. 
Tanti, S. Giorgetti-Peraldi, F. Bost, Metformin, Independent of AMPK, Induces mTOR Inhibition and 
Cell-Cycle Arrest through REDD1, Cancer Res. 71, 4366–4372 (2011). 
345. T. A. Guimarães, L. C. Farias, E. S. Santos, C. A. de C. Fraga, L. A. Orsini, L. de F. Teles, J. D. 
Feltenberger, S. F. de Jesus, M. G. de Souza, S. H. S. Santos, A. M. B. de Paula, R. S. Gomez, A. L. S. 
Guimarães, Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces 
cell death in oral squamous cell carcinoma, Oncotarget 7, 55057 (2016). 
346. X. Zhou, J. Chen, G. Yi, M. Deng, H. Liu, M. Liang, B. Shi, X. Fu, Y. Chen, L. Chen, Z. He, J. Wang, J. 
Liu, Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of 
oxygen metabolism in hepatocellular carcinoma., Oncotarget 7, 873–84 (2016). 
347. S. Narravula, S. P. Colgan, Hypoxia-Inducible Factor 1-Mediated Inhibition of Peroxisome 
Proliferator-Activated Receptor α Expression During Hypoxia, J. Immunol. 166, 7543–7548 (2001). 
210 
 
348. X. Cai, X. Hu, X. Tan, W. Cheng, Q. Wang, X. Chen, Y. Guan, C. Chen, X. Jing, Metformin Induced 
AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal 
Squamous Cell Carcinomas In Vitro and In Vivo., PLoS One 10, e0133349 (2015). 
349. Y. Zhuang, W. K. Miskimins, Cell cycle arrest in Metformin treated breast cancer cells involves 
activation of AMPK, downregulation of cyclin D1, and requires p27&lt;sup&gt;Kip1&lt;/sup&gt; or 
p21&lt;sup&gt;Cip1&lt;/sup&gt;, J. Mol. Signal. 3, 18 (2008). 
350. O. Moiseeva, X. Deschênes-Simard, E. St-Germain, S. Igelmann, G. Huot, A. E. Cadar, V. 
Bourdeau, M. N. Pollak, G. Ferbeyre, Metformin inhibits the senescence-associated secretory 
phenotype by interfering with IKK/NF-κB activation, Aging Cell 12, 489–498 (2013). 
351. D. Chen, D. Xia, Z. Pan, D. Xu, Y. Zhou, Y. Wu, N. Cai, Q. Tang, C. Wang, M. Yan, J. J. Zhang, K. 
Zhou, Q. Wang, Y. Feng, X. Wang, H. Xu, X. Zhang, N. Tian, Metformin protects against apoptosis and 
senescence in nucleus pulposus cells and ameliorates disc degeneration in vivo, Cell Death Dis. 7, 
e2441–e2441 (2016). 
352. T. Tomic, T. Botton, M. Cerezo, G. Robert, F. Luciano, A. Puissant, P. Gounon, M. Allegra, C. 
Bertolotto, J.-M. Bereder, S. Tartare-Deckert, P. Bahadoran, P. Auberger, R. Ballotti, S. Rocchi, 
Metformin inhibits melanoma development through autophagy and apoptosis mechanisms, Cell 
Death Dis. 2, e199–e199 (2011). 
353. W.-Y. Shi, D. Xiao, L. Wang, L.-H. Dong, Z.-X. Yan, Z.-X. Shen, S.-J. Chen, Y. Chen, W.-L. Zhao, 
Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR 
pathway and induction of autophagy, Cell Death Dis. 3, e275–e275 (2012). 
354. Z. Xie, K. Lau, B. Eby, P. Lozano, C. He, B. Pennington, H. Li, S. Rathi, Y. Dong, R. Tian, D. Kem, M.-
H. Zou, Improvement of cardiac functions by chronic metformin treatment is associated with 
enhanced cardiac autophagy in diabetic OVE26 mice., Diabetes 60, 1770–8 (2011). 
355. Y. M. Song, Y. Lee, J.-W. Kim, D.-S. Ham, E.-S. Kang, B. S. Cha, H. C. Lee, B.-W. Lee, Metformin 
alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated 
protein kinase-independent pathway, Autophagy 11, 46–59 (2015). 
356. K. Isoda, J. L. Young, A. Zirlik, L. A. MacFarlane, N. Tsuboi, N. Gerdes, U. Schönbeck, P. Libby, 
Metformin Inhibits Proinflammatory Responses and Nuclear Factor-κB in Human Vascular Wall Cells, 
Arterioscler. Thromb. Vasc. Biol. 26, 611–617 (2006). 
357. H.-M. Lee, J.-J. Kim, H. J. Kim, M. Shong, B. J. Ku, E.-K. Jo, Upregulated NLRP3 Inflammasome 
Activation in Patients With Type 2 Diabetes, Diabetes 62, 194–204 (2013). 
211 
 
358. T. Quentin, M. Steinmetz, A. Poppe, S. Thoms, Metformin differentially activates ER stress 
signaling pathways without inducing apoptosis, Dis. Model. Mech. 5, 259–269 (2012). 
359. Q. Chen, J. Thompson, Y. Hu, A. Das, E. J. Lesnefsky, Metformin attenuates ER stress–induced 
mitochondrial dysfunction, Transl. Res. 190, 40–50 (2017). 
360. Y. Xue, H. Zhang, X. Sun, M.-J. Zhu, X. Han, Ed. Metformin Improves Ileal Epithelial Barrier 
Function in Interleukin-10 Deficient Mice, PLoS One 11, e0168670 (2016). 
361. J. Deng, L. Zeng, X. Lai, J. Li, L. Liu, Q. Lin, Y. Chen, Metformin protects against intestinal barrier 
dysfunction via AMPKα1-dependent inhibition of JNK signalling activation., J. Cell. Mol. Med. 22, 
546–557 (2018). 
362. A. Spruss, G. Kanuri, C. Stahl, S. C. Bischoff, I. Bergheim, Metformin protects against the 
development of fructose-induced steatosis in mice: role of the intestinal barrier function, Lab. 
Investig. 92, 1020–1032 (2012). 
363. T. M. Z. Waise, M. Rasti, F. A. Duca, S.-Y. Zhang, P. V. Bauer, C. J. Rhodes, T. K. T. Lam, Inhibition 
of upper small intestinal mTOR lowers plasma glucose levels by inhibiting glucose production, Nat. 
Commun. 10, 714 (2019). 
364. M. Massollo, C. Marini, M. Brignone, L. Emionite, B. Salani, M. Riondato, S. Capitanio, F. Fiz, A. 
Democrito, A. Amaro, S. Morbelli, M. Piana, D. Maggi, M. Cilli, U. Pfeffer, G. Sambuceti, Metformin 
temporal and localized effects on gut glucose metabolism assessed using 18F-FDG PET in mice., J. 
Nucl. Med. 54, 259–66 (2013). 
365. M. R. Open Access Citation: Luizon, W. L. Eckalbar, Y. Wang, S. L. Jones, R. P. Smith, M. 
Laurance, Genomic Characterization of Metformin Hepatic Response, PLoS Genet 12, 1006449 
(2016). 
366. A. S. Kulkarni, E. F. Brutsaert, V. Anghel, K. Zhang, N. Bloomgarden, M. Pollak, J. C. Mar, M. 
Hawkins, J. P. Crandall, N. Barzilai, Metformin regulates metabolic and nonmetabolic pathways in 
skeletal muscle and subcutaneous adipose tissues of older adults, Aging Cell 17, e12723 (2018). 
367. W. Yue, T. Wang, E. Zachariah, Y. Lin, C. S. Yang, Q. Xu, R. S. DiPaola, X.-L. Tan, Transcriptomic 
analysis of pancreatic cancer cells in response to metformin and aspirin: an implication of synergy, 
Sci. Rep. 5, 13390 (2015). 
368. Z. E. Gillespie, C. Wang, F. Vadan, T. Y. Yu, J. Ausió, A. Kusalik, C. H. Eskiw, Metformin induces 
the AP-1 transcription factor network in normal dermal fibroblasts, Sci. Rep. 9, 5369 (2019). 
212 
 
369. D. Grün, A. Lyubimova, L. Kester, K. Wiebrands, O. Basak, N. Sasaki, H. Clevers, A. van 
Oudenaarden, Single-cell messenger RNA sequencing reveals rare intestinal cell types, Nature 525, 
251–255 (2015). 
370. K. Cusi, A. Consoli, R. A. DeFronzo, Metabolic effects of metformin on glucose and lactate 
metabolism in noninsulin-dependent diabetes mellitus., J. Clin. Endocrinol. Metab. 81, 4059–4067 
(1996). 
371. G. Wu, Intestinal Mucosal Amino Acid Catabolism, J. Nutr. 128, 1249–1252 (1998). 
372. Y. Pan, H. Chen, F. Siu, M. S. Kilberg, Amino acid deprivation and endoplasmic reticulum stress 
induce expression of multiple activating transcription factor-3 mRNA species that, when 
overexpressed in HepG2 cells, modulate transcription by the human asparagine synthetase 
promoter., J. Biol. Chem. 278, 38402–12 (2003). 
373. J. Nikkanen, S. Forsström, L. Euro, I. Paetau, R. A. Kohnz, L. Wang, D. Chilov, J. Viinamäki, A. 
Roivainen, P. Marjamäki, H. Liljenbäck, S. Ahola, J. Buzkova, M. Terzioglu, N. A. Khan, S. Pirnes-Karhu, 
A. Paetau, T. Lönnqvist, A. Sajantila, P. Isohanni, H. Tyynismaa, D. K. Nomura, B. J. Battersby, V. 
Velagapudi, C. J. Carroll, A. Suomalainen, Mitochondrial DNA Replication Defects Disturb Cellular 
dNTP Pools and Remodel One-Carbon Metabolism, Cell Metab. 23, 635–648 (2016). 
374. N. A. Khan, J. Nikkanen, S. Yatsuga, C. Jackson, L. Wang, S. Pradhan, R. Kivelä, A. Pessia, V. 
Velagapudi, A. Suomalainen, mTORC1 Regulates Mitochondrial Integrated Stress Response and 
Mitochondrial Myopathy Progression., Cell Metab. 26, 419-428.e5 (2017). 
375. Y. Benita, H. Kikuchi, A. D. Smith, M. Q. Zhang, D. C. Chung, R. J. Xavier, An integrative genomics 
approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to 
hypoxia, Nucleic Acids Res. 37, 4587–4602 (2009). 
376. L. B. Tanner, A. G. Goglia, M. H. Wei, T. Sehgal, L. R. Parsons, J. O. Park, E. White, J. E. Toettcher, 
J. D. Rabinowitz, Four Key Steps Control Glycolytic Flux in Mammalian Cells, Cell Syst. 7, 49-62.e8 
(2018). 
377. D. Da Silva, P. Ausina, E. M. Alencar, W. S. Coelho, P. Zancan, M. Sola-Penna, Metformin 
reverses hexokinase and phosphofructokinase downregulation and intracellular distribution in the 
heart of diabetic mice, IUBMB Life 64, 766–774 (2012). 
378. D. Di Fusco, V. Dinallo, I. Monteleone, F. Laudisi, I. Marafini, E. Franzè, A. Di Grazia, R. Dwairi, A. 
Colantoni, A. Ortenzi, C. Stolfi, G. Monteleone, Metformin inhibits inflammatory signals in the gut by 
controlling AMPK and p38 MAP kinase activation, Clin. Sci. 132, 1155–1168 (2018). 
213 
 
379. A. S. Marsin, L. Bertrand, M. H. Rider, J. Deprez, C. Beauloye, M. F. Vincent, G. Van den Berghe, 
D. Carling, L. Hue, Phosphorylation and activation of heart PFK-2 by AMPK has a role in the 
stimulation of glycolysis during ischaemia., Curr. Biol. 10, 1247–55 (2000). 
380. N. S. Chandel, E. Maltepe, E. Goldwasser, C. E. Mathieu, M. C. Simon, P. T. Schumacker, 
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription., Proc. Natl. Acad. Sci. 
U. S. A. 95, 11715–20 (1998). 
381. A. Mogavero, M. V. Maiorana, S. Zanutto, L. Varinelli, F. Bozzi, A. Belfiore, C. C. Volpi, A. 
Gloghini, M. A. Pierotti, M. Gariboldi, Metformin transiently inhibits colorectal cancer cell 
proliferation as a result of either AMPK activation or increased ROS production, Sci. Rep. 7, 15992 
(2017). 
382. Y. Pan, K. D. Mansfield, C. C. Bertozzi, V. Rudenko, D. A. Chan, A. J. Giaccia, M. C. Simon, 
Multiple Factors Affecting Cellular Redox Status and Energy Metabolism Modulate Hypoxia-Inducible 
Factor Prolyl Hydroxylase Activity In Vivo and In Vitro, Mol. Cell. Biol. 27, 912–925 (2007). 
383. H. Lu, R. A. Forbes, A. Verma, Hypoxia-inducible factor 1 activation by aerobic glycolysis 
implicates the Warburg effect in carcinogenesis, J. Biol. Chem. 277, 23111–23115 (2002). 
384. D. Zhang, Z. Tang, H. Huang, G. Zhou, C. Cui, Y. Weng, W. Liu, S. Kim, S. Lee, M. Perez-Neut, J. 
Ding, D. Czyz, R. Hu, Z. Ye, M. He, Y. G. Zheng, H. A. Shuman, L. Dai, B. Ren, R. G. Roeder, L. Becker, Y. 
Zhao, Metabolic regulation of gene expression by histone lactylation, Nature 574, 575–580 (2019). 
385. M. Heishi, J. Ichihara, R. Teramoto, Y. Itakura, K. Hayashi, H. Ishikawa, H. Gomi, J. Sakai, M. 
Kanaoka, M. Taiji, T. Kimura, Global gene expression analysis in liver of obese diabetic db/db mice 
treated with metformin, Diabetologia 49, 1647–1655 (2006). 
386. M. Croset, F. Rajas, C. Zitoun, J. M. Hurot, S. Montano, G. Mithieux, Rat small intestine is an 
insulin-sensitive gluconeogenic organ, Diabetes (2001), doi:10.2337/diabetes.50.4.740. 
387. K. C. Patra, N. Hay, The pentose phosphate pathway and cancer, Trends Biochem. Sci. 39, 347–
354 (2014). 
388. R. Hanczko, D. R. Fernandez, E. Doherty, Y. Qian, G. Vas, B. Niland, T. Telarico, A. Garba, S. 
Banerjee, F. A. Middleton, D. Barrett, M. Barcza, K. Banki, S. K. Landas, A. Perl, Prevention of 
hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in 
transaldolase-deficient mice by N-acetylcysteine., J. Clin. Invest. 119, 1546–57 (2009). 
389. G. Mithieux, L. Guignot, J.-C. Bordet, N. Wiernsperger, Intrahepatic mechanisms underlying the 




390. E. A. Horne, H. E. Magee, Glycogen synthesis in the small intestine., J. Physiol. 78, 288–94 
(1933). 
391. C. Jang, S. Hui, W. Lu, A. J. Cowan, R. J. Morscher, G. Lee, W. Liu, G. J. Tesz, M. J. Birnbaum, J. D. 
Rabinowitz, The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids., Cell 
Metab. 27, 351-361.e3 (2018). 
392. X. Zhang, A. Grosfeld, E. Williams, D. Vasiliauskas, S. Barretto, L. Smith, M. Mariadassou, C. 
Philippe, F. Devime, C. Melchior, G. Gourcerol, N. Dourmap, N. Lapaque, P. Larraufie, H. M. Blottière, 
C. Herberden, P. Gerard, J. F. Rehfeld, R. P. Ferraris, J. C. Fritton, S. Ellero-Simatos, V. Douard, 
Fructose malabsorption induces cholecystokinin expression in the ileum and cecum by changing 
microbiota composition and metabolism, FASEB J. 33, 7126–7142 (2019). 
393. J. B. Spinelli, M. C. Haigis, The multifaceted contributions of mitochondria to cellular 
metabolism, Nat. Cell Biol. 20, 745–754 (2018). 
394. X. Liu, I. L. Romero, L. M. Litchfield, E. Lengyel, J. W. Locasale, Metformin Targets Central 
Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers., Cell Metab. 24, 
728–739 (2016). 
395. S. Saladini, M. Aventaggiato, F. Barreca, E. Morgante, L. Sansone, M. A. Russo, M. Tafani, 
Metformin Impairs Glutamine Metabolism and Autophagy in Tumour Cells, Cells 8, 49 (2019). 
396. D. Y. Gui, L. B. Sullivan, A. Luengo, A. M. Hosios, L. N. Bush, N. Gitego, S. M. Davidson, E. 
Freinkman, C. J. Thomas, M. G. Vander Heiden, Environment Dictates Dependence on Mitochondrial 
Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin, 
Cell Metab. (2016), doi:10.1016/j.cmet.2016.09.006. 
397. K. K. Birsoy, T. Wang, W. W. W. Chen, E. Freinkman, M. Abu-Remaileh, D. M. M. Sabatini, An 
Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable 
Aspartate Synthesis, Cell 162, 540–551 (2015). 
398. M. C. G. Van De Poll, G. C. Ligthart-Melis, P. G. Boelens, N. E. P. Deutz, P. A. M. Van Leeuwen, C. 
H. C. Dejong, Intestinal and hepatic metabolism of glutamine and citrulline in humans, J. Physiol. 
581, 819–827 (2007). 
399. S. Osowska, C. Moinard, N. Neveux, C. Loï, L. Cynober, Citrulline increases arginine pools and 
restores nitrogen balance after massive intestinal resection., Gut 53, 1781–6 (2004). 
215 
 
400. D. G. Burrin, P. J. Reeds, Alternative fuels in the gastrointestinal tract, Curr. Opin. Gastroenterol. 
13, 165–170 (1997). 
401. P. Crenn, B. Messing, L. Cynober, Citrulline as a biomarker of intestinal failure due to enterocyte 
mass reduction, Clin. Nutr. 27, 328–339 (2008). 
402. L. Lutgens, P. Lambin, Biomarkers for radiation-induced small bowel epithelial damage: an 
emerging role for plasma Citrulline., World J. Gastroenterol. 13, 3033–42 (2007). 
403. G. S. Ducker, J. D. Rabinowitz, One-Carbon Metabolism in Health and Disease, Cell Metab. 25, 
27–42 (2017). 
404. C. F. Labuschagne, N. J. F. van den Broek, G. M. Mackay, K. H. Vousden, O. D. K. Maddocks, 
Serine, but Not Glycine, Supports One-Carbon Metabolism and Proliferation of Cancer Cells, Cell Rep. 
7, 1248–1258 (2014). 
405. S. J. Mentch, M. Mehrmohamadi, L. Huang, X. Liu, D. Gupta, D. Mattocks, P. Gómez Padilla, G. 
Ables, M. M. Bamman, A. E. Thalacker-Mercer, S. N. Nichenametla, J. W. Locasale, Histone 
Methylation Dynamics and Gene Regulation Occur through the Sensing of One-Carbon Metabolism, 
Cell Metab. 22, 861–873 (2015). 
406. G. Kikuchi, K. Hiraga, T. Yoshida, Role of the glycine-cleavage system in glycine and serine 
metabolism in various organs., Biochem. Soc. Trans. 8, 504–6 (1980). 
407. X. R. Bao, S.-E. Ong, O. Goldberger, J. Peng, R. Sharma, D. A. Thompson, S. B. Vafai, A. G. Cox, E. 
Marutani, F. Ichinose, W. Goessling, A. Regev, S. A. Carr, C. B. Clish, V. K. Mootha, Mitochondrial 
dysfunction remodels one-carbon metabolism in human cells, Elife 5 (2016), 
doi:10.7554/eLife.10575. 
408. L. L. Sampson, A. K. Davis, M. W. Grogg, Y. Zheng, mTOR disruption causes intestinal epithelial 
cell defects and intestinal atrophy postinjury in mice, FASEB J. 30, 1263–1275 (2016). 
409. J. J. Geerling, M. R. Boon, G. C. van der Zon, S. A. A. van den Berg, A. M. van den Hoek, M. 
Lombès, H. M. G. Princen, L. M. Havekes, P. C. N. Rensen, B. Guigas, Metformin lowers plasma 
triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice., Diabetes 63, 
880–91 (2014). 
410. M. Ahmadian, J. M. Suh, N. Hah, C. Liddle, A. R. Atkins, M. Downes, R. M. Evans, PPARγ signaling 
and metabolism: the good, the bad and the future, Nat. Med. 19, 557–566 (2013). 
411. D. F. Egan, D. B. Shackelford, M. M. Mihaylova, S. Gelino, R. A. Kohnz, W. Mair, D. S. Vasquez, A. 
216 
 
Joshi, D. M. Gwinn, R. Taylor, J. M. Asara, J. Fitzpatrick, A. Dillin, B. Viollet, M. Kundu, M. Hansen, R. J. 
Shaw, Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing 
to Mitophagy, Science (80-. ). 331, 456–461 (2011). 
412. D. Zhang, W. Wang, X. Sun, D. Xu, C. Wang, Q. Zhang, H. Wang, W. Luo, Y. Chen, H. Chen, Z. Liu, 
AMPK regulates autophagy by phosphorylating BECN1 at threonine 388, Autophagy 12, 1447–1459 
(2016). 
413. C. He, H. Zhu, H. Li, M.-H. Zou, Z. Xie, Dissociation of Bcl-2-Beclin1 Complex by Activated AMPK 
Enhances Cardiac Autophagy and Protects Against Cardiomyocyte Apoptosis in Diabetes, Diabetes 
62, 1270–1281 (2013). 
414. J. Kim, M. Kundu, B. Viollet, K.-L. Guan, AMPK and mTOR regulate autophagy through direct 
phosphorylation of Ulk1, Nat. Cell Biol. 13, 132–141 (2011). 
415. J. L. Benjamin, R. Sumpter, B. Levine, L. V. Hooper, Intestinal Epithelial Autophagy Is Essential 
for Host Defense against Invasive Bacteria, Cell Host Microbe 13, 723–734 (2013). 
416. L. A. Baxt, R. J. Xavier, Role of Autophagy in the Maintenance of Intestinal Homeostasis., 
Gastroenterology 149, 553–62 (2015). 
417. K. Cadwell, J. Y. Liu, S. L. Brown, H. Miyoshi, J. Loh, J. K. Lennerz, C. Kishi, W. Kc, J. A. Carrero, S. 
Hunt, C. D. Stone, E. M. Brunt, R. J. Xavier, B. P. Sleckman, E. Li, N. Mizushima, T. S. Stappenbeck, H. 
W. Virgin, IV, A key role for autophagy and the autophagy gene Atg16l1 in mouse and human 
intestinal Paneth cells., Nature 456, 259–63 (2008). 
418. K. G. Lassen, P. Kuballa, K. L. Conway, K. K. Patel, C. E. Becker, J. M. Peloquin, E. J. Villablanca, J. 
M. Norman, T.-C. Liu, R. J. Heath, M. L. Becker, L. Fagbami, H. Horn, J. Mercer, O. H. Yilmaz, J. D. 
Jaffe, A. F. Shamji, A. K. Bhan, S. A. Carr, M. J. Daly, H. W. Virgin, S. L. Schreiber, T. S. Stappenbeck, R. 
J. Xavier, Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling 
and decreased antibacterial defense, Proc. Natl. Acad. Sci. 111, 7741–7746 (2014). 
419. P. Brest, P. Lapaquette, M. Souidi, K. Lebrigand, A. Cesaro, V. Vouret-Craviari, B. Mari, P. Barbry, 
J.-F. Mosnier, X. Hébuterne, A. Harel-Bellan, B. Mograbi, A. Darfeuille-Michaud, P. Hofman, A 
synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-
dependent xenophagy in Crohn’s disease, Nat. Genet. 43, 242–245 (2011). 
420. K. L. Conway, P. Kuballa, J. Song, K. K. Patel, A. B. Castoreno, O. H. Yilmaz, H. B. Jijon, M. Zhang, 
L. N. Aldrich, E. J. Villablanca, J. M. Peloquin, G. Goel, I. Lee, E. Mizoguchi, H. N. Shi, A. K. Bhan, S. Y. 
Shaw, S. L. Schreiber, H. W. Virgin, A. F. Shamji, T. S. Stappenbeck, H. Reinecker, R. J. Xavier, Atg16l1 
217 
 
is Required for Autophagy in Intestinal Epithelial Cells and Protection of Mice From Salmonella 
Infection, Gastroenterology 145, 1347–1357 (2013). 
421. K. Y. Hur, M.-S. Lee, New mechanisms of metformin action: Focusing on mitochondria and the 
gut, J. Diabetes Investig. 6, 600–609 (2015). 
422. L. Azzolin, T. Panciera, S. Soligo, E. Enzo, S. Bicciato, S. Dupont, S. Bresolin, C. Frasson, G. Basso, 
V. Guzzardo, A. Fassina, M. Cordenonsi, S. Piccolo, YAP/TAZ Incorporation in the β-Catenin 
Destruction Complex Orchestrates the Wnt Response, Cell 158, 157–170 (2014). 
423. J. Cai, N. Zhang, Y. Zheng, R. F. de Wilde, A. Maitra, D. Pan, The Hippo signaling pathway 
restricts the oncogenic potential of an intestinal regeneration program, Genes Dev. 24, 2383–2388 
(2010). 
424. F. D. Camargo, S. Gokhale, J. B. Johnnidis, D. Fu, G. W. Bell, R. Jaenisch, T. R. Brummelkamp, 
YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells, Curr. Biol. 17, 2054–2060 
(2007). 
425. M. DeRan, J. Yang, C.-H. Shen, E. C. Peters, J. Fitamant, P. Chan, M. Hsieh, S. Zhu, J. M. Asara, B. 
Zheng, N. Bardeesy, J. Liu, X. Wu, Energy Stress Regulates Hippo-YAP Signaling Involving AMPK-
Mediated Regulation of Angiomotin-like 1 Protein, Cell Rep. 9, 495–503 (2014). 
426. J.-S. Mo, Z. Meng, Y. C. Kim, H. W. Park, C. G. Hansen, S. Kim, D.-S. Lim, K.-L. Guan, Cellular 
energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway, Nat. Cell Biol. 17, 
500–510 (2015). 
427. M. Mohseni, J. Sun, A. Lau, S. Curtis, J. Goldsmith, V. L. Fox, C. Wei, M. Frazier, O. Samson, K.-K. 
Wong, C. Kim, F. D. Camargo, A genetic screen identifies an LKB1–MARK signalling axis controlling 
the Hippo–YAP pathway, Nat. Cell Biol. 16, 108–117 (2014). 
428. W. Wang, Z.-D. Xiao, X. Li, K. E. Aziz, B. Gan, R. L. Johnson, J. Chen, AMPK modulates Hippo 
pathway activity to regulate energy homeostasis, Nat. Cell Biol. 17, 490–499 (2015). 
429. H. Jiang, M. O. Grenley, M.-J. Bravo, R. Z. Blumhagen, B. A. Edgar, EGFR/Ras/MAPK Signaling 
Mediates Adult Midgut Epithelial Homeostasis and Regeneration in Drosophila, Cell Stem Cell 8, 84–
95 (2011). 
430. V. W. Y. Wong, D. E. Stange, M. E. Page, S. Buczacki, A. Wabik, S. Itami, M. van de Wetering, R. 
Poulsom, N. A. Wright, M. W. B. Trotter, F. M. Watt, D. J. Winton, H. Clevers, K. B. Jensen, Lrig1 




431. J. Holmberg, M. Genander, M. M. Halford, C. Annerén, M. Sondell, M. J. Chumley, R. E. Silvany, 
M. Henkemeyer, J. Frisén, EphB Receptors Coordinate Migration and Proliferation in the Intestinal 
Stem Cell Niche, Cell 125, 1151–1163 (2006). 
432. I. N. Alimova, B. Liu, Z. Fan, S. M. Edgerton, T. Dillon, S. E. Lind, A. D. Thor, Metformin inhibits 
breast cancer cell growth, colony formation and induces cell cycle arrest in vitro, Cell Cycle 8, 909–
915 (2009). 
433. X. Sun, Q. Yang, C. J. Rogers, M. Du, M.-J. Zhu, AMPK improves gut epithelial differentiation and 
barrier function via regulating Cdx2 expression, Cell Death Differ. 24, 819–831 (2017). 
434. M. Lynch, G. K. Marinov, The bioenergetic costs of a gene., Proc. Natl. Acad. Sci. U. S. A. 112, 
15690–5 (2015). 
435. T. Kempf, A. Guba-Quint, J. Torgerson, M. C. Magnone, C. Haefliger, M. Bobadilla, K. C. Wollert, 
Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in 
obese nondiabetic individuals: results from the XENDOS trial, Eur. J. Endocrinol. 167, 671–678 (2012). 
436. G. Vila, M. Riedl, C. Anderwald, M. Resl, A. Handisurya, M. Clodi, G. Prager, B. Ludvik, M. Krebs, 
A. Luger, The Relationship between Insulin Resistance and the Cardiovascular Biomarker Growth 
Differentiation Factor-15 in Obese Patients, Clin. Chem. 57, 309–316 (2011). 
437. M. Karczewska-Kupczewska, I. Kowalska, A. Nikolajuk, A. Adamska, E. Otziomek, M. Gorska, M. 
Straczkowski, Hyperinsulinemia acutely increases serum macrophage inhibitory cytokine-1 
concentration in anorexia nervosa and obesity, Clin. Endocrinol. (Oxf). 76, 46–50 (2012). 
438. M. H. Schernthaner-Reiter, D. Kasses, C. Tugendsam, M. Riedl, S. Peric, G. Prager, M. Krebs, M. 
Promintzer-Schifferl, M. Clodi, A. Luger, G. Vila, Growth differentiation factor 15 increases following 
oral glucose ingestion: effect of meal composition and obesity, Eur. J. Endocrinol. 175, 623–631 
(2016). 
439. I. Dostálová, T. Roubíček, M. Bártlová, M. Mráz, Z. Lacinová, D. Haluzíková, P. Kaválková, M. 
Matoulek, M. Kasalický, M. Haluzík, Increased serum concentrations of macrophage inhibitory 
cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie 
diet, Eur. J. Endocrinol. 161, 397–404 (2009). 
440. N. Nair, E. Gongora, GDF-15 Correlates Positively with Matrix Metalloproteinases in Idiopathic 
Dilated Cardiomyopathy, J. Hear. Lung Transplant. 35, S274 (2016). 
441. T. Kempf, M. Eden, J. Strelau, M. Naguib, C. Willenbockel, J. Tongers, J. Heineke, D. Kotlarz, J. 
Xu, J. D. Molkentin, H. W. Niessen, H. Drexler, K. C. Wollert, The Transforming Growth Factor-β 
219 
 
Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From 
Ischemia/Reperfusion Injury, Circ. Res. 98, 351–360 (2006). 
442. D. A. Brown, J. Moore, H. Johnen, T. J. Smeets, A. R. Bauskin, T. Kuffner, H. Weedon, S. T. 
Milliken, P. P. Tak, M. D. Smith, S. N. Breit, Serum macrophage inhibitory cytokine 1 in rheumatoid 
arthritis: A potential marker of erosive joint destruction, Arthritis Rheum. 56, 753–764 (2007). 
443. K. H. Kim, S. H. Kim, D. H. Han, Y. S. Jo, Y. Lee, M.-S. Lee, Growth differentiation factor 15 
ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice, Sci. Rep. 8, 6789 
(2018). 
444. Y. Kim, N. Noren Hooten, M. K. Evans, CRP Stimulates GDF15 Expression in Endothelial Cells 
through p53, Mediators Inflamm. 2018, 1–9 (2018). 
445. M. Tan, Y. Wang, K. Guan, Y. Sun, PTGF-beta, a type beta transforming growth factor (TGF-beta) 
superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling 
pathway., Proc. Natl. Acad. Sci. U. S. A. 97, 109–14 (2000). 
446. N. M. Ratnam, J. M. Peterson, E. E. Talbert, K. J. Ladner, P. V. Rajasekera, C. R. Schmidt, M. E. 
Dillhoff, B. J. Swanson, E. Haverick, R. D. Kladney, T. M. Williams, G. W. Leone, D. J. Wang, D. C. 
Guttridge, NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor 
development, J. Clin. Invest. 127, 3796–3809 (2017). 
447. Y. Fujita, M. Ito, T. Kojima, S. Yatsuga, Y. Koga, M. Tanaka, GDF15 is a novel biomarker to 
evaluate efficacy of pyruvate therapy for mitochondrial diseases, Mitochondrion 20, 34–42 (2015). 
448. R. Montero, D. Yubero, J. Villarroya, D. Henares, C. Jou, M. A. Rodríguez, F. Ramos, A. 
Nascimento, C. I. Ortez, J. Campistol, B. Perez-Dueñas, M. O’Callaghan, M. Pineda, A. Garcia-Cazorla, 
J. C. Oferil, J. Montoya, E. Ruiz-Pesini, S. Emperador, M. Meznaric, L. Campderros, S. G. Kalko, F. 
Villarroya, R. Artuch, C. Jimenez-Mallebrera, G. Nogales-Gadea, Ed. GDF-15 Is Elevated in Children 
with Mitochondrial Diseases and Is Induced by Mitochondrial Dysfunction, PLoS One 11, e0148709 
(2016). 
449. S. Kalko, S. Paco, C. Jou, M. Rodríguez, M. Meznaric, M. Rogac, M. Jekovec-Vrhovsek, M. 
Sciacco, M. Moggio, G. Fagiolari, B. De Paepe, L. De Meirleir, I. Ferrer, M. Roig-Quilis, F. Munell, J. 
Montoya, E. López-Gallardo, E. Ruiz-Pesini, R. Artuch, R. Montero, F. Torner, A. Nascimento, C. Ortez, 
J. Colomer, C. Jimenez-Mallebrera, Transcriptomic profiling of TK2 deficient human skeletal muscle 
suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as 
a potential novel biomarker for mitochondrial myopathies, BMC Genomics 15, 91 (2014). 
220 
 
450. P. M. Quirós, M. A. Prado, N. Zamboni, D. D’Amico, R. W. Williams, D. Finley, S. P. Gygi, J. 
Auwerx, Multi-omics analysis identifies ATF4 as a key regulator of the mitochondrial stress response 
in mammals., J. Cell Biol. 216, 2027–2045 (2017). 
451. D. Li, H. Zhang, Y. Zhong, Hepatic GDF15 is regulated by CHOP of the unfolded protein response 
and alleviates NAFLD progression in obese mice, Biochem. Biophys. Res. Commun. 498, 388–394 
(2018). 
452. V. Vasiliou, D. Ross, D. W. Nebert, Update of the NAD(P)H:quinone oxidoreductase (NQO) gene 
family., Hum. Genomics 2, 329–35 (2006). 
453. M. A. Bianchet, M. Faig, L. M. Amzel, in Methods in enzymology, (2004), vol. 382, pp. 144–174. 
454. A. E. Dikalova, A. T. Bikineyeva, K. Budzyn, R. R. Nazarewicz, L. McCann, W. Lewis, D. G. 
Harrison, S. I. Dikalov, Therapeutic targeting of mitochondrial superoxide in hypertension., Circ. Res. 
107, 106–16 (2010). 
455. E. L. Robb, J. M. Gawel, D. Aksentijević, H. M. Cochemé, T. S. Stewart, M. M. Shchepinova, H. 
Qiang, T. A. Prime, T. P. Bright, A. M. James, M. J. Shattock, H. M. Senn, R. C. Hartley, M. P. Murphy, 
Selective superoxide generation within mitochondria by the targeted redox cycler MitoParaquat, 
Free Radic. Biol. Med. 89, 883–894 (2015). 
456. L. M. Booty, J. M. Gawel, F. Cvetko, S. T. Caldwell, A. R. Hall, J. F. Mulvey, A. M. James, E. C. 
Hinchy, T. A. Prime, S. Arndt, C. Beninca, T. P. Bright, M. R. Clatworthy, J. R. Ferdinand, H. A. Prag, A. 
Logan, J. Prudent, T. Krieg, R. C. Hartley, M. P. Murphy, Selective Disruption of Mitochondrial Thiol 
Redox State in Cells and In Vivo, Cell Chem. Biol. 26, 449-461.e8 (2019). 
457. N. Moullan, L. Mouchiroud, X. Wang, D. Ryu, E. G. Williams, A. Mottis, V. Jovaisaite, M. V 
Frochaux, P. M. Quiros, B. Deplancke, R. H. Houtkooper, J. Auwerx, Tetracyclines Disturb 
Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research., Cell 
Rep. 10, 1681–1691 (2015). 
458. U. Richter, T. Lahtinen, P. Marttinen, F. Suomi, B. J. Battersby, Quality control of mitochondrial 
protein synthesis is required for membrane integrity and cell fitness., J. Cell Biol. 211, 373–89 (2015). 
459. D. V Dabir, S. A. Hasson, K. Setoguchi, M. E. Johnson, P. Wongkongkathep, C. J. Douglas, J. 
Zimmerman, R. Damoiseaux, M. A. Teitell, C. M. Koehler, A small molecule inhibitor of redox-
regulated protein translocation into mitochondria., Dev. Cell 25, 81–92 (2013). 
460. S. E. Calvo, K. R. Clauser, V. K. Mootha, MitoCarta2.0: an updated inventory of mammalian 
mitochondrial proteins, Nucleic Acids Res. 44, D1251–D1257 (2016). 
221 
 
461. J. Deng, H. P. Harding, B. Raught, A.-C. Gingras, J. J. Berlanga, D. Scheuner, R. J. Kaufman, D. 
Ron, N. Sonenberg, Activation of GCN2 in UV-Irradiated Cells Inhibits Translation, Curr. Biol. 12, 
1279–1286 (2002). 
462. H. P. Harding, Y. Zhang, A. Bertolotti, H. Zeng, D. Ron, Perk is essential for translational 
regulation and cell survival during the unfolded protein response., Mol. Cell 5, 897–904 (2000). 
463. S. K. Young, R. C. Wek, Upstream Open Reading Frames Differentially Regulate Gene-specific 
Translation in the Integrated Stress Response., J. Biol. Chem. 291, 16927–35 (2016). 
464. T. Narita, S. Yin, C. F. Gelin, C. S. Moreno, M. Yepes, K. C. Nicolaou, E. G. Van Meir, Identification 
of a novel small molecule HIF-1alpha translation inhibitor., Clin. Cancer Res. 15, 6128–36 (2009). 
465. N. M. Chau, P. Rogers, W. Aherne, V. Carroll, I. Collins, E. McDonald, P. Workman, M. Ashcroft, 
Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block 
hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1α induction in response to hypoxic 
stress and growth factors, Cancer Res. 65, 4918–4928 (2005). 
466. S. Song, L. J. Wheeler, C. K. Mathews, Deoxyribonucleotide pool imbalance stimulates deletions 
in HeLa cell mitochondrial DNA., J. Biol. Chem. 278, 43893–6 (2003). 
467. S. Song, Z. F. Pursell, W. C. Copeland, M. J. Longley, T. A. Kunkel, C. K. Mathews, DNA precursor 
asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through 
reduced replication fidelity., Proc. Natl. Acad. Sci. U. S. A. 102, 4990–5 (2005). 
468. J. A. Stuart, M. F. Brown, Mitochondrial DNA maintenance and bioenergetics, Biochim. Biophys. 
Acta - Bioenerg. 1757, 79–89 (2006). 
469. N. Gattermann, M. Dadak, G. Hofhaus, M. Wulfert, M. Berneburg, M. L. Loeffler, H. A. 
Simmonds, Severe Impairment of Nucleotide Synthesis Through Inhibition of Mitochondrial 
Respiration, Nucleosides, Nucleotides and Nucleic Acids 23, 1275–1279 (2004). 
470. M. Löffler, J. Jöckel, G. Schuster, C. Becker, Dihydroorotat-ubiquinone oxidoreductase links 
mitochondria in the biosynthesis of pyrimidine nucleotides., Mol. Cell. Biochem. 174, 125–9 (1997). 
471. E. B. Nygaard, S. G. Vienberg, C. Ørskov, H. S. Hansen, B. Andersen, Metformin Stimulates 
FGF21 Expression in Primary Hepatocytes, Exp. Diabetes Res. 2012, 1–8 (2012). 
472. N. Li, K. Ragheb, G. Lawler, J. Sturgis, B. Rajwa, J. A. Melendez, J. P. Robinson, Mitochondrial 
Complex I Inhibitor Rotenone Induces Apoptosis through Enhancing Mitochondrial Reactive Oxygen 
Species Production, J. Biol. Chem. 278, 8516–8525 (2003). 
222 
 
473. W. H. Park, Y. W. Han, S. H. Kim, S. Z. Kim, An ROS generator, antimycin A, inhibits the growth of 
HeLa cells via apoptosis, J. Cell. Biochem. 102, 98–109 (2007). 
474. C. M. Haynes, D. Ron, The mitochondrial UPR - protecting organelle protein homeostasis., J. Cell 
Sci. 123, 3849–55 (2010). 
475. A. M. Nargund, M. W. Pellegrino, C. J. Fiorese, B. M. Baker, C. M. Haynes, Mitochondrial import 
efficiency of ATFS-1 regulates mitochondrial UPR activation., Science 337, 587–90 (2012). 
476. Q. Zhao, J. Wang, I. V. Levichkin, S. Stasinopoulos, M. T. Ryan, N. J. Hoogenraad, A 
mitochondrial specific stress response in mammalian cells, EMBO J. 21, 4411–4419 (2002). 
477. B. M. Baker, A. M. Nargund, T. Sun, C. M. Haynes, N.-G. Larsson, Ed. Protective Coupling of 
Mitochondrial Function and Protein Synthesis via the eIF2α Kinase GCN-2, PLoS Genet. 8, e1002760 
(2012). 
478. E. Rath, E. Berger, A. Messlik, T. Nunes, B. Liu, S. C. Kim, N. Hoogenraad, M. Sans, R. B. Sartor, D. 
Haller, Induction of dsRNA-activated protein kinase links mitochondrial unfolded protein response to 
the pathogenesis of intestinal inflammation, Gut 61, 1269–1278 (2012). 
479. T. Quentin, M. Steinmetz, A. Poppe, S. Thoms, Metformin differentially activates ER stress 
signaling pathways without inducing apoptosis., Dis. Model. Mech. 5, 259–69 (2012). 
480. A. Tsuru, Y. Imai, M. Saito, K. Kohno, Novel mechanism of enhancing IRE1α-XBP1 signalling via 
the PERK-ATF4 pathway, Sci. Rep. 6, 24217 (2016). 
481. M. Zhang, W. Sun, J. Qian, Y. Tang, Fasting exacerbates hepatic growth differentiation factor 15 
to promote fatty acid β-oxidation and ketogenesis via activating XBP1 signaling in liver, Redox Biol. 
16, 87–96 (2018). 
482. C. Loubiere, S. Clavel, J. Gilleron, R. Harisseh, J. Fauconnier, I. Ben-Sahra, L. Kaminski, K. Laurent, 
S. Herkenne, S. Lacas-Gervais, D. Ambrosetti, D. Alcor, S. Rocchi, M. Cormont, J.-F. Michiels, B. Mari, 
N. M. Mazure, L. Scorrano, A. Lacampagne, A. Gharib, J.-F. Tanti, F. Bost, The energy disruptor 
metformin targets mitochondrial integrity via modification of calcium flux in cancer cells, Sci. Rep. 7, 
5040 (2017). 
483. S. Lakhal, N. P. Talbot, A. Crosby, C. Stoepker, A. R. M. Townsend, P. A. Robbins, C. W. Pugh, P. J. 
Ratcliffe, D. R. Mole, Regulation of growth differentiation factor 15 expression by intracellular iron., 
Blood 113, 1555–63 (2009). 
484. A. J. Majmundar, W. J. Wong, M. C. Simon, Hypoxia-Inducible Factors and the Response to 
223 
 
Hypoxic StressMol. Cell 40, 294–309 (2010). 
485. E. Berger, E. Rath, D. Yuan, N. Waldschmitt, S. Khaloian, M. Allgäuer, O. Staszewski, E. M. 
Lobner, T. Schöttl, P. Giesbertz, O. I. Coleman, M. Prinz, A. Weber, M. Gerhard, M. Klingenspor, K.-P. 
Janssen, M. Heikenwalder, D. Haller, Mitochondrial function controls intestinal epithelial stemness 
and proliferation, Nat. Commun. 7, 13171 (2016). 
486. K. B. Hahm, Y. H. Im, T. W. Parks, S. H. Park, S. Markowitz, H. Y. Jung, J. Green, S. J. Kim, Loss of 
transforming growth factor beta signalling in the intestine contributes to tissue injury in 
inflammatory bowel disease., Gut 49, 190–8 (2001). 
487. H. Xiao, J. Zhang, Z. Xu, Y. Feng, M. Zhang, J. Liu, R. Chen, J. Shen, J. Wu, Z. Lu, X. Fang, J. Li, Y. 
Zhang, Metformin is a novel suppressor for transforming growth factor (TGF)-β1., Sci. Rep. 6, 28597 
(2016). 
488. T. Ikeda, K. Iwata, H. Murakami, Inhibitory effect of metformin on intestinal glucose absorption 
in the perfused rat intestine, Biochem. Pharmacol. 59, 887–890 (2000). 
489. C. WILCOCK, C. J. BAILEY, Reconsideration of inhibitory effect of metformin on intestinal glucose 
absorption, J. Pharm. Pharmacol. 43, 120–121 (1991). 
490. T. Özülker, F. Özülker, M. Mert, T. Özpaçacı, Clearance of the high intestinal 18 F-FDG uptake 
associated with metformin after stopping the drug, Eur. J. Nucl. Med. Mol. Imaging 37, 1011–1017 
(2010). 
491. V. Gorboulev, A. Schürmann, V. Vallon, H. Kipp, A. Jaschke, D. Klessen, A. Friedrich, S. 
Scherneck, T. Rieg, R. Cunard, M. Veyhl-Wichmann, A. Srinivasan, D. Balen, D. Breljak, R. Rexhepaj, H. 
E. Parker, F. M. Gribble, F. Reimann, F. Lang, S. Wiese, I. Sabolic, M. Sendtner, H. Koepsell, Na(+)-D-
glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent 
incretin secretion., Diabetes 61, 187–96 (2012). 
492. P. V. Röder, K. E. Geillinger, T. S. Zietek, B. Thorens, H. Koepsell, H. Daniel, The role of SGLT1 and 
GLUT2 in intestinal glucose transport and sensing, PLoS One 9 (2014), 
doi:10.1371/journal.pone.0089977. 
493. E. M. Wright, THE INTESTINAL Na + IGLUCOSE COTRANSPORTER (1993; 
www.annualreviews.org). 
494. M. G. Martín, E. Turk, M. P. Lostao, C. Kerner, E. M. Wright, Defects in Na+/glucose 
cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption, Nat. Genet. 
12, 216–220 (1996). 
224 
 
495. M. Kasahara, M. Maeda, S. Hayashi, Y. Mori, T. Abe, A missense mutation in the Na + /glucose 
cotransporter gene SGLT1 in a patient with congenital glucose-galactose malabsorption: Normal 
trafficking but inactivation of the mutant protein, Biochim. Biophys. Acta - Mol. Basis Dis. 1536, 141–
147 (2001). 
496. J. T. Lam, M. G. Martín, E. Turk, B. A. Hirayama, N. U. Bosshard, B. Steinmann, E. M. Wright, 
Missense mutations in SGLT1 cause glucose-galactose malabsorption by trafficking defects, Biochim. 
Biophys. Acta - Mol. Basis Dis. 1453, 297–303 (1999). 
497. M. Uldry, M. Ibberson, M. Hosokawa, B. Thorens, GLUT2 is a high affinity glucosamine 
transporter., FEBS Lett. 524, 199–203 (2002). 
498. C. I. Cheeseman, GLUT2 is the transporter for fructose across the rat intestinal basolateral 
membrane., Gastroenterology 105, 1050–6 (1993). 
499. B. Thorens, Z. Q. Cheng, D. Brown, H. F. Lodish, Liver glucose transporter: a basolateral protein 
in hepatocytes and intestine and kidney cells., Am. J. Physiol. 259, C279-85 (1990). 
500. G. L. Kellett, E. Brot-Laroche, Apical GLUT2: A major pathway of intestinal sugar 
absorptionDiabetes 54, 3056–3062 (2005). 
501. F. Gouyon, L. Caillaud, V. Carriere, C. Klein, V. Dalet, D. Citadelle, G. L. Kellett, B. Thorens, A. 
Leturque, E. Brot-Laroche, Simple-sugar meals target GLUT2 at enterocyte apical membranes to 
improve sugar absorption: a study in GLUT2-null mice., J. Physiol. 552, 823–32 (2003). 
502. J. A. Affleck, P. A. Helliwell, G. L. Kellett, Immunocytochemical detection of GLUT2 at the rat 
intestinal brush-border membrane., J. Histochem. Cytochem. 51, 1567–74 (2003). 
503. O. J. Mace, J. Affleck, N. Patel, G. L. Kellett, Sweet taste receptors in rat small intestine stimulate 
glucose absorption through apical GLUT2., J. Physiol. 582, 379–92 (2007). 
504. A. Au, A. Gupta, P. Schembri, C. I. Cheeseman, Rapid insertion of GLUT2 into the rat jejunal 
brush-border membrane promoted by glucagon-like peptide 2, Biochem. J. 367, 247–254 (2002). 
505. A. Ait-Omar, M. Monteiro-Sepulveda, C. Poitou, M. Le Gall, A. Cotillard, J. Gilet, K. Garbin, A. 
Houllier, D. Château, A. Lacombe, N. Veyrie, D. Hugol, J. Tordjman, C. Magnan, P. Serradas, K. 
Clément, A. Leturque, E. Brot-Laroche, GLUT2 accumulation in enterocyte apical and intracellular 
membranes: a study in morbidly obese human subjects and ob/ob and high fat-fed mice., Diabetes 
60, 2598–607 (2011). 
506. M. T. Guillam, R. Burcelin, B. Thorens, B. Thorens, Normal hepatic glucose production in the 
225 
 
absence of GLUT2 reveals an alternative pathway for glucose release from hepatocytes., Proc. Natl. 
Acad. Sci. U. S. A. 95, 12317–21 (1998). 
507. F. Manz, H. Bickel, J. Brodehl, D. Feist, K. Gellissen, B. Geschöll-Bauer, G. Gilli, E. Harms, H. 
Helwig, W. Nützenadel, Fanconi-Bickel syndrome., Pediatr. Nephrol. 1, 509–18 (1987). 
508. M. Brivet, N. Moatti, A. Corriat, A. Lemonnier, M. Odievre, Defective galactose oxidation in a 
patient with glycogen storage disease and Fanconi syndrome., Pediatr. Res. 17, 157–61 (1983). 
509. T. Yoshikawa, R. Inoue, M. Matsumoto, T. Yajima, K. Ushida, T. Iwanaga, Comparative 
expression of hexose transporters (SGLT1, GLUT1, GLUT2 and GLUT5) throughout the mouse 
gastrointestinal tract, Histochem. Cell Biol. 135, 183–194 (2011). 
510. S. Boyer, P. A. Sharp, E. S. Debnam, S. A. Baldwin, S. K. S. Srai, Streptozotocin diabetes and the 
expression of GLUT1 at the brush border and basolateral membranes of intestinal enterocytes, FEBS 
Lett. 396, 218–222 (1996). 
511. H. Takayama, M. Ohta, K. Tada, K. Watanabe, T. Kawasaki, Y. Endo, Y. Iwashita, M. Inomata, 
Additional effects of duodenojejunal bypass on glucose metabolism in a rat model of sleeve 
gastrectomy., Surg. Today 49, 637–644 (2019). 
512. N. O. Davidson, A. M. Hausman, C. A. Ifkovits, J. B. Buse, G. W. Gould, C. F. Burant, G. I. Bell, 
Human intestinal glucose transporter expression and localization of GLUT5, Am. J. Physiol. Physiol. 
262, C795–C800 (1992). 
513. C. F. Burant, J. Takeda, E. Brot-Laroche, G. I. Bell, N. O. Davidson, Fructose transporter in human 
spermatozoa and small intestine is GLUT5., J. Biol. Chem. 267, 14523–6 (1992). 
514. S. Barone, S. L. Fussell, A. K. Singh, F. Lucas, J. Xu, C. Kim, X. Wu, Y. Yu, H. Amlal, U. Seidler, J. 
Zuo, M. Soleimani, Slc2a5 (Glut5) Is Essential for the Absorption of Fructose in the Intestine and 
Generation of Fructose-induced Hypertension, J. Biol. Chem. 284, 5056–5066 (2009). 
515. C. Cheeseman, GLUT7: a new intestinal facilitated hexose transporter, Am. J. Physiol. Metab. 
295, E238–E241 (2008). 
516. T. Wu, C. Xie, H. Wu, K. L. Jones, M. Horowitz, C. K. Rayner, Metformin reduces the rate of small 
intestinal glucose absorption in type 2 diabetes, Diabetes, Obes. Metab. 19, 290–293 (2017). 
517. B. Bybel, I. D. Greenberg, J. Paterson, J. Ducharme, W. D. Leslie, Increased F-18 FDG intestinal 




518. E. Gontier, E. Fourme, M. Wartski, C. Blondet, G. Bonardel, E. Le Stanc, M. Mantzarides, H. 
Foehrenbach, A. P. Pecking, J. L. Alberini, High and typical 18F-FDG bowel uptake in patients treated 
with metformin, Eur. J. Nucl. Med. Mol. Imaging 35, 95–99 (2008). 
519. L. Bahler, K. Stroek, J. B. Hoekstra, H. J. Verberne, F. Holleman, Metformin-related colonic 
glucose uptake; potential role for increasing glucose disposal?-A retrospective analysis of 18F-FDG 
uptake in the colon on PET-CT, Diabetes Res. Clin. Pract. 114, 55–63 (2016). 
520. S. H. Lee, S. Jin, H. S. Lee, J. S. Ryu, J. J. Lee, Metformin discontinuation less than 72 h is 
suboptimal for F-18 FDG PET/CT interpretation of the bowel, Ann. Nucl. Med. 30, 629–636 (2016). 
521. R. Hamidizadeh, A. Eftekhari, E. A. Wiley, D. Wilson, T. Alden, F. Bénard, Metformin 
discontinuation prior to FDG PET/CT: A randomized controlled study to compare 24- and 48-hour 
bowel activity, Radiology 289, 418–425 (2018). 
522. D. W. Steenkamp, M. E. Mcdonnell, S. Meibom, Metformin may be associated with false-
negative cancer detection in the gastrointestinal tract on PET/CTEndocr. Pract. 20, 1079–1083 
(2014). 
523. Y. Sakar, B. Meddah, M. A. Faouzi, Y. Cherrah, A. Bado, R. Ducroc, Metformin-induced 
regulation of the intestinal D-glucose transporters., J. Physiol. Pharmacol. 61, 301–7 (2010). 
524. J. Walker, H. B. Jijon, H. Diaz, P. Salehi, T. Churchill, K. L. Madsen, 5-Aminoimidazole-4-
carboxamide riboside (AICAR) enhances GLUT2-dependent jejunal glucose transport: A possible role 
for AMPK, Biochem. J. 385, 485–491 (2005). 
525. M. Panayotova-Heiermann, D. D. F. Loo, E. M. Wright, Kinetics of steady-state currents and 
charge movements associated with the rat Na+/glucose cotransporter, J. Biol. Chem. 270, 27099–
27105 (1995). 
526. K. Kapoor, J. S. Finer-Moore, B. P. Pedersen, L. Caboni, A. Waight, R. C. Hillig, P. Bringmann, I. 
Heisler, T. Müller, H. Siebeneicher, R. M. Stroud, Mechanism of inhibition of human glucose 
transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides, Proc. Natl. Acad. 
Sci. U. S. A. 113, 4711–4716 (2016). 
527. S. Wandel, A. Buchs, A. Schürmann, S. A. Summers, A. C. Powers, M. F. Shanahan, H. G. Joost, 
Glucose transport activity and ligand binding (cytochalasin B, IAPS-forskolin) of chimeric constructs 
of GLUT2 and GLUT4 expressed in COS-7-cells, Biochim. Biophys. Acta - Biomembr. 1284, 56–62 
(1996). 
528. B. Hellwig, H. G. Joost, Differentiation of erythrocyte-(GLUT1), liver-(GLUT2), and adipocyte-
227 
 
type (GLUT4) glucose transporters by binding of the inhibitory ligands cytochalasin B, forskolin, 
dipyridamole, and isobutylmethylxanthine., Mol. Pharmacol. 40 (1991). 
529. L. Bultot, T. E. Jensen, Y. C. Lai, A. L. B. Madsen, C. Collodet, S. Kviklyte, M. Deak, A. Yavari, M. 
Foretz, S. Ghaffari, M. Bellahcene, H. Ashrafian, M. H. Rider, E. A. Richter, K. Sakamoto, 
Benzimidazole derivative small-molecule 991 enhances AMPK activity and glucose uptake induced by 
AICAR or contraction in skeletal muscle, Am. J. Physiol. - Endocrinol. Metab. 311, E706–E719 (2016). 
530. B. Xiao, M. J. Sanders, D. Carmena, N. J. Bright, L. F. Haire, E. Underwood, B. R. Patel, R. B. 
Heath, P. A. Walker, S. Hallen, F. Giordanetto, S. R. Martin, D. Carling, S. J. Gamblin, Structural basis 
of AMPK regulation by small molecule activators., Nat. Commun. 4, 3017 (2013). 
531. S. Lenzen, S. Lortz, M. Tiedge, Effects of metformin on SGLT1, GLUT2, and GLUT5 hexose 
transporter gene expression in small intestine from rats, Biochem. Pharmacol. 51, 893–896 (1996). 
532. C. Chen, N. Pore, A. Behrooz, F. Ismail-Beigi, A. Maity, Regulation of glut1 mRNA by hypoxia-
inducible factor-1. Interaction between H-ras and hypoxia., J. Biol. Chem. 276, 9519–25 (2001). 
533. Y. Wang, Y. Liu, S. N. Malek, P. Zheng, Y. Liu, Targeting HIF1α eliminates cancer stem cells in 
hematological malignancies, Cell Stem Cell 8, 399–411 (2011). 
534. J. Karhausen, G. T. Furuta, J. E. Tomaszewski, R. S. Johnson, S. P. Colgan, V. H. Haase, Epithelial 
hypoxia-inducible factor-1 is protective in murine experimental colitis., J. Clin. Invest. 114, 1098–106 
(2004). 
535. J. D. Cremin, S. E. Fleming, Glycolysis is a source of pyruvate for transamination of glutamine 
amino nitrogen in jejunal epithelial cells, Am. J. Physiol. Liver Physiol. 272, G575–G588 (1997). 
536. P. J. Hanson, D. S. Parsons, Factors affecting the utilization of ketone bodies and other 
substrates by rat jejunum: effects of fasting and of diabetes., 278, 55–67 (1978). 
537. J. Storch, Y. X. Zhou, W. S. Lagakos, Metabolism of apical versus basolateral sn -2-
monoacylglycerol and fatty acids in rodent small intestine, J. Lipid Res. 49, 1762–1769 (2008). 
538. S. E. Fleming, M. D. Fitch, S. DeVries, M. L. Liu, C. Kight, Nutrient Utilization by Cells Isolated 
from Rat Jejunum, Cecum and Colon, J. Nutr. 121, 869–878 (1991). 
539. M. D. Robertson, M. Parkes, B. F. Warren, D. J. P. Ferguson, K. G. Jackson, D. P. Jewell, K. N. 
Frayn, Mobilisation of enterocyte fat stores by oral glucose in humans., Gut 52, 834–9 (2003). 
540. S. R. Moore, M. M. Guedes, T. B. Costa, J. Vallance, E. A. Maier, K. J. Betz, E. Aihara, M. M. 
Mahe, A. A. M. Lima, R. B. Oriá, N. F. Shroyer, Glutamine and alanyl-glutamine promote crypt 
228 
 
expansion and mTOR signaling in murine enteroids., Am. J. Physiol. Gastrointest. Liver Physiol. 308, 
G831-9 (2015). 
541. H. Yang, X. Wang, X. Xiong, Y. Yin, Energy metabolism in intestinal epithelial cells during 
maturation along the crypt-villus axis, Sci. Rep. (2016), doi:10.1038/srep31917. 
542. R. W. Hunter, C. C. Hughey, L. Lantier, E. I. Sundelin, M. Peggie, E. Zeqiraj, F. Sicheri, N. Jessen, 
D. H. Wasserman, K. Sakamoto, Metformin reduces liver glucose production by inhibition of 
fructose-1-6-bisphosphatase., Nat. Med. 24, 1395–1406 (2018). 
543. C. A. Chu, N. Wiernsperger, N. Muscato, M. Knauf, D. W. Neal, A. D. Cherrington, The acute 
effect of metformin on glucose production in the conscious dog is primarily attributable to inhibition 
of glycogenolysis, Metabolism 49, 1619–1626 (2000). 
544. M. Otto, J. Breinholt, N. Westergaard, Metformin inhibits glycogen synthesis and 
gluconeogenesis in cultured rat hepatocytes., Diabetes. Obes. Metab. 5, 189–94 (2003). 
545. M. M. González-Barroso, A. Anedda, E. Gallardo-Vara, M. Redondo-Horcajo, L. Rodríguez-
Sánchez, E. Rial, Fatty acids revert the inhibition of respiration caused by the antidiabetic drug 
metformin to facilitate their mitochondrial β-oxidation, Biochim. Biophys. Acta - Bioenerg. 1817, 
1768–1775 (2012). 
546. I. A. Okkelman, T. Foley, D. B. Papkovsky, R. I. Dmitriev, Live cell imaging of mouse intestinal 
organoids reveals heterogeneity in their oxygenation, Biomaterials 146, 86–96 (2017). 
547. N. Berndt, O. Kann, H.-G. Holzhütter, Physiology-Based Kinetic Modeling of Neuronal Energy 
Metabolism Unravels the Molecular Basis of NAD(P)H Fluorescence Transients, J. Cereb. Blood Flow 
Metab. 35, 1494–1506 (2015). 
548. A. M. Brennan, J. A. Connor, C. W. Shuttleworth, NAD(P)H Fluorescence Transients after 
Synaptic Activity in Brain Slices: Predominant Role of Mitochondrial Function, J. Cereb. Blood Flow 
Metab. 26, 1389–1406 (2006). 
549. C. Manlio Díaz-García, R. Mongeon, C. Lahmann, D. Koveal, H. Zucker, G. Y. Correspondence, G. 
Yellen, Neuronal Stimulation Triggers Neuronal Glycolysis and Not Lactate Uptake Cell Metabolism 
Article Neuronal Stimulation Triggers Neuronal Glycolysis and Not Lactate Uptake, Cell Metab. 26, 
361-374.e4 (2017). 
550. C. W. Shuttleworth, Use of NAD(P)H and flavoprotein autofluorescence transients to probe 
neuron and astrocyte responses to synaptic activation, Neurochem. Int. 56, 379–386 (2010). 
229 
 
551. T. Schulze, M. Morsi, K. Reckers, D. Brüning, N. Seemann, U. Panten, I. Rustenbeck, Metabolic 
amplification of insulin secretion is differentially desensitized by depolarization in the absence of 
exogenous fuels, Metabolism 67, 1–13 (2017). 
552. K. Eto, Y. Tsubamoto, Y. Terauchi, T. Sugiyama, T. Kishimoto, N. Takahashi, N. Yamauchi, N. 
Kubota, S. Murayama, T. Aizawa, Y. Akanuma, S. Aizawa, H. Kasai, Y. Yazaki, T. Kadowaki, Role of 
NADH Shuttle System in Glucose-Induced Activation of Mitochondrial Metabolism and Insulin 
Secretion, Science (80-. ). 283, 981–985 (1999). 
553. R. Dumollard, Z. Ward, J. Carroll, M. R. Duchen, Regulation of redox metabolism in the mouse 
oocyte and embryo., Development 134, 455–65 (2007). 
554. S. A. Mookerjee, D. G. Nicholls, M. D. Brand, J. Zhang, Ed. Determining Maximum Glycolytic 
Capacity Using Extracellular Flux Measurements, PLoS One 11, e0152016 (2016). 
555. B. Trivedi, W. H. Danforth, Effect of pH on the kinetics of frog muscle phosphofructokinase., J. 
Biol. Chem. 241, 4110–2 (1966). 
556. D. Benjamin, D. Robay, S. K. Hindupur, J. Pohlmann, M. Colombi, M. Y. El-Shemerly, S.-M. Maira, 
C. Moroni, H. A. Lane, M. N. Hall, Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is 
Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells, Cell Rep. 25, 3047-3058.e4 
(2018). 
557. M. J. Ovens, A. J. Davies, M. C. Wilson, C. M. Murray, A. P. Halestrap, AR-C155858 is a potent 
inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site 
involving transmembrane helices 7–10, Biochem. J. 425, 523–530 (2010). 
558. S. B. Jadaho, R.-Z. Yang, Q. Lin, H. Hu, F. A. Anania, A. R. Shuldiner, D.-W. Gong, Murine alanine 
aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse 
fatty liver, Hepatology 39, 1297–1302 (2004). 
559. E. L. Mills, K. A. Pierce, M. P. Jedrychowski, R. Garrity, S. Winther, S. Vidoni, T. Yoneshiro, J. B. 
Spinelli, G. Z. Lu, L. Kazak, A. S. Banks, M. C. Haigis, S. Kajimura, M. P. Murphy, S. P. Gygi, C. B. Clish, 
E. T. Chouchani, Accumulation of succinate controls activation of adipose tissue thermogenesis, 
Nature 560, 102–106 (2018). 
560. R. Hussain, Z. Shaukat, M. Khan, R. Saint, S. L. Gregory, Phosphoenolpyruvate Carboxykinase 
Maintains Glycolysis-driven Growth in Drosophila Tumors, Sci. Rep. 7, 11531 (2017). 
561. A. L. Orr, D. Ashok, M. R. Sarantos, R. Ng, T. Shi, A. A. Gerencser, R. E. Hughes, M. D. Brand, V. D. 
Appanna, Ed. Novel Inhibitors of Mitochondrial sn-Glycerol 3-phosphate Dehydrogenase, PLoS One 
230 
 
9, e89938 (2014). 
562. S. Köhler, U. Winkler, M. Sicker, J. Hirrlinger, NBCe1 mediates the regulation of the NADH/NAD + 
redox state in cortical astrocytes by neuronal signals, Glia 66, 2233–2245 (2018). 
563. A. Pecinova, Z. Drahota, J. Kovalcikova, N. Kovarova, P. Pecina, L. Alan, M. Zima, J. Houstek, T. 
Mracek, Pleiotropic Effects of Biguanides on Mitochondrial Reactive Oxygen Species Production, 
Oxid. Med. Cell. Longev. 2017, 1–11 (2017). 
564. J. Pfleger, M. He, M. Abdellatif, Mitochondrial complex II is a source of the reserve respiratory 
capacity that is regulated by metabolic sensors and promotes cell survival, Cell Death Dis. 6, e1835–
e1835 (2015). 
565. N. D. Amoedo, G. Punzi, E. Obre, D. Lacombe, A. De Grassi, C. L. Pierri, R. Rossignol, AGC1/2, the 
mitochondrial aspartate-glutamate carriers, Biochim. Biophys. Acta - Mol. Cell Res. 1863, 2394–2412 
(2016). 
566. B. Raud, D. G. Roy, A. S. Divakaruni, T. N. Tarasenko, R. Franke, E. H. Ma, B. Samborska, W. Y. 
Hsieh, A. H. Wong, P. Stüve, C. Arnold-Schrauf, M. Guderian, M. Lochner, S. Rampertaap, K. Romito, 
J. Monsale, M. Brönstrup, S. J. Bensinger, A. N. Murphy, P. J. McGuire, R. G. Jones, T. Sparwasser, L. 
Berod, Etomoxir Actions on Regulatory and Memory T Cells Are Independent of Cpt1a-Mediated 
Fatty Acid Oxidation, Cell Metab. 28, 504-515.e7 (2018). 
567. A. S. Divakaruni, W. Y. Hsieh, L. Minarrieta, T. N. Duong, K. K. O. Kim, B. R. Desousa, A. Y. 
Andreyev, C. E. Bowman, K. Caradonna, B. P. Dranka, D. A. Ferrick, M. Liesa, L. Stiles, G. W. Rogers, D. 
Braas, T. P. Ciaraldi, M. J. Wolfgang, T. Sparwasser, L. Berod, S. J. Bensinger, A. N. Murphy, Etomoxir 
Inhibits Macrophage Polarization by Disrupting CoA Homeostasis, Cell Metab. 28, 490-503.e7 (2018). 
568. C.-H. Yao, G.-Y. Liu, R. Wang, S. H. Moon, R. W. Gross, G. J. Patti, J. Locasale, Ed. Identifying off-
target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell 
proliferation independent of β-oxidation, PLOS Biol. 16, e2003782 (2018). 
569. A. R. Cameron, L. Logie, K. Patel, S. Erhardt, S. Bacon, P. Middleton, J. Harthill, C. Forteath, J. T. 
Coats, C. Kerr, H. Curry, D. Stewart, K. Sakamoto, P. Repiščák, M. J. Paterson, I. Hassinen, G. 
McDougall, G. Rena, Metformin selectively targets redox control of complex I energy transduction., 
Redox Biol. 14, 187–197 (2018). 
570. M.-Y. El-Mir, V. Nogueira, E. Fontaine, N. Avéret, M. Rigoulet, X. Leverve, Dimethylbiguanide 
Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I, J. Biol. 
Chem. 275, 223–228 (2000). 
231 
 
571. E. Gaude, C. Schmidt, P. A. Gammage, A. Dugourd, T. Blacker, S. P. Chew, J. Saez-Rodriguez, J. S. 
O’Neill, G. Szabadkai, M. Minczuk, C. Frezza, NADH Shuttling Couples Cytosolic Reductive 
Carboxylation of Glutamine with Glycolysis in Cells with Mitochondrial Dysfunction, Mol. Cell (2018), 
doi:10.1016/j.molcel.2018.01.034. 
572. A. Janzer, N. J. German, K. N. Gonzalez-Herrera, J. M. Asara, M. C. Haigis, K. Struhl, Metformin 
and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell 
transformation and NTPs in cancer stem cells., Proc. Natl. Acad. Sci. U. S. A. 111, 10574–9 (2014). 
573. L. B. Sullivan, D. Y. Gui, A. M. Hosios, L. N. Bush, E. Freinkman, M. G. Vander Heiden, Supporting 
Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells, Cell (2015), 
doi:10.1016/j.cell.2015.07.017. 
574. S.-M. Fendt, E. L. Bell, M. A. Keibler, S. M. Davidson, G. J. Wirth, B. Fiske, J. R. Mayers, M. 
Schwab, G. Bellinger, A. Csibi, A. Patnaik, M. J. Blouin, L. C. Cantley, L. Guarente, J. Blenis, M. N. 
Pollak, A. F. Olumi, M. G. Vander Heiden, G. Stephanopoulos, Metformin decreases glucose 
oxidation and increases the dependency of prostate cancer cells on reductive glutamine 
metabolism., Cancer Res. 73, 4429–38 (2013). 
575. A. R. Mullen, W. W. Wheaton, E. S. Jin, P.-H. Chen, L. B. Sullivan, T. Cheng, Y. Yang, W. M. 
Linehan, N. S. Chandel, R. J. DeBerardinis, Reductive carboxylation supports growth in tumour cells 
with defective mitochondria, Nature 481, 385–388 (2012). 
576. K. S. McCommis, Z. Chen, X. Fu, W. G. McDonald, J. R. Colca, R. F. Kletzien, S. C. Burgess, B. N. 
Finck, Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and 
compensation via pyruvate-alanine cycling, Cell Metab. (2015), doi:10.1016/j.cmet.2015.07.028. 
577. L. R. Gray, M. R. Sultana, A. J. Rauckhorst, L. Oonthonpan, S. C. Tompkins, A. Sharma, X. Fu, R. 
Miao, A. D. Pewa, K. S. Brown, E. E. Lane, A. Dohlman, D. Zepeda-Orozco, J. Xie, J. Rutter, A. W. 
Norris, J. E. Cox, S. C. Burgess, M. J. Potthoff, E. B. Taylor, Hepatic mitochondrial pyruvate carrier 1 is 
required for efficient regulation of gluconeogenesis and whole-body glucose homeostasis, Cell 
Metab. (2015), doi:10.1016/j.cmet.2015.07.027. 
578. M. MacDonald, N. Neufeldt, B. Park, M. Berger, N. Ruderman, Alanine metabolism and 
gluconeogenesis in the rat, Am. J. Physiol. Content 231, 619–626 (1976). 
579. J. Mendes-Mourão, A. Halestrap, D. M. Crisp, C. I. Pogson, The involvement of mitochondrial 
pyruvate transport in the pathways of gluconeogenesis from serine and alanine in isolated rat and 
mouse liver cells, FEBS Lett. 53, 29–32 (1975). 
232 
 
580. P. Felig, T. Pozefsky, E. Marliss, G. F. Cahill, Alanine: key role in gluconeogenesis., Science 167, 
1003–4 (1970). 
581. R.-Z. Yang, S. Park, W. J. Reagan, R. Goldstein, S. Zhong, M. Lawton, F. Rajamohan, K. Qian, L. 
Liu, D.-W. Gong, Alanine aminotransferase isoenzymes: Molecular cloning and quantitative analysis 
of tissue expression in rats and serum elevation in liver toxicity, Hepatology 49, 598–607 (2009). 
582. Y. Adachi, A. L. De Sousa-Coelho, I. Harata, C. Aoun, S. Weimer, X. Shi, K. N. Gonzalez Herrera, H. 
Takahashi, C. Doherty, Y. Noguchi, L. J. Goodyear, M. C. Haigis, R. E. Gerszten, M.-E. Patti, l-Alanine 
activates hepatic AMP-activated protein kinase and modulates systemic glucose metabolism, Mol. 
Metab. 17, 61–70 (2018). 
583. J. W. Locasale, L. C. Cantley, Metabolic Flux and the Regulation of Mammalian Cell Growth, Cell 
Metab. 14, 443–451 (2011). 
584. R. J. DeBerardinis, J. J. Lum, G. Hatzivassiliou, C. B. Thompson, The Biology of Cancer: Metabolic 
Reprogramming Fuels Cell Growth and Proliferation, Cell Metab. 7, 11–20 (2008). 
585. H. Hu, A. Juvekar, C. A. Lyssiotis, E. C. Lien, J. G. Albeck, D. Oh, G. Varma, Y. P. Hung, S. Ullas, J. 
Lauring, P. Seth, M. R. Lundquist, D. R. Tolan, A. K. Grant, D. J. Needleman, J. M. Asara, L. C. Cantley, 
G. M. Wulf, Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from 
the Actin Cytoskeleton, Cell 164, 433–446 (2016). 
586. A. A. Shestov, X. Liu, Z. Ser, A. A. Cluntun, Y. P. Hung, L. Huang, D. Kim, A. Le, G. Yellen, J. G. 
Albeck, J. W. Locasale, Quantitative determinants of aerobic glycolysis identify flux through the 
enzyme GAPDH as a limiting step., Elife 3 (2014), doi:10.7554/eLife.03342. 
587. H. R. Christofk, M. G. Vander Heiden, M. H. Harris, A. Ramanathan, R. E. Gerszten, R. Wei, M. D. 
Fleming, S. L. Schreiber, L. C. Cantley, The M2 splice isoform of pyruvate kinase is important for 
cancer metabolism and tumour growth, Nature 452, 230–233 (2008). 
588. O. Alcazar, M. Tiedge, S. Lenzen, Importance of lactate dehydrogenase for the regulation of 
glycolytic flux and insulin secretion in insulin-producing cells., Biochem. J. 352 Pt 2, 373–80 (2000). 
589. P. Hahn, H. Wei-Ning, Gluconeogenesis from Lactate in the Small Intestinal Mucosa of Suckling 
Rats, Pediatr. Res. 20, 1321–1323 (1986). 
590. P. Hahn, H. Wei-Ning, Gluconeogenesis from lactate in the small intestinal mucosa of suckling 
rats, Pediatr. Res. (1986), doi:10.1203/00006450-198612000-00027. 




592. T. Ikeda, K. Iwata, H. Murakami, Inhibitory effect of metformin on intestinal glucose absorption 
in the perfused rat intestine, Biochem. Pharmacol. 59, 887–890 (2000). 
593. S. Van Welden, A. C. Selfridge, P. Hindryckx, Intestinal hypoxia and hypoxia-induced signalling as 
therapeutic targets for IBD, Nat. Rev. Gastroenterol. Hepatol. 14, 596–611 (2017). 
594. R. I. Misbin, L. Green, B. V. Stadel, J. L. Gueriguian, A. Gubbi, G. A. Fleming, Lactic Acidosis in 
Patients with Diabetes Treated with Metformin, N. Engl. J. Med. 338, 265–266 (1998). 
595. P. J. Connelly, M. Lonergan, E. Soto-Pedre, L. Donnelly, K. Zhou, E. R. Pearson, Acute kidney 
injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study, 
Diabetes, Obes. Metab. 19, 1579–1586 (2017). 
596. D. A. Goldspink, F. Reimann, F. M. Gribble, Models and Tools for Studying Enteroendocrine 
CellsEndocrinology 159, 3874–3884 (2018). 
597. X. Wang, Y. Yamamoto, L. H. Wilson, T. Zhang, B. E. Howitt, M. A. Farrow, F. Kern, G. Ning, Y. 
Hong, C. C. Khor, B. Chevalier, D. Bertrand, L. Wu, N. Nagarajan, F. A. Sylvester, J. S. Hyams, T. 
Devers, R. Bronson, D. B. Lacy, K. Y. Ho, C. P. Crum, F. McKeon, W. Xian, Cloning and variation of 
ground state intestinal stem cells, Nature 522, 173–178 (2015). 
598. M. Schweinlin, S. Wilhelm, I. Schwedhelm, J. Hansmann, R. Rietscher, C. Jurowich, H. Walles, M. 
Metzger, Development of an Advanced Primary Human In Vitro Model of the Small Intestine., Tissue 
Eng. Part C. Methods 22, 873–83 (2016). 
599. M. Heishi, J. Ichihara, R. Teramoto, Y. Itakura, K. Hayashi, H. Ishikawa, H. Gomi, J. Sakai, M. 
Kanaoka, M. Taiji, T. Kimura, M. J. Heishi Ichihara R Teramoto Y Itakura K Hayashi H Ishikawa H Gomi 
J Sakai M Kanaoka M Taiji T Kimura, M. Heishi, J. Ichihara, R. Teramoto, Y. Itakura, K. Hayashi, H. 
Ishikawa, H. Gomi, J. Sakai, M. Kanaoka, M. Taiji, T. Kimura, Global gene expression analysis in liver 
of obese diabetic db/db mice treated with metformin, Diabetologia 49, 1647–1655 (2006). 
600. N. Saeidi, L. Meoli, E. Nestoridi, N. K. Gupta, S. Kvas, J. Kucharczyk, A. A. Bonab, A. J. Fischman, 
M. L. Yarmush, N. Stylopoulos, Reprogramming of intestinal glucose metabolism and glycemic 
control in rats after gastric bypass, Science (80-. ). 341, 406–410 (2013). 
601. C. R. Flynn, V. L. Albaugh, S. Cai, J. Cheung-Flynn, P. E. Williams, R. M. Brucker, S. R. Bordenstein, 
Y. Guo, D. H. Wasserman, N. N. Abumrad, Bile diversion to the distal small intestine has comparable 
metabolic benefits to bariatric surgery, Nat. Commun. 6 (2015), doi:10.1038/ncomms8715. 
234 
 
602. G. Baud, M. Daoudi, T. Hubert, V. Raverdy, M. Pigeyre, E. Hervieux, M. Devienne, M. Ghunaim, 
C. Bonner, A. Quenon, P. Pigny, A. Klein, J. Kerr-Conte, V. Gmyr, R. Caiazzo, F. Pattou, Bile diversion in 
roux-en-y gastric bypass modulates sodium-dependent glucose intestinal uptake, Cell Metab. 23, 
547–553 (2016). 
603. V. Tremaroli, F. Karlsson, M. Werling, M. Ståhlman, P. Kovatcheva-Datchary, T. Olbers, L. 
Fändriks, C. W. Le Roux, J. Nielsen, F. Bäckhed, Roux-en-Y Gastric Bypass and Vertical Banded 
Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass 
Regulation, Cell Metab. 22, 228–238 (2015). 
604. M. Kleinert, K. N. Bojsen-Møller, N. B. Jørgensen, M. S. Svane, X. C. Martinussen, B. Kiens, J. F. P. 
Wojtaszewski, S. Madsbad, E. A. Richter, X. C. Clemmensen, Effect of bariatric surgery on plasma 
gdf15 in humans, Am. J. Physiol. - Endocrinol. Metab. 316, E615–E621 (2019). 
605. H. Frikke-Schmidt, K. Hultman, J. W. Galaske, S. B. Jørgensen, M. G. Myers, R. J. Seeley, GDF15 
acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric 








Drug/Reagent Mechanism of Action and Target  
Chapter 4 
Antimycin A Inhibitor of mitochondrial respiration and oxygen consumption by 
targeting Complex III of electron transport chain 
Rotenone Inhibitor of mitochondrial respiration and oxygen consumption by 
targeting Complex I of electron transport chain 
FCCP Mitochondrial proton uncoupler that maximises oxygen consumption 
Az-991 AMPK activator 
UK-5099 Inhibitor of mitochondrial pyruvate carrier (MPC) 
NMN (Nicotinamide 
Mononucleotide) 
Increases cellular NAD+ via the salvage pathway 
Duroquinone Substrate for NAD(P)H dehydrogenase (NQOs) involved in redox 
balance predominantly in the cytosol. 
MitoTEMPO MnSOD mimetic superoxide scavenger (Mitochondrial targeted 
antioxidant) 
MitoPQ Redox cycler that stimulates mitochondrial superoxide production  
MitocDNB1 Depletes glutathione by acting as a substrate for glutathione S-
transferase 
Doxycycline Inhibitor of mitochondrial translation 
Actinonin Inhibitor of de novo turnover of mitochondrial proteins 
MitoBloCK6 Inhibitor of mitochondrial protein import through TIM22 and 
Mia40/Erv1 pathways 
Ciprofloxacin Inhibitor of mtDNA replication by inhibiting mitochondrial 
topoisomerases from relaxing its supercoil structure 
ISRIB Inhibitor of eIF2A phosphorylation and activation of the integrated 
stress response 
GSK-2606414 Inhibits PERK activation 
A-92 Inhibitor of GCN2 
Histidinol Inhibitor of histidyl-tRNA syntethetase to mimic amino acid deprivation 
KC7F2 Inhibitor of HIF-1A translation by targeting Rps6 pathway 
NSC-134754 Inhibitor of HIF-1A transcription, translation and stability 
Chapter 5 
Phloridzin Non-specific blocker of SGLTs 
Phloretin Non-specific blocker of GLUTs 
Cytochalasin B Non-specific blocker of GLUTs 
Forskolin Non-specific blocker of GLUTs, with a higher affinity for GLUT1/3/4 
compared to GLUT2 
Glucosamine High affinity substrate for GLUT2 
Fructose Substrate for GLUT2 with similar affinity compared to glucose 
Chapter 6 
2-Deoxyglucose Inhibitor of hexokinase and therefore glycolysis 
Oxamate Inhibitor of LDH 
AR-C155858 Inhibitor of MCT2 and MCT4 
Syrosingopine Inhibitor of MCT1 and MCT4 
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AOA (Aminooxyacetate) Broad-spectrum inhibitor of transaminase enzymes, including aspartate 
transaminases involved in the malate-aspartate shuttle and alanine 
transaminases 
βCLA (β-chloro-alanine) Selective inhibitor of alanine transaminases 
Phenylsuccinate Inhibitor of oxoglutarate-glutamate transporters involved in the malate-
aspartate shuttle 
iGP-1 Inhibitor of mGPDH involved in the glycerolphosphate shuttle 
GPi-688 Inhibitor of glycogen phosphorylase, therefore glycogenolysis 
Etomoxir Inhibitor of CPT-1 shuttle involved in fatty acid oxidation in the 
mitochondria 
 
Appendix 1: Mechanisms of drugs and reagents used in this study. 
 
